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Voor Ingrid
IMDM Iscove’s Modified Dulbecco’s Medium
IT Immunotherapy
Kd Dissociation constant
kDa Units of molecular mass in kilo Daltons
L. Lactobacillus
LAB Lactic acid bacteria
LPS Lipopolysaccharide
LS Light scattering
LTP Lipid transfer protein
MALDI-TOF Matrix-assisted laser desorption/ionization time- 
 of-flight
MAMPs Microbe-associated molecular patterns
MHC Major histocompatibility complex
MLN Mesenteric lymph nodes
MMC Mucosal mast cell
Mr Relative molecular mass
MRA Mediator release assay
MS Mass spectroscopy
Mw Molecular weight
N (n) Native (unheated)
NA Non-allergic
NBT Nitroblue tetrazolium
NK cell Natural killer cell
NLRs Nucleotide oligomerisation domain(NOD)-like  
 receptors
nsLTP Nonspecific lipid transfer proteins
OAS Oral allergy syndrome
OD Optical density
OPA o-Phthaldialdehyde
PBMC Peripheral blood mononuclear cells
PBS Phosphate buffered saline
PHA Phytohemaglutinin
PI Propidium iodide
PMA Phorbol myristate acetate
PR Pathogenesis-related
PRR Pathogen-recognition receptor
r Recombinant
R Isolated from roasted peanuts
R+g Heated in a dry form for 20 min at 145°C in the  
 presence of glucose
R-g Heated in a dry form for 20 min at 145°C in the  
 absence of glucose
RAST Radioallergosorbent test
RBL cells Rat basophilic leukaemia cells
Rpm Rounds per minute
RPMI Roswell Park Memorial Institute medium
RT  Room temperature
SD Standard deviation
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel  
 electrophoresis
SEC Size exclusion chromotography
SILT Small intestinal lymphoid tissue
SLIT Sublingual immunotherapy
SPT Skin prick test
Tc Cytotoxic T cell
T-cell Thymus-derived lymphocyte
TCR T cell receptor
TGF-β Transforming growth factor-beta
Th T helper cell
TLR Toll-like receptor
TNF-α Tumor necrosis factor-α
Treg cell Regulatory T cell
AA Amino acid
Ab Antibody
ACB Allergen challenge buffer
Ag Antigen
AP Allergic patient
AFM Atomic force microscopy
AGE Advanced glycation end products
ALT Alanine transaminase (or SGPT/ALAT; liver  
 enzyme)
ANOVA Analysis of variance
APC Antigen-presenting cell
Ara h Arachis hypogaea (peanut)
ASIT Allergen-specific immunotherapy
AST Aspartate transaminase (or SGOT/ASAT; liver  
 enzyme)
αCD3 Antibody directed against CD3
αCD28 Antibody directed against CD28
BAT Basophil activation test
BCA Bicinchoninic assay
B-cell Lymphocyte which matures in bone marrow
Bet Betula pendula/verrucosa (birch)
BHR Basophil histamine release
BrdU 5-bromo-2′-deoxyuridine
BSA Bovine serum albumin
CBA Cytometric bead array
Ca-I Calcium ionophore
CAST Cellular antigen stimulation test
CCD Carbohydrate determinant
CD Circular dichroism
CDx Cluster of differentiation x
CFSE Carboxyfluorescein diacetate succinimidyl ester
ConA Concanavalin A
Cor a Corylus avellana (hazelnut)
CRD Component-resolved diagnosis/diagnostics
Da Dalton
DBPCFC Double-blind, placebo-controlled food challenges
DC Dendritic cell
DH Degree of hydrolysis
DNA Deoxyribonucleic acid
EAST Enzyme allergosorbent test
EC50 Allergen dose inducing 50% of the max. release  
 (half maximal effective conc.)
ELISA Enzyme-linked immunosorbent assay
EPSB EuroPrevall serum bank
ESIT Anti-IgE immunotherapy
FACS Fluorescence-activated cell sorter
FCS Fetal calf serum
FcεR1 High affinity receptor for IgE
FT-IR Fourier transform infrared sprectroscopy
G Heated in wet form for 15 min at 110/110°C in  
 the presence of glucose
GALT Gut-associated lymphoid tissue
GI Gastrointestinal
Gly m Glycine max (soy)
GGT Gamma-glutamyl transpeptidase
H Heated in wet form for 15 min at 110/110°C in  
 the absence of glucose
HPLC High-performance liquid chromotography
IC50 Concentration inhibitor (competitor) that inhibits
 50% of the IgE binding to the native allergen
IFN-γ Interferon-γ
Ig Immunoglobulin
IL Interleukin
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Chapter 1
General introduction
Parts of the introduction are from Chapter 12: Influence of food processing, digestion and 
the food matrix on allergenicity & cellular measures of allergenicity. Yvonne M. Vissers, 
Harry J. Wichers and Huub F.J. Savelkoul; In: Multidisciplinary Approaches to Allergies, 
Edited by Zhongshan Gao, Huahao Shen, Min Zheng, Lynn J. Frewer and Luud J.W.J. 
Gilissen, Co-publishing by Zhejiang University Publishing and Springer, 2011 (in press) 
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Food allergy and immune cells
Adverse food reaction represents any abnormal clinical response associated with ingestion of 
a food or a food additive. There are two main adverse reactions to food: non-toxic and toxic 
(Fig. 1). The non-toxic reactions can be further classified as non-immune-mediated (food intol-
erance) and immune mediated (food allergy) based on the pathophysiological mechanism of 
the reaction. In addition, the immunological or truly allergic reactions to food can be further 
classified in IgE mediated (type 1 hypersensitivity) and non-IgE mediated (type III or type IV 
hypersensitivity) reactions [1,2]. This thesis is focussed on IgE mediated allergic reactions. in 
which the allergic symptoms are initiated by IgE antibodies that are produced in response to 
otherwise harmless environmental antigens, i.e. allergens.
Adverse reactions to foods
Non-toxic Toxic
Non-immune medated
(food intolerance)
Immune mediated
(food allergy)
IgE mediated Non-IgE mediated
Fig. 1. Classification of adverse reactions to foods (adapted from [1,2]).
The incidence of IgE mediated allergies in most developed countries is commonly in the 
range of 20 to 30% of the total population, of which half may develop allergic rhinitis. This inci-
dence has been rising since about 1960 with a possible recent plateau in developed countries, 
as indicated from the International Study of Asthma and Allergies in Childhood (ISAAC). This 
study summarized worldwide trends in the prevalence of asthma, rhinoconjunctivitis and ec-
zema [3]. A large variation was observed among centres and increases in the prevalence of all 
allergic conditions in the period 1994-2003 were reported in more centres than decreases, but 
a tendency was found for a lack of increase in asthma and eczema in centres with previously 
high prevalence [3,4]. Explanations for this increase in allergy and asthma have been associ-
ated with an increased exposure to house dust mite because of modern housing, the improved 
hygiene and cleanliness and widespread antibiotic use, an increased prevalence of obesity and 
dietary changes [5]. Current allergy treatment is almost exclusively concerned with the man-
agement of allergic symptoms using drugs such as anti-histamines and steroids supplemented 
with, in the case of allergic asthma, drugs to improve breathing such as beta-2 agonists. Al-
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though these symptomatic drugs provide temporary relief, they can be inconvenient to use and 
can cause unwanted side effects. For IgE mediated food allergy there is currently no other cure 
than complete allergen avoidance, which is often difficult to achieve and better knowledge 
of allergenicity of food allergens, the process of allergic sensitization and the development of 
clinical symptoms is urgently needed.
IgE mediated food allergy is a disease affecting all age groups. There is no well-established 
cure or preventative treatment for food allergy at the present time. As management is re-
stricted to avoidance of problematic allergens, having a food allergy changes the quality of 
life experienced by a food allergy sufferer and their caregivers in a profoundly negative way. 
Food allergic adolescents and adults reported to have poorer overall health, more limitations 
in social activities and less vitality compared to individuals from the general population [6]. 
Mothers of children having a peanut allergy reported to have a significantly poorer quality of 
life and suffered more anxiety and stress than fathers [7]. In addition, peanut allergic subjects 
felt more threatened by potential hazards within their environment, felt more restricted by 
their peanut allergy regarding physical activities, and worried more about being away from 
home. They reported lower scores on quality of life than children with insulin dependent dia-
betes mellitus [7,8].
Sensitization and clinical symptoms
Sensitization is the initial phase in the development of IgE-mediated allergy. When an allergen 
enters the body via the epithelial barrier of the skin, airway or gut, it is taken up by antigen-
presenting cells (APCs), such as dendritic cells (DCs). After processing of the allergen, the aller-
gen-derived peptides are bound to major histocompatibility complex (MHC) class II molecules 
on the surface of APCs. In this way these peptides are presented to the T cell receptor (TCR) on 
naïve CD4+ antigen-specific T cells which triggers these cells to develop into Th1, Th2 or Th17 
effector cells or regulatory T (Treg) cells. If APCs cause differentiation to Th2 cells, production of 
IL-4 and IL-13 from these cells will drive neighbouring B cell heavy-chain class-switching to IgE 
production and secretion of allergen-specific IgE antibodies. The secreted allergen-specific IgE 
will subsequently bind to the high affinity FcεR1 receptor of mast cells in the tissue or basophils 
in the blood, which completes the sensitization phase.
Upon a second exposure to the same allergen, this can bind to the cell-bound IgE and in 
that way cluster and cross-link two or more FcεR1 receptors on the surface of the mast cell 
or basophil. The number and duration of cross-links per basophil or mast cell should be at 
least 100 for at least 100 seconds to induce mast cell and/or basophil activation, subsequent 
degranulation and the release of inflammatory mediators [9] like histamine, leukotrienes, 
platelet-activating factor, prostaglandins and cytokines. Within minutes after the allergen ex-
posure, histamine and leukotrienes cause increased local blood flow and vascular permeability, 
leading to swelling and an increased cellular infiltration, while proteases cause tissue damage 
and platelet-activating factor has been shown to play an important role in the induction of 
anaphylaxis. Subsequently, this will lead to a variety of immediate cutaneous, respiratory, and/
or gastrointestinal symptoms (Fig. 2).
The release of pro-inflammatory mediators and cytokines from mast cells, and the increase 
in vascular permeability promotes subsequent recruitment of other effector cells, e.g. eosino-
phils neutrophils, basophils and Th2 lymphocytes [10]. In some patients, this can lead after 
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6-24 h to a late-phase, cell-mediated response frequently seen in allergic nasal, respiratory 
and skin disease (atopic eczema). This could convert into a chronic inflammatory response, like 
in chronic asthma, if antigen persists and stimulates allergen-specific Th2 cells, which in turn 
promote eosinophilia and further IgE production.
It is not known why some individuals start producing IgE when encountering allergens 
while others do not. Probably there are several factors involved, such as the host genotype, 
type of allergen, allergen concentration in the environment, route of exposure and whether 
exposure occurs together with agents that can either enhance or down-regulate the sensiti-
zation process [11]. It is also unclear what factors act to prevent the development of clinical 
(symptomatic) food allergy in otherwise sensitised individuals. In addition, it is only partly clear 
what factors determine the severity of food allergic reactions. Threshold of exposure for elicita-
tion of a food allergic reaction during challenge of food allergic subjects, and the intensity of 
those reactions, differ between individuals, and vary with time in the same individual. Genetic 
background, medication history, disease history, the time of the day or the stage of the year of 
exposure to allergens, geographical parameters, variation in diet, the abundance of an allergen 
in the diet, the degree of digestion by the gastro-intestinal tract, the degree of processing, and 
the impact of embedding in food matrix components are all conditions that can influence this 
threshold and the severity of the allergic reactions [12,13].
Fig. 2. Sensitization and elicitation phase of the allergic reaction (adapted from [14]).
Peripheral blood mononuclear cells (PBMCs)
The cells in human blood consists of erythrocytes (red blood cells), leukocytes (white blood 
cells) and thrombocytes (blood platelets). The leukocytes part (with a normal range of 4.0 
– 11.0 x 109/L) is made up of granulocytes (neutrophils (54-62%), eosinophils (1-6%) and ba-
sophils (<1%)), monocytes (2-10%, with a normal range of 0.2 – 0.8 x 109/L) and lymphocytes 
(25-33%, with a normal range of 1.5 – 4.5 x 109/L consisting of T cells, B cells and natural killer 
[NK] cells). The monocytes and lymphocytes together form the peripheral blood mononuclear 
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cell fraction (PBMC). PBMC can be isolated from the peripheral blood by density gradient sepa-
ration and these cells can be used to assess cell-mediated immunity in general or, via antigen-
specific stimulation, to detect previous exposure to a variety of antigens/allergens and to moni-
tor for example the response to immunotherapy.
T cells and antigen-presenting cells (APCs)
In the blood, 60-70% of T cells (normal range of CD3+ T-cells is 0.69 – 2.54 x 109/L) are CD4+ 
(normal range is 0.41 – 1.59 x 109/L) and 30-40% express CD8+ (normal range is 0.19 – 1.14 x 
109/L). CD4+ T cells are generally designated helper cells and activate both humoral immune 
responses (B-cell help) and cellular responses (delayed-type hypersensitivity responses and 
others). CD8+ cells show a major cytotoxic activity against cells infected with intracellular mi-
crobes, and against tumour cells. In the blood of healthy controls activated CD3+CD25+ T-cells 
are present with a normal range of <0.1 – 0.4 x 109/L. A portion of the circulating CD4+ cells 
play an important regulatory role that acts to down modulate immune responses. These regu-
latory T (Treg) cells consist of natural occurring Treg cells (CD4+CD25+ Treg) and adaptive or 
induced Treg cells (Tr1). Treg cells are able to inhibit the development of allergen-specific Th2 
and Th1 cell responses and therefore play an important role in a healthy immune response to 
allergens [15].
Both CD4+ and CD8+ T cells differentiate into functionally distinct subsets after exposure to 
antigenic peptides processed and presented by antigen presenting cells (APCs), like dendritic 
cells, B cells and monocytes/macrophages. This is best described for the transition of CD4+ T 
cells from naïve to effector populations. Resting naïve CD4+ T cells (designated Th cells) release 
very low levels of cytokines. Soon after stimulation by antigen and APC, the Th cells begin to 
produce IL-2 and are designated Th0. As the Th cells continue to respond to the activating sig-
nal, they differentiate to designated Th1, Th2, and Th17 cells depending on the local cytokine 
micro-environment at the site of activation [16]. IL-12 produced by macrophages or NK cells 
induces differentiation toward Th1; IL-4 produced by NK1.1+ T cells, basophils, or mast cells 
induces differentiation toward Th2; and TGF-β produced by Foxp3+ regulatory T-cells and IL-6 
from innate immune cells or IL-21 produced by T cells and NKT cells induce differentiation 
toward Th17. Th1 cells are characterized by the production of IL-2, IFN-γ, and lymphotoxin, 
whereas Th2 cells produce IL-4, IL-5, IL-9, IL-13, and granulocyte-macrophage colony stimulat-
ing factor (GM-CSF) and Th17 cells produce the cytokines IL-6 and IL-17 [17,18]. These effector 
cytokines that are produced can potentially feedback to amplify Th1, Th2 and Th17 cells and 
further enhance differentiation of the respective T cell subset.
The differentiation factors (TGF-β plus IL-6 or IL-21), the growth and stabilization factor 
(IL-23) primarily secreted by activated DCs, monocytes and macrophages, and the transcrip-
tion factors (STAT3, RORγt, and RORα) involved in the development of Th17 cells have been 
identified. The participation of transforming growth factor-β (TGF-β) in the differentiation of 
Th17 cells places the Th17 lineage in close relationship with CD4+CD25+Foxp3+ Treg cells, as 
TGF-β also induces differentiation of naïve T cells into Foxp3+ Treg cells in the peripheral im-
mune compartment [19]. Recently, a new population of T helper cells separate from Th2 have 
been distinguished that produces IL-9 in large quantities (‘Th9’ cells). Under certain conditions 
relevant to chronic disease (through combined actions of IL-4 and TGF-β), these ‘Th9’ helper T 
cells seem to lack suppressive function, promote tissue inflammation and may regulate chronic 
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allergic inflammation [20-22].
In T-cell polarisation assays based on human PBMC-cultures, blood is obtained from allergic 
persons and healthy controls and PBMC are isolated by means of Ficoll separation. After per-
forming density gradient separation, the upper fraction consists of plasma and thrombocytes, 
the middle fraction is the PBMC fraction, the lower fraction consists of Ficoll and granulocytes 
and the pellet of the erythrocytes. Because antigen-specific cultures require the presence of 
APCs, PBMC providing autologous APCs, instead of purified T cells are a preferred model to 
use. Antigen presentation in in vitro PBMC cultures is mainly accounted for by monocytes. The 
PBMC consisting of T and B cells, NK cells and monocytes are cultured and stimulated with the 
allergen of interest. In the cultures the allergens are presented by APCs to the adaptive im-
mune cells via presentation of small peptide fragments of the allergens (T-cell epitopes) on the 
surface of the APCs. T-cell activation requires at least two signals. The MHC-peptide complex 
associating with the T-cell receptor (TCR/CD3) provides signal 1, whereas signal 2 is delivered 
via the binding of CD28 to B7-1/2 (CD80/CD86) expressed on antigen presenting cells (also 
called co-stimulatory interaction). Subsequently, an immunological synapse is formed, result-
ing in the activation of several tyrosine kinases and recruitment of adapter proteins and spe-
cific downstream signalling leading to T-cell activation and specific cytokine production [23].
Flow cytometry provides the cornerstone of cellular immunological assays and is depend-
ent on the availability of monoclonal antibody reagents reactive with human surface and intra-
cellular antigens. The semi-automated, rapid, accurate and large cell number measurements of 
cells, comprise major advantages of flow cytometric analysis. By using combinations of surface 
marker sets and performing multicolour flow cytometric stainings, the phenotype of the cells 
in culture can be analysed. A control which allows correction for possible differences between 
individual donors regarding proliferation or cytokine production is to perform a surface marker 
staining of the PBMC fraction immediately after isolation of the PBMC (Fig. 3).
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Fig. 3. (previous page) Typical data of freshly isolated human peripheral blood mononuclear cells (hPBMC) isolated 
from a healthy donor and stained directly with a mixture of anti (α)-hCD3 (T cells), α-hCD4 (T helper cells), α-hCD8 
(cytotoxic T cells), α-hCD25 (activated cells), α-hCD16/α-hCD56 (NK cells), α-hCD14 (monocytes) and α-hCD19 (B 
cells). First the PBMC fraction was gated (debris was gated out) and within this PBMC fraction the percentages of T 
cells (65±4%), NK cells (10±3%), NKT cells (natural killer T cells) (4±3%), monocytes (12±4%) and B cells (8±2%) were 
determined. Within the T-cell fraction the percentage T helper cells (61±10%) and cytotoxic T cells (32±11%) were 
assessed. As virtually no activated cells (CD25+) were present, this result is not shown. Average±SD values were 
obtained from the average values of PBMC stained directly after isolation from the blood of 10 healthy controls. 
Seven-colour flowcytometric acquisition was performed on a FACSCanto II (BD Biosciences), using the BD FACS-
Diva software. Per sample 10.000 events in the PBMC fraction were acquired. The following monoclonal antibody 
mixture was used: α-hCD3 (V450), α-hCD4 (PerCP Cy5.5), α-hCD8 (PE-Cy7), α-hCD25 (APC-H7) α-hCD14 (APC), 
α-hCD16 (PE), α-hCD19 (FITC) and α-hCD56 (PE).
Mast cells and basophils
Mast cells are tissue-based inflammatory cells, located primarily in association with blood ves-
sels and in mucosal tissues lined by epithelial surfaces in the respiratory system, gastro-intes-
tinal system, and skin, where they also mature. Mast cells that complete their differentiation 
in the skin or in the intestine develop into connective tissue mast cells (CTMCs) and mucosal 
mast cells (MMCs), respectively. Mast cells express the high-affinity type IgE receptor, FcεR1 
which binds IgE with a K
D
 of around 10-10 M. The density of human basophil FcεRI expression 
correlates directly with serum IgE levels, where binding of IgE stabilizes the receptor at the cell 
surface. FcεRI not occupied by IgE has a half-life on the mast cell surface of 24 hours in vitro, 
whereas receptors bound to IgE appear to be expressed for the life of the cell (around 14 days). 
In addition, the presence of IL-3 slows degradation of internalized receptor and some recep-
tors appear to re-cycle to the cell surface. Mediators produced by mast cells can be divided in 
preformed mediators (i.e. histamine, tryptase, chymase), newly synthesized lipid mediators, 
and cytokines/chemokines. Collectively, these mediators are associated with the immediate 
hypersensitivity reaction and with the often occurring late-phase reaction occurring 6-24 h 
after allergen exposure. Newly released histamine has a half-life of around 1 minute in the 
extracellular fluid [24].
Circulating basophils share many features with mast cells, including expression of FcεRI, 
secretion of Th2 cytokines, metachromatic staining, and the release of histamine after IgE-
mediated activation. A notable feature of basophils is their rapid and strong production of IL-4 
and IL-13 when stimulated with cross-linking of FcεR1 and IL-3 [24]. Basophils also express 
Toll-like receptor (TLR)1, TLR2, TLR4, and TLR6 and produce Th2 cytokines in response to IL-3 
plus corresponding TLR ligands [25]. Basophils are 5 to 8 µm in diameter, exhibit a segmented 
condensed nucleus and contain fewer but larger granules compared to those seen in mast 
cells. Basophils develop from CD34+ progenitors, differentiate and mature in the bone marrow, 
and circulate in the periphery, where they account for less than 1% of blood leukocytes (normal 
range 0.01 - 0.2 x 109/L) and are thought to have a half-life of a few days. Basophils express a 
complete FcεRI, the surface expression of which directly correlates with free IgE concentration, 
as noted for mast cells. Aggregation of FcεRI bound to IgE by multi valent anti gen leads to ba-
sophil activation, granule exocytosis, and mediator release [24]. In addition, the proposed role 
of the basophil in functioning as professional APC promoting Th2 differentiation is still under 
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debate [25].
Even though basophils differ from mast cells in some aspects, in a clinical setting, basophils 
are a practical and convenient surrogate for mast cells when diagnosing allergen sensitization 
in patients for the practical reason that circulating basophils are much more accessible than 
tissue-resident mast cells [26].
Prevalence of allergy and EuroPrevall
Prevalence data
The true prevalence of food allergies is still being assessed, but is recently estimated to be 
around 2-5% in the US population, [27,28]. The determination of accurate food allergy preva-
lence rates is hampered by the lack of studies applying reliable diagnostic methodologies, such 
as double blind placebo controlled food challenges (DBPCFC), to large unselected populations. 
New data on prevalence, risk factors, quality-of-life and costs of food allergies obtained from 
the multi-centre birth cohort study within the EuroPrevall project (see next paragraph), is cur-
rently being analysed which may provide new insights regarding the true prevalence of food 
allergy [29,30].
Recent studies showed a prevalence of peanut and tree nut allergy of 1-2% in the US and 
Canadian population [31,32]. In some studies the prevalence was found to be much higher, 
with approximately 10% of 8-year-old children in the UK being sensitised to peanut, of whom 
2% have a clinical peanut allergy [33]. In addition, the prevalence of peanut and tree nut al-
lergy in children appears to be increasing [31], which contributes to a growing global concern, 
particularly given the severity of the allergic reactions. Furthermore, although patients with 
cow’s milk or egg allergies have a high chance of eventually tolerating these foods or ‘outgrow-
ing’ their allergy, peanut allergy tends to persist throughout life. Of the more than 3 million 
Americans with a peanut or tree nut allergy [31], fewer than 20% will ‘‘outgrow’’ the allergy 
naturally [34,35].
EuroPrevall
In 2005 a large EU-funded project on food allergy started named EuroPrevall (www.europrevall.
org), which aimed to gain insight into the prevalence of food allergies across Europe [36]. To 
provide accurate information on the prevalence of food allergies, in particular standardisation 
of test protocols is needed. This implies also more knowledge on allergens and allergies is 
needed, and on the influence of food processing, digestion and the food matrix on allergenic-
ity of individual allergens i.e. both on their potential to sensitise atopic individuals and to elicit 
clinical manifestations in already sensitised individuals. More knowledge on the influences of 
food processing and the matrix on clinical reactivity of components consumed by diet is of 
great importance to establish authentic standardized food materials for DBPCFC [37], which 
can then be used as a reference method for confirming clinical diagnosis of food allergy. This 
would provide, as far as possible, a concordance of clinical challenge results across the clinical 
centres involved in the EuroPrevall project. 
More knowledge on the influence of processing is also highly relevant to the development 
of in vitro methods for diagnosing allergy since many of the foods that are consumed are ther-
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mally processed and hence the original sensitising agent may be a modified, not native, al-
lergen. Such information on the nature of such neo-allergens is also highly relevant to the 
development of effective in vitro component-resolved diagnostic methods. In addition, data 
on processing may allow the allergen content to be reduced in highly refined derived products 
below any established thresholds. This might thus provide justified criteria for exemption to 
the labelling regulation with no risk for allergic consumers.
Results obtained within the EuroPrevall project on the influence of processing on aller-
genicity of individual allergens are partly presented in this thesis.
Allergens
Food allergens are named by the first three letters of the taxonomic name of the genus of its 
botanical source, followed by the first letter of the species, and an Arabic number to indicate 
the chronology of allergen discovery and purification. As example, the first described allergen 
of peanut (Arachis hypogaea) is named, Ara h 1.
Although the diversity of the human diet is enormous, only a limited number of foods ac-
count for the majority of food allergies, with shellfish, peanut and tree nut allergies predomi-
nating in adults, whereas cow’s milk, hen’s egg and peanut are important in infants [28]. In ad-
dition, most allergens can only be found in a very restricted number of protein families which 
strongly suggests the existence of properties that would render a protein allergenic [38]. Major 
class I food allergens characterized to date share a number of common features; they are most-
ly proteins and many of these are water-soluble glycoproteins, 10 to 70 kD in size, overall highly 
abundant in the food, and relatively stable to heat and acid conditions, and to the presence of 
proteases. A protein that is stable to digestive enzymes and to processing conditions and that 
is abundant in the food or consumed in large amounts, is more likely to survive gastrointestinal 
digestion, and pass the mucosal barriers having intact epitopes that can subsequently induce 
an allergic reaction. However, it is clear that additional features, such as food preparation and 
factors derived from allergen carriers (e.g. the food matrix, microbial molecules from house 
dust mite and pollen grains), and the environment, can also affect the allergenicity of the com-
pound [28,39], and no single characteristic shared by all known food allergens has been identi-
fied so far that determine or predict allergenicity of an individual protein.
In contrast to class I food allergens, class II allergens are considered to be more sensitive 
to heat and digestive enzymes and, therefore, cannot cause sensitizations via the oral route. 
Instead, they provoke allergic reactions in already sensitized patients by means of IgE cross-
reactivity between sensitizing aeroallergens and symptom-eliciting food allergens leading to 
pollinosis-associated food allergies [40]. A well-known example is the widespread occurrence 
of apple allergy in North-West Europe, in birch sensitized individuals. Moreover, the different 
properties of class I and II food allergens also determine the clinical manifestation of food aller-
gy. For example, allergy to fresh fruits in North-West Europe is generally associated with mild 
local reactions of the oral cavity, the so-called oral allergy syndrome (OAS), whereas allergy to 
peanuts is considered a major cause of severe anaphylaxis.
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Epitopes
Binding of IgE antibodies to specific regions of allergens, known as antigenic determinants 
or epitopes, is a prerequisite for triggering of IgE-mediated allergic reactions. In order to bind 
two or more IgE molecules that can cross-link two or more FcεR1 receptors, an allergen must 
contain at least two IgE binding epitopes or should occur as a dimer or oligomer. Such IgE 
binding epitopes, also called B-cell epitopes, are frequently categorized as conformational or 
discontinuous epitopes or as linear, continuous or sequential epitopes (Fig. 4).
In conformational epitopes, the amino acid residues recognized by the binding site of an-
tibodies are distributed discontinuously over the protein sequence and are brought together 
by folding of the polypeptide chain. Their antigenic reactivity depends on the native conforma-
tion of the protein. In linear epitopes, the amino acid residues recognized by the antibody are 
typically derived from short contiguous 8-10 amino acid segments which are often situated on 
a 30-50 amino acid stretch. However, even a sequential epitope adopts, at least transiently, a 
defined configuration upon interaction with an antibody complementarity-determining region 
which is the portion of the variable light and heavy chains that interact with the target mol-
ecule [41,42]. The conformational epitopes are expected to be more susceptible to processing-
induced structural changes while the linear epitopes, are likely to be more resistant to physi-
cal treatments, and thus suggested to be more important in food allergens to cause systemic 
reactions. However, also linear epitopes could still be disrupted by hydrolysis and (digestive) 
enzymes. Conformational epitopes are important for allergens involved in OAS and respiratory 
allergy [43].
a. Linear epitopes        b. Conformational      c.  IgE binding of epitopes
epitopes
denaturation          digestion denaturation          digestion
Mast
Cell
Fc  R1
Allergen
C
L
L
C
IgE
Fig. 4. Schematic representation of two antibodies interacting with linear and conformational epitopes. (a) Linear 
epitopes are continuous and may still be able to bind the antibody after denaturation and/or digestion (b) Confor-
mational epitopes are discontinuously over the protein sequence and can no longer bind the antibody after dena-
turation and/or digestion (Adapted from www.rostlab.org/services/epitome/background.html). (c) Both linear (L) 
and conformational (C) epitopes recognized by different IgE antibodies bound to the FcεR1 on the mast cell (Fig. 
4c: Adapted from Thesis Tiiu Saarna, 2009).
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The procedures to identify conformational epitopes are technically challenging; therefore, 
conformational epitopes are less well studied compared to linear epitopes, even though con-
formational epitopes have also shown to contribute to the allergenicity of e.g. tree nut [44] and 
peanut [41] allergens. In addition, It has been suggested that a differential responsiveness to 
linear versus conformational epitopes in allergic patients could be used to better predict the 
severity and/or persistence of food allergies such as milk allergy [45,46].
Furthermore, allergens contain multiple T-cell epitopes, i.e. the small proteolytically 
cleaved linear peptides that interact with the receptors of T cells. Protein uptake by profes-
sional antigen-presenting cells through endocytosis or phagocytosis leads to formation of 
endosomes, which become increasingly acidic as they progress and eventually fuse with lys-
osomes containing MHC class II molecules. These vesicles contain aspartic and cysteine pro-
teases which degrade the protein into peptides. The activities and specificities of the proteases 
in the MHC class II presentation pathway are poorly characterized. The core binding motif of 
both MHC I and MHC II is approximately nine amino acids long. The binding groove in MHC 
class II molecules has open ends, and therefore accommodates much longer peptides, possibly 
even whole, unfolded proteins [47-49], but typically 12-15 amino acid residues in length [50].
Respectively, 23 and 10 distinct IgE-binding epitopes were recognized along the primary 
amino acid sequence of Ara h 1 and Ara h 2 [51]. Five major epitopes of Ara h 1 that bound 
peanut-specific serum IgE from more than 60% of patients tested were identified, and were 
located at AA 21-34, 89-98, 393-403, 498-507, and 594-605 [52], while peptides located at AA 
25-34, 65-74, 89-98 and 498-507 showed to contain immunodominant epitopes by Burks et 
al. [53]. Moreover, the epitopes 498-507 and 594-605, which were located in the C-terminal 
end of the protein, were in a region that shares significant sequence similarity with vicilins 
from other legumes [53]. In addition, 9 out of 23 sequential B-cell epitopes identified in the 
N-terminal part of the Ara h 1 monomer are specific for Ara h 1, while the remaining 14 char-
acterized in the C-terminal regon of Ara h 1 shared high degree of homology and conformation 
with other legume vicilins [54]. This may explain the possible cross-reacting antibodies to other 
legumes that can be found in the sera of peanut allergic patients. Immunodominant regions for 
serum IgE-binding for Ara h 2 have been identified at AA 27–36, 57–66 and 65–74 [55].
Data for T-cell epitopes of the peanut allergens are limited. Initial studies have identified 
two highly immunogenic T-cell reactive regions of Ara h 2 located at AA 19–47 and 73–119 [56]. 
Three major and two minor T-cell epitopes were predicted for Ara h 1 [54].
Classification of plant food allergens into superfamilies
Plant food allergens can be classified into families and superfamilies based on their structural 
and functional properties. The most widespread groups of plant proteins that contain allergens 
are the cupin superfamily (7S and 11S seed storage proteins), the prolamin superfamily (2S al-
bumins, nonspecific lipid transfer proteins [nsLTPs], α-amylase/trypsin inhibitors, and prolamin 
storage proteins of cereals) and the protein families of the plant defence system (e.g. patho-
genesis-related [PR] proteins, certain proteases and protease inhibitors) [57]. Fig. 5 shows a 
classification of 7S and 11S globulins and 2S albumins from peanut, hazelnut and soy allergens 
in their respective (super)families.
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Cupin
superfamily
Vicilin (7S)
Peanut: Ara h 1
Hazelnut: Cor a 11
Soy: Gly m 5
Legumin (11S)
Peanut: Ara h 3,4
Hazelnut: Cor a 9
Soy: Gly m 6
Prolamin
superfamily
Albumin (2S)
Peanut: Ara h 2, 6, 7
Hazelnut: 2S albumin
Soy: 2S albumin
Fig. 5. Classification of 7S, 11S and 2S peanut, hazelnut and soy allergens in their respective (super)families.
Peanut allergens
Peanuts are known to cause the largest number of cases of severe anaphylaxis and deaths 
in the US [28]. Peanuts consist of approximately 45-50% oil, 25-30% protein, 8-12% carbohy-
drates, 5% water, 3% fibre and 2.5% ash [58]. Until now, 11 peanut allergens have been identi-
fied and accepted by the Allergen Nomenclature Subcommittee of the International Union 
of Immunological Societies (IUIS), termed Ara h 1 to Ara h 11 (see Table 1). Eighty to ninety 
percent of peanut proteins belong to the seed storage proteins of the 7S vicilin, 11S legumin 
or 2S conglutin type. The amounts of Ara h 1 and Ara h 2 are estimated to be 12-16% and 5.9-
9.3%, respectively of the total protein extract [59]; however, this can differ per peanut variety 
[60,61].
The two major peanut allergens, Ara h 1 and 2, are part of the vicilin and conglutin families 
of storage proteins, respectively and are further described below. Ara h 3 is a glycinin seed 
storage protein thought to occur naturally as a hexameric structure resulting from the stacking 
of two similarly oriented homotrimers. It is designated both as a minor and a major allergen 
[51,62]. Ara h 4, previously described as a distinct peanut allergen, is found to be a nearly 
identical isoform of Ara h 3 and therefore Ara h 3 and Ara h 4 are denoted as Ara h 3/4 in table 
1 [63].
Ara h 6 and Ara h 7 are very similar to Ara h 2 and also further described below. Two of the 
11 identified peanut allergens, Ara h 5 and Ara h 8, are proteins associated with pollen-related 
food allergy (class II allergens) and mostly associated with mild symptoms like OAS. Ara h 5 
belongs to the profilin family, a group of actin-binding proteins responsible for cytoskeleton 
formation in plant cells. Eight surface-exposed epitopes were predicted, of which three were 
found common among various profilins, which could explain their cross-reactivity [64]. Ara h 
8 is a member of the PR-10 family and is known to cross-react with the major birch pollen al-
lergen Bet v 1. Birch pollen sensitized patients often show IgE binding to Ara h 8, despite their 
tolerance to peanut. Therefore, Ara h 8 sensitization is mainly associated with no clinical symp-
toms or with OAS symptoms [65-68].
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Table 1. Identified peanut allergens.
Allergen
Size 
(kDa)
Type of protein
# of 
epitopes
% IgE 
bindinga
References
Ara h 1 (conarachin) 63 7S globulin (vicilin) 23 35-95 [69-72]
Ara h 2 (conglutin) 17-19 2S albumin (conglutin) 10 75-100 [73-77]
Ara h 3/4 (arachin) 60* 11S globulin (glycinin/legumin) 8 20-77 [51,62,63]
Ara h 5 (class II) 15 G-actin-binding (profilin) 8 9-18 [64,78]
Ara h 6 15 2S albumin (conglutin) no linear 38-92 [66,76,79-81]
Ara h 7 16-17 2S albumin (conglutin) nd 43 [66,82,83]
Ara h 8 (class II) 16 PR-10 (like Bet v 1) nd minor [67,68]
Ara h 9 9-10 LTP nd minor [84,85]
Ara h 10 16 oleosin nd minor [86]
Ara h 11 14 oleosin nd minor [86]
aPrecentage of total peanut-allergic patients sensitized to allergen; LTP: lipid transfer protein; PR: pathogenesis-
related; nd: not determined; minor: less than 50% of the peanut allergic patients have IgE in their serum that binds 
to this allergen. *Ara h 3 consists of an acidic and basic polypeptide of 45 and 23 kDa, respectively, linked together 
by disulphide bonds.
Ara h 9 is a non-specific lipid transfer protein, of which the two known isoforms (Ara h 
9.0101 and Ara h 9.0201) share 90% sequence identity. Sensitization in most cases is probably 
due to primary sensitization to peach or other LTP-containing fruits, seen mostly in Mediter-
ranean countries, and is often associated with systemic and more severe reactions next to 
OAS. Ara h 9 is a minor allergen in non-Mediterranean subjects, while it is a major allergen in 
peanut-allergic patients from the Mediterranean area. The frequency of sensitization to the 
classic major peanut allergens Ara h 1, Ara h 2, and Ara h 3 in these patients is low [84,85].
Ara h 10 and 11, both oleosins, were described as candidate minor allergens from peanut, 
but their clinical relevance across Europe is not yet known [86].
Ara h 1 
Ara h 1, also known as conarachin is a vicilin-like seed storage 7S globulin. 7S globulins consist 
of glycoproteins that are post-translationally N-glycosylated during their processing along the 
endoplasmic reticulum and the Golgi apparatus before they accumulate into the protein bod-
ies of the ripening seeds [87]. Mature 7S globulins typically comprise of 50 to 60 kDa subunits 
assembled into trimeric proteins of about 150 to 190 kDa.
Ara h 1 was described as a 63.5 kDa protein, that occurs naturally in trimeric form (Fig. 
6a) of approximately 180 kDa, that often aggregates forming multimers of up to 600-700 kDa 
[69,71,72]. It consists of 31% α-helices, 36% β-structures and 33% random coil and contains 23 
linear IgE epitopes. The majority of the epitopes are located in the areas of the subunit-subunit 
contacts that are protected from protease degradation [57,70,88] (Fig. 6b).
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Fig. 6. (a) Ribbon diagram showing the back face of the Ara h 1 homotrimer. Strands of β-sheet and stretches of 
α-helix are coloured green and red, respectively. Coil structures and loops are coloured light grey (Adapted from 
[54]). (b) Space filling model of Ara h 1 tertiary structure. The red areas represent the IgE binding epitopes, and the 
yellow atoms are the residues that were determined to be critical for IgE binding to occur. The majority of the Ara 
h1 IgE binding epitopes are clustered in two regions of the allergen, near the areas of monomer-monomer contact 
(Adapted from [71]).
Ara h 2/6/7
The abundant peanut 2S albumins Ara h 2 and Ara h 6 and the low-abundant Ara h 7 are mem-
bers of the prolamin superfamily that share a characteristic cysteine skeleton with at least 8 
conserved cysteine residues [83,89]. 2S albumins share a common three-dimensional structure 
made of 5 α-helices arranged in a right-handed super helix and connected by more or less ex-
tended loops. This conformation is maintained by 4 or 5 disulphide bridges for Ara h 2 and Ara 
h 6, respectively, and makes the protein structure stable to, for example, thermal processing 
and proteolysis [90-93].
Ara h 2, 6 and 7 comprise several isoforms of Mr 17 kDa [74,75,93], 15 kDa [79,81,93] 
and 16-17 kDa [83], respectively. Produced as a single chain precursor they are proteolytically 
processed in peanut seeds resulting in two subunits linked by intramolecular disulphide bonds 
[79,89]. Ara h 2 has been found to act as a weak trypsin inhibitor, that protects Ara h 1 from 
degradation by trypsin [94]. In addition, the low abundance of Ara h 7, might indicate a func-
tion of Ara h 7 as a novel form of trypsin or amylase inhibitors [83].
Between 75 and 100% of the peanut-allergic patients is sensitised to Ara h 2 [73,74,76,77]. 
Ara h 6 has also been identified as a major peanut allergen [76,79-81] whilst the allergenic pea-
nut 2S albumin, Ara h 7 was recognised by 40-43% of peanut allergic sera [82] and has recently 
a b
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been confirmed as a low abundance allergen in peanuts [66,83]. Ara h 6 and, to a lesser extent, 
Ara h 7 are homologous to Ara h 2 and show 59 and 35% of amino acid sequence identity, re-
spectively [78] which may explain the high amount of cross-reactivity observed between these 
allergens.
Fig. 7. (a) Ribbon diagram showing the Ara h 2 monomer. Ara h 2 differs from other 2S albumins by two additional 
loops located at the N- and C-terminal ends of the polypeptide chain, respectively (indicated by stars) (b) Space 
filling model of Ara h 2 tertiary structure. Coloured areas represent the areas occupied by 3 of 10 linear IgE binding 
epitopes; N-termini are oriented left (Adapted from [90]).
Cross-reactivity of peanut proteins
A cross-reaction occurs when epitopes on different allergens are structurally alike, so that an 
IgE antibody directed against one allergen also binds with other allergens. The degree of cross-
reactivity depends among others on the extent of protein homology [95]. A high level of overall 
sequence homology is likely to result in IgE-binding epitopes that are of high sequence similar-
ity, leading to cross-reactive IgE antibody interactions [96,97].
Cross-reactivity of peanut and tree nut allergens could contribute to the high incidence 
of tree nut sensitisation in peanut allergic individuals. Sera of peanut-allergic patients that 
strongly interact with Ara h 1 were shown to often react with the corresponding vicilin aller-
gens (Cor a 11, Ana o 1, Jug r 2) from tree nuts, with Gly m 5 (ß-conglycinin) from soy and with 
Pis s 1 from pea [87,98]. Sequence homology of 7S globulins from hazelnut (Cor a 11), soy (Gly 
m 5) and pea (Pis s 1) to peanut 7S (Ara h 1) are 33-34%, 40-49% and 43-52%, respectively [99].
In addition, Ara h 2 shares common IgE-binding epitopes with almond and Brazil nut aller-
gens [97], and Ara h 3 to soybean, pea and tree nut glycinins. The glycinins in Ara h 3, soybean, 
and pea have a sequence similarity of 62% to 72% [100,101]. The PR-10 protein from peanut, 
Ara h 8, shows cross-reactivity to lupine and Gly m 4 from soybean and allergy to these proteins 
is likely due to primary sensitization to birch [102,103]. Ara h 9 is a lipid transfer protein (LTP) 
protein and sensitization in most cases is probably due to primary sensitization to peach or 
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other LTP-containing fruits and is most common in southern Europe [62].
Besides the serological aspect of the cross-reactivity between peanut, tree nuts, soy and 
lupin, not all cross-reactive antibodies give rise to clinical food allergy [104]. Usually, IgE re-
acts with higher affinity with the homologous epitope used for raising the antibody than with 
cross-reacting epitopes [42]. Clinically irrelevant positive in vitro test results may arise from 
low affinity cross-reacting IgE and therefore serological cross-reactivity is always broader than 
clinical cross-reactivity. The clinical relevance of cross-reacting IgE in allergic individuals still re-
mains a puzzling question. Studying serological cross-reactivity by inhibition assays can reveal 
which allergen source causes sensitization, although it will not reveal which food will and which 
food will not give rise to clinical allergy [104]. Furthermore, it was shown that peanut cross-
reacting allergens from lupine might have a higher clinical relevance compared with peanut 
cross-reacting allergens from other legumes [105]. Cross-reacting carbohydrate determinants 
(CCDs) or glyco-epitopes on structurally related vicilin allergens could also be seen as an addi-
tional source of clinically irrelevant cross-reactivity [106,107], and could result in false-positive 
specific IgE tests. In addition, patterns of cross-reactivity differ greatly from one patient to 
another [103]. 
In conclusion, cross-reactivity of peanut allergens to homologues proteins is common. 
However, as serological cross-reactivity could be clinically irrelevant, attention should be paid 
when evaluating IgE profiles in patients.
Diagnosis of allergy and component resolved diagnosis (CRD)
The diagnosis of food allergy can often be made or eliminated with a focused history and physi-
cal examination. If the medical history does not clearly reveal an association between a sus-
pected food and the patient’s symptoms or if it fails to identify a specific food, a diet diary may 
be useful. Rather than disclosing unrecognized food allergy, diet diaries often rule out allergy 
by revealing ingestions of the suspected food that are clearly not associated with clinical symp-
toms. To date, the best available test to diagnose food allergy is the double-blind, placebo-
controlled food challenge (DBPCFC), which is regarded as the gold standard for food allergy 
diagnosis. In a DBPCFC a patient is challenged with incrementing amounts of the suspected al-
lergenic food (verum) and with a placebo food. The verum and placebo challenges are conduct-
ed in random order and the verum is disguised (blinded) in a test food matrix. Both the patient 
and the physician are blinded for the sequence of the challenges. Purposes of the DBPCFC are 
to diagnose (the persistence of) a food allergy, to determine thresholds in food allergic patients 
and to gain scientific knowledge and data on food allergy. Even though the DBPCFC is the gold 
standard to diagnose a food allergy, it is conducted only in a limited number of centres. Reason 
are that the test is expensive, time-consuming, labour intensive and it also carries some risks 
on severe allergic reactions during the challenge. The use of standardized and validated pro-
tocols is important to perform a proper DBPCFC. Therefore specialized centres are needed to 
perform such tests and routine use in normal clinical settings is generally not possible. Studies 
are needed to develop these standardized protocols and more validated recipes, a.o. with a 
higher top dose than have been validated to date [108]. In addition, the added diagnostic value 
of the DBPCFC as compared to open food challenge tests is still under debate [109].
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Sensitisation can be diagnosed in vivo by different skin tests and in vitro by different se-
rum or plasma tests. The most commonly used skin test is the skin prick test (SPT) using food 
extracts and is a very sensitive test; however, it merely indicates if the patient has been sen-
sitized to a particular food or not. There are many assays that can quantitatively measure cir-
culating allergen-specific IgE antibodies in serum. Most common in clinical routine diagnostics 
worldwide are the ImmunoCAP system (Phadia AB, Uppsala, Sweden) and the Immulite system 
(Siemens Healthcare Diagnostics, Berlin, Germany). The ImmunoCAP is a capsule with a solid 
phase of a cellulose derivative to which allergens are covalently bound, while the Immulite 
system uses a biotinylated allergen that is bound to an avidin solid phase. IgE antibodies that 
react with the sample are detected by enzyme-labelled anti-IgE and a WHO reference standard 
for human IgE (0.35-100 kU/L) is used as a standard [110]. The different methods for diagnosis 
are still largely based on the use of natural total protein extracts of food products. The major 
disadvantages of such extracts are that these are difficult to standardize, do not allow the 
precise identification of the specific disease-eliciting allergens, and have, in some cases, been 
demonstrated to be contaminated with allergens from other sources. Well-known examples 
of components that could be present in the extracts and which can bind IgE, but have mostly 
no clinical relevance, are cross-reactive carbohydrate determinants and, to some extent, ho-
mologous cross-reactive proteins. In addition, also false-positive tests could result from testing 
extracts in which the disease-eliciting allergen is not present at all, or not present in a high 
enough quality or quantity to result in a positive test. Spiking of extracts with recombinant al-
lergens could therefore be used to increase test sensitivity.
Single recombinant allergens or cocktails of a few defined recombinant allergens can be 
used in allergy diagnosis to determine a patient’s individual reactivity profile, e.g. for identifi-
cation of the initial sensitising allergen. Subsequently, a more appropriate form of treatment 
may be chosen for the individual patient as certain marker allergens could differentiate pa-
tients at risk for developing severe food allergic symptoms and patients experiencing rather 
mild symptoms. For this reason, such a procedure is called, component-resolved diagnosis or 
CRD. In addition, CRD-research will provide information on sensitization patterns in patient 
groups, e.g. due to geographical differences or dietary habits as recently observed for CRD of 
hazelnut allergy [111]. However, the specificity of the test should be investigated as well as IgE 
reactivity. Allergens used for CRD are mostly recombinant allergens, and thus consist of only 1 
isoform, while purified native allergens often consist of a mixture of isoforms. The advantage 
of using recombinant allergens is that it enables production of standardized allergen prepara-
tions. However, different isoforms could differ in their allergenicity. Therefore testing for one 
recombinant isoform might biologically be less relevant then testing the native, purified al-
lergen, consisting of a mixture of all isoforms. Recently, microarray chip technology has been 
introduced which makes it possible to test a large number of allergens with just a small amount 
of serum sample. This test is commercialized and available as the Immuno Solid-phase Aller-
gen CHIP (ImmunoCAP ISAC, VBC Genomics-Phadia) It currently has 103 native/recombinant 
component allergens from 43 allergen sources [110]. It is important to note that, although the 
likelihood of clinical reactivity increases with increasing levels of food-specific IgE, the actual 
level often has no correlation with the severity of the reaction [112]. It will also be a new chal-
lenge for professionals involved in the care of allergic patients to properly interpret test results; 
clinicians should know about the basics of allergen components, their clinical implications and 
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should always keep in mind that sensitization does not necessarily imply a clinical allergy.
Research on CRD has increased enormously over the last years. A research from the UK 
including 8-year old children estimated the prevalence of clinical peanut allergy among sensi-
tized subjects as 22.4%, while Ara h 2 was shown to be the most important predictor in clinical 
allergy [33]. In a population-based study, 87% of children sensitized to Ara h 1, 2 or 3 but not 
Ara h 8 reported symptoms after peanut intake, while of the Ara h 8 mono-sensitized persons, 
only 17% reported symptoms. Ara h 8 is a heat-labile protein and cooked food is therefore of-
ten tolerated. IgE analysis to peanut allergen components may be used to distinguish between 
peanut-sensitized individuals at risk of severe symptoms and those likely to have milder or no 
symptoms to peanut if sensitized to pollen allergens and their peanut homologue allergens 
[113].
In addition, also research on the use of recombinant peanut allergens for CRD to predict 
severity of the allergic symptoms has been increased over the last years. Sera from individuals 
with a history of severe peanut allergy, were shown to recognize more Ara h 1, Ara h 2- and 
Ara h 3-epitopes than sera from individuals with milder symptoms [114]. This was confirmed 
by a study that showed a correlation between the clinical sensitivity and the height of the 
polyclonal IgE response, presented by the number of epitopes recognized. No specific epitopes 
were associated with severe reactions to peanut [115].
Even though the DBPCFC is still regarded as the gold standard, in vitro diagnostic methods 
such as CRD could give further insight in the diagnosis and treatment of food allergy. Both CRD 
by measuring specific IgE using the ImmunoCAP/Immulite, as well as by microarray chip tech-
nology will be subject of further research.
Determination of allergenicity of food proteins
Antigenicity, which is a chemical property describing the ability of an epitope to react with an 
antibody, must be distinguished from its immunogenicity or ability of the protein to induce 
antibodies in a competent vertebrate host. Immunogenicity is therefore a biological property 
and depends on extrinsic factors such as the host immunoglobulin repertoire and self-toler-
ance, the induction of cytokines as well as cellular and regulatory mechanisms of the immune 
system. A peptide fragment showing antibody-binding, is not necessarily also able to elicit 
antibodies that cross-react with the protein fragment [42]. To a clinical allergist, allergenicity 
reflects the capacity of an allergen to induce symptoms or a skin reaction, whereas to an im-
munologist, it reflects either a peculiar type of immunogenicity (ie, the capacity of a protein to 
induce IgE antibodies) or simply the capacity to bind IgE antibodies [116]. In this dissertation 
we will mainly refer to immunoreactivity as the capacity of an allergen to bind IgE antibodies 
and to allergenicity as the capacity to cross-link IgE and thereby release mediators from baso-
philic granulocytes. In this thesis we did not study the capacity of proteins to sensitize and thus 
the capacity to induce IgE antibodies.
IgE binding
To assess the allergenicity of allergens, IgE binding studies are usually performed using meth-
ods such as enzyme immunoassays or immunoblotting. In those studies, sera from individu-
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als with a known allergy that will contain allergen-specific IgE antibodies are determined by 
binding to a solid phase-bound allergen. These assays have a few drawbacks. Interactions with 
other competitors such as specific IgG antibodies may impair the binding to IgE antibodies, and 
binding the allergens to a plate could change the folding and thus the structure of the proteins 
and could make certain epitopes unavailable for IgE binding. Both drawbacks could be solved 
by performing a reverse assay in which anti-IgE instead of the allergen is coated to the plate 
and a biotinylated allergen is used as tracer in solution. A reverse inhibition assay can be used 
to study the inhibition of the IgE binding to the allergens. Competition is conducted by adding 
increasing concentrations of the allergens as competitors at the same time as the allergen-trac-
er. Results can be expressed as B/B0, where B0 and B represent the amount of labelled allergen 
bound to the immobilized IgE antibodies in the absence or presence of a known concentration 
of inhibitor, respectively. Calculated IC50 values correspond to the concentrations of competi-
tor that inhibit 50% of the IgE binding to the labelled allergen [117].
A drawback of all IgE binding assays in general is that they detect only the binding capacity 
of the allergen to IgE and do not determine whether the allergen can cause cross-linking of 
FcεR1 bound IgE antibodies on a basophil or mast cell. This is crucial since such interactions 
determine the ability of proteins to trigger degranulation of effector cells, resulting in mediator 
release and finally in clinical manifestations of the allergic reaction. More than one epitope or 
IgE binding site is required to cause IgE cross-linking and an allergen with a single IgE binding 
site must be bound or cross-linked to another molecule with another or similar IgE binding site 
in order to cause histamine release. Therefore, the biological activity of proteins cannot be as-
sessed by IgE binding tests such as an ELISA alone, and cellular assays, in which cross-linking 
is required to provoke a response, are needed for the proper determination of the elicitation 
potential of allergens.
In vitro cellular tests such as histamine release tests using autologous or passively sensi-
tized heterologous human basophils, or the cellular allergen stimulation tests (CAST) measur-
ing sulfidoleukotriene release from basophils, can assess the ability of proteins (allergens) to 
degranulate basophils from human blood. An alternative readout of allergenic activity is to 
analyse upregulation of the basophil-specific activation markers CD63 or CD203c by flow cy-
tometry, which is called the basophil activation test (BAT). BAT and CAST assess the biological 
function of the observed IgE reactivity, this in contrast to serological assays which solely indi-
cate sensitization rather than clinically relevant IgE reactivity resulting in food allergy. Examples 
where BAT and CAST are used in the diagnostic process of several IgE-mediated allergies are 
classical inhalant allergies (directed against house dust mite, cat epithelium, and pollen), hy-
menoptera venom allergy, natural rubber latex allergy, primary and secondary food allergies, 
drugs, NSAID hypersensitivity and component-resolved diagnosis [118]. The BAT and the CAST 
may complete the conventional SPT and specific IgE levels to discriminate between clinically 
relevant food-specific IgE vs. irrelevant IgE responses.
In vitro functional tests with a heterologous rat basophil cell line that is stably transfected 
with the genes of the human FceRI could be used instead of donor-derived basophils that have 
to be freshly analysed to study the biological activity of purified proteins or to study the effect 
of processing or digestion on their allergenic potential. Elicitation of an allergic reaction upon 
allergen exposure in recently developed animal models can be used to assess the potential 
of such an allergen to elicit clinical manifestations in already sensitised individuals (elicitation 
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potential). A comprehensive and complete overview on in vivo and in vitro techniques to deter-
mine the biological activity of food allergens can be found in the review of Poulsen [119] and 
more recently immunological techniques have been described by Sancho et al. [120]. A recent 
review extensively discussed physicochemical and immunological techniques to characterize 
plant food allergens [121].
Besides assessing IgE binding and cross-linking of allergens, another informative aspect is 
to determine T-cell mediated immune reactions. To assess whether the processed or digested 
food protein is still able to activate CD4+ helper T cells and skew the responding cells towards a 
Th2 like profile, T-cell polarisation assays can be used. Some treatments (such as cooking or in 
vitro digestion) could have a different effect on IgE binding and cross-linking compared to T-cell 
mediated immune responses [122,123], which makes it interesting to perform both types of 
assay. Below, basophil assays (basophil histamine release tests and the mediator release assay 
using RBL cells) and T-cell assays will be discussed more in detail.
IgE cross-linking using mediator release assays
Basophil Histamine Release test (BHR)
The principle of the basophil histamine release test is to challenge isolated and sensitized ba-
sophils with an allergen which will cross-link surface-bound specific IgE antibodies causing his-
tamine to be released from the cells. Distinct properties of the IgE repertoire, such as total and 
allergen-specific IgE antibody concentration, IgE affinity, and IgE clonality, are all correlated 
with the extent of effector cell degranulation [124]. Histamine can be measured fluorometri-
cally after coupling to a fluorophore (O-phthaldialdehyde), immunochemically (by the Immu-
notech Radioimmunoassay) or by performing an automated fluorometric histamine assay. In 
one application of the histamine release method, glass-fibre coated microtiter plates are used 
for separation of histamine from other constituents of the assay. Histamine content is deter-
mined and a dose–response curve can be constructed and be compared with an appropriate 
standard. The amount of released histamine can also be expressed as a percentage of total his-
tamine content of non-challenged cells using detergent-induced release. Furthermore, besides 
using blood from sensitized patients, a passive sensitization method can be applied. Basophils 
from a non-sensitized person are used, the receptor-bound IgE which is natively present is 
stripped from the surface of the donor basophils, and the cells are subsequently passively 
sensitized with human serum containing specific and relevant IgE-antibodies [119,125-127].
Despite the widespread use, the above described methods suffer from some drawbacks. 
Basophils are present in blood in low numbers (less than 1% of leukocytes equalling 0.01 – 0.2 
x 109/L ), and they are difficult to purify [128]. Furthermore, fresh blood cells from specific 
allergic donors or non-allergic donors in case of passive sensitization, are needed for each 
experiment and it requires processing of blood samples immediately after collection, which 
may present logistical obstacles. Another drawback is that around 10% of basophil donors have 
non-responsive basophils [129,130] which makes the test less reliable in assessing the level of 
individual responsiveness. An option to overcome these problems is by using a stable cell line 
which can be passively sensitised with serum IgE from allergic individuals.
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Mediator release assay using RBL cells
The RBL assay which mimics the mechanism of a type 1 allergic reaction [131] uses trans-
fected rat basophilic leukaemia (RBL) cells that recombinantly express the human FcεR1 re-
ceptor [132-137]. These cells bind human IgE antibodies and have all functional properties 
of mast cells and basophils. β-hexosaminidase, which is present in the granules and released 
together with histamine, has been chosen as a surrogate marker for histamine release. The 
added substrate is hydrolysed by this active enzyme, resulting in a coloured product that can be 
measured in a spectrophotometer. A microscopic picture of RBL cells in culture and a simplified 
graph of the histamine release test are depicted in Fig. 8.
 
Fig. 8. (a) Microscopic picture of RBL-cells in a culture flask. Cells are not confluent yet, therefore some cells are 
still stretched. Furthermore it can be observed that the cells grow in layers (b) Simplified graph of the histamine 
release test using glass-fibre coated microtiter plates (Adapted from: Roitt, Brostoff & Male, Immunology (5th edn) 
Mosby, Londen 1998, p.301).
The mediator release assay allows, among others, the measurement of the biological activ-
ity (or potency) of allergens, the detection of allergens in various samples and the analysis of 
cross-reactivities between allergens. A useful indicator of the allergenic potency of allergens is 
the dose needed to efficiently induce cell degranulation and values corresponding to the dose 
of allergen that induced 50% of the maximum release (EC50 values). A limitation of this cell-
based test is that in general only sera with higher percentages of allergen-specific versus total 
IgE can be used. It was found that, for sera from peanut allergic patients, the most effective 
sera had at least 50 kU/L of total IgE and 15 kU/L of peanut-specific IgE and contained >10% 
peanut-specific IgE [132]. Furthermore, the number of FcεRI on the transfected RBL cell-lines 
may be limiting. For example, RBL SX-38 cells have approximately 100,000 receptors/cell [138] 
versus 500,000 receptors/cell on basophils from atopic individuals [139]. Together, the low 
levels of specific IgE in the serum and low expression levels of FcεRI on the RBL cells may re-
sult in most of the IgE receptors being occupied with non-specific IgE antibodies. A number of 
serum factors, as well as the degree of severity of the allergic subjects clinical response have 
been suggested as important for inducing mediator release with these cell-lines [135]. A recent 
study showed that IgE affinity purification of sera increased the reproducibility and sensitivity 
of RBL SX-38 cells, which suggested that some factors in the serum may hamper the binding of 
IgE to the FcεRI [140].
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T-cell polarization assays
T-cell polarization assays are used to investigate T-cell mediated reactivity towards allergens 
and allergenic proteins. Allergic diseases result from an abnormal T-cell response to allergens 
dominated by long-lived Th2 cells [141]. Allergen-specific CD4+ Th2 cells secrete high amounts 
of IL- 4 and IL-13, which induce the production of allergen-specific IgE antibodies that mediate 
immediate allergic symptoms [124,142]. In addition to this indirect involvement in immediate 
reactions, allergen-specific Th2 cells have been demonstrated to be directly involved in clinical 
late-phase reactions in target organs such as the lung and skin [122,143].
Cytokine production
Activated (and differentiated) cells will produce a characteristic cytokine production profile. T 
cells of allergic individuals will typically produce IL-4, IL-5 and IL-13, which are signature Th2 
type cytokines. Cytokine production can be measured in several ways. Most often the cytokine 
production is measured in the supernatant of the cultured cells. Cytokine enzyme-linked im-
munoabsorbent assay (ELISA) or flow cytometric techniques like the multiplexed bead assay 
(Cytometric Bead Array Flex sets, BD Biosciences) are commonly used to detect cytokines from 
cell supernatant or serum. Real-time quantitative polymerase chain reaction (RT-qPCR) tech-
nique can be implemented to assess mRNA expression of the cytokines in T-cell fractions. How-
ever, these methods do not allow determining which proportion of the cells is responsible for 
the production of specific cytokines. Multiple staining using combinations of cell surface mark-
ers and staining for intracellular cytokines permit the assessment which type of cell produces 
what cytokines. This approach can give valuable extra information at the single-cell level. Op-
timizing experiments by assessing the optimal stimulation period for the different cytokines is 
important as each stimulus results in different kinetics and these kinetics are crucially different 
for the individual cytokines. For example, monocyte derived cytokines such as TNF-α and IL-1β 
were present in cell cultures already after 1 day of culture and amounts decreased significantly 
over time, while T-cell derived cytokines such as IL-5, IL-13 and IFN-γ showed a slower kinetics 
and were highest on day 7 of the culture [23].
Proliferation
This optimization is also important when measuring proliferation of cells. Proliferation of PBMC 
can be measured using different methods, such as incorporation of 3H-thymidine, staining with 
Ki-67 antibodies, loading with BrdU (5-bromo-2′-deoxyuridine), and CFSE (carboxyfluoresce-
in diacetate succinimidyl ester) staining, each provide slightly different information. The 3H-
thymidine and BrdU methods determines the S phase of the cell cycle activity by measuring 
the thymidine incorporation into newly synthesized DNA of replicating cells. The Ki-67 antigen 
however, is expressed in all active stages of the cell cycle (all phases except the G
0
 phase) and 
cells which are still in the G
1
 phase of the cell cycle will be detected by a Ki-67 staining and not 
by a 3H-thymidine incorporation assay or a BrdU assay. Upon cell division, the CFSE is covalently 
bound to free amine groups of intracellular macromolecules in the cell, is distributed uniformly 
between daughter cells. CFSE staining can be the method of choice especially when the rate 
of the divisions of the cells is studied and when working with a uniformly sized cell popula-
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tion (such as resting T or B lymphocytes). However, hPBMC consist of a non-homogeneous 
population of cells (not uniformly sized and therefore not uniformly stained) which can make 
it difficult to differentiate between undivided and divided cells. As a result, this could decrease 
the sensitivity of the test. Furthermore, care should be taken when using CFSE because of its 
toxicity for dividing cells and effect on the expression of activation markers, like CD69 and 
CD25. A disadvantage of 3H-thymidine incorporation is that it does not allow identification of 
the phenotype of the proliferating cells, as it can only measure bulk cell divisions, a limitation 
overcome by flow cytometry (Ki-67 and CFSE staining), which enables analysis at a single-cell 
level. The use of selected CD markers in the same staining will enable to specify the phenotype 
of proliferating cells. It is difficult to directly compare the methods as they use different detec-
tion techniques (flowcytometry using fluorochromes versus scintillation using radio-activity) 
and furthermore, they also give different types of information. Therefore, it is advisable to use 
the same method in all experiments to be able to compare results.
Stimuli
The frequency of an antigen-specific lymphocyte in the blood is in general low. The frequency 
of Bet v 1-specific CD4+ T cell was estimated to be in the range of 0.0001 to 0.001% of circulat-
ing CD4+ T cells outside the birch pollen season, for both allergic and non-allergic individuals 
and up to 0.1% of allergen-specific T cells for both groups during the pollen season. A sig-
nificant expansion of specific T cells occurred during exposure to seasonal allergens [144,145]. 
The frequency of antigen-specific T cells is observed to differ per allergen. The frequency of 
peanut-specific circulating CD4+ precursors was found to be 0.604±0.043% in peanut allergic 
patients and about 10 times lower in both non-allergic and peanut sensitized donors. Frequen-
cies of house dust mite-specific T cells in the blood of patients with atopic dermatitis varied 
between 0.002–0.026% [146]. As a result of the low frequency of antigen-specific T cells, an-
tigenic stimulation typically activates only a very small fraction of T cells. In mildly sensitized 
patients in particular, allergen-specific stimulation will reveal hardly any significant prolifera-
tion and cytokine synthesis. Therefore, amplification of the response by the use of polyclonal 
stimuli is often used. 
As a positive control, polyclonal stimuli can be used to assess the maximum stimulation 
capacity of the PBMC in vitro and thereby assess possible differences in the intrinsic immune 
responsiveness of antigen-specific cell cultures of different donors. Examples of mitogens are 
concanavalin A (ConA), phytohemaglutinin (PHA), phorbol myristate acetate (PMA) plus cal-
cium ionophore (Ca-I) and lipopolysaccharide (LPS). Each stimulus acts at different cell surface 
molecules or by direct activation of intracellular molecules and uses different signal transduc-
tion pathways to activate the cells. Anti (α)-CD3 and αCD28 have been widely used to pro-
vide all T cells with the required antigen-driven activation signals, and involves the TCR-CD3 
complex thereby mimicking antigen presentation. It is therefore the most physiological way 
of stimulating all T cells in a polyclonal fashion to assess the maximal stimulation capacities 
of the PBMC of the different donors. Microscopic pictures of unstimulated and αCD3/αCD28 
stimulated cells are depicted in Fig. 9. Furthermore, αCD3/αCD28 can also be used as in vitro 
polyclonal activation stimulus for T cells in long-period cultures to re-activate and increase the 
antigen-specific signal. A disadvantage is that also non-specific T cells that survived the long-
term culture will react upon polyclonal activation.
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Fig. 9. Microscopic picture of (a) unstimulated cells after 4 days of culture (b) αCD3αCD28 stimulated cells after 4 
days of culture. Cell clones are clearly visible after this stimulation condition.
Factors influencing allergenicity
More knowledge on the influence of food processing, digestion and the food matrix on aller-
genicity of individual allergens is important in diagnostic procedures, e.g for development of in 
vitro diagnostic tests and in particular when food challenges are part of the diagnostic process. 
In addition, more knowledge on processing of allergens could help in modulating the allergenic 
properties of foods and develop desensitisation strategies, all of which may potentially reduce 
the disease-burden for those affected. For more information see section ‘Prevalence of allergy 
and EuroPrevall’. 
However, as a result of its complex nature, the impact of food processing and the food 
matrix on allergenicity of proteins has only recently become a subject of research. Such inves-
tigations are fraught with difficulties, not least the fact that food processing often renders food 
proteins insoluble in the simple salt solutions frequently employed in serological or clinical 
studies. As a consequence, our understanding of the impact of food processing on allergenicity 
is limited to the more soluble and extractable residues in foods, and the allergenic potential of 
insoluble protein complexes is virtually unstudied despite representing the vast bulk of food 
proteins consumed [147].
Processing
Nowadays, foods are increasingly processed, which may serve a variety of purposes. These 
could include improving general food qualities such as flavour, texture, taste and colour; im-
proving food preservation and safety; enhancing suitability of food components for specific 
product applications; consumers convenience, pleasure and variety; and finally, to obtain or 
generate useful by-products and increase marketability of foods [148]. Frequently applied 
methods of food processing performed at home, in a restaurant or by the industry are peeling, 
cooking, frying, roasting, toasting, baking, cooling, freezing, drying, high pressure processing, 
sonication, sterilization and many other processing methods. 
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Food processing offers opportunities to alter the nature of epitopes of a protein, which 
is important for immune recognition by food component-specific antibodies. For example, 
three-dimensional epitope conformation may be modified as a result of protein denaturation 
treatments (e.g. various thermal processing treatments) leading to destruction or break up of 
epitopes and therefore leading to reduction in IgE binding capacity. However, denaturation 
treatments can also lead to generation of new epitopes, or to exposure of formerly hidden 
antigenic sites, resulting in an increase in IgE binding. Acid or enzyme hydrolysis of an allergenic 
protein may help to delete critical amino acids of an epitope. Whether caused by protein de-
naturation or hydrolysis, loss of epitope and ensuing loss of IgE binding may help to reduce the 
bioactivity of an allergen [148]. Different food processing methods may impact the allergenic 
potential of foods or proteins, but there is no general rule on how different allergenic foods or 
proteins respond to physical, chemical, or biochemical exposures during processing [149]. The 
effects of food processing may be governed by the molecular properties of an allergen and its 
interactions with food components.
Heating
Thermal processing is one of the most commonly used methods in food processing and effects 
of thermal processing on food protein allergenicity have therefore been reviewed in several 
recent articles [147,148,150-154]. Typically, loss of tertiary structure is followed by (revers-
ible) unfolding, loss of secondary structure (55–70°C), cleavage of disulphide bonds (70–80°C), 
formation of new intra-/inter-molecular interactions, rearrangements of disulphide bonds 
(80–90°C) and the formation of aggregates (90–100°C) [155]. These modifications reflect a pro-
gressive passage to a disorganized structure with denaturation of the proteins that adopt an 
unfolded, random-coil conformation. The denatured molecules associate to form aggregates 
and then gels resulting in a modification of the surface properties and an increase in size [154].
Some plant proteins such as the Bet v 1 homologues from apple and cherry are considered 
to (partially) lose their allergenic activity upon food processing. This is well reflected by the fact 
that thermally processed fruit and vegetable products often show non- or less severe effects 
towards patients than the corresponding fresh plant material [156]a recombinant major aller-
gen from peanut (Arachis hypogaea. Also Bohle et al. showed that in vivo ingestion of cooked 
foods containing birch pollen-related allergens did not induce OAS and that, in general, such 
foods can be consumed without difficulty because PR-10–like food proteins are easily dena-
tured by thermal processing. However, in vivo ingestion of these birch pollen-related allergen 
containing foods could cause atopic eczema to worsen. In a study it was shown that 60 minutes 
cooking of the different recombinant Bet v 1-related allergens completely abolished IgE bind-
ing, but no reduction of the capacity to activate allergen-specific T-cells was observed [122]. 
Other commonly plant-derived ingredients, such as soya isolates, often comprise 11S and 7S 
seed storage globulins, which are relatively thermostable. 7S globulins have their major ther-
mal transition at around 70–75°C, whilst 11S globulins unfold at temperatures above 94°C, as 
determined by differential scanning calorimetry. However, even upon heating to such tempera-
tures these proteins only appear to unfold partially, while undergoing only minor conforma-
tional changes that suggest that the β-barrel motif, characteristic of these proteins, is a highly 
stable structure [147,157].
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Maillard reaction
One of the most important chemical modifications occurring in foods during thermal pro-
cessing is the Maillard reaction, which involves the reaction of free amino groups on proteins 
(generally lysine residues) with reducing sugars. The extent of glycation depends on different 
environmental conditions such as temperature, pH, water activity, duration of the heating and 
the concentration of the reducing sugars present [158]. The Maillard reaction may play a pos-
sible role in the allergenicity of foods as shown in several studies [156,159-166]. As mentioned 
before, the impact of processing methods may be different from food to food or protein to 
protein. Depending on the studied protein or food and the processing method applied, heat-
ing may have no effect or it may decrease or increase allergenicity. The existence of sequential 
and conformational epitopes, the demasking of new epitopes or the modification of epitopes 
through Maillard reactions can explain some of the results reported in the literature. 
The type of allergen, type of food structure, and type of thermal processing may be of great 
importance when studying the impact of processing on food allergenicity. However, lack of 
knowledge on the influence of processing of different allergens and in different matrices makes 
it still difficult to predict the allergenicity of foods and provide allergic patients with appropri-
ate advice on what is safe to consume [151].
Digestion
Due to the very acidic conditions in the stomach and the intense proteolysis occurring in the 
stomach and intestine, only small amounts of intact or immunologically active proteins are 
taken up by the gut mucosa. This suggested that food allergens are, at least partially, resistant 
to gastro-duodenal digestion in order to be able to sensitize the mucosal immune system. Sus-
ceptibility to digestion has therefore been considered an important biomarker for food allergy, 
the idea being that proteins or at least peptides of a few kDa that survive digestion are more 
likely to be allergens. Whilst this idea has some appeal, the evidence is rather equivocal; show-
ing that peptide fragments of various sizes, produced during the digestion of a protein can 
still be immunologically active [167]. Furthermore, it is shown that some food allergens are 
rapidly and extensively degraded during digestion, whereas some other food proteins that are 
resistant to digestion are not allergenic. It is also noteworthy that a pregastric absorption also 
occurs, i.e. in the oral cavity, which explains the occurrence of symptoms few minutes after 
ingestion of food allergens [168].
Furthermore, even though the immune system is mostly exposed to digested proteins, it is 
to a lesser extent also exposed to intact allergens. It is assumed that a small fraction of intact 
dietary proteins are absorbed from the mature gut [169-172], thus leaving the option open 
that undigested proteins play a role in the allergic sensitisation process. A review on intestinal 
barrier function also summarized evidence from studies demonstrating that intestinal barrier 
dysfunction leading to increased intestinal permeability and exposure to intact proteins which 
in turn might promote sensitization and enhance the severity of food induced allergic reactions 
[173]. In addition, it has been widely documented both in humans and in animal models, that 
an increase in gastric pH (e.g. caused by antacid therapies) impedes the gastric protein diges-
tion [174] and presumably facilitates the presentation of food peptides to intestinal T cells.
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Few detailed reports have addressed the effects of matrices on allergenicity. Grimshaw et al. 
demonstrated a profound impact of the fat content of chocolate, in which peanut allergen was 
embedded, on both the clinical reactions and on the recognition of peanut allergen in ELISA-
testing. Higher fat contents resulted in a lower ELISA-detection of the peanut and a larger 
dose of peanut protein was needed in the food challenge to cause a clinical reaction, but the 
reaction was more severe. It was suggested that the allergenic epitopes are concealed by the 
relatively high-fat food matrix, and are detected only after digestion of the fat. The allergens 
are thus released and absorbed more slowly than they were in a lower-fat matrix. This slower 
absorption may explain why the subjects did not experience the oral warning symptoms pre-
ceding the more severe symptoms. This research indicated the importance of the fat content 
of provocation recipes, because it can influence the clinical reaction of the provoked person 
[175].
Non-enzymatically active food matrix components, such as fats, may affect allergo-reactivi-
ty of proteins. Effects of other matrix components are also obvious, such as raw-material borne 
proteolytic [176] and oxidative enzymes [160,177,178]. During in-plant maturation of the pea-
nut allergen Ara h 1, for instance, an immunologically active N-terminal peptide is cleaved off 
[176]. For allergens belonging to the PR-10 family and the 2S-albumin family, treatment with 
polyphenol oxidases and/or with peroxidases decreases their IgE-reactivity, and both enzymes 
are ubiquitously present in plant material [160,177,178]. The mechanism that underlies these 
activities is as yet not fully clear; but both allergen cross-linking, or binding of phenolics to the 
allergens might be involved. 
It can be concluded that food processing, digestion and the food matrix affect food al-
lergenicity, and the magnitude of these effects can be examined by combining various assays.
Immunomodulation by lactic acid bacteria
Treatment and prevention of allergies
Currently, management of food allergies consists of educating the patient to avoid ingesting 
the responsible allergen and to initiate therapy (e.g. with injected epinephrine for anaphylaxis) 
in case of an unintended ingestion [28]. At the present time there is no curative therapy avail-
able once peanut or tree nut allergy has been established. However, several approaches are 
studied to decrease both the number of allergies and the severity of the allergic reactions.
One approach to mitigate the allergic symptoms is via modulation of the allergen itself by 
removing or diminishing the allergenic properties of a protein, e.g. in such a way that the IgE 
binding epitopes are eliminated or reduced, or reducing the size of the protein so that FcεR1 
cannot longer be cross-linked, which could result in the production of hypoallergenic foods. 
Examples are elimination of the apple allergen Mal d 1 by RNA interference [179], transgene-
induced silencing of allergens in soy [180] and peanut [181] and hypoallergenic, transgenic 
tomato fruits [182]. Another approach is traditional breeding as seen for the putatively hypoal-
lergenic Santana apple cultivar [183,184]. However it should always be kept in mind that a pro-
posed hypoallergen could still be allergenic for individual patients. In addition, hypoallergens 
could also be helpful to improve allergen immunotherapy (see below) as recently proposed for 
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hypoallergenic rBet v 1 derivatives for birch pollen immunotherapy [185], and for a hypoaller-
genic Fel d 1 variant which might be a promising candidate for application in immunotherapy 
of cat allergy [186]. These hypoallergens will have reduced allergenic capacity, but retained 
T-cell reactivity and thus immunogenicity. A phase I clinical safety study using modified peanut 
allergens is currently enrolling adult subjects with peanut allergy. In addition, modified food 
allergens can be combined with bacterial adjuvants (eg, heat-killed Listeria moncytogenes or 
heat killed Eschrichia coli) to enhance the Th1-skewing effect and decrease the Th2-skewing 
effect. In future studies, probiotic bacteria might also be used as bacterial adjuvants to avoid 
the concerns of excessive Th1 stimulation by killed pathogenic bacteria [187,188].
The most commonly studied therapeutic strategy to decrease both the number of aller-
gies and the severity of allergic reactions and that has already been studied for 100 years is 
the use of allergen-specific immunotherapy as a desensitizing therapy for allergic diseases. 
Immunotherapy (IT) is now implemented for seasonal pollen allergy, bee and wasp stings, and 
mite allergy. However, in the case of food allergies, further studies are required to establish 
the safety and efficacy of this approach and to define proper dose and length of treatment and 
duration of the treatment effect. Until now, this therapy in peanut-allergic subjects led to an 
unacceptable high rate of adverse reactions and experts in this field suggest that formal guide-
lines need to be established before use in a clinical setting [189-191]. A first study on sublingual 
immunotherapy (SLIT) treatment of peanut allergy in children showed primarily oropharyngeal 
side effects during dosing and could safely induce clinical desensitization in these children. 
Even though SLIT could possibly be a safer approach, larger studies are needed (now on-going: 
ClinicalTrials.gov no. NCT00580606) and long-term effects of continued peanut SLIT should be 
determined [192].
Several mechanisms of IT are proposed, e.g. the reduction of allergen-specific IgE produc-
tion, the increase of the production of allergen-specific IgG, which can act as “blocking antibod-
ies” and the reduction of allergen-specific inflammation in target organs. Other mechanisms 
could depend on modification of the phenotype of allergen-specific Th cells, e.g. stimulation 
of Th0/Th1 lymphocytes, rather than Th2 cells, and induction of Treg cells, which produce cy-
tokines such as IL-10 and TGF-β. It remains unclear to what extent either altered memory T-cell 
responses, altered B-cell responses, or both are responsible for the long-lived antigen-specific 
tolerance that characterizes successful allergen immunotherapy [193,194]. In addition, the 
mechanism may differ depending on the allergen (bee and wasp venoms or inhalant allergens) 
and the route of immunisation [195]. Other therapies being evaluated to treat or prevent food 
allergy are anti-IgE monoclonal antibodies (e.g. omalizumab), vaccines using modified proteins 
or overlapping peptides (tested in murine models), conjugation of immune stimulatory se-
quences to allergen, plasmid DNA encoded vaccines and cytokines/anti-cytokine treatment 
[28,196]. A comprehensive and extensive review on future therapies for food allergies written 
by Nowak-Węgrzyn and Sampson is published recently [188].
Another approach and recent topic of interest is the use of food supplements, such as ß-
glucans, fungal immunomodulatory proteins and pro- and prebiotics, which could modulate 
the immune system and thereby suppress the allergic symptoms. The skewing of cytokine pro-
files from Th2 to Th1 is an often observed response to these food components [197]. Immune 
regulation and the microbiota in the intestine, the hygiene hypothesis and the mechanism and 
the use of probiotic bacteria to prevent or treat allergies is discussed below.
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Immune regulation and the microbiota in the intestine
Epithelial cells in the gut (enteroendocrine cells, mucus producing goblet cells and enterocytes) 
express in a similar manner to immune cells, pattern recognition receptors (PRRs) to sense the 
presence of microbe-associated molecular patterns (MAMPs). These PRRs can be divided into 
three families: Toll-like receptors (TLR), nucleotide oligomerisation domain(NOD)-like recep-
tors (NLRs) and retinoic acid inducible gen I (RIG-I)-like receptors (RLR). These receptors acti-
vate signalling cascades that finely tune epithelial cell production of antimicrobial products like 
secretory IgA and secretion of a diversity of cytokines and chemokines (such as IL-6, IL-8, IL-1β, 
IL-7, IL-15 and CCL20), depending on the signals that are delivered by the microbes. 
TLRs, which are the best characterized PRRs, are type I transmembrane proteins with ecto-
domains containing leucine-rich repeats that mediate the recognition of MAMPs; transmem-
brane domains; and intracellular Toll–interleukin 1 (IL-1) receptor (TIR) domains required for 
downstream signal transduction. So far, 10 functional TLRs, TLR1-TLR10, have been identified 
in humans [198]. Each TLR family member is endowed with the ability to recognise a distinct 
class of conserved MAMPs. With respect to microbial recognition, TLR 1, 2, 4, 5, 6, and 9 signal 
via binding to common bacterial structures whereas TLR 3, 7 and 8 are aimed primarily at viral 
detection [199]. Microbe–epithelial interactions do not necessarily involve intact bacteria be-
cause diffusible compounds released from live or dead bacterial cells could also interact with 
the cognate PRR of the host. TLR and NLR can trigger expression of a surprising diversity of 
chemokines, cytokines, and effectors of innate immunity [200].
Epithelial cells can also recruit leukocytes to complement their barrier function or to partic-
ipate in the activation of gut adaptive immune responses. The gut immune system is composed 
of the gut-associated lymphoid tissue (GALT), such as the Peyer’s patches and small intestinal 
lymphoid tissue (SILT) in the small intestine, lymphoid aggregates in the large intestine, and 
diffusely spread lymphoid cells and plasma cells in the lamina propria of the gut. These im-
mune cells are in contact with the rest of the immune system via local mesenteric lymph nodes 
(MLN). Even though the development of the GALT is initiated before birth, GALT maturation 
and recruitment of IgA-secreting plasma cells and activated T cells to mucosal sites only occurs 
after birth and is strictly dependent on microbiota-derived signals. These signals influence the 
crosstalk between epithelial cells and gut dendritic cells (DCs), thereby modulating the nature 
and intensity of intestinal B and T cell responses. It is increasingly clear how these adaptive im-
mune elements cooperate with innate immune cells to strengthen the gut barrier and protect 
the host from invading pathogens [201].
The intestine is an open ecological system that is colonized immediately after birth by a mi-
crobial population that reaches an impressive amount of ~1 x 1014 commensal bacteria [202], 
70-80% of which cannot yet be cultured [203]. In addition, each individual harbours at least 
160 different prevalent bacterial species [202]. The number of bacterial cells present in the 
mammalian gut shows a continuum that goes from 101 to 103 bacteria per gram of contents in 
the stomach and duodenum, progressing to 104 to 107 bacteria per gram in the jejunum and 
ileum and culminating in 1011 to 1012 cells per gram in the colon, which contributes to 60% of 
faecal mass [204]. The intestinal microbiota is derived at least in part from the mother dur-
ing birth and is modified thereafter by factors such as diet, antibiotic use, host genetics and 
other environmental factors. These commensal bacteria accomplish many beneficial functions, 
such as vitamin synthesis, the digestion of dietary fibre and the regulation of inflammatory 
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responses. The bacterial flora differs between individuals but mainly belong to two bacterial 
phylotypes, Firmicutes spp. (most notably Clostridium spp., Enterococcus spp. and Lactobacil-
lus spp.) and Bacteroidetes spp. [203,205]. 
The microbiota might influence the balance between pro-inflammatory and regulatory 
host responses and alterations in the composition of the microbiota could jeopardize host im-
mune responses and promote the development of various inflammatory disorders. Important 
is to define how individual members of the microbiota or how microbiota-derived products 
can affect the balance between pro-inflammatory and regulatory immune responses and to 
establish whether the composition of the microbiota can influence the development of inflam-
matory diseases in and beyond the gut [201].
Hygiene hypothesis
The ‘hygiene hypothesis’ first proposed by Strachan in 1989 [206], offers an explanation for 
the correlation between improved living conditions, higher personal hygiene and fewer sib-
lings associated with life in the industrialized world, and increased incidence of asthma and 
allergies. It suggests that infections and unhygienic contact may confer protection from the 
development of allergic illnesses [206,207]. Even though next to allergies and asthma, a va-
riety of auto-immune disorders have now been linked to the hypothesis [208], the hygiene 
hypothesis is still under investigation, and also other factors e.g. the diet can be of importance 
[205]. The hygiene hypothesis is based upon epidemiological data, particularly migration stud-
ies, showing that subjects migrating from a low-incidence to a high incidence country acquire 
the immune disorders with a high incidence at the first generation [209]. However this cor-
relation between change in lifestyle and modifications of the incidence of immune disorders 
does not necessarily prove a causal relationship. In addition, the existence of conflicting epi-
demiological evidence would speculate that only specific infectious agents are responsible for 
a protective influence against atopic and autoimmune diseases [210]. Underlying mechanisms 
of the hygiene hypothesis are multiple and complex. They include decreased homeostasis of 
the immune system by a decreased antigenic competition and a decreased immunoregulation, 
involving various regulatory T-cell subsets and Toll-like receptor stimulation [211]. In a recent 
review on the mechanism of the protective effect of living on a farm for developing asthma 
and allergy it was postulated that activation and modulation of innate and adaptive immune 
responses by intense microbial exposures and possibly xenogeneic signals delivered before 
or soon after birth was held responsible for the decreased risk of asthma and hay fever [212].
In addition, several studies have reported differences in the composition of the faecal mi-
crobiota of infants who develop an allergic disease and those who do not. Notably, a decreased 
frequency of Lactobacillus and Bifidobacterium spp. has been suggested to precede the onset 
of allergy [213], and prophylactic approaches, which are based on the administration of pro-
biotics to mothers and newborns at high risk for IgE-associated allergies, have been initiated.
Probiotic bacteria
Probiotics are live microorganisms, such as lactic acid bacteria, that confer a health benefit on 
the host when administered in adequate amounts [214]. Probiotics may alleviate inflammatory 
bowel disease and irritable bowel syndrome, reduce infectious diarrhoea (acute and antibiotic 
associated), inhibit Salmonella and Helicobacter pylori infection, influence metabolism of di-
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etary compounds in the gut lumen (e.g. lactose digestion and lipid and oxalate metabolism) 
and secret enzymes and bacteriocins into the gastrointestinal tract (Fig. 10). Probiotics might 
also be useful in treating and preventing allergic diseases and may provide an alternative to 
the pharmacological approach in patients who require lifetime treatment and/or suffer from 
serious side effects or drug resistance development [215,216].
At the cellular level, probiotic micro-organisms have several possible modes of action. They 
may be able to directly inhibit or kill pathogenic bacteria, or inhibit the attachment of patho-
gens to the wall of the gastrointestinal tract. This could reduce the virulence of the pathogens. 
In addition, probiotics have also been implicated in direct interaction with the immune system 
and immunomodulation by probiotics is presumed to be one of the main mechanisms of pro-
biotic action observed in inflammatory diseases of the gut and in allergic diseases [217,218]. 
L. plantarum, L. acidophilus and L. paracasei are among the most predominant Lactobacillus 
species in the gut [219,220] and several strains within these species are marketed as probiot-
ics. Lactobacillus strains are generally strong inducers of the pro-inflammatory cytokines TNF-α 
[221-223] and IL-12 [222,224-226], although several studies observed that the bacteria give a 
low or non-significant increase in IL-12 production [227,228]. Stimulation of IFN-γ production 
[225,226] or stimulation of the regulatory cytokine IL-10 could downregulate Th2 cytokine pro-
duction which could be beneficial in allergic patients. In addition, Lactobacilli can upregulate 
the induction of Treg cells, triggering the release of regulatory cytokines (IL-10, TGF-β) and 
controlling the delicate balance between Th1 and Th2 immunity as well as tolerance [229-232].
In brief, probiotics may have a favourable role in immune disorders like allergy; however, 
further investigation on the possible mechanism and on possible effects are still required. In 
addition, it has been suggested that not all Lactobacillus strains exert a similar effect, therefore 
in vivo studies are often proceeded by in vitro studies. In these in vitro studies several strains 
can be tested followed by a selection of the most promising strains to test in an in vivo setting. 
However, the correlation between in vitro and in vivo findings have rarely been studied [233], 
most probably because of a variety of parameters that interfere in the systematic comparison 
of strains such as the bacterial preparations used (viability, growth phase, dose and timing of 
administration) [234], the method of hPBMC preparation, and variable responsiveness of the 
donors. Even though probiotics might have a beneficial effect in several diseases, including al-
lergy, more well-designed studies are needed to confirm these observations.
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Fig. 10. Mechanisms of probiotic action: within the lumen, at the mucosal surface, and by stimulation of innate and 
acquired immunity. The predominant mechanism varies among different probiotic strains and is dependent on the 
clinical indication (Adapted from [235]).
Research aim and thesis outline
This thesis consists of two parts both centred around the theme of allergies. The first part 
of this thesis (chapter 2-6) studies the effect of processing on the allergenicity of purified al-
lergens from peanut and hazelnut and contains a diagnostic paper on CRD in peanut/soy al-
lergic patients. In the second part of this thesis (chapter 7-9) immunomodulating effects of 
Lactobacillus strains were studied, with as final aim to test whether consumption of selected 
strains could be beneficial for allergic patients. Fig. 11 shows an overview of the structure of 
this thesis.
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Food allergens and processing
Changes in protein structure by processing methods might enhance or decrease IgE binding, 
but the changes by processing might also enhance or hinder the digestibility of a particular pro-
tein. Several studies have shown altered rate and pattern of proteolysis by processing methods 
such as heating and high pressure treatment [236-238]. An explanation could, for example, 
lie in the fact that thermal treatment causes unfolding of a protein leading to an increased 
accessibility of the specific peptide bonds to digestive enzymes like trypsin and chymotrypsin, 
which increase the rate of hydrolysis. Against this, prolonged heating time causing aggregation 
of the protein could cause a lower accessibility of the specific bonds and thereby decrease the 
rate of hydrolysis. This altered digestibility could modify the form in which allergens are taken 
up across the gut mucosal barrier and presented to the immune system with regards to both 
sensitisation and elicitation.
The effect of wet-heating and glycation on protein structure, IgE-binding properties and 
biological activity (i.e. mediator releasing capacities and T-cell proliferation and cytokine induc-
tion capacity) of peanut allergens is studied in chapter 2 (Ara h 2/6) and chapter 3 (Ara h 1). 
In addition, in chapter 2 and chapter 3 respectively, Ara h 1 and Ara h 2 and 6 from roasted 
peanuts were isolated, tested and results were compared to the effect of processing on the 
purified allergens. Chapter 4 is also focussed on Ara h 1 and Ara h 2/6; however, now the effect 
of roasting (thus dry-heating) is studied on both IgE binding and degranulation capacities. In 
chapter 5 we focus on the 7S globulin from hazelnut, Cor a 11, and study the effect of heating 
at three different temperatures in the presence or absence of glucose. The extent of Maillard 
reaction, IgG and IgE binding capacity and degranulation capacity were assessed using in the 
latter test both sera high in Cor a 11 specific IgE and sera from peanut allergic patients only 
containing cross-reactive IgE. Chapter 6 consists of a short diagnostic paper in which we deter-
mined IgE profiles to peanut and soy allergens from adult peanut and/or soy allergic patients 
to investigate whether component-resolved diagnosis could help to predict clinical relevance 
of soy sensitization.
Immunomodulatory effects of lactic acid bacteria
As in vitro studies show that probiotics may be beneficial in allergic subjects, suggest it to be 
interesting to test the preselected strains with immune cells from allergic individuals, and to 
examine allergen-specific stimulation in the presence or absence of different bacterial strains. 
This will reveal whether the strains suppress the Th2 cytokine profile by stimulation of the 
Th1 response or by induction of Treg cells. This approach can help in alleviating the symptoms 
observed when having an allergy. As a follow up, a human trial testing the immunomodula-
tory effects of consumption of specific selected stains should be performed. For our studies 
we have chosen birch- and grass pollen allergic patients as our research population as these 
are common seasonal allergies. The prevalence of pollen allergy is estimated to be up to 40%, 
depending on tested age group, country etc. [239], with the major allergen from birch pollen 
(Betula pendula also Betula verrucosa), Bet v 1, as the most allergenic tree pollen in Northern, 
Central and Eastern Europe [240]. Therefore, a possible benefit of the use of probiotic strains 
could be of use for a large part of the population. In addition, birch-pollen allergic patients are 
easier to include compared to food allergic patients as the number of pollen allergic patients is 
much higher. However, assuming mechanistic similarities between respiratory and food aller-
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gies, probiotics that demonstrate to be beneficial in pollen allergic patients, might be consid-
ered to explore for possible benefits to food allergic patients.
We started our research described in chapter 7 by using hPBMC from healthy donors to as-
sess the immunomodulatory effects of Lactobacillus species on the cytokine profiles and pro-
liferative response of these hPBMC. From all tested strains, six were selected and now tested 
for potential immunomodulatory effects on hPBMC isolated from pollen-allergic patients in 
chapter 8. Chapter 9 is the follow up of our in vitro studies in which oral treatment with five 
Lactobacillus strains are tested in a double-blind, placebo-controlled parallel study for their 
immunomodulatory properties in birch-pollen-allergic subjects.
Chapter 10 concludes this thesis with a general discussion on the results and conclusions 
from the previous chapters. It discusses the future perspectives for both allergy research with 
respect to the influence of processing as the use of probiotics in allergic patients.
Immunomodulation by LAB
tested on/in:
hPBMC of healthy patients
hPBMC of birch pollenAP
Birch pollenAP
7
8
9
1
Introduction
Food allergy LAB
Influence of processing on:
Ara h 2/6 (wet, 3*)
Ara h 1 (wet, 3)
Ara h 1 &Ara h 2/6 (dry, 6)
Cor a 11 (dry, 7)
2
3
4
5
6
Component resolved diagnosis
in food allergy
10
Discussion
Food allergy LAB
Fig. 11. Overview of the structure of the thesis *number of treatments tested; hPBMC: human peripheral blood 
mononuclear cells; LAB: lactic acid bacteria; AP: allergic person; wet/dry: wet or respectively dry-processing meth-
ods.
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Abstract
Background: Peanut allergy is one of the most common and severe food allergies, and process-
ing is known to influence the allergenicity of peanut proteins. We aimed to establish the effect 
of heating and glycation on the IgE-binding properties and biological activity of 2S albumins 
(Ara h 2/6) from peanut. 
Methodology/Principal Findings: Native Ara h 2/6 was purified from raw peanuts and heated 
in solution (15 min, 110°C) in the presence or absence of glucose. Ara h 2 and 6 were also 
purified from roasted peanut. Using PBMC and sera from peanut-allergic patients, the cellular 
proliferative potency and IgE reactivity (reverse EAST inhibition) and functionality (basophil 
degranulation capacity) of allergens were assessed. Heating Ara h 2/6 at 110°C resulted in 
extensive denaturation, hydrolysis and aggregation of the protein, whilst Ara h 2 and 6 isolated 
from roasted peanut retained its native conformation. Allergen stimulation of PBMC induced 
proliferation and Th2 cytokine secretion which was unaffected by thermal processing. Con-
versely, IgE reactivity and functionality of Ara h 2/6 was decreased by heating. Whilst heating-
glycation further reduced the IgE binding capacity of the proteins, it moderated their loss of 
histamine releasing capacity. Ara h 2 and 6 purified from roasted peanut demonstrated the 
same IgE reactivity as unheated, native Ara h 2/6.
Conclusions/Significance: Although no effect of processing on T-cell reactivity was observed, 
heat induced denaturation reduced the IgE reactivity and functionality of Ara h 2/6. Conversely, 
Ara h 2 and 6 purified from roasted peanut retained the structure and IgE reactivity/function-
ality of the native protein which may explain the allergenic potency of this protein. Through 
detailed molecular study and allergenicity assessment approaches, this work then gives new 
insights into the effect of thermal processing on structure/allergenicity of peanut proteins.
Introduction
Peanut allergy is relatively common in the USA and certain European countries with the preva-
lence of sensitization being estimated as 2% and clinical peanut allergy as 1.2% of 3-4 years old 
children in the UK [1]. Whilst the incidence appears to be stabilising in the UK [1], it is still rising 
in the USA [2]. The peanut 2S albumins Ara h 2 and Ara h 6 together with a third low abundance 
2S albumin, Ara h 7 have been identified as major peanut allergens [3-5]. Ara h 2 and 6 com-
prise several isoforms of Mr 17 kDa and 15 kDa, respectively [6-8]. Produced as a single chain 
precursor they are proteolytically processed in peanut seeds into two subunits linked by intra-
molecular disulphide bonds [6,9]. Ara h 2, 6 and 7 are all members of the prolamin superfamily 
and share a characteristic cysteine skeleton with at least 8 conserved cysteine residues [9] and 
a three-dimensional structure comprising 5 α-helices arranged in a right-handed super helix. It 
appears this scaffold is stable to thermal processing and proteolysis [7,10,11].
Thermal processing of proteins can lead to alterations in their structure that can result in 
changes in their immunoreactivity/allergenicity. Typically, loss of tertiary structure is followed 
by reversible unfolding, while loss of secondary structure (70-80°C) leads to the formation of 
new intra/intermolecular interactions, rearrangements of disulfide bonds (80-90°C), and for-
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mation of aggregates (90-100°C) [12]. Heating in the presence of sugars found in the foods also 
leads to modification by the Maillard reaction (non-enzymatic browning). Free primary amino 
groups are attacked by carbonyl compounds during the Maillard reaction, leading to the for-
mation of stable advanced glycation end products (AGE). Several studies have been performed 
to assess the IgE-binding capacity of purified allergens modified in vitro by heating and/or by 
Maillard reactions. In some cases, glycation of allergens enhanced their IgE binding capacity 
[13] or their T-cell immunogenicity [14,15] whereas in other studies, glycation had no effect 
or caused even decreased IgE-binding capacity [16,17]. Heati ng for 90 min at 100°C of recom-
binant refolded Ara h 2 led to a slight increase in its IgE binding capacity, which was further 
enhanced in the presence of glucose, maltose or ribose [18]. Heating native Ara h 2 for several 
days at 55°C in the presence of different sugars increased its IgE binding capacity compared to 
protein heated without sugar, which was related to the formation of AGE products [19]. Ara h 
2 extracted from heat-processed peanut, such as roasting (140°C) was also found to enhance 
its IgE-binding capacity [20].
Although IgE binding capacities of modified allergens have been studied, sometimes with 
conflicting results, few data are available on the impact of heating on the protein structure 
and on the resultant biological activity of modified allergens compared to unmodified ones. 
In order to give new insights into the effect of thermal processing on structure/allergenicity 
of peanut proteins, we then purified and produced well-characterized native, heated and gly-
cated Ara h 2/6, as well as corresponding protein from roasted peanut. Using a large panel of 
sera and peripheral blood mononuclear cells (PBMC) from well-characterized peanut-allergic 
patients recruited in different European countries, we then investigated the effect of thermal 
modifications on IgE reactivity of Ara h 2/6, but also on its biological activity, i.e. basophil acti-
vation, T-cell induced proliferation and cytokine production capacities.
Materials and Methods
Ethics statement
A written informed consent was obtained before the sample collection (serum or serum and 
PBMC) and the performed experiments were approved by the corresponding local ethical 
committees (Kantonale Ethikkommission Zürich, Medical ethical committee of the Amsterdam 
Medical Centre, Ethics Committee of Medical University of Vienna, Commissie Mensgebonden 
Onderzoek regio Arnhem-Nijmegen).
Patient characteristics 
Thirty-four peanut-allergic (PA) patients (17 males and 17 females, mean age: 23 years) were 
recruited in Zurich, Amsterdam, Vienna and Arnhem, or were provided by the EuroPrevall Se-
rum Bank (EPSB) (Table 1). Peanut allergy was established using clinical history, physical ex-
amination, peanut specific IgE (ImmunoCAP and/or RAST (Phadia AB)) and/or objective clinical 
manifestations observed after peanut ingestion. Grading of food-induced anaphylaxis was ac-
cording to severity of clinical symptoms [35,36]. Twelve PA subjects and 12 non-allergic (NA) 
controls, all recruited from the Allergology Practice Arnhem (APA, the Netherlands), donated 
cells for PBMC cultures.
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Peanut 2S albumins (Ara h 2/6) preparations 
Native 2S albumins containing both Ara h 2 and Ara h 6 (N-Ara h 2/6) were purified from 
unroasted redskin type peanut as described previously [21] and stored at -20oC prior to use. 
This purification involves ammonium sulphate fractionation and gel-filtration chromatography, 
avoiding the use of denaturing conditions such as reverse phase HPLC. Allergen identity was 
confirmed by in gel-trypsin digestion and MALDI mass spectrometry. Ara h 2 and Ara h 6 were 
purified from commercial roasted peanut as previously described [20] which involves anion 
exchange chromatography in 4 M urea followed by reverse phase HPLC, and then mixed (62% 
Ara h 2 and 38% Ara h 6) in proportions representative of proportions found in peanut [37] to 
provide a preparation further referred to as R-Ara h 2/6.
Proteins were standardized according to BCA kit from Pierce, following provider recom-
mendations.
Heating and glycation treatments of peanut 2S albumins (Ara h 2/6)
Native Ara h 2/6 (N-Ara h 2/6, 4 mg/ml) in 32.5 mM phosphate buffer containing 100 mM NaCl, 
was heated for 15 min to 110oC alone (H-Ara h 2/6) or in the presence of 100 mM glucose (G-
Ara h 2/6). Heating in the presence of glucose was undertaken to glycate the protein based on 
a previously used protocol [38]. Protein solutions were allowed to cool to room temperature 
prior to analysis.
Biochemical characterization of native and modified Ara h 2/6
Changes in Ara h 2/6 secondary structure were assessed using far-UV (190-260 nm) circular di-
chroism (CD) spectroscopy using either a J-710 or a JASCO-810 spectropolarimeter (Jasco Ltd., 
Japan) as previously described [7,21]. All data were calculated in terms of molar ellipti city. Ag-
gregation state was monitored using size exclusion chromatography on a Superdex-75 column 
attached to an Äkta Basic FPLC (Amersham Biosciences, Little Chalfont, UK) [21], and calibrated 
with a set of gel filtration molecular weight standards (BioRad, Hertfordshire, UK).
Isolation, culture and stimulation of human peripheral blood mononuclear cells
PBMC were isolated and cultured as previously described [39]. Immunological phenotyping 
of freshly isolated PBMC was performed on a FACS Canto II (BD Pharmingen, San Diego, USA), 
using monoclonal antibodies and the procedure from BD Pharmingen (San Diego, USA). Stimuli 
were incubated for at least 30 min with polymyxin B (50 μg/ml, Sigma, Zwijndrecht, the Neth-
erlands) to remove potential endotoxin activity prior to addition of the stimuli to the PBMC. 
PBMC were stimulated with αCD3/αCD28 (150 ng/ml αCD3, 100 ng/ml αCD28) or N-, H- or 
G-Ara h 2/6 (20 μg/ml) and supernatants harvested after 4 and 7 days of culture and stored at 
-80°C. The 20 µg/ml dose was determined as optimal in preliminary studies (data not shown). 
Early apoptosis and late apoptosis/necrosis was assessed on freshly prepared and 7 day cul-
tured cells using double staining with APC-Annexin V and propidium iodide (PI) [40]. PBMC 
proliferation was studied on day 4 and day 7 by analysis of intracellular expression of the nu-
clear Ki-67 antigen (BD Pharmingen, San Diego, USA) [40] of PBMC previously stained with 
anti-CD4/CD25 antibody. Ki-67 expression by CD4+ and CD25+ cells was then determined by 
flow cytometry.
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Cytokine analysis
Cytokine production by PBMC was analysed in supernatants of cells cultured for 4 and 7 days. 
The production of IL-5, IL-10, IL-13, IFN-γ and IL-17 by PBMC cultures was determined in har-
vested supernatants using Cytometric Bead Array (CBA, BD Biosciences, San Diego, CA) on a 
FACSCanto II cytometer and the procedure was performed according to the manufacturer’s 
protocol. The detection limit was 1.1 pg/ml for IL-5, 0.13 pg/ml for IL-10, 0.6 pg/ml for IL-13, 
1.8 pg/ml for IFN-γ and 0.3 pg/ml for IL-17.
IgE immunoreactivity
Concentrations of IgE specific to whole protein extract from raw peanut and to N-Ara h 2/6 
were determined using enzyme allergosorbent tests (EAST) as previously described [3,20]. 
Reverse EAST inhibition was performed as described elsewhere [41] using anti-human IgE 
(mouse monoclonal, clone LE27) as a capture antibody, biotinylated N-Ara h 2/6 (200 ng/ml) 
as tracer and N-, H-, G- or R-Ara h 2/6 as inhibitors. N-Ara h 2/6 was labelled with biotin us-
ing EZ-link sulfo-NHS-LC biotin (Pierce, Rockford, IL). Assays were developed using streptavidin 
labelled with acetylcholine esterase (AChE) and Ellman’s reagent. The absorbance of each well 
was measured at 414 nm and results expressed as B/B0, where B0 and B represent the amount 
of native Ara h 2/6 tracer bound to captured IgE in the absence or presence of a known con-
centration of inhibitor, respectively.
Effector cells activation by natural and modified allergens
Basophil histamine release (BHR) tests were performed as described in [42] using stripped 
basophils from fresh buffy coats (Blood Bank, National University Hospital of Copenhagen, 
Denmark) and reagents from RefLab (Copenhagen, Denmark). Twenty-three sera out of the 34 
available were used individually in the BHR test, corresponding to all sera from Zurich, Amster-
dam, Vienna and EPSB, and sera 54A to 58A from Wageningen.
RBL-2H3 cells expressing the α-chain of the human FcεRI receptor [43] were kindly pro-
vided by Drs. Vieths and Vogel (Paul-Ehrlich-Institut, Langen, Germany). RBL cells were cultured 
in MEM medium supplemented with 5% fetal calf serum and 1% glutamine (all from Gibco-BRL, 
Paisley, UK) at 37°C in a humidified atmosphere with 5% CO
2
. Cells in stationary growth phase 
were harvested and plated in 96-well plates at 1.5 × 105 cell/well. Six sera from PA patients 
(#65, #66, #67, #70, #55A and #56A) at pre-determined convenient dilutions and two sera from 
non-allergic patients were added and incubated overnight to passively sensitize the cells. After 
washing, the cells were stimulated for 1 h with the allergens diluted in Tyrode’s buffer con-
taining 50% deuterium oxide [43]. The antigen-specific release was quantified by measuring 
β-hexosaminidase activity and expressed as percentage of the total β-hexosaminidase content 
that was obtained by lysing the cells with Triton-X100 (Sigma-Aldrich, Zwijndrecht, the Nether-
lands). The release data were fitted to four-parameter-logistic curves by non-linear regression 
using the SigmaPlot 10.0 software package, and EC50 values were calculated accordingly.
Statistical analysis
Statistical analysis was performed by using SPSS (v18.0, SPSS Inc., Chicago, USA) or GraphPad 
Prism v4.00 for Windows (GraphPad Software, San Diego, CA). Means and medians were ana-
lysed using Wilcoxon signed rank test for specific IgE levels and PBMC cytokine production and 
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the Mann-Witney U test for comparing PBMC cytokine production between PA and the control 
patient groups. Differences were interpreted as significant when P < 0.05.
Results
Effect of thermal processing on Ara h2/6 structure
Native Ara h 2/6 (N-Ara h 2/6) gave a far-UV CD spectrum typical of an α-helix rich protein (Figs 
1A and 1B) consistent with previous studies [21] and was monomeric with a Mr of ~16 kDa (Fig. 
1C) consistent with a mixed preparation of Ara h 2/6 [7]. 
Fig. 1. Effect of heating on secondary structure and oligomeric state of Ara h 2/6. Far-UV CD spectra of Ara h 2/6 
heated alone (A, H-Ara h 2/6) or in the presence of 100 mM glucose (B, G-Ara h 2/6) before heating (N-Ara h 2/6, 
──) and for heated-cooled protein after heating to 110oC for 15 min (−−−) and 60 min (----). Inset graphs show 
change in molar residue ellipticity at 228 nm with heating time. Size exclusion chromatography profiles (C) are 
shown of the Ara h 2/6 before and after heating for 15 min at 110oC in the presence or absence of glucose. Reten-
tion volumes of molecular weight standards (size indicated in kDa) are shown by arrow heads. D. Far-UV CD spectra 
of Ara h 6 purified from roasted peanut.
After heating at 110oC for 5-10 min in the absence [H-Ara h 2/6, Fig. 1A] or presence [G-Ara 
h 2/6, Fig. 1B] of glucose secondary structure shifted toward an unordered state which domi-
nated after 15 min heating, with a loss of both the maximum at 198 nm and the minima at 
  Effect of heating and glycation on allergenicity of Ara h 2/6   
 61 
6
5
4
3
2
209 and 222 nm. Heating in the presence or absence of glucose also affected the aggregation 
state of the protein, with only ~20% of the protein remaining in its monomeric state (Fig. 1C). 
A broad peak eluting with a Mr ~28-30 kDa of aggregated protein, together with a smear of 
material of Mr 44-150 kDa corresponding to larger oligomers was observed. In addition, ther-
mal treatment resulted in hydrolysis of the Ara h 2/6 to yield fragments of smaller size than 
the parent protein. Far-UV CD spectra obtained for Ara h 2 (data not shown) and Ara h 6 (Fig. 
1D) purified from roasted peanut were comparable and demonstrated the same α-helix rich 
protein structure as N-Ara h 2/6. Non-denaturating electrophoresis showed the proteins were 
mainly monomeric (data not shown).
In order to study the effect of heat-induced structural changes on allergenicity of 2S albu-
mins, N-Ara h 2/6 was then further heated for 15 minutes at 110°C in the presence or absence 
of glucose.
Effect of thermal processing on PBMC induced proliferation and cytokine production capacity
No difference was observed between PBMC from PA or NA patients regarding differentiation 
markers, viability and cytokine secretion potency at the time of sampling and/or after poly-
clonal activation using αCD3/αCD28 antibodies (data not shown). Stimulation with Ara h 2/6 
did not induce significant proliferation in the NA controls (Fig. 2A) and only three of the 12 PA 
subjects showed detectable numbers of Ki-67+ proliferating cells (10.5±4.8%) in the Ara h 2/6 
stimulated cultures compared with medium alone (4.7±2.7). The CD4+CD25+ subset was the 
largest cell population present in the corresponding proliferating PBMC. Thermal treatment 
of N-Ara h 2/6 had no effect on its capacity to induce PBMC proliferation in the three subjects 
(Fig. 2B). 
Fig. 2. Effect of thermal treatment on subpopulation of proliferating cells. A. Fresh PBMC were left unstimulated 
(Med) or stimulated with N-Ara h 2/6 for 7 days. After harvesting, the cells were incubated with anti-CD4/CD25 an-
tibody and afterwards stained for an anti-Ki-67 PE antibody. Data are mean percentage of Ki-67 positive cells ± SEM 
values for three (#65, #66 and #70) of the 12 PA subjects and seven NA controls. The percentage Ki-67+ cells was 
divided in the following subpopulations of cells: CD4-CD25- (dark grey bars), CD4+CD25- (white bars), CD4-CD25+ 
(black bars) and CD4+CD25+ (light grey bars) cells. B. Fresh PBMC were left unstimulated (Med) or stimulated with 
N-, H- or G-Ara h 2/6 for 7 days. Data are mean percentage of Ki-67 positive cells ± SEM values for three peanut-
allergic patients (#65, #66 and #70) (white bars) and seven non-allergic controls (grey bars). 
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IL-5 and IL-13 production was significantly and equally enhanced in PBMC cultures from 5 out 
of 12 PA subjects following stimulation with N-, H- or G-Ara h 2/6 (Figs 3A and 3B), and not in 
PBMC cultures from NA subjects (Fig. 3 and data not shown). IL-4 correlated with IL-5 and IL-
13 secretion although with lower levels (data not shown). Enhanced production of IL-10 and 
IFN-γ was observed in stimulated PBMC of PA subjects compared to NA subjects but was not 
significant for all stimuli tested (Figs 3C and 3D). IL-17 production was below 20 pg/ml for all 
tested conditions (data not shown). 
Fig. 3. Effect of thermal treatment on cytokine induction capacity. Fresh PBMC were left unstimulated (Med) or 
stimulated with N-, H- or G-Ara h 2/6 and production of IL-5 (A), IL13 (B), IL-10 (C) and IFN-γ (D) was measured after 
7 days of culture. Symbols represent peanut-allergic patients #65 ( ), #66 (¿), #70 ( ), #67 (●) and #73 (x). Hori-
zontal bars represent the mean of the five PA responder subjects (solid) and the mean of 7 NA controls (dotted). 
Asterisks indicate statistically significant differences between the PA and the NA group and # indicate statistically 
significant differences between the medium and allergen-stimulated cultures for the PA group (*, # P < 0.05). No 
differences between the medium and allergen-stimulated cultures were observed for the NA group.
Effect of thermal processing on the IgE binding capacity 
Screening of the serum panel (n = 34, Table 1) showed variable levels of IgE specific to raw 
peanut extract and N-Ara h 2/6. Four sera with low specific IgE were excluded from subsequent 
analysis (sera #69, #76, #80 and #82). Effect of thermal treatment on the IgE binding capacity of 
Ara h 2/6 was then assessed using reverse inhibition. A typical inhibition curve for the reverse 
EAST assay obtained with serum #05-0209 is shown in Figure 4A and demonstrated that the 
thermal treatment of N-Ara h 2/6 at 110oC reduced its IgE binding capacity. Ara h 2/6 from 
roasted peanut (R-Ara h 2/6) had a similar albeit slightly reduced immunoreactivity to N-Ara h 
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2/6 from raw peanut. IC50 values calculated for the entire serum panel (n=30) are consistent 
with this and show that extreme thermal processing did reduce the IgE binding capacity of Ara 
h 2/6 in a significant manner (Fig. 4B). The IC50 values for all tested sera increased 1.2 to 44-
fold (mean = 9.6, n = 30) for H-Ara h 2/6 compared to N-Ara h 2/6 (Fig. 4B). For 25 out the 30 
tested patients, IC50 values for G-Ara h 2/6 were equivalent or 3.4-fold higher than those of H-
Ara h 2/6 (mean = 1.7). For the last 5 patients, IC50 values were 1.2 to 1.7-fold lower for G-Ara 
h 2/6 compared to H-Ara h 2/6 (mean 1.4). These data show that for most patients glycation 
reduced the IgE reactivity of Ara h 2/6 still further compared with thermal treatment alone, 
and is consistent with the fact that IC50 values for G-Ara h 2/6 were 1.3 to 73-fold higher than 
that of N-Ara h 2/6 (mean = 14.5, n = 30). Ara h 2/6 from roasted peanut (R-Ara h 2/6) had a 
similar albeit slightly reduced immunoreactivity compared to N-Ara h 2/6.
Fig. 4. Effect of thermal treatment on the IgE binding capacity of Ara h 2/6. A. IgE capture inhibition curves obtained 
for sera #05-0209 with N-Ara h 2/6 (●), H-Ara h 2/6 (¿) or G-Ara h 2/6 ( ). IgE binding capacities of native and 
heated processed Ara h 2/6 was assessed by competitive assays in the IgE capture format. Inhibition was per-
formed into microtiter plates coated with anti-IgE, and previously incubated with allergic patient sera at convenient 
dilution. Competition was then conducted by adding increasing concentrations of competitors at the same time as 
biotinylated N-Ara h 2/6. Competition obtained with Ara h 2/6 purified from roasted peanut is shown as a clear 
circle. B. Analysis of IC50 (ng/ml) values obtained using an IgE capture inhibition assay with native and heat pro-
cessed Ara h 2/6 as competitors using 30 individual sera from peanut-allergic patients. Increase in IC50 value cor-
responds to a decrease in IgE-binding capacity. R-Ara h 2/6: mix of Ara h 2 and Ara h 6 purified from roasted peanut. 
Bars indicate a significant difference between the 2 corresponding treatments (P < 0.05, non-parametric Wilcoxon 
signed rank test).
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Table 1. Serological and clinical information for the 34 peanut allergic patients recruited in different European 
centres, within the EuroPrevall European project, used in EAST studies, basophil histamine release tests and/or 
PBMC proliferation tests.
Code
Gen-
der 
(f/m)
Age
Peanut SPT 
(HEP Index 
numbers)
Grade 
peanut 
allergy
Peanut 
RAST 
class
Peanut 
CAP  
(IU/mL)
Anti-whole 
peanut 
(IU/mL)
anti-Ara 
h 2/6 IgE 
(IU/mL)
Other food allergies
2A m 31 positive 3/4 5 51.7 43 31
52A m 41 nd 4 5 nd 166 62
54A f 11 2.2 1 6 >100 72 57
55A f 14 3.3 4 6 >100 363 137
56A m 16 1.5 2 6 >100 79 56
58A f 22 2.5 4 6 >100 171 110 Soy, Lupine, Pea
65 f 19 positive 3/4 6 >100 587 208
66 m 18 positive 4 6 >100 290 71
67 f 46 nd 3 5 54.4 95 35 Hazelnut, Kiwi, Cherries
68 f 20 positive 1 4 17.6 16 6
69 m 21 positive 3/4 3 6.98 3.5 1.2
70 f 21 positive 3/4 6 >100 224 76 Soy, Pea, Apple
73 f 22 positive 2/3 4 33.6 21 3.7 Hazelnut
76 m 23 positive 3 3 8.6 4.2 0.3
77 m 25 positive 2 4 33.2 22 3.5
78 f 24 positive 3 5 79.6 65 29 Hazelnut
80 m 27 positive 3 3 16 12 17
82 f 18 positive 1/2 3 4.7 25 6.4 Kiwi, Cherries
1682 m 33 nd 4 6 >100 13 10
1691 m 22 nd 3 5 nd 50 54
2207 m 28 nd 4 4 nd 38 26 Wheat, Hazelnut, Egg, Almond
2209 f 27 nd 4 6 nd 75 51 Hazelnut, Egg, Wheat
2304 m 25 nd 3 6 nd 90 50
2305 f 18 nd 4 nd nd 52 36
03-0043 f 20 1.54 3/4 6 >100 nd 852 Hazelnut, Walnut, Melon
03-0044 m 23 4.33 3 6 >100 nd 231
Egg, Fish, Shrimp, Hazelnut, Wal-
nut, Sesame, Wheat, Sunflower
03-0079 f 16 2.22 3 6 >100 nd 88 Pistachio, Almond, Brazil nut
05-0128 f 25 1.92 3 6 >100 nd 358 Soy, Hazelnut, Apple, Peach
05-0165 f 18 0 3/4 6 >100 nd 429 Chickpea, Bean, Hazelnut, Lentil
05-0195 m 31 2.13 3 5 63.5 nd 64 Soy
05-0209 m 20 99.98 4 5 70.2 nd 81 Pea, Soy, Bean
06-0010 m 19 2.2 3/4 5 67.4 nd 67 Fish
08-0069 m 17 2.08 1 6 >100 nd 139 Kiwi
12-0048 f 21 5.8 3/4 5 54.6 nd 88 Shrimp
HEP: histamine equivalent prick test; nd: not determined. Where known, other allergies of the subjects are indi-
cated. The origin of the sera is as follows: 2A: Zurich, 52A: Amsterdam, 54A-82: Arnhem, 1682-2305: Vienna; 03-
0043 till 12-0048 EuroPrevall Serum Bank. 
Grading is based on Brockow and Ring and on Sampson et al. [35,36]. Grade 1 = dermal symptoms; grade 2 = gastro-
intestinal problems like nausea and or cramping; grade 3 = any of the former grades plus vomiting/diarrhoea and 
respiratory tract problems like throat pruritus or tightness, grade 4 = any of the former grades and respiratory ar-
rest plus cardiovascular problems like hypotension.
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Effect of thermal processing on the mediator-releasing capacity 
Subsequently an analysis of the effects of heating on the histamine releasing capacity of the 
Ara h 2/6 preparations was undertaken using human stripped basophils passively sensitized 
with 23 of the 34 peanut-allergic patients sera and compared with whole protein extract from 
raw or roasted peanut. No histamine release was induced by the different allergens when us-
ing a serum from patients not sensitized to peanut (data not shown), and the 23 sera from PA 
patients gave similar results. An example curve (serum #2305, Fig. 5A) shows significant hista-
mine release for both extracts and purified allergens, the whole protein extract from raw and 
roasted peanut being comparable. As previously observed using RBL SX38 cells and Ara h 2 and 
Ara h 6 from roasted peanut [22], histamine release was induced at lower concentrations of 
these purified allergens when compared to peanut extracts. Heating reduced the biological po-
tency of the Ara h 2/6, (Fig. 5A, P < 0.05 when considering 23 sera), but intriguingly histamine 
release was induced at a lower concentration of heated-glycated than heated Ara h 2/6. The 
maximum histamine release induced by the purified allergens was only affected when compar-
ing N-Ara h 2/6 to H-Ara h 2/6 (P < 0.05 when considering the 23 sera). 
Additionally, a mediator release assay using humanized Rat Basophilic Leukaemia cells was 
also performed using 6 individual sera. Figure 5B shows typical results of a representative se-
rum (#70) and the inserted table represents the average protein concentrations needed to 
obtain 50% of the maximum mediator release induced by the native allergen (EC50). A 150 and 
130 times increased EC50 value, corresponding to a decreased allergenic activity, was observed 
for H-Ara h 2/6 and G-Ara h 2/6, respectively, in comparison to N-Ara h 2/6. The EC50 value of 
G-Ara h 2/6 was lower compared to the EC50 value of H-Ara h 2/6; however, this was not tested 
to be significantly different.
Fig. 5. Effect of thermal treatment on the activation of effector cells induced by Ara h 2/6. A. Human stripped ba-
sophils were passively sensitized with individual sera (#2305) and then incubated with increasing concentrations of 
N-Ara h 2/6 (●), H-Ara h 2/6 (¿), and G-Ara h 2/6 ( ), or whole peanut extract from raw («) or roasted (○) peanut. 
Histamine release was assayed in corresponding supernatants. Twenty-three sera out of the 35 available corre-
sponding to all sera from Zurich, Amsterdam, Vienna and EPSB, and sera 54A to 58A from Arnhem were used, giving 
similar results (not shown). No histamine release was induced by the different allergens when using a serum from 
patients not sensitized to peanut (data not shown). B. Humanized RBL-2H3 cells were passively sensitized with sera 
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from peanut-allergic patients (#70) and stimulated with increasing concentrations of native (N; ―●―), heated (H; 
– –¿– –) or glycated (G; - - - - - -) Ara h 2/6. Error bars represent the SD of triplicate values. No β-hexosaminidase 
release was induced by the different allergens when using sera from non-allergic patients (data not shown). The 
table presented within the figure represents the average protein concentrations (ng/ml, n = 6) to obtain 50% of the 
maximum allergen release of the native allergen (EC50). Means without a common letter differ (P < 0.05).
Discussion
Boiled peanuts are consumed in many countries, from China to the Southern states of the 
USA. Boiling is performed for 2 to 7 hours, depending on the peanut source, and boiled peanut 
can be further canned, then involving further extensive heating (45 minutes at 120°C under 
10 pounds pressure per square inch). Study of heat-induced structural changes and its im-
pact on allergenicity of peanut allergens after wet-thermal processing then appears of interest. 
Achieving model processing conditions to ensure that thermal modifications can be monitored 
by structural and immunological analysis is difficult since heating frequently renders much of 
the protein insoluble. This makes purification of proteins from cooked foods, such as roasted 
or boiled peanuts, cumbersome [23]. We then analyzed the effect of wet thermal processing 
on major peanut allergens, i.e. N-Ara h 2/6, previously purified from raw peanut. Like other 
members of the prolamin superfamily, the 2S albumin allergens of peanut appeared to be 
highly thermostable, properties which may contribute to their allergenic potency. Through our 
detailed molecular study we have shown that these proteins only begin to unfold following 
heating at temperatures over 100oC, conditions which equate to boiling for extended times 
(longer than 15 min). After this time, the protein adopts a random coil conformation and forms 
dimers and higher order oligomers, accompanied by hydrolysis of the peptide backbone. Such 
effects of thermal denaturation have been observed for other food proteins, including the lipid 
transfer protein from barley which shares the same protein scaffold as the 2S albumins [24]. 
Certainly the Ara h 2 and 6 purified from roasted peanuts had retained the structural charac-
teristics of the native protein purified from raw peanuts, as indicated by far-UV CD spectra and 
non-denaturing electrophoresis. These data demonstrate that the proportion of the protein in 
roasted peanut that was still soluble had not been denatured by the roasting process. In addi-
tion, this proportion was shown to have a similar immunoreactivity as the unheated protein.
In order to assess the effect of heat-induced structural changes on allergenicity of Ara h 
2/6, we first assessed the in vitro proliferative capacity of the native vs heated proteins using 
PBMC from 12 peanut allergic (PA) and 12 control human donors. Out of the 12 PA, only 5 dem-
onstrated a significant cytokine production after in vitro stimulation. All of them had high levels 
of peanut specific IgE antibodies. This corroborates studies demonstrating a significant posi-
tive correlation between allergen-specific serum IgE levels and high numbers of IL-4-producing 
cells [25] or active proliferation of T cells and Th2 cytokine production [26]. However, it is worth 
noting that peanut-specific T-helper cells in PBMC of peanut allergic patients were found to be 
only 0.6% of the total CD4+ T cells [27]. This explains the quite low rate of responders in our 
ex vivo stimulation assays. Nevertheless, we could still conclude that heat treatment of Ara h 
2/6 did not influence cytokine production by PBMC from either of the 5 PA. These results then 
demonstrated that the unfolding of the Ara h 2/6 by intense heating had no effect on the PBMC 
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stimulating activity of Ara h 2/6, as has been shown before for Bet v 1-related allergens [28,29]. 
The IgE-binding capacity and the elicitation potency of the native vs heat-processed aller-
gens were then studied using a large panel of sera from peanut allergic patients (n = 30 and 23, 
respectively). In fact, most of the studies aiming at analyzing the relationship between struc-
ture and allergenicity, and particularly the effect of processing on allergenicity of food proteins, 
generally use very few individual sera from allergic patients [18,23,30,31], even sometimes 
only one pool of such sera is available [11,19,32,33]. Our results show that heat-induced dena-
turation of Ara h 2/6 did result in a significant loss in IgE-binding capacity and ability of the pro-
tein to elicit histamine release. This indicates that thermal processing can reduce the allergenic 
activity of peanut proteins in terms of elicitation potential, and may explain why processes 
such as boiling of peanuts, can reduce their allergenic activity [32]. Our data also suggest that 
IgE responses in peanut-allergic individuals are directed towards the natively folded protein 
and/or that oligomerisation observed after heating with or without glucose led to epitope 
masking. Thus, it appears that the sensitizing agent driving B-cell responses in this population 
was native Ara h 2/6 which may have originated from either consumption of raw nuts, or more 
probably, represent the fraction of Ara h 2/6 that remains soluble and in its native state even 
after roasting.
We found that glycation in conjunction with thermal denaturation generally led to a further 
decrease of IgE binding capacity, rather than the increase found by others [18,34], although 
glycation did appear to preserve slightly more of the proteins mediator releasing capacity com-
pared with heating alone. Some of these differences may relate to the wet-thermal processing 
procedures employed in this study. Further investigation using heat-denaturation of Ara h 2/6 
under low moisture conditions will be required to explain these differences more fully.
In conclusion, we demonstrated that heating to temperatures able to denature Ara h 2/6 
caused a significant decrease in the proteins allergenicity whereas T cell stimulation was not 
affected. It is evident that a soluble fraction of the Ara h 2/6 from roasted peanuts retains the 
conformation and allergenic activity of the native protein, explaining the allergenic potency of 
this protein.
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Abstract 
Scope: It has been proposed that roasting versus boiling and Maillard modifications may modu-
late peanut allergenicity. We investigated how these factors affect the allergenic properties of 
a major peanut allergen, Ara h 1. 
Methods and results: Ara h 1 was purified from either raw (N-Ara h 1) or roasted (R-Ara h 
1) peanuts. Boiling (100°C 15 min; H-Ara h 1) resulted in a partial loss of Ara h 1 secondary 
structure and formation of rod-like branched aggregates with reduced IgE binding capacity 
and impaired ability to induce mediator release. Glycated Ara h 1 (G-Ara h 1) formed by boil-
ing in the presence of glucose behaved similarly. However, H- and G-Ara h 1 retained the T-cell 
reactivity of N-Ara h 1. R-Ara h 1 retained no native secondary structure, comprised compact, 
globular aggregates, showed no evidence of glycation but retained the IgE binding capacity of 
the native protein. 
Conclusion: Ara h 1 aggregates formed by boiling were morphologically distinct from those 
formed by roasting and had lower allergenic activity. Simple glycation did not affect Ara h 1 
allergenicity. These data help to explain differences in the allergenicity of boiled and roasted 
peanuts and provides insights into how boiling may reduce elicitation capacity.
Introduction
Peanut allergy is a common, severe and generally persistent food allergy in the North America 
and several European countries [1]. It appears to be less prevalent in other parts of the world 
and it has been proposed that differences in cooking practices maybe responsible [2]. Differ-
ent types of thermal processing (blanching, boiling, roasting or frying) will alter protein struc-
ture in different ways, potentially changing its immunoreactivity and allergenicity. Since foods 
are complex mixtures of many different constituents, notably sugars, cooking can also modify 
proteins chemically. One of the most important of these cooking-related changes is the Mail-
lard reaction, or non-enzymatic browning, which leads to the formation of stable advanced 
glycation end products (AGE) through the reaction of reducing sugars with free amino groups 
on proteins. It has been proposed that this type of processing can also affect allergenicity of 
peanuts [2].
This has been particularly well studied for the peanut allergen Ara h 1, to which 55-95% of 
peanut-allergic patients are sensitized. Belonging to the 7S globulin protein family it possesses 
the β-barrel structural motif characteristic of the cupin superfamily [3-6]. When purified from 
raw peanut it is a Mr 210 kDa trimeric protein [7], composed of 63 kDa N-glycosylated subunits 
which can form multimers of up to Mr 600-700 kDa depending on extraction conditions [8]. 
Like other cupins Ara h 1 is thermostable, only undergoing irreversible denaturation and ex-
tensive aggregation after passing through the main endotherm transition occurring above 80°C 
[9]. However, more extreme thermal processing such as roasting at 140°C appears to enhance 
IgE-binding capacity of Ara h 1 [10]. In model systems heating native Ara h 1 for several days at 
55°C in the presence of different sugars increased its IgE binding capacity, which was related 
to the formation of AGE products although the IgE binding capacity of the modified Ara h 1 
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and untreated allergen was not directly compared [11]. Such modifications may explain the 
enhanced IgE-binding capacity of Ara h 1 from roasted peanuts.
The problems of handling and investigating the structures of thermally aggregated proteins 
with reduced solubility has made it difficult to link effects of thermal processing on structure to 
effects on allergenic properties. In addition, few data are available comparing the functionality 
of modified and unmodified allergens. We have addressed this gap using structurally well-
characterized thermally modified Ara h 1 preparations (including model processed Ara h 1 and 
the cognate protein from roasted peanuts). We investigated the effect of thermal treatment on 
both the allergen structure and its IgE binding capacity, potency to stimulate histamine release 
and ability to induce T-cell proliferation and cytokine production using sera and peripheral 
blood mononuclear cells (PBMC) from peanut allergic patients.
Materials and Methods
Ethics statement
A written informed consent was obtained before the sample collection (serum or serum and 
PBMC) and the performed experiments were approved by the corresponding local ethical 
committees (Kantonale Ethikkommission Zürich, Medical ethical committee of the Amsterdam 
Medical Centre, Ethics Committee of Medical University of Vienna, Commissie Mensgebonden 
Onderzoek regio Arnhem-Nijmegen).
Patient sera and peripheral blood mononuclear cells (PBMC)
Sera were obtained from a population of 35 peanut-allergic (PA) patients (18 males and 17 fe-
males, mean age: 23 years) recruited from clinical centers in Zurich, Amsterdam, Arnhem, and 
Vienna, or were provided by the EuroPrevall Serum Bank (EPSB) (Table S1). Twelve PA subjects 
(underlined in Table S1) and 12 non-allergic (NA) controls, all recruited from the Allergology 
Practice Arnhem (APA, the Netherlands), donated cells for PBMC cultures. Peanut allergy was 
established using clinical history, physical examination, peanut specific IgE (ImmunoCAP and/
or RAST (Phadia AB; Table S1)) and objective clinical manifestations observed after peanut con-
sumption (anaphylaxis in the history or positive food challenge).
Protein preparations 
Whole Peanut Protein Extract (WPPE) was prepared from peeled raw and commercially roast-
ed peanuts (Virginian variety) from which R-Ara h 1 was purified [10]. Native Ara h 1 (N-Ara h 
1) was purified from a single batch of peeled redskin type raw peanuts (obtained from local 
suppliers, UK) as described by Marsh et al. [12]. N-Ara h 1 (4 mg/ml) in 32.5 mM phosphate 
buffer containing 100 mM NaCl, was heated to 100oC alone (heated Ara h 1, H-Ara h 1) or in the 
presence of 100 mM glucose (glycated Ara h 1, G-Ara h 1) for 15 min. Protein solutions were 
allowed to cool to room temperature prior to analysis. Changes in secondary structure were 
defined using circular dichroism and Fourier transform infrared spectroscopy [12]. Aggregation 
state was defined using atomic force microscopy (AFM) depositing protein (40 µg/mL diluted 
50-fold from a 2 mg/mL stock solution with water) on to freshly prepared poly-l-lysine coated 
muscovite mica (Agar Scientific, UK). The sample was inserted into the liquid cell of the AFM 
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(East Coast Scientific, Cambridge, England) and imaged in contact mode at a set point force of 
around 200 pN under redistilled n-butanol (Sigma, Dorset, UK) for the aggregates and buffer 
for the unheated proteins using 100 µm long oxide-sharpened Nanoprobe levers (NP-S, Veeco 
Instruments Inc., California, USA) with a quoted force constant of k = 0.38 Nm-1. Complimen-
tary analysis was undertaken using fixed angle light scattering carried out on a Zetasizer Nano 
(Malvern Instruments, Worcestershire, UK).
IgE immunoreactivity to the native and modified Ara h 1 by direct and reverse EAST inhibition
IgE specific to whole protein extract from roasted or raw peanut and to N-Ara h 1 or R-Ara h 
1 were determined using the EAST (enzyme allergosorbent test) as previously described on 
allergen-coated plates [3,10]. Reverse EAST inhibition was performed as described elsewhere 
[13] using anti-human IgE (mouse monoclonal, clone LE27) coated plates. Inhibitors consisted 
of increasing concentrations of R-, N-, H- or G-Ara h 1 using either N-Ara h 1 or R-Ara h 1 labeled 
with acetylcholinesterase (AChE) [14] as the tracer. Results were expressed as B/B0, where B0 
and B represent the amount of Ara h 1 tracer linked to immobilized IgE in the absence or pres-
ence of a known concentration of inhibitor, respectively.
Mediator release assay (MRA) using Rat Basophilic Leukemia (RBL) cells
RBL-2H3 cells expressing the α-chain of the human FcεRI receptor [15] were kindly provided by 
the Paul-Ehrlich-Institut (Langen, Germany) and MRA were performed as described previously 
(Vissers et al., submitted) using human sera annotated with an asterisk in Table S1. Antigen-
specific release induced by N-, H- and G-Ara h 1 was quantified by measuring β-hexosaminidase 
activity and expressed as percentage of the total β-hexosaminidase content that was obtained 
by lysing the cells with 1% Triton-X100 (Sigma-Aldrich, Zwijndrecht, the Netherlands). 
Effect of thermal processing on PBMC induced proliferation and cytokine production capacity
PBMC were isolated from PA (n = 12) and NA (n = 12) donors and cultured according to pre-
viously described procedures ([16] and Vissers et al., submitted). No differences in viability, 
proliferation or cytokine secretion could be evidenced between PA and NA after polyclonal 
activation with αCD3/αCD28 (suppl file 1). PBMC were stimulated with 20 µg/ml of N-, H- and 
G-Ara h 1 or with medium alone, cultured for 7 days at 37°C and supernatants were stored as 
previously described (Vissers et al., submitted). Harvested PBMC were characterized using flow 
cytometry using a FACSCanto II (BD Biosciences San Diego, CA, USA) as previously described 
(Vissers et al., submitted) using labeled anti-CD4, anti-CD25 and anti-Ki-67 antibodies or the 
corresponding isotype controls, all from BD Pharmingen (San Diego, USA). Cytokine production 
was determined using Cytometric Bead Array (CBA, BD Biosciences, San Diego, CA), according 
to the manufacturer’s protocol. The detection limits were 1.1 pg/ml for IL-5, 0.13 pg/ml for IL-
10, 0.6 pg/ml for IL-13, 1.8 pg/ml for IFN-γ and 0.3 pg/ml for IL-17.
Statistical analysis
Means and medians were analyzed using nonparametric methods (Wilcoxon signed rank test 
or Mann-Witney U test) using SPSS Software (version 18.0, SPSS Inc., Chicago, USA) or Graph-
Pad Prism (version 4.00 GraphPad Software, San Diego, CA) with a difference interpreted as 
significant when P < 0.05. MRA data were fitted to four-parameter-logistic curves by non-linear 
regression using the SigmaPlot 10.0 and EC50 values determined.
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Results
Boiling (H-Ara h 1) resulted in aggregation and hydrolysis of Ara h 1 as indicated by the appear-
ance of lower Mr polypeptides ranging from ~6-67 kDa and the generally smeared appearance 
of the gel track (Fig. 1A track 3) compared to the Mr ~ 67 kDa and ~ 33 kDa polypeptides of 
native (N-) Ara h 1 (Fig. 1A track 2) [12]. Addition of glucose during boiling (G-Ara h 1) resulted 
in the formation of high Mr polypeptides of masses > 200 kDa (Fig. 1A track 4). Ara h 1 isolated 
from roasted peanuts (R-Ara h 1) resembled the heated and glycated protein (Fig. 1A track 5) 
with much of the protein migrating as a poorly resolved smear at the top of the gel. Boiling, 
alone or in the presence of glucose caused a partial loss of secondary structure, as indicated by 
the loss of the positive maximum at 192-195 nm, and the positive molar ellipticity at 190 nm in 
the CD spectra of H- and G-Ara h 1 (Fig. 1B). However, the protein from roasted peanuts (R-Ara 
h 1) appeared to be highly denatured having only a slight positive maximum at 190 nm, and a 
negative minimum at 205 nm of reduced intensity (Fig. 1B). 
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Fig. 1. (previous page) Physicochemcial characterisation of heat-treated Ara h 1. A. SDS-PAGE analysis of Ara h 1 
preparations. Track 1: Molecular weight markers; 2: native (N-) Ara h 1; 3: heated (H-) Ara h 1; 4: heated and gly-
cated (G-) Ara h 1; 5: R-Ara h 1 from roasted peanuts. B. Circular dichroism (CD) spectra of native and heat treated 
Ara h 1. N-Ara h 1 (––––); H-Ara h 1 ( - -- -- ); G-Ara h 1 (− − −); R-Ara h 1 (− - - −). C. Fourier transform infrared spec-
troscopy (FT-IR) spectra of native and heat treated Ara h 1. N-Ara h 1 (––––); H-Ara h 1 ( - -- -- ); G-Ara h 1 (− − −); R-Ara 
h 1 (− - - −); D. Second derivatives of the amide band region of the Fourier transform infrared spectroscopy (FT-IR) 
spectra of native and heat treated Ara h 1. N-Ara h 1 (––––); H-Ara h 1 ( - -- -- ); G-Ara h 1 (− − −); R-Ara h 1 (− - - −). 
Complementary fourier transform infrared spectroscopic analysis (FT-IR) was undertaken 
to provide additional information on secondary structure content and to obtain an indication 
of glycation state of the different protein preparations (Fig. 1 C, D). The amide I band shape 
of N-Ara h 1 gave an amide I band maximum at 1634 cm-1 characteristic of the natively folded 
β-sheet rich protein, with a small shoulder at 1656 cm-1 corresponding to α-helix. After heating 
the 1634 cm-1 band was reduced in intensity and a new band appeared at 1621 cm-1 which is 
generally accepted as an indication of the formation of intermolecular β-sheet structures and 
protein aggregation [17]. Heating in the presence of glucose (G-Ara h 1) resulted in similar, but 
smaller, changes in secondary structure as well as glycation as indicated by the intense bands 
in the 1200-900 cm-1 region. Roasting, i.e. heating at high temperature in low moisture envi-
ronment, had a completely different effect. The amide I band shape of R-Ara h 1 gave an even 
more pronounced amide I band maximum at 1634 cm-1 characteristic of the natively folded 
β-sheet rich protein, while the shoulder at 1656 cm-1 corresponding to α-helix was reduced. 
Only a small new band related to intermolecular β-sheet formation, appeared at 1621 cm-1. 
Furthermore the R-Ara h 1 had only a very minor absorption in the 1200-900 cm-1 region, indi-
cating a very limited level of glycation of the protein.
Fig. 2. Fixed angle light scattering analysis of heat-treated Ara h 1. Light scattering measurements of native and 
heat treated Ara h 1. N-Ara h 1 (––––), H-Ara h 1 ( –– ––), G-Ara h 1 (− − −) or R-Ara h 1 (− - - −). Results are shown 
as size distribution by volume, percentage volume versus size in nm. Data represent the mean of three measure-
ments per sample.
H-, G- and R-Ara h 1 were all highly aggregated with Mrs of > 640,000 by gel permeation 
chromatography and dimensions of in excess of 50 nm by fixed angle dynamic light scattering 
(Fig. 2). Characterization of boiled Ara h 1 aggregate topography using AFM showed they had 
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either a rod-like branched aggregate structure (H-Ara h 1, Fig. 3B) or simpler rod-like structures 
when glucose was added (G-Ara h 1, Fig. 3C) both with variable heights between 10-15 nm. The 
R-Ara h 1 aggregates had a very different morphology (Fig. 3D) and were either more globular 
or comprised slightly shorter rods with significantly lower heights of around 7-8 nm. 
Fig. 3. Atomic force microscopy topographic images of heat-treated Ara h 1. A. N-Ara h 1; B. H-Ara h 1; C. G-Ara h 
1; D. R-Ara h 1. Profiles beneath each image depict feature heights along marker line. 
Boiled H- and G-Ara h 1 had greatly reduced IgE binding capacities for all patient sera ana-
lyzed using reverse EAST inhibition, although the pattern of reactivity was heterogeneous (Fig. 
4). Typically boiling resulted in either a very slight (#2206, Fig. 4A) or more marked (#66, Fig. 
4B) reduction in IgE binding capacity of Ara h 1. This was reflected in the increase in IC50 values 
for H-Ara h 1 compared to N-Ara h 1 of 1.5 to 5800 fold (mean = 715) and 1.8 to ≥ 10000 fold 
(mean = 1236) for G-Ara h 1 (Fig. 4C). IC50 values were higher for H- than for G-Ara h 1, for 5 
out of 26 sera, showing for these patients that H-Ara h 1 was slightly, but significantly, more IgE 
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reactive, whilst the remaining 19 sera showed the opposite pattern of reactivity. Remarkably, 
the IgE immunoreactivity of the R-Ara h 1 was almost identical to that of N-Ara h 1, with mean 
IC50 values of 31.6 and 37.3 ng/ml respectively, and showed less inter-individual variability 
than the N-Ara h 1 (Fig. 4C).
Fig. 4. IgE binding capacity of native and heat-treated Ara h 1. A, B: IgE capture inhibition curves obtained for serum 
#2205 and serum #66 respectively with N-Ara h 1 (●), H-Ara h 1 (¿) or G-Ara h 1 ( ). C. Analysis of IC50 (ng/ml) 
values obtained using IgE capture inhibition assay with N-, H- G- and R-Arah 1 as competitors and labeled N-Ara h 
1 as a tracer (similar results were obtained when using labeled R-Ara h 1 as a tracer, data not shown). A serum 
panel from 26 peanut allergic patients was used with a reverse EAST inhibition assay and horizontal bars represents 
the median values of these patients. IC50 values are inversely proportional to IgE-binding capacity. Bars indicate a 
significant difference between the 2 corresponding Ara h 1 samples determined using a non-parametric Wilcoxon 
signed rank test. *0.01< P <0.05, **0.001< P <0.01, ***P < 0.0001. Individual symbols represent serum samples 
from individuals #55 (○), #65 ( ), #66 (¿), #70 ( ) and #73 (x) also used in the RBL assay and who also donated 
PBMC samples. 
Similar patterns of reactivity were observed when following β-hexosaminidase release with 
a humanized RBL cell line passively sensitized with sera from six patients (Table S1; Fig. 4B and 
5A, serum #66). However, the loss of reactivity of the H- and G-Ara h 1 was smaller than that 
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observed by EAST, the EC50 values being increased 6.9 and 7.5-fold respectively for H-Ara h 1 
and G-Ara h 1 compared to N-Ara h 1 (Fig. 5B).
Fig. 5. Effect of thermal treatment on β-hexosaminidase release from humanized rat basophilic leukaemia (RBL) 
cells. A. Humanized RBL-2H3 cells were passively sensitized with sera from peanut allergic patients (serum #66) and 
stimulated with increasing concentrations of native (N; ―●―), heated (H; – – ¿– –) or glycated (G; - - - - - -) Ara 
h 1. Error bars represent the SD of triplicate values. No β-hexosaminidase release was induced by the different al-
lergens when using sera from non-allergic patients (data not shown). B. IC50 values (µg/ml) obtained by MRA using 
6 sera from peanut-allergic patients: #55 (○), #65 ( ), #66 (¿), #67 (●), #70 ( ), and #73 (x). Horizontal bars repre-
sent the means of the six PA subjects. Bars indicate a significant difference between the 2 corresponding treat-
ments.
In addition, the impact of the thermal modifications of Ara h 1 on the T-cell responses of 
PBMC from peanut allergic patients were assessed. Multicolour FACS-staining assessing sur-
face marker expression in combination with intracellular Ki-67 expression as a sensitive meth-
od to detect antigen-specific proliferation [18], enabled us to measure subsets of proliferating 
cells. Stimulation of PBMC cultures from NA controls by Ara h 1 did not induce significant pro-
liferation (2.9±0.8% and 1.9±0.5% for unstimulated (medium) and allergen-stimulated (Ara h 1) 
cultures, respectively; Fig. 6A). Only three of the 12 PA subjects showed detectable numbers of 
Ki-67+ proliferating cells in the Ara h 1 stimulated cultures (subjects #65, #66 and #70; Fig. 6A) 
with a corresponding mean percentage of Ki-67+ cells of 4.7±2.7 for medium and 11.9±3.4% 
for the Ara h 1 stimulation. Proliferating cells consisted of 81% CD4+ cells and the CD4+CD25+ 
subset of cells was the largest cell population present in the proliferating cell fraction. For 
these three PA subjects, thermal treatment of N-Ara h 1 had no effect on its capacity to induce 
PBMC proliferation (Fig. 6B). Whilst no cytokine production was induced by Ara h 1 in PBMC 
cultures from the NA subjects (Fig. 6C, D; and data not shown), the production of IL-5 and IL-13 
was significantly enhanced in the culture of PBMC from 5 out of 12 PA subjects (patients #65, 
#66, #67, #70 and #73) upon stimulation with N-Ara h 1. Heating in the presence or absence 
of glucose had no effect on these cytokine secretions. In PA subjects, an enhanced production 
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(compared to NA subjects) was also observed for IL-10 and IFN-γ, albeit not significant for all 
stimuli tested (data not shown). IL-17 production was below 20 pg/ml for all tested conditions 
(data not shown).
Fig. 6. Effect of thermal treatment on subpopulation of proliferating cells and cytokine induction capacity. A. Fresh 
PBMC were left unstimulated (Med) or stimulated with N-Ara h 1 for 7 days. After harvesting, the cells were incu-
bated with anti-CD4/CD25 antibody and afterwards stained for an anti-Ki-67 PE antibody. Data are mean percent-
age of Ki-67 positive cells ± SEM values for three (#65, #66 and #70) of the 12 PA subjects and seven NA controls. 
The percentage Ki-67+ cells is divided in the following subpopulations of cells: CD4-CD25- (dark grey bars), 
CD4+CD25- (white bars), CD4-CD25+ (black bars) and CD4+CD25+ (light grey bars) cells. B. Fresh PBMC were left 
unstimulated (Med) or stimulated with N-, H- or G-Ara h 1 for 7 days. Data are mean percentage of Ki-67 positive 
cells ± SEM values for three peanut-allergic patients (#65, #66 and #70) (open bars) and seven non-allergic controls 
(closed bars). Fresh PBMC were left unstimulated (Med) or stimulated with N-, H- or G- Ara h 1 and production of 
IL-5 (C) and IL13 (D), were measured after 7 days of culture. Symbols represent peanut-allergic patients #65 ( ), #66 
(¿), #70 ( ), #67 (●) and #73 (x). Horizontal bars represent the means of the five PA subjects or the 7 NA controls. 
Asterisks indicate statistically significant differences between the PA and the NA group and # indicate statistically 
significant difference between the medium and allergen-stimulated cultures for the PA group (*, # P < 0.05). No dif-
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ferences between the medium and allergen-stimulated cultures were observed for the NA group.
Discussion
We have sought to overcome the poor solubility and stability of thermally unfolded and aggre-
gated proteins [2,9,19] by using a combination of model processing of purified allergens and 
purification of allergens from thermally-processed peanuts. For the first time we have shown 
that boiled Ara h 1 forms complex branched aggregates which have a much reduced IgE-bind-
ing capacity. The aggregates also had a reduced capacity to elicit histamine release, a measure 
of functional biological activity more indicative of a potential reduced allergenic potency in 
vivo. However, this reduction was not as marked as might be expected given the reduction in 
IgE-binding capacity, and may reflect the likely multiple IgE epitopes present on the aggregates 
which might be more efficient in cross-linking surface bound IgE. Further studies in vivo will be 
required to confirm the potential clinical relevance of this observation. 
By comparison, Ara h 1 purified from roasted peanuts formed aggregates which were 
smaller and morphologically distinct from those induced by boiling and appeared to retain 
more native-like β-sheet structures by FT-IR than the boiled protein. Such structural features 
account for R-Ara h 1 retaining its allergenic IgE-binding capacity, and is consistent with previ-
ous observations that Ara h 1 purified from peanuts heated up to 140°C retained its IgE binding 
capacity [9]. These data suggest aggregate morphology could play a role in affecting IgE binding 
by altering Ara h 1 epitope availability, a greater proportion of epitopes being masked in aggre-
gates formed by boiling of Ara h 1, compared to the smaller, less complex aggregates adopted 
by the R-Ara h 1 from roasted peanuts. The formation of branched aggregates with reduced IgE 
binding capacity following boiling supports the proposition that boiling reduces the allergenic-
ity of peanut kernels and suggests that many Ara h 1 epitopes are found on the surface of the 
native proteins and are conformational in nature [2].
The ability of Ara h 1 to retain, or even have enhanced allergenicity following roasting, has 
also been attributed to Maillard modifications. However the R-Ara h 1 was not as extensively 
glycated as the model processed G-Ara h 1 suggesting that roasting may cause other, unchar-
acterized modifications of the protein which contribute to its allergenic activity. This may in-
clude modification of amino acid residues, such as lysoalanine formation, or adducts formed 
with other peanut constituents such as lipids. Further characterization of processing induced 
modification of this protein from roasted peanuts will be required to fully understand what 
contributes to the ability of this protein to retain its allergenic activity after processing.
In contrast, the ability of Ara h 1 to simulate the proliferative activity of PBMC from peanut 
allergic patients was unaltered following heat treatment and/or glycation, as has been shown 
before for Bet v 1-related allergens [20,21] and for heat-treated Ara h 2/6 (Vissers et al., sub-
mitted). The peanut allergic patients who showed an Ara h 1 specific T-cell response in this 
study also showed an Ara h 2/6 specific T-cell response and were all characterized by high pea-
nut specific IgE. The magnitude of the stimulation, in terms of proliferation and IL-5 and IL-13 
cytokine induction, was comparable for Ara h 1 and Ara h 2/6 (Vissers et al., submitted). This 
suggests that peanut allergic individuals who have high peanut-specific IgE titers have a higher 
prevalence of allergen-specific T cells and therefore give the most pronounced responses in 
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primary PBMC cultures. However, Turcanu et al. observed that peanut-specific T-helper cells in 
PBMC of peanut allergic patients were 0.6% of the total CD4+ T cells in peanut allergic patients 
and about 10 times lower in non-allergic and peanut sensitized donors [22]. Altogether these 
results may explain the low rate of responders in our ex vivo stimulation assays. 
Studies of other allergens, particularly in the search for hypoallergenic allergens support 
the view that aggregation of proteins may affect the quality of immune responses. Recent 
studies having shown that for the Bet v 1 allergens, aggregation may play an important role 
in establishing protective antibody titers in immunotherapy [23]. The aggregates produced by 
boiling Ara h 1 presented here resemble the properties of allergoids which have been well ac-
cepted for immunotherapy for many years and tend to have lower IgE reactivity, whilst retain-
ing their ability to activate T-cells [24]. Whilst boiling for 15 min did not completely abrogate 
IgE reactivity there is potential to reduce it further through application of more longer or more 
severe wet-heating regimes. Our results suggest that aggregated forms of allergens induced by 
physical processes like boiling may provide a novel form of antigen for use in allergen-specific 
immunotherapy as well as supporting the premise that boiling, as opposed to roasting, may 
reduce the allergenicity of peanut.
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Supplement file
Table S1. Serological and clinical information for the 35 peanut allergic patients recruited in different European 
centers, within the EuroPrevall European project, used in EAST studies (bold), RBL tests (*) and/or PBMC prolif-
eration tests (#).
Code
Gender 
(f/m)
Age
Peanut SPT (HEP 
Index numbers)
Grade pea-
nut allergy
Peanut 
RAST class
Peanut CAP  
(IU/mL)
Other food allergies
2A m 31 positive 3/4 5 51.7
52A m 41 nd 4 5 nd
54A f 11 2.2 1 6 >100
55A* f 14 3.3 4 6 >100
56A m 16 1.5 2 6 >100
58A f 22 2.5 4 6 >100 Soy, Lupine, Pea
65*# f 19 positive 3/4 6 >100
66*# m 18 positive 4 6 >100
67*# f 46 nd 3 5 54.4 Hazelnut, Kiwi, Cherries
68# f 20 positive 1 4 17.6
69# m 21 positive 3/4 3 6.98
70*# f 21 positive 3/4 6 >100 Soy, Pea, Apple
73*# f 22 positive 2/3 4 33.6 Hazelnut
76# m 23 positive 3 3 8.6
77# m 25 positive 2 4 33.2
78# f 24 positive 3 5 79.6 Hazelnut
80# m 27 positive 3 3 16
82# f 18 positive 1/2 3 4.7 Kiwi, Cherries
1682 m 33 nd 4 6 >100
1691 m 22 nd 3 5 nd
2205 m 25 nd 3 5 nd Hazelnut
2207 m 28 nd 4 4 nd Wheat, Hazelnut, Egg, Almond
2209 f 27 nd 4 6 nd Hazelnut, Egg, Wheat
2304 m 25 nd 3 6 nd
2305 f 18 nd 4 nd nd
03-0043 f 20 1.54 3/4 6 >100 Hazelnut, Walnut, Melon
03-0044 m 23 4.33 3 6 >100
Egg, Fish, Shrimp, Hazelnut, Wal-
nut, Sesame, Wheat, Sunflower
03-0079 f 16 2.22 3 6 >100 Pistachio, Almond, Brazil nut
05-0128 f 25 1.92 3 6 >100 Soy, Hazelnut, Apple, Peach
05-0165 f 18 0 3/4 6 >100 Chickpea, Bean, Hazelnut, Lentil
05-0195 m 31 2.13 3 5 63.5 Soy
05-0209 m 20 99.98 4 5 70.2 Pea, Soy, Bean
06-0010 m 19 2.2 3/4 5 67.4 Fish
08-0069 m 17 2.08 1 6 >100 Kiwi
12-0048 f 21 5.8 3/4 5 54.6 Shrimp
HEP: histamine equivalent prick test; EPSB: EuroPrevall Serum Bank; nd: not determined; Where known, other 
allergies of the subjects are indicated. The origin of the sera is as follows: 2A: Zurich, 52A: Amsterdam, 54A-82: 
Arnhem, 1682-2305: Vienna; 03-0043 till 12-0048 EuroPrevall Serum Bank.
Grading is based on Brockow and Ring and on Sampson et al. [25,26]. Grade 1 = dermal symptoms; grade 2 = 
gastro-intestinal problems like nausea and or cramping; grade 3 = any of the former grades plus vomiting/diarrhea 
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and respiratory tract problems like throat pruritus or tightness; grade 4 = any of the former grades and respiratory 
arrest plus cardiovascular problems like hypotension 
Directly after isolation of the PBMC from the 12 peanut allergic (PA) and 12 non allergic (NA) 
donors, a surface marker staining showed that the subset composition of the peanut-allergic 
patients was comparable to the subset composition of cells of the non-allergic donors. All val-
ues were within the normal range of leukocytes present in the peripheral blood as assessed 
previously [27,28]. Median percentages and ranges (percentile 5-95) of cell subsets within 
the PBMC population for the 24 subjects were as follows: 39% (25-57) CD3+CD4+, 20% (8-
35) CD3+CD8+, 13% (6-26) CD14+, 8% (4-11) CD19+, 9% (6-14) CD16+CD56+CD3-, 4% (1-9) 
CD16+CD56+CD3+ cells. The average percentage of viable and early apoptotic lymphocytes 
directly after isolation was 92±1% and 8±1%, respectively (data not shown). To exclude possible 
toxic effects of the allergen preparations tested and to ensure the viability of the cells of the 
long-term cultures, an Annexin V/PI staining was performed after 7 days of allergen-stimulated 
cultures and of the unstimulated control. No difference was observed between the different 
stimuli and the medium, or between the PA subjects and the NA controls. On average 84±1% 
of the cells was regarded as viable cells.
After 4 days of culture, proliferation was measured on both unstimulated and αCD3/αCD28-
stimulated cultures to assess the maximal intrinsic capacity of the T cells of both tested groups 
to respond to a stimulus. Without stimulus the percentage of Ki-67 positive cells was below 
8% for all 24 patients tested. The average percentage of Ki-67 positive cells of αCD3/αCD28-
stimulated cultures was 58.3±3.9% for the PA subjects and 54.0±4.6% for the NA controls, 
which was not significantly different (Fig. S1). For the 24 subjects tested, the proliferating cell 
population after the αCD3/αCD28-stimulation consisted of 97% CD25+ cells and 48% were CD4 
positive (Fig. S1). In the unstimulated cultures, IL-5, IFN-γ and IL-17 levels were below 20 pg/ml 
for all patients tested and below 50 pg/ml for IL-10 and IL-13. After αCD3/αCD28-stimulation, 
cytokine levels of the PA subjects versus the NA controls were respectively IL-10=675±155 
vs 905±216, IFN-γ=6654±1242 vs 7925±1106, IL-17=209±94 vs 134±12, IL-13=479±113 vs 
514±226 and IL-5=64±20 vs 251±215. Due to high inter-individual variation, these cytokine 
values did not significantly differ between the two donor-groups tested.
The analysis of proliferation and cytokine production after polyclonal αCD3/αCD28 stimula-
tion thus revealed that the T-cell compartments in the NA and PA subjects did not show intrin-
sic differences in their activation potential and characteristics
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Fig. S1. Fresh PBMC were left unstimulated (Med) or stimulated with αCD3/αCD28 for 4 days. After harvesting, 
the cells were incubated with anti-CD4/CD25 antibody and afterwards stained for an anti-Ki-67 PE antibody. Data 
are mean percentage of Ki-67 positive cells ± SEM values for 12 peanut allergic (PA) and 12 non allergic (NA) con-
trols. The percentage Ki-67+ cells is divided in the following subpopulations of cells: CD4-CD25- (dark grey bars), 
CD4+CD25- (white bars), CD4-CD25+ (black bars) and CD4+CD25+ (light grey bars) cells.
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Summary
Background: Peanuts are often consumed after roasting, a process which alters the three-
dimensional structure of allergens and leads to Maillard modification. Such changes are likely 
to affect their allergenicity.
Objective: We aimed to establish the effect of thermal treatment mimicking the roasting pro-
cess on the allergenicity of Ara h 1 and a mix of 2S albumins from peanut (Ara h 2/6). 
Methods: Ara h 1 and Ara h 2/6 were purified from raw peanuts and heated in a dry form for 
20 min at 145°C in the presence (R+g) or absence (R-g) of glucose, and soluble proteins were 
then extracted. Sera obtained from 12 well-characterized peanut-allergic patients were used 
to assess the IgE binding and degranulation capacities of the allergens.
Results: Extensive heating at low moisture resulted in hydrolysis of both Ara h 1 and Ara h 2/6. 
However, in contrast to Ara h 2/6, soluble R+g Ara h 1, formed large aggregates. Although the 
IgE binding capacity of R+g and R-g Ara h 1 was decreased 9000- and 3.6-fold respectively com-
pared with native Ara h 1, their capacity to elicit mediator release was increased. Conversely, 
both IgE binding capacity and degranulation capacity of R-g Ara h 2/6 were 600-700-fold lower 
compared with the native form, although the presence of glucose during heating significantly 
moderated these losses.
Conclusions and Clinical Relevance: Extensive heating reduced degranulation capacity of Ara h 
2/6 but significantly increased the degranulation capacity of Ara h 1. This observation can have 
important ramifications for component resolved approaches for diagnosis and demonstrates 
the importance of investigating the degranulation capacity in addition to IgE reactivity when 
assessing effects of food processing on the allergenicity of proteins.
Introduction
Peanut allergy is a common food allergy in the USA and in European countries affecting around 
1% of the population [1,2]. In some studies the prevalence was found to be much higher, with 
approximately 10% of 8-year-old children in the UK being sensitised to peanut, of whom 2% 
have a clinical peanut allergy [3]. In additi on, the prevalence of peanut allergy in children ap-
pears to be increasing [2], which contributes to a growing global concern, particularly given the 
severity of peanut-allergic reactions.
Recent studies indicate that peanut-allergic patients are most frequently sensitized to Ara 
h 2 and Ara h 6, followed by Ara h 1, Ara h 3 and Ara h 7 [4,5]. Ara h 6 and Ara h 7 show around 
55% and 40% amino acid sequence homology with Ara h 2, respectively [6,7], suggesting that 
these three proteins could share a number of identical epitopes [6,8]. However, epitopes spe-
cific to Ara h 2 and Ara h 6 also exist [4]. Ara h 2, 6 and 7 all belong to the family of the 2S 
albumin storage proteins and have a molecular weight between 16 and 20 kDa [6]. Ara h 1 
is a vicilin-like 7S seed storage globulin, also known as conarachin. Ara h 1, comprising 63.5 
kDa subunits that assemble naturally into trimers of approximately 180 kDa, often aggregates 
forming multimers of up to 600-700 kDa [9-11]. Twenty-three linear IgE epitopes have been 
identified within Ara h 1, mainly in the areas of the subunit-subunit contacts that are protected 
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from protease degradation [12-14].
Food processing can potentially destroy or conversely create linear and conformational IgE 
binding epitopes, establish the exposure of formerly hidden antigenic sites, and change the 
susceptibility to digestion [15]. These changes may affect allergic sensitization to food proteins 
and elicitation of allergic reactions in sensitised individuals thereby impacting on the allergenic 
potential of the food proteins. Important modifications that food proteins may undergo are 
observed as a consequence of the Maillard reaction, which involves the reaction of free amino 
groups on proteins (particularly lysine residues) with reducing sugars, thereby inducing flavour 
and colour of processed foods including peanuts [16,17]. The extent of glycation depends on 
the temperature, pH, water activity, duration of the heating and the concentration of the re-
ducing sugars present [18]. Whilst the Maillard reaction can affect the allergenicity of peanut 
proteins, this has not been conclusively demonstrated and depends on the type of protein and 
the conditions under which the Maillard reaction occurred. In addition, the type and amount of 
carbohydrate used and other matrix compounds present during heating also affect allergenic-
ity [16,17,19-23].
The effect of processing on the allergenicity of proteins has been assessed by determining 
the IgE binding capacity using immunoassays and/or immunoblotting. However, the impact of 
food processing on the cross-linking and degranulation capacity is important, since processing-
induced modifications are likely to affect the availability of the multiple epitopes required for 
effective cross-linking of cell surface bound IgE. In the current study, the effects of processing 
were also assessed using two cellular mediator release assays to determine allergen cross-
linking capacity of IgE antibodies bound to FcεRI of mast cells/basophils. Roasting induces an 
array of protein modifications due to interaction with the food matrix, affecting the purification 
efficacy of the modified allergens. Therefore, the allergens were first purified from untreated 
peanut, lyophilized and then subjected to a model thermal treatment mimicking the roasting 
process.
Materials and Methods
Patients
Peanut-allergic patients from the Allergology Practice Arnhem (APA, the Netherlands) were ap-
proached to participate via an invitation letter. Written informed consent was obtained before 
sample collection and the experiments performed were approved by the local ethical commit-
tee (Commissie Mensgebonden Onderzoek regio Arnhem-Nijmegen). The studied population 
included 12 peanut-allergic patients. All patients had a well-documented peanut allergy based 
on an extensive medical history, physical examination, and objective clinical manifestations ob-
served after peanut ingestion. Grading of food-induced anaphylaxis was according to severity 
of clinical symptoms [24,25]. From all patients, except one, a skin prick test with commercial 
peanut extract (ALK-Abelló, Nieuwegein, the Netherlands) was performed and peanut-specific 
IgE levels were determined using ImmunoCAP (Phadia AB, Uppsala, Sweden).
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Isolation of Ara h 1 and Ara h 2/6
Native Ara h 1 (N-Ara h 1) was purified from redskin type raw peanuts (obtained from local 
suppliers, UK) as described by Marsh et al. [26]. The purification is based on affinity chroma-
tography using concanavalin A-Sepharose followed by gel permeation chromatography using 
a Superdex Preparative Grade S200 column (GE Healthcare, Buckinghamshire, UK). Protein 
preparations were adjudged >99% pure by SDS-PAGE.
Native 2S albumins containing both Ara h 2 and Ara h 6 (N-Ara h 2/6) were purified from 
unroasted redskin type peanuts as described previously and allergen identity was confirmed 
by in gel-trypsin digestion and MALDI-TOF mass spectrometry [27]. This purification involved 
ammonium sulphate fractionation and gel-filtration chromatography, avoiding the use of de-
naturing conditions such as reverse phase HPLC. Purified native proteins were stored at -20°C 
prior to use.
Roasting treatment of the purified allergens
Purified native Ara h 1 in 32.5 mM phosphate buffer (pH 7.6) containing 100 mM NaCl and puri-
fied native Ara h 2/6 in 25 mM phosphate buffer (pH 7.4) containing 150 mM NaCl and 0.02% 
(w/v) NaN
3
 were split in three batches. One batch of the protein was kept untreated (native 
form). One batch was mixed with glucose (Sigma-Aldrich, Steinheim, Germany) in a ratio of 
1:2 (protein:glucose, w/w) in PBS. The batch with glucose and one batch without glucose were 
placed in glass bottles, frozen at -70°C and lyophilized. Lyophilized samples were then heated in 
a forced convection Chamber of Thermal Research (Wamed, KBC-65W) under conditions cho-
sen according to Saklar et al. [28]. Aft er establishing a steady temperature of 145°C, the pro-
teins were heated for 20 min and then samples were allowed to cool to ambient temperature. 
Samples were dissolved in Milli-Q water, centrifuged (5000×g, 15 min, 4°C) and the superna-
tant collected and ultrafiltered by Amicon Ultra-15 centrifugal filters (10,000 nominal molecu-
lar weight limit (NMWL) for Ara h 1 and 5,000 NMWL for Ara h 2/6) (Millipore, Billerica, MA, 
USA) against PBS for several rounds to remove the residual glucose, the hydrophilic glucose 
degradation products from the glycated proteins and other small molecular weight products. 
By this, the allergenic activity of the protein itself, and not of other compounds formed during 
roasting, was assessed. Finally, the protein concentration was assessed by the BCA-assay and 
aliquots were stored at -70°C. Samples will be referred to as N (native), R+g (heated at low 
moisture in the presence of glucose) or R-g (heated at low moisture in the absence of glucose).
Biochemical characterization
SDS-PAGE and Western blot analysis
SDS-PAGE (12%) was performed under reducing conditions on a mini-protean II gel apparatus 
(Bio-Rad, Veenendaal, the Netherlands) [29]. The gels were stained using Gel Code blue stain 
(Pierce, Rockford, IL, USA) and the precision plus protein dual colour MwM was used as the 
molecular weight standard (Bio-Rad).
For analysis of IgE-binding fragments of the thermally processed Ara h 1 and Ara h 2/6, 
a Western blot analysis was performed using a plasma pool of the first nine peanut-allergic 
patients described in Table 1. SDS-PAGE (12%)-separated proteins were electrophoretically 
transferred to Protan nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany). The 
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membranes were blocked in Tris-buffered saline with Tween-20 (TBST; 20 mM Tris, 500 mM 
NaCl, 0.05% (v/v) Tween, pH 7.5) plus 3% BSA for 1 h at room temperature and then incu-
bated with a 1:15 dilution of the pooled human plasma overnight at 4°C in 0.5% BSA in TBST. 
After incubation for 1 h with biotin labelled mouse anti-human IgE (1:250, BD Pharmingen, 
San Diego, CA, USA) in TBST plus 5% non-fat dry milk, membranes were washed and bound IgE 
was detected by streptavidin poly-horse radish peroxidase (1:4000, Sanquin, Amsterdam, the 
Netherlands) in TBST plus 5% milk powder for 1 h at room temperature. Between each incuba-
tion step, membranes were washed twice with TBST/Triton (TBST, 0.2% (v/v) Triton X-100) and 
once with TBST, for 10 min at room temperature. Signal was detected by development with 
a chemiluminescence kit (Amersham Biosciences, Roosendaal, the Netherlands) according to 
the manufacturer’s protocol and visualized by the use of Lumi-film chemiluminescent Detec-
tion Film (Roche, Mannheim, Germany).
Protein size measurement by light scattering
The measurements of the average size were carried out on a Malvern Zetasizer Nano-ZS ana-
lyser (Malvern Instruments Ltd., Malvern, Worcestershire, UK). Dynamic light scattering (DLS) 
was performed and the intensity of the light scattered by the protein was measured at an angle 
of 173°. Samples were measured in disposable micro cuvettes (Malvern) at a concentration of 
250 μg/mL in sterile PBS, pH 7.4. First, the sample was equilibrated for 300 seconds at 20°C 
after which a time scale of the scattered light intensity fluctuations was measured. Every sam-
ple was measured in triplicate and autocorrelation analysis was carried out with the use of the 
Zetasizer software for the Nano, v6.20 (Malvern Instruments Ltd). Data was processed using 
multiple narrow modes (high resolution) as analysis model, which gave the lowest multimodal 
fit error. Data are presented both as size distribution by volume as by intensity.
o-Phthaldialdehyde (OPA) Assay 
The OPA assay was applied to determine the quantity of free amino groups according to Niels-
en et al. [30] with slight modifications. The protein solution (250 µg/ml) was mixed with the 
reagent in a ratio of 1:10 (v/v) and incubated for 20 min at room temperature. The absorbance 
was measured at 340 nm and samples were measured in triplicate. Unreacted amino groups 
were estimated from a calibration curve established with L-leucine.
Analysis of the IgE immunoreactivity 
Concentrations of total IgE and of IgE specific to purified Ara h 1 and Ara h 2/6 were deter-
mined using the enzyme allergosorbent assay (EAST) as previously described [21,31]. 
Enzymatic Ara h 1 tracer was prepared by covalent linkage of N-Ara h 1 to the tetrameric 
form of acetylcholinesterase (AChE using N-succinimidyl-S-acetyl-thioacetate (SATA) reacting 
with maleimido groups previously incorporated into AChE with N-succinimidyl-4-(maleido-
methyl)-cyclohexane-1-carboxylate (SMCC) as described [32,33]. Native Ara h 2/6 was dialyzed 
against borate buffer 0.1 M pH 9 (NMWL 3500 Da), and then incubated for 45 min at room 
temperature with EZ-link sulfo-NHS-LC biotin (Pierce, Rockford, IL, USA) using a 10:1 molecular 
ratio biotin:N-Ara h 2/6. Biotinylation was stopped by further incubation for 1 h in 1 M Tris 
buffer, pH 8.5. Biotinylated N-Ara h 2/6 were then dialyzed and diluted in EIA buffer and kept 
at 4°C until use.
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Inhibitions were performed in a reverse EAST [32]. Briefly, 50 µL/well of different dilutions 
of each serum which were optimized in an initial experiment were distributed on plates coated 
with the anti-human IgE (mouse monoclonal, clone LE27; described by Grassi et al. [34]) and 
incubated overnight at 4°C. After washing, 25 µL of inhibitor and 25 µL of tracers were added 
and incubated for 4 h at room temperature. Inhibitors consisted of increasing concentrations 
of N-, R+g or R-g Ara h 1 (10-4 – 100 µg/mL) or Ara h 2/6 (10-5 – 10 µg/mL). Enzymatic tracers 
consisted of N-Ara h 1 labelled with AChE or biotinylated N-Ara h 2/6 (200 ng/mL). When using 
a biotinylated tracer, an additional 45 min incubation with 50 µL of streptavidin labelled with 
AChE was performed. After washing, Ellman’s reagent was used as an enzyme substrate [35]. 
Results were expressed as B/B0, where B0 and B represent the amount of N-Ara h 1 or N-Ara h 
2/6 tracers linked to immobilized IgE in the absence or presence of a known concentration of 
inhibitor, respectively.
Indirect basophil histamine release (BHR)
Buffy coats were obtained from the hospital blood bank in Copenhagen and cells were screened 
and selected for a high anti-IgE response and no allergies. Peripheral blood mononuclear cells 
(PBMC) were isolated by Lymphoprep gradient centrifugation, cell-bound IgE was stripped 
from the cells by a phosphate buffer and BHR tests were performed as described previously 
[36]. Six dilutions (0.001 – 100 µg/mL) were tested for Ara h 1 and 12 (0.0002 - 20 µg/mL) for 
Ara h 2/6 and the concentration range chosen was based on earlier optimization experiments. 
Allergens were graded based on the lowest concentration inducing a histamine release (HR) 
of > 10 ng/mL, in which grade 1 is basophils only reacting to the highest concentration of the 
allergen tested, and 6 is basophil reaction to the lowest concentration tested.
Mediator release assay (MRA) using Rat Basophilic Leukemia (RBL) cells
RBL-2H3 cells expressing the α-chain of the human FcεRI receptor [37] were kindly provided 
by Drs. Vieths and Vogel (Paul-Ehrlich-Institut, Langen, Germany). In a preliminary experiment, 
four sera dilutions (1:20, 1:30, 1:40 and 1:50) and three concentrations of a peanut extract 
(0.01, 0.1 and 1 μg/mL) were tested for all 12 sera and suitable sera were selected based on 
the percentage β-hexosaminidase release. Cells were cultured in MEM medium supplemented 
with 5% FCS and 1% glutamine (all from Gibco, Paisley, UK) at 37°C in a humidified atmosphere 
with 5% CO
2
. Cells in stationary growth phase (confluent or slightly overgrown) were harvested 
and plated in 96-well plates at 1.5 × 105 cells/well. Human sera (1:30) were added and incu-
bated overnight to passively sensitize the cells. After washing, the cells were stimulated for 
1 h with the allergens diluted in Tyrode’s buffer containing 50% deuterium oxide [37]. The 
antigen-specific release was quantified by measuring β-hexosaminidase activity and expressed 
as percentage of the total β-hexosaminidase content that was obtained by lysing the cells with 
1% Triton-X100 (Sigma-Aldrich, Zwijndrecht, the Netherlands) [38]. Spontaneous release was 
determined on cells not sensitized nor cross-linked. Toxicity of each serum was also checked 
using sensitized cells not further cross-linked with allergens. The release data were fitted to 
four-parameter-logistic curves by non-linear regression using the SigmaPlot v10.0 software 
package, and IC50 values were assessed accordingly.
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Statistical analysis
Due to a non-normal distribution of the data, the nonparametric Wilcoxon signed rank test was 
used to compare IC50 values and allergen classes between the native and treated allergens. 
The difference was considered statistically significant for P < 0.05. The statistical analysis was 
performed by using SPSS Software (v15.0, SPSS Inc., Chicago, USA).
Results
Effect of model thermal treatment on allergen structure 
Blanched kernels of peanuts are subjected to oil roasting for around 5-8 min at 149-163°C for 
optimum flavour and colour [39], a process which results in extensive, but not complete, dena-
turation of peanut kernel proteins. In order to mimic this process, purified proteins were freeze 
dried to reduce the moisture content to about 4-5% [40], which corresponds to the moisture 
content of blanched peanuts. Inclusion of sugar in the samples prior to freeze-drying resulted 
in a further reduction of the moisture content, to about 1.5-3% [40].
Samples heated in the presence of glucose turned brown due to the formation of Maillard 
browning products. Soluble proteins were recovered from the thermally-treated proteins and 
this yield differed for the individual proteins. Around 75% of the Ara h 1 and 53% of the Ara 
h 2/6 remained soluble after heating without glucose. The addition of glucose resulted in a 
dramatic loss of soluble protein for Ara h 1, with only 5% of the protein being recovered. Ara 
h 2/6 solubility (58%) was very similar to that of the sample heated without glucose (data not 
shown).
Analysis of the residual soluble Ara h 1 showed that heating had resulted in significant 
hydrolysis of the protein (Fig. 1A), with appearance of two new polypeptides of about 23 and 
33 kDa and substantial material of < 15 kDa appearing at the gel dye front after heating in 
the absence of glucose. This was accompanied by a loss of the parent 63.5 kDa polypeptide. 
The faint smeared appearance is indicative of some level of polypeptide aggregation and the 
formation of numerous heterogeneous structures due to different stages of the Maillard reac-
tion. Addition of glucose during the heating resulted in a loss of any polypeptides resolvable by 
SDS-PAGE with all the stained proteins having a Mr < 15 kDa and a faint smear present in the 
protein stained gel, suggesting that heating in the presence of glucose had resulted in more 
extensive degradation. However, much of the protein did not enter the SDS-PAGE due to large 
aggregate formation as substantiated by the light scattering results (see below). The degrada-
tion products in both samples were still able to bind IgE antibodies from the peanut-allergic 
patients in the IgE-immunoblot experiment (Fig. 1C) despite R+g Ara h 1 being present at such 
low levels they were barely discernable on the protein stained gel (Fig. 1A). The thermal treat-
ment also resulted in degradation of Ara h 2/6 to low molecular weight polypeptides below 
the resolving capacity of the SDS-PAGE gel used, with a substantial amount of protein-staining 
observed at the dye front of the gel (Fig. 1B). Heating in the presence of glucose resulted in 
the protein being poorly resolved with a smear evident in the protein stained gel. The pyrolysis 
products of the Ara h 2/6 were able to bind IgE, with individual polypeptides discernable on the 
Western blot (Fig. 1D) showing that Ara h 2/6 also retained its IgE binding capacity even after 
such extreme thermal treatment.
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Fig. 1. SDS-PAGE and Western blot of the native and 
thermally processed Ara h 1 and Ara h 2/6 proteins. 
Ara h 1 (A) and Ara h 2/6 (B) were run on SDS-PAGE 
and stained with Coomassie blue stain. The same sam-
ples were transferred to nitrocellulose and analysed 
by Western blot analysis using a pool of plasma from 9 
peanut-allergic patients. The bound plasma IgE was 
recognized by biotin labelled mouse anti-human IgE in 
combination with strep poly HRP and visualized by 
chemoluminescence (C for Ara h 1 and D for Ara h 
2/6). MwM = molecular weight standard; R-g = heated 
in the absence of glucose; R+g = heated in the pres-
ence of glucose
The content of free amino groups was significantly lower in the heated Ara h 1 samples 
and lowest in the Ara h 1 heated in the presence of glucose as determined by the OPA assay 
(Table 2). For Ara h 2/6 roasting did not significantly change the free amino groups content 
significantly (data not shown).
The effect of thermal treatment on aggregation state of the soluble fraction of the Ara h 1 
was also assessed using fixed angle dynamic light scattering (Table 2, Fig. 2). The unheated na-
tive Ara h 1 sample had a mean hydrodynamic diameter of around 15 nm, consistent with the 
protein being present in its native trimeric state. Heating alone resulted in the soluble fraction 
of Ara h 1 having a slightly reduced size of around 12 nm, consistent with the hydrolysis of the 
protein observed by SDS-PAGE although part of these degraded polypeptides were clearly as-
sembled into much larger aggregated structures, ranging in size from 30 to 400 nm analysed by 
intensity (Fig. 2B). The soluble fraction remaining after heating in the presence of glucose was 
present as an ensemble of very large aggregated structures ranging from ~200 to 1000 nm in 
size, with an average diameter of 560 nm (Table 2, Fig. 2). Due to the relatively small dimen-
sions of Ara h 2/6 this type of analysis was not performed for the 2S albumins.
Table 1. Biochemical analysis of native and heated allergens.
N-Ara h 1 R+g Ara h 1 R-g Ara h 1
Percentage free primary amino groups in relation to the native allergen (mean SD) 100 16.1±1.4 35.1±3.6
Mean size ± width (d.nm)* 15.1±3.2 563±191 12.1±2.6
Zav (d.nm)** 16.2±0.1 389±13.3 45±0.5
* Analysed as size distribution by volume of the most common peak which represented for all samples >98% of 
the total volume. ** Z-average (Mean±SEM) of triplicate measurements; analysed as size distribution by intensity 
and including all peaks
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Allergenic activity of thermally-modified peanut allergens
Nine of the 12 peanut-allergic patients (5 males and 7 females, median age: 22 years) showed 
grade 3 or 4 clinical peanut allergy and all except one a highly positive (++) SPT (Table 1). Specif-
ic IgE values for peanut extract, Ara h 1 and Ara h 2/6 were assessed in the sera of the patients 
(Table 1). All patients were polysensitized for the different peanut allergens tested (Ara h 1 and 
Ara h 2/6), which is in accordance with a recent study that showed only a low percentage (7%) 
of mono-allergen sensitized peanut-allergic patients [4].
Table 2. Serological and clinical information for the 12 peanut-allergic patients recruited from the Allergology 
Practice Arnhem, the Netherlands.
Code
Age (years)/
sex (f/m)
Grade pea-
nut allergy
SPT (-/+/++)
Other food          
allergies
Total IgE 
(kU/L)
Specific IgE (kU/L)
Peanut (f13) Ara h 1 Ara h 2/6
65 19/f 3/4 ++ no 787 >100 267 208
66 18/m 4 ++ no 514 >100 173 71
70 21/f 3/4 ++ soy, pea, apple 1869 >100 117 76
78 24/f 3 ++ HN 406 79.6 62 29
67 46/f 3 nd HN, kiwi, cherries 3986 54.4 51 35
73 22/f 3/4 ++ HN 96 33.6 19 3.7
77 25/m 2 ++ no 86 33.2 21 3.5
68 20/f 1 ++ no 109 17.6 10 6
80 27/m 3 ++ no 110 16 6.9 17
76 23/m 3 ++ no 108 8.59 6 0.3
69 21/m 3/4 ++ no 200 6.98 2.2 1.2
82 18/f 1/2 + kiwi, cherries 23 4.75 2.3 6.4
IgE concentrations (IU/mL) of total IgE and IgE specific for Ara h 1 and Ara h 2/6 were determined by EAST assay 
Fig. 2. Particle size distribu-
tion of N, R+g and R-g Ara h 
1 measured with dynamic 
light scattering. Light scatter-
ing measurements of native 
(N; ––––), heated in the pres-
ence of glucose (R+g; –– ––) 
or heated in the absence of 
glucose (R-g; - - - -) Ara h 1 
protein particles. Results are 
shown as size distribution by 
A. volume, percentage vol-
ume versus size in nm and B. 
intensity, percentage intensity 
versus size in nm. Data repre-
sent the mean of three meas-
urements per sample.
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on anti-IgE or allergens coated plates. Each serum was tested as serial dilutions from 1/4 to 1/2500, in duplicates. 
Limits of detection of the assays were 0.1 IU/mL, permitting detection values > 100 kU/l. Specific IgE for peanut 
(f13) was determined using ImmunoCAP (Phadia AB) and values were capped at 100 kU/l. nd = not determined, 
HN = hazelnut
Grading is based on Brockow and Ring and on Sampson et al. [24, 25]. Grade 1 = dermal symptoms; grade 2 = 
gastro-intestinal problems such as nausea and or cramping, grade 3 = any of the former grades plus vomiting/diar-
rhoea and respiratory tract problems such as throat pruritus or tightness, grade 4 = any of the former grades and 
respiratory arrest plus cardiovascular problems such as hypotension.
IgE immunoreactivity of heated Ara h 1 and Ara h 2/6 was analysed by reverse EAST inhibi-
tion. Control experiments were performed using sera from non-allergic subjects and showed 
no IgE binding at all. Figure 3 shows inhibition of the IgE binding to N-Ara h 1 (Fig. 3A) and N-Ara 
h 2/6 (Fig. 3B) by N, R+g and R-g allergens obtained for representative sera. 
Fig. 3. IgE capture inhibition curves obtained for N, R+g, and R-g Ara h 1 (A) and N, R+g, and R-g Ara h 2/6 (B) as 
competitors. IgE binding capacities of native and heat modified +/- glucose allergens were assessed by competitive 
assays in the IgE capture format. Inhibition was performed into microtiter plates coated with anti-IgE, and previ-
ously incubated with allergic patient sera at convenient dilution. Competition was conducted accordingly, by add-
ing increasing concentrations of competitors, i.e. native (N; ― ―), heated in the presence of glucose (R+g; – –●– –) 
or heated in the absence of glucose (R-g; - - - - - -) allergens, at the same time as labelled native allergens (Ara h 1 
(A) or Ara h 2/6 (B)). Results are shown of representative sera of peanut-allergic patients (serum #78 for Ara h 1 and 
serum #70 for Ara h 2/6). Averages are shown of duplicate values ± SD.
IC50 values obtained for the different sera and allergens were then calculated (Fig. 4). Heat-
ing decreased the IgE binding capacity of Ara h 1, IC50 values for R+g and R-g Ara h 1 being 
~9000- and 3.6-fold higher, respectively, compared with the N-Ara h 1. Heating also decreased 
the IgE binding capacity of Ara h 2/6, resulting in a 22- and almost 600-fold decrease of the 
inhibition potency for R+g and R-g Ara h 2/6, respectively, when compared with N-Ara h 2/6.
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Fig. 4. Analysis of IC50 (ng/mL) values obtained using IgE capture inhibition assay with N, R+g, and R-g Ara h 1 (A) 
and N, R+g, and R-g Ara h 2/6 (B) as competitors. Protein amounts to obtain 50% inhibition of the Native Ara h 
1-tracer (A) or the Native Ara h 2/6 tracer (B) were determined using five (A) or eight (B) individual sera from pea-
nut-allergic patients. The average IC50 values are shown ± SEM. Increase of IC50 value corresponds to a decrease 
in IgE-binding capacity. Means without a common letter differ (P < 0.05).
The IgE cross-linking capacities of native and heated allergens were initially determined 
using histamine release tests that were performed employing passively sensitized human 
stripped basophils. Sera from the selected peanut-allergic patients were first screened to de-
termine the optimal concentration range of the allergens. Sera from two non-allergic controls 
were included for which histamine release levels were < 10 ng/mL for all allergens (data not 
shown). Histamine release dose-response curves were similar for all patients’ sera tested and 
titration curves of representative sera are represented in Figure 5. Native Ara h 2/6 (Fig. 5B) 
demonstrated a profoundly higher biological activity than N-Ara h 1 (Fig. 5A), showing HR of 
> 10 ng/mL at a protein concentration of 0.001 μg/mL compared to the 10 μg/mL of N-Ara h 
1 needed to elicit equivalent HR. Despite reducing the IgE binding capacity of Ara h 1, heating 
in the presence or absence of glucose profoundly increased the degranulation potency of this 
allergen, and showed a HR of > 10 ng/mL at a concentration of 0.01 μg/mL for both heated in 
the presence and absence of glucose (Fig. 5A). In contrast, heating reduced the degranulation 
activity of Ara h 2/6, particularly in the absence of glucose (Fig. 5B). The different proteins were 
graded from 1 to 6, a higher grade indicating a higher histamine releasing capacity. Thus, Ara 
h 1 showed a significantly higher allergen class after heating (independent of the addition of 
glucose), whilst Ara h 2/6 had a significantly lower allergen class after heating in the absence 
of glucose.
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Fig. 5. Histamine release (ng/mL) by passively sensitized basophils induced by (non) modified allergens. Basophils 
were passively sensitized with sera from a peanut-allergic patient and stimulated with increasing concentrations of 
native (N; ― ―), heated in the presence of glucose (R+g; – –●– –) or heated in the absence of glucose (R-g; - - - 
- - -) Ara h 1 (A) or Ara h 2/6 (B). Results are shown of representative sera of peanut allergic patients (serum #67 for 
Ara h 1 and serum #69 for Ara h 2/6). Error bars represent the SD of duplicate values. The column graphs presented 
within each figure represent the classes of the allergens, based on grading of the responses from 1 to 6. The grading 
is based on the lowest concentration inducing a histamine release of > 10 ng/mL, in which grade 1 is basophils only 
reacting to the highest concentration of the allergen tested, and 6 is basophil reaction to the lowest concentration 
tested (n = 6-7). Means without a common letter differ (P < 0.05).
The biological mediator-releasing activity of the native versus the heat-modified allergens 
was also assessed in the RBL mediator release assay. The sera that showed significant degranu-
lation capacity in this test were generally those sera having high peanut-specific IgE levels. 
After passive sensitization of RBL cells with IgE from peanut-allergic patients, the cells were 
challenged by serial dilutions of the native or processed allergens which resulted in a dose-
dependent mediator release. Figure 6 shows typical results of representative sera. In addi-
tion, the table presented within each figure represents the average protein concentrations 
to provoke 50% of the maximum mediator release induced by the native allergen (EC50). The 
allergenic activity of the thermally-treated Ara h 1 was dramatically increased with a 700- and 
1700- fold reduction in EC50 for R+g and R-g Ara h 1, respectively, compared to the native 
protein (Fig. 6A). The presence of glucose during heating had only a minor influence on the 
allergenic activity. Similar results were obtained with respect to light scattering, IgE reactivity 
and RBL degranulation capacity with a different batch of heated and heat-glycated Ara h 1 (data 
not shown).
In contrast, extensive heating of Ara h 2/6 increased the IC-50 values by 19- and 661-fold 
for R+g and R-g, respectively (Fig. 6B). The presence of glucose significantly moderated this loss 
in degranulation capacity over heating alone. Non-specific binding to the protein (and possibly 
other products present after Maillard modification) was not observed as no β-hexosaminidase 
release was induced by the different allergens when using sera from non-allergic patients (data 
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not shown). Furthermore, testing the native allergens, N-Ara h 2/6 showed the highest de-
granulating activity with a maximum release obtained at 1 ng/mL versus 1 μg/mL for N-Ara h 1.
Fig. 6. Percentage of β-hexosaminidase release from humanized rat basophilic leukaemia (RBL) cells induced by 
(non) modified allergens. Humanized RBL cells were passively sensitized with sera from a peanut-allergic patient 
and stimulated with increasing concentrations of native (N; ― ―), heated in the presence of glucose (R+g; – –●– –) 
or heated in the absence of glucose (R-g; - - - - - -) Ara h 1 (A) or Ara h 2/6 (B). Results are shown of representative 
sera of peanut-allergic patients (serum # 70 for Ara h 1 and serum # 66 for Ara h 2/6 ). Error bars represent the SD 
of triplicate values. The table presented within each figure represents the average protein concentrations (μg/mL 
for Ara h 1 and ng/mL for Ara h 2/6) to obtain 50% of the maximum allergen release of the native allergen (IC50) (n 
= 4-5). Means without a common letter differ (P < 0.05).
Discussion
In order to relate processing effects to the impact on structure of allergens more directly we 
studied the effects of thermal treatments on the allergenic activity of Ara h 1 and Ara h 2/6 
purified from raw peanut. Many thermal treatments employed in the processing of peanuts, 
such as roasting and frying, are undertaken when the water content is low, usually around 
4%. The present paper describes a model treatment for purified allergens which attempts to 
mimic these processing conditions, using freeze-dried allergens heated at 145°C for 20 min 
in the presence or absence of glucose. The presence of water can have a profound effect on 
the denaturation behaviour of proteins as these tend to be more thermostable when water 
content is limiting [41]. In the present study, the effect of the heating was pyrolysis of the 
proteins, resulting in their degradation to much smaller polypeptides. However, we observed 
that these degradation products were assembled into larger structures, mainly for Ara h 1 that 
is present as very large macromolecular aggregates after extensive heating with glucose. In 
addition, besides pyrolysis followed by aggregation, also aggregation of monomers resulting 
in large fragments not dissolvable in SDS might have occurred. The greater thermal stability of 
the 2S albumins resulted in a greater proportion of the Ara h 2/6 being soluble after application 
of heat in the dry state compared to Ara h 1, irrespective of whether glucose was included. It 
seems thus likely that the peptides resulting from pyrolysis will remain assembled into larger 
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structures. In addition, covalent cross-linking of the protein as a consequence of Maillard re-
actions [17,42] explains the low protein extraction yield of Ara h 1 heated in the presence of 
glucose. The soluble fractions used in the current study represent parts of the proteins which 
might be readily soluble from roasted peanuts and hence involved in the rapid reactions ob-
served in peanut-allergic individuals, particularly in the oral cavity. These were observed to 
be present in an aggregated form but comprised thermally-induced hydrolysis products, since 
almost no intact Ara h 1 or Ara h 2/6 remained after the thermal treatment.
The decrease in IgE binding capacity of the thermally treated peanut allergens indicates 
structural changes induced by heating which results in epitopes having either reduced affin-
ity and/or accessibility for specific IgE. This was particularly marked for Ara h 1 heated in the 
presence of glucose, which on the basis of the loss of primary amino groups suggests that 
non-enzymatic glycosylation of the protein changed or destroyed the epitopes. Alternatively, 
shielding of the epitopes by covalently attached polysaccharide chains or by the higher extent 
of aggregation may render it less able to bind IgE. In addition, the hydrophilic glucose could 
have changed the hydrophobicity of the protein resulting in a decrease in IgE binding as the 
hydrophobic amino acid residues located in the centre of the epitope appeared to be the most 
critical for IgE binding [10].
Besides determining the IgE binding capacity of the allergen, we also assessed the biologi-
cal activity of the native and processed allergens, i.e. their potency to cross-link cell bound IgE 
and to induce effector cell degranulation. Even though a highly significant decrease in IgE bind-
ing capacity was observed for heated Ara h 1, its capacity to elicit mediator release was signifi-
cantly enhanced. Theoretically, more than one IgE binding site is required per fragment of an 
allergen to induce IgE cross-linking. The R+g Ara h 1 aggregates present a large surface contain-
ing multiple copies (of the same) IgE epitopes which clearly enhances the cross-linking capacity 
of the protein, in comparison to its intrinsic IgE-binding capacity, as defined by immunoassays. 
There is other evidence that aggregated structures are more effective at triggering histamine 
release than soluble monomeric forms of the same protein [43]. As both R+g Ara h 1 as well 
as R-g Ara h 1 had a strongly increased degranulation capacity, we can conclude that these 
aggregated Ara h 1 structures having a hydrodynamic diameter of at least 30 nm are better in 
degranulating cells then Ara h 1 being in its native trimeric state having a diameter of 16 nm.
In contrast to Ara h 1, Ara h 2/6 does not form large aggregates, but does form dimers and 
tetramers following heat-induced denaturation [27,44]. Although most studies that investi gat-
ed the effect of processing on allergenicity assessed only the IgE binding capacity, Lehmann et 
al. [45] also studied IgE cross-linking capacity. They observed that even though IgE antibody-
binding capacity of peanut 2S albumins was decreased after protease treatment, this did not 
result in a reduction of the allergenic potential using RBL cells. In our study, heating at 145°C for 
20 min decreased IgE binding as well as IgE cross-linking capacity of Ara h 2/6, and the presence 
of glucose during roasting moderated these losses. This protective effect of glucose was also 
observed both for the IgE binding and the biological activity for the non-specific lipid transfer 
protein from apple (Mal d 3) after heating at 100°C for 2 h [23]. Furthermore, we showed that 
heating had a different effect on Ara h 1 compared with Ara h 2/6 with respect to cross-linking 
capacity. Heating of Ara h 1 resulted in an increased cross-linking and degranulation capacity, 
while this was decreased after heating for Ara h 2/6. These data demonstrate that only study-
ing the effect of food processing using IgE binding capacity tests is insufficient to fully assess 
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the degree of allergenicity of the (modified) protein and that effects on the biological activity, 
such as mediator release, must also be considered.
In summary, the effect of roasting on allergenicity in the presence or absence of glucose 
depends on the allergenic protein tested and cannot be generalised for all proteins. We ob-
served that in both cellular mediator release assays used in this study, heating at low moisture 
of purified Ara h 1 in the presence or absence of glucose resulted in an increased degranulation 
capacity, while for Ara h 2/6 the degranulation capacity was decreased. In addition, in contrast 
to Ara h 2/6, the IgE binding capacity of Ara h 1 did not correlate to IgE cross-linking capacity 
and conclusions drawn from individual assays have to be taken with care. Gaining more knowl-
edge on the effect of the food matrix and the role of food processing on individual allergenic 
proteins enables better understanding of their clinical impact, e.g. in terms of severity of reac-
tions. It is also of importance in diagnostic procedures, in particular when food challenges are 
part of the diagnostic process. Threshold studies of peanut exposure may require standardiza-
tion of the peanut roasting conditions to make the challenges used in clinical trials comparable. 
In addition, the results from this study can have important ramifications for approaches using 
purified components for component resolved diagnosis.
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Abstract
Few studies exist on the influence of processing methods on structural changes and allergenic 
potential of hazelnut proteins. Our study focused on the effect of glycation (Maillard reaction) 
on the immunoreactivity and degranulation capacity of the purified hazelnut 7S globulin, Cor a 
11. After heating, the extent of the Maillard reaction, sensitivity to proteolysis, binding of hu-
man IgE or rabbit IgG, and degranulation capacity were analyzed. Changes in electrophoretic 
mobility, amount of free amino groups, content of bound sugar and fructosamine indicated 
that glycation of Cor a 11 occurred at all conditions. Glycation at 37°C did not influence the 
specific IgG or IgE binding, and was decreased after heating at 60°C and 145°C. Heating, with 
or without glucose at 145°C increased basophil degranulation capacity. The results suggest that 
glycation of Cor a 11 at 60°C and 145°C may decrease the IgE/IgG binding properties but not 
the degranulation capacity of basophils. This is possibly related to aggregation of the proteins 
as a result of the Maillard reaction.
Introduction
Food allergy is one of the major health concerns in the highly industrialized societies [1,2] with 
hazelnuts (Corylus avellana) being one of the commonest food sensitizers, in terms of presence 
of IgE in the sera, in Europe [3,4].  Recent research showed that when all birch allergic subjects 
were excluded from the tested population, hazelnut remained among the four most common 
food sensitizers, indicating that cross-reactions between the birch pollen allergens Bet v 1 and 
Bet v 2 and the hazelnut allergens Cor a 1 and Cor a 2, respectively does not explain this high 
sensitization rate for hazelnut [3]. Non-pollen related hazelnut allergens that have been identi-
fied so far are the 7S globulin Cor a 11 [5,6], 11S globulin Cor a 9, lipid transfer protein Cor a 8, 
hazelnut oleosin and the recently identified 2S albumins from hazelnut [7].
Besides Cor a 11, several 7S vicilin-like seed storage proteins have been identified as impor-
tant food allergens, including Ara h 1 in peanut, Jug r 2 in walnut and Ana o 1 in cashew [8]. The 
high homology between different 7S globulins from peanuts and tree nuts leads to the widely 
observed IgE-binding cross-reactivity [8], and therefore many patients allergic to peanuts have 
a reaction to other tree nuts and vice versa [9,10]. Hazelnut vicilin Cor a 11 is responsible for 
oral sensitization through ingestion of the food, and the percentage of positive IgE responses 
to Cor a 11 in hazelnut allergic patients has been shown to be between 47-95% [5,6]. Molecular 
properties of Cor a 11 such as protein structure, amino acid sequence, glycosylation sites and 
epitope localization are described [5,11]. However, data on the influence of food processing 
conditions on immunoreactivity and allergenic properties of Cor a 11 are scarce, while hazel-
nuts are used in many processed foods [12]. Moreover hazelnuts have been classified as one of 
the most common hidden allergens in foodstuffs, especially in sweets [13].
Different processing conditions applied during food manufacturing may alter protein struc-
ture and may cause a change in the allergenicity of the whole product [14]. The IgE-binding 
capacity of hazelnut allergens was shown to be stable to heat treatment [15]. On the other 
hand Hansen et al. showed a decreased allergenicity, in a DBPCFC, of roasted compared to raw 
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hazelnut [16]. Muller et al. identified Cor a 11 as the heat stable allergen which was recognized 
after roasting (40 min, 145°C) by specific IgE [17]. Reported data suggest that hazelnut aller-
gens possess different susceptibility to heat and it is not clear whether heat treatment may 
result in a change of the allergenic potential. Additionally, during food processing proteins are 
mostly treated in the presence of different types of sugar what presents conditions that allow 
further protein modifications [18,19]. One of the most widespread modifications of proteins 
that occurs during food processing is the Maillard reaction (glycation) between reducing sugars 
and amino groups of proteins [20]. A cascade of chemical rearrangements including condensa-
tion, oxidation, hydration (and dehydration), leads to formation of numerous Maillard reaction 
products (MRPs) including components that may impact on human health, such as acrylamide, 
heterocyclic amines (HCAs) and glycation/lipoxidation end products (AGE/ALEs). This changes 
bioavailability and nutritional values of food [21] and influences food properties such as flavor, 
color and taste [22,23]. Recent studies have shown that the Maillard reaction also alters the 
allergenicity and immunoreactivity of food proteins e.g. by the formation of new IgE binding 
epitopes or by destruction of existing ones [18,24].
The aim of this study was to determine the influence of the Maillard reaction occurring at 
three different temperatures on the physicochemical properties, antibody binding and degran-
ulation capacity of the hazelnut allergen Cor a 11. The three different temperatures chosen 
were: 37°C, which corresponds with the human body temperature and has only a minor effect 
on protein structure [25], 60°C, which changes the secondary and tertiary structure of proteins 
[19] and is often applied during food manufacturing [26] and 145°C which is the routine hazel-
nut roasting condition [27].
Material and Methods
Protein Extraction and Purification 
Fresh hazelnuts (Corylus spp) from Turkey were ground and defatted with n-hexane (2 times 
for 15 minutes). Defatted hazelnut flour was extracted according to Rigby et al. [11]. The su-
pernatant was collected and proteins were precipitated with ammonium sulphate to 60% satu-
ration. After centrifugation (10000×g, 30 min, 4°C), the supernatant was dialyzed overnight 
against 50 mM Tris-HCl buffer. Further purification was performed by concanavalin A affinity 
chromatography (Sigma Aldrich, Germany) [11] and elution was carried out with 50 mM α-D-
methylmannoside (Sigma Aldrich, Germany). Protein containing peak fractions were pooled 
and dialyzed overnight against phosphate buffered saline (PBS), pH 7.4 at 4°C. The protein 
concentration was assessed by the BCA-assay (Pierce, USA) and purity was determined by SDS-
PAGE as described below.
Protein Glycation 
The protein solution was split into seven batches of 10 mg each and contained 0.01% sodium 
azide. To three batches, glucose (Sigma Aldrich, Germany) was added in a ratio of 1:2 (w/w 
protein:glucose) [28]. All seven samples were placed into glass bottles, frozen at -70°C and 
lyophilized (Christ, Alpha 1-4 LSC). Next, the lyophilized protein samples (one with glucose 
and one without) were heated for 7 days at 37°C or for 3 days at 60°C in a laboratory incuba-
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tor with gravitational circulation of air (Wamed, C-30G), or for 20 minutes at 145°C in a forced 
convection chamber of thermal research (Wamed, KBC 65W). One batch was not treated and 
regarded as the native, non-modified form. After treatment, the samples were allowed to grad-
ually cool to room temperature. Proteins were slowly dissolved in Milli-Q water, centrifuged 
(5000×g, 15 min, 4°C) and supernatant was collected and ultrafiltrated (Millipore, Amicon Ul-
tra-15, 10,000 NMWL) against PBS for several rounds to remove the residual glucose and other 
small molecular weight products. The protein concentration and changes in solubility were 
assessed by the BCA-assay (Pierce, USA) and aliquots were stored at -70°C. All treatments were 
performed in duplicate.
SDS-PAGE Analysis 
Native (non-modified) and modified Cor a 11 samples were separated by SDS-PAGE under re-
ducing conditions. Protein samples in SDS-sample buffer were boiled and loaded (10 µg/lane) 
on a 12% polyacrylamide gel and afterwards stained using colloidal Coomassie (Sigma Aldrich, 
Germany) [29]. A molecular weight marker ranging from 6.5 to 200 kDa (Sigma Aldrich, Germa-
ny) was included and molecular masses were calculated by the use of GelScan 1.10 software.
o-Phthaldialdehyde (OPA) Assay 
The OPA assay was applied to determine the proportion of reacted amino groups of Cor a 11 in 
glycated and control samples. Protein samples (250 µg/ml) were mixed with the OPA reagent 
[30] in a ratio of 1:10 (v/v). The mixed solutions were incubated for 20 minutes at room tem-
perature and the absorbance was measured at 340 nm against a control containing PBS and 
the OPA reagent. Unreacted amino groups were estimated from a calibration curve established 
with L-leucine.
Anthrone-Sulfuric Acid Colorimetric Microassay
The anthrone-sulfuric acid colorimetric microassay was performed to analyze bound glucose. 
The reagent was freshly prepared by dissolving 20 mg anthrone in 10 ml of 14 M sulphuric acid. 
The protein solutions (250 µg/ml) were mixed in 96-well plates (Sigma Aldrich, Germany) with 
the cooled reagent in a ratio of 1:10 (v/v) [31]. A glucose standard curve was used to calculate 
the sugar content. 
Nitroblue Tetrazolium (NBT) Assay
The NBT method is based on the ability of ketoamines (fructosamines) to act as reducing agents 
in alkaline solutions. The reagent was prepared by mixing solution A (0,82 mM nitroblue tetra-
zolium, 7 mM sodium cholate, 70 mM KCl in 70 mM phosphate buffer, pH 8.2 including 3% of 
Tween-20) and solution B (833 mM potassium carbonate buffer, pH 11.2) in a 14:6 ratio. Sub-
sequently, mixture and sample were mixed (19:1 ratio) and incubated at 37oC. Fructosamine 
(320 µM/L) was used as a standard and absorbance was measured in a microplate reader (Asys 
UVM 340) at 550 nm after 9 and 10 minutes of incubation. The results were calculated using 
the following formula:
fructosamine concentration [μmol] = [(∆A sample - ∆A blind sample) / (∆A calibrator - ∆A 
blind sample)] x calibrator concentration 
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Protein Hydrolysis 
For pepsin hydrolysis, the protein solution was adjusted to pH 2.2 using 1 M HCl. Pepsin (3,200-
4,500 units/mg protein, Sigma Aldrich, Germany) was dissolved in simulated gastric fluid (0.15 
M NaCl, adjusted to pH 2.0 with HCl) and added to the protein solution in a final enzyme-
substrate ratio of 1:10 (w/w). The hydrolysis was performed for 1 h at 37°C with agitation. The 
enzyme was inactivated by increasing the pH of the samples to 7 - 8 with 1 M NaOH and subse-
quently samples were directly cooled in an ice bath. The degree of hydrolysis was determined 
by measuring the increase in the number of free α-amino groups after the hydrolysis using the 
OPA method as described before [26]. 
Production of Antibodies 
Antibodies were produced using three New Zealand white rabbits by mixing 1 mg of native 
purified Cor a 11 to 1 ml of sterile PBS emulsified with an equal volume of Freund’s adjuvant 
(Sigma Aldrich, Germany). Complete Freund’s adjuvant was used in the first dose and an in-
complete Freund’s adjuvant in the following doses. The rabbits were immunized subcutane-
ously, three times, at three-week intervals. The blood samples obtained from a marginal rabbit 
ear vein were collected every three weeks and the increase of IgG titer was monitored by 
performing an indirect ELISA. Ten days after the last immunization, the rabbits were exsan-
guinated. The blood was incubated for 1 h at 37°C and centrifuged at 1500×g for 20 minutes. 
Serum IgG antibodies were purified using ammonium sulphate precipitation (20% saturation). 
After centrifugation at 1500×g for 30 min, the pellet was dissolved in a phosphate buffer of 
pH 7.4 and dialyzed for 15 h at 4°C. The IgG fraction was lyophilized before use and purity was 
estimated by SDS-PAGE. The Local Care Use of Animals Committee approved animal handling 
and experimental procedures.
Competitive ELISA 
Competitive ELISA was used to assess immunoreactivity as the ability of a polyclonal anti Cor 
a 11 antiserum to recognize Cor a 11 after the different treatments. All ELISA steps were per-
formed at 37°C in a thermo-shaker (ELMI). Microtiter 96-well plates (Corning, medium binding) 
were coated with native Cor a 11 (100 ng/well) in a sodium carbonate buffer pH 9.6. Plates 
were incubated for 1 h and residual free binding sites were blocked with 1% BSA (Sigma Al-
drich, Germany) in PBS for 30 minutes. Then, plates were washed three times with PBS contain-
ing 0.5% Tween-20. Native Cor a 11 or the competing antigen (modified Cor a 11) in PBS was 
added (50 μl/well) in increasing concentrations ranging from 2x10-3 to 2x104 ng/ml. Immedi-
ately afterwards, rabbit polyclonal anti-Cor a 11 antibodies (5 μg/ml in PBS, 50 μl/well) were 
added. The plates were incubated for 1 h and then washed four times. Peroxidase-conjugated 
goat anti-rabbit IgG antibodies (Sigma Aldrich, Germany) were added (100 μl/well). The plates 
were incubated for 1 h and washed four times. The substrate, OPD (Sigma Aldrich, Germany) in 
50 mM citrate-phosphate buffer, pH 5.0 was added in a ratio of 1:2 (w/v) with 0,6% hydrogen 
peroxide (100 μl/well). After 30 minutes of incubation the enzymatic reaction was stopped by 
addition of 5 M HCl (50 μl/well) and the absorbance was measured at 492 nm on an automatic 
plate reader (Asys UVM 340). The analysis was performed four times in triplicate each time. 
A maximal signal (100%) was obtained by not adding a competitor and a negative control by 
omitting the Cor a 11 antibodies. Results were expressed as B/B0, where B is the mean ab-
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sorbance of the known concentration of inhibitor and B0 represent the maximal absorbance 
obtained in the absence of inhibitor. Using sigmoid curves, the EC
50
 values were read and per-
centages of cross-reaction were calculated using the following formula: 
CR% = (EC
50
N / EC
50
C) × 100% 
where CR% - percentage of cross-reaction, EC
50
N - concentration of specific antigen needed to 
bind 50% of the available antibodies, EC
50
C - concentration of cross-reacting antigen needed to 
bind 50% of the available antibodies.
Dot-Blot Immunoassay 
To test the specific IgE binding capacity of Cor a 11 after the different treatments, an immuno-
dot blot assay was performed using pooled sera obtained from eight hazelnut allergic patients 
with specific IgE against hazelnut varying from 0,9 to 33,4 kU/l. The diagnosis of hazelnut al-
lergy was based on clinical history and IgE measurement. Double-blind, placebo-controlled 
food challenges were not performed because of the severities of the systemic reactions. Native 
and heated Cor a 11 (1.25 and 2.5 µg) was spotted on the nitrocellulose membrane (Millipore). 
Nitrocellulose membranes were air-dried and unbound protein-binding sites were blocked us-
ing 5% skim milk powder (w/v) and 0.1% Tween 20 (v/v) in PBS. After each step the membranes 
were washed 4 times with PBS containing 0.1% Tween 20. The allergic sera were diluted 1:3 in 
PBS with 0.01% BSA and incubated with the membranes for 2.5 h at 37°C with gentle shaking. 
After washing, the membranes were incubated during 1 h with mouse anti-human IgE (Sigma 
Aldrich, Germany) diluted 1:1000. The signal of the reaction was developed with 3,3’-Diami-
nobenzidine (DAB, Sigma Aldrich, Germany) and the membranes were scanned on an ImageS-
canner (GE Healthcare). The optical density was analyzed by the use of GelScan v1.10 software.
Mediator Release Assay (MRA) using Rat Basophilic Leukemia (RBL) Cells
Sera used in the MRA were derived from healthy (n = 2) and peanut allergic (n = 5) donors and 
sera high in Cor a 11 specific IgE (n = 2). First, concentrations of IgE specific to 7S globulins puri-
fied from hazelnut and peanut were determined using the enzyme allergosorbent assay (EAST) 
as previously described [32]. 
RBL-2H3 cells stably expressing the α-chain of the human Fcε-RI receptor [33] were kindly 
provided by Drs. Vieths and Vogel (Paul-Ehrlich-Institut, Langen, Germany). Cells were cultured 
in MEM medium supplemented with 5% FCS and 1% glutamine (all from Gibco, Paisley, UK) at 
37°C in a humidified atmosphere with 5% CO
2
. Cells in stationary growth phase (which were 
more than confluent) were harvested and plated in 96-well plates at 1.5 × 105 cells/well. Hu-
man sera were added at a pre-determined convenient dilution of 1:30 and incubated over-
night to passively sensitize the cells. After washing, the cells were stimulated for 1 h with the 
allergens diluted in Tyrode’s buffer containing 50% deuterium oxide [33]. The antigen-specific 
release was quantified by measuring β-hexosaminidase activity and expressed as percentage 
of the total β-hexosaminidase content that was obtained by lysing the cells with Triton-X100 
(Sigma-Aldrich, Zwijndrecht, the Netherlands). Spontaneous release was determined on cells 
not sensitized nor cross-linked. The release data were fitted to four-parameter-logistic curves 
by non-linear regression using the SigmaPlot v10.0 software package, and EC50 values were 
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assessed accordingly.
Statistics 
Results were expressed as mean ± SD of three to five independent measurements (each meas-
urement was performed in triplicate). Statistical analysis was carried out by GraphPad Prism 
4 software. A one-way ANOVA test with Tukey post-hoc (P < 0.05) was used to evaluate the 
significance.
Results
The Influence of Thermal Processing in the Presence and Absence of Glucose on 
Physicochemical Properties of Cor a 11
The temperature-dependent changes in Cor a 11 solubility and color after heat treatments are 
shown in Table 1. Solubility of protein decreased with increasing temperature and with the 
presence of glucose during the heating at 60°C and 145°C. Heating at 37°C reduced the solubil-
ity only slightly, while heating at 60°C decreased the solubility of Cor a 11 to 91% after heating 
without the presence of glucose and 65% after heating in the presence of glucose. Around 76% 
and 9% of Cor a 11 remained soluble after heating at 145°C in the absence and presence of 
glucose during heating, respectively.
Table 1. The influence of heat treatment on Cor a 11 solubility and color changes.
 C37°C G37°C C60°C G60°C C145°C G145°C
Solubility (%) 97 ± 2.8  95 ± 2.5 91 ± 4.9 65 ± 1.4 76 ± 10.5 9 ± 1.7
Colour transparant transparant transparant light brown light brown brown
Average percentage of solubility of two heating-treatments performed independently ± SD  
SDS-PAGE analysis under reducing conditions (Figure 1) showed a purity of the Cor a 11 of 
98% (lane 1) of which ~90% consisted of the main subunit with a molecular mass estimated to 
be 47 kDa. For all treatments, differences in the SDS-protein pattern were observed between 
Cor a 11 heated in the absence and presence of glucose. 38% and 52% of the total fraction of 
Cor a 11 heated at 37°C in the absence and presence of glucose respectively, degraded (line 2 
and 3), and was observed as two or three bands. Furthermore, in the sample treated without 
glucose an additional band with a molecular weight higher than 200 kDa was observed, which 
constituted about 9% of the total fraction. Cor a 11 heated at 60°C in the absence of glucose 
partly degraded into two low molecular weight proteins (line 4), while the protein heated in 
the presence of glucose appeared to be more stable and was seen as one band (line 5) with a 
molecular weight slightly higher than native Cor a 11 (line 1). Heating at 145°C caused aggrega-
tion of Cor a 11; however, 40% of Cor a 11 heated at 145°C without glucose appeared as a 47 
kDa band (line 6), similar to the native Cor a 11. Cor a 11 heated at 145°C in the presence of 
glucose resulted in a total loss of the 47 kDa protein and proteins appeared as a smear in the 
range of molecular masses higher than the mass of the native protein (line 7).
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Figure 1. SDS-PAGE patterns of native and treated Cor a 11. N – na-
tive (non-modified) protein; C37°C – control sample (without glu-
cose) treated at 37°C for 7 days; G37°C – sample treated in the pres-
ence of glucose at 37°C for 7 days; C60°C – control sample (without 
glucose) treated at 60°C for 3 days; G60°C – sample treated in the 
presence of glucose at 60°C for 3 days; C145°C – control sample 
(without glucose) treated at 145°C for 20 minutes; G145°C – sample 
treated in the presence of glucose at 145°C for 20 minutes; MS – mo-
lecular weight marker [kDa]. Arrow indicates the molecular mass 
corresponding with the mass of native form of Cor a 11.
To assess the extent of the Maillard reaction after heating at these different temperatures, 
three analytical methods have been applied. The OPA analysis (Figure 2) showed a not signifi-
cant 10% loss of primary amino groups in the protein heated at 37°C in relation to the native 
protein. A 50% and 58% decrease of free amino groups was observed for Cor a 11 heated at 
60°C and 145°C, respectively, which suggests an increase in the rate of the reaction of glucose 
with the ε-amino group of lysine or the α-amino groups of terminal amino acids at higher 
temperatures. When analyzing the subsequent temperatures of modification, the amount of 
free amino groups was negatively correlated with the amount of protein-bound sugar (Pearson 
r = -0.856, P = 0.029; Figure 2). No differences in the percentages of primary amino groups 
and bound sugar were observed between all samples heated without the presence of glucose 
and the native protein (data not shown). An increase in fructosamine content was observed 
in all protein samples heated in the presence of glucose for all tested temperature conditions 
(Figure 3). This indicates that the reaction has reached at least the second stage of the Maillard 
reaction, the formation of Amadori products. The brown color of Cor a 11 glycated at 60°C and 
145°C is most likely a result of involvement of fructosamine which leads to the formation of 
insoluble brown products (Table 1) [23].
Figure 2. Percentage of primary amino groups (black 
bars) and bound sugar (white bars) in relation to na-
tive Cor a 11 (100%). Data are reported as the mean 
± SD (n = 5 for free amino groups, n = 4 for bound 
sugar). *P < 0.05 compared to native Cor a 11 (lower 
part); statistical differences between Cor a 11 treat-
ed at different temperatures (upper part).
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The high degree of Maillard reaction observed after heating at 60°C and 145°C in the pres-
ence of glucose (Table 1, Figure 2 and 3) was accompanied with a significant decrease in sus-
ceptibility of Cor a 11 to pepsin hydrolysis. The degree of Cor a 11 pepsin hydrolysis (DH) is 
presented as a percentage of cleaved peptide bonds (Figure 4). Significant differences were 
observed in the susceptibility to hydrolysis between Cor a 11 heated in the presence and ab-
sence of glucose. A 5% increase of the susceptibility to hydrolysis was observed after heating 
at 37°C in the absence of glucose, while heating in the presence of glucose showed the same 
DH as native Cor a 11. The structural changes of Cor a 11 after heating at 60°C in the absence of 
glucose, resulted in a 60% increase of susceptibility to hydrolysis in relation to the native pro-
tein. After glycation at 60°C, a 95% decrease of hydrolysis was observed, while heating at 145°C 
decreased the degree of hydrolysis to 30% in the absence and 62% in the presence of glucose.
Figure 3. The level of browning prod-
ucts determined with the NBT assay 
of Cor a 11 treated without glucose 
– control (C) and in the presence of 
glucose – glycation (G). Data are re-
ported as the mean ± SD. Analysis was 
performed in fivefold and repeated 
once for the first batch and two times 
for the second batch (n = 5). *P < 0.05 
compared to native Cor a 11 (lower 
part); statistical differences between 
Cor a 11 treated in the presence and 
absence of glucose (upper part).
Figure 4. Hydrolysis degree of Cor 
a 11 treated without glucose – 
control (C) and in the presence of 
glucose – glycation (G). Data are 
reported as the mean ± SD (n = 
3). *P < 0.05 compared to native 
Cor a 11 (lower part); statistical 
differences between Cor a 11 
treated in the presence and 
absence of glucose (upper part).
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The Influence of Thermal Processing in the Presence and Absence of Glucose on Antibody 
Binding Properties 
The immunoreactivity was determined quantitatively as the percentage of cross-reactivity be-
tween native and modified Cor a 11 with the use of polyclonal rabbit IgG antibodies against 
native Cor a 11 (Figure 5). Glycation of Cor a 11 at 37°C did not alter its immunoreactivity sig-
nificantly, while heating at 37°C without sugar resulted in a 30% decrease in immunoreactivity 
as reflected in Figures 5A and B. Heating of Cor a 11 in the presence of glucose at 60°C triggered 
loss of immunoreactivity of 53% while in the non-glucose control heating to 60°C resulted in an 
increase of the immunoreactivity of Cor a 11 of 28% (Figure 5A, C). The extent of cross-reactivi-
ty between native Cor a 11 and Cor a 11 heated at 145°C was estimated to be 2% and no cross-
reactivity was observed between native Cor a 11 and Cor a 11 glycated at 145°C (Figure 5A, D).
Figure 5. Competitive ELISA inhibition of the binding between treated Cor a 11 and its specific polyclonal anti-
native Cor a 11 antibodies. The plates were coated with native Cor a 11. A. The results expressed as the percentage 
of cross-reactivity in relation to native Cor a 11 (100%). Cor a 11 treated without glucose - control (C), Cor a 11 
treated in the presence of glucose - glycation (G). B-D. Representative curves obtained for Cor a 11 treated at 37°C, 
60°C and 145°C, respectively. Data are reported as the mean ± SD (n = 4). *P < 0,05 compared to native Cor a 11 
(lower part); statistical differences between Cor a 11 treated in the presence and absence of glucose (upper part). 
The table presented within each figure represents the average protein concentrations (μg/ml) to obtain 50% of the 
maximum allergen release of the native allergen (EC50) (n = 5-8).
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The binding properties of the native and heated Cor a 11 to allergen-specific IgE antibodies 
were analyzed in immuno-dot assays performed with the use of pooled sera from 8 hazelnut 
allergic patients (Figure 6). The specificity of the reaction was tested using pooled sera from 
10 non-allergic patients (data not shown). Crude hazelnut extract, purified Ara h 1 (7S globulin 
isolated from peanut), and ovalbumin and ovomucoid as common food allergens were used as 
control proteins. The highest IgE binding reactivity was shown for the crude hazelnut extract, 
resulting in intensive dots with a high optical density. No signal was observed for ovalbumin 
and ovomucoid; however, a positive reaction for Ara h 1 was observed (data not shown). No 
significant differences in IgE reactivity between native Cor a 11 and the proteins modified at 
37°C was observed. A decreased capacity to bind to Cor a 11 was observed after heating to 
60°C in the presence of glucose. A significant reduction in IgE reactivity was observed after 
treatment at 145°C without sugar. The IgE antibodies from the serum pool did not recognize 
Cor a 11 treated at 145°C in the presence of glucose in the tested concentrations (Figure 6).
A        B
Figure 6 A. Reactivity of human IgE in immuno-dot assay calculated as the percentage of optical dentisity in the 
relation to the native Cor a 11 (100%). N – native (non-modified) protein; C37°C – control sample (without glucose) 
treated at 37°C for 7 days; G37°C – sample treated in the presence of glucose at 37°C for 7 days; C60°C – control 
sample (without glucose) treated at 60°C for 3 days; G60°C – sample treated in the presence of glucose at 60°C 
for 3 days; C145°C – control sample (without glucose) treated at 145°C for 20 min; G145°C – sample treated in the 
presence of glucose at 145°C for 20 min; HnE – the pure extract of hazelnut proteins; Data are reported as the mean 
± SD (n = 3). *P < 0,05 compared to native Cor a 11 (lower part); statistical differences between Cor a 11 treated in 
the presence and absence of glucose (upper part). B. Human IgE immuno-dot assay. The first two rows show Cor a 
11 dotted on a PVDF membrane in the amount of 1.25 µg per dot in the following order: protein treated in the pres-
ence (row A) and absence (row B) of glucose.  The second two rows present Cor a 11 dotted in the amount of 2.5 µg 
per dot in the same order: protein treated in the presence (row C) and absence (row D) of glucose. Numbers from 1 
to 3 indicate treatments: 1 – Cor a 11 treated at 37°C for 7 days; 2 – Cor a 11 treated at 60°C for 3 days; 3 – Cor a 11 
treated at 145°C for 20 minutes; 4 – the native (untreated) Cor a 11 in both concentrations in duplicate; 5B and 5D 
– a hazelnut crude extract; 5A and 5C – peanut 7S globulin Ara h 1, 6A and 6C – ovalbumin; 6B and 6D ovomucoid. 
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The Influence of Thermal Processing in the Presence and Absence of Glucose on Mediator 
Release Assay using RBL Cells
The biological mediator-releasing activity of the native versus the 145°C heated Cor a 11 was 
assessed in the RBL MRA. First, concentrations of IgE specific to 7S globulins purified from ha-
zelnut and peanut were determined for the included sera. The level of Cor a 11 specific IgE was 
overall very low for the sera from peanut allergic patients (1-12 kU/l) and did not correlate with 
the specific IgE to total hazelnut extract; however, it did correlate with peanut 7S specific IgE 
(data not shown). In addition, IgE levels of two sera containing high Cor a 11 specific IgE were 
57.8 kU/l and 47.8 kU/l and both sera contained >100 kU/l of hazelnut specific IgE.
No β-hexosaminidase release was induced by the native and heated Cor a 11 allergens 
when sera were used from patients not sensitized to hazelnut (data not shown). Figure 7 
shows typical results of two representative sera. In addition, the table presented within each 
figure represents the average protein concentrations to obtain 50% of the maximum mediator 
release induced by the native allergen (EC50). When sera from five peanut allergic patients 
were used (Figure 7A), no significant difference in degranulating capacity was observed be-
tween native and 145°C heated Cor a 11 (EC50 for all sera and all proteins between 0.6 and 
6.8 µg/ml). However, EC50 values for Cor a 11 heated at 145°C in the presence or absence of 
glucose were respectively ca. 100- and 300-fold lower than those for native purified Cor a 11 
when using the two sera high in hazelnut 7S-specific IgE. Furthermore, for native Cor a 11, the 
maximum release was obtained between 10-100 µg/ml using the peanut allergic sera, while 
this maximum release was already observed at ~1 µg/ml using the two sera high in hazelnut 
7S specific IgE.
Figure 7. Percentage β-hexosaminidase release from humanized rat basophilic leukaemia (RBL) cells induced by 
native and modified Cor a 11. Humanized RBL cells were passively sensitized with either sera from peanut allergic 
patients (n = 5) or sera high in Cor a 11 specific IgE (n = 2) and stimulated with increasing concentrations of native 
(N; ― ―), heated in the presence of glucose (C145°C; – –●– –) or heated in the absence of glucose (C145°C; - - - 
- - -) Cor a 11. Results are shown of one representative serum of a peanut allergic patient (A) and a sera high in Cor 
a 11 specific IgE (B). Error bars represent the SD of triplicate values. The table presented within each figures repre-
sents the average protein concentrations (μg/ml) to obtain 50% of the maximum allergen release of the native al-
lergen (EC50) (n = 2-5).
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Discussion
Food manufacturing uses thermal processing to improve food quality, safety and shelf life [34]. 
However, food processing results in changes of protein structure which may alter allergenic 
properties [20]. Moreover, processing may result in formation of neoallergens. This may par-
tially explain tolerance to unprocessed food by some allergic patients who have been sensitized 
against processed food [35,36]. Even though widely-used food antigen tests in commercial 
laboratories mostly use raw food isolates, by testing a large variety of commercially available 
food products, it has been shown that 31% of the included allergic individuals showed higher 
IgE antibodies against processed food antigens as compared to the raw food antigens [37]. 
The extent of the Maillard reaction and the type of reducing sugar are important param-
eters that are of importance for the biological properties of food derived proteins [22]. Struc-
tural characteristics of a protein (e.g. its primary structure and the accessibility of residues 
to reaction) are crucial for their propensity to participate in Maillard reactions [23,25,28,38]. 
In this study, three different temperatures of glycation were applied which resulted in differ-
ent types of Maillard reaction products, namely early stage Amadori rearrangement product 
(37°C), more advanced products of their degradation (60°C) and finally advanced glycation end 
products (145°C) [23]. This enabled us to study the effect of different degrees of glycation on 
the immunoreactivity and degranulation capacity of Cor a 11. Pedrosa et al. showed an effec-
tive Maillard reaction of pea vicilin carried out at 37°C for 50 h with glucose, galactose, lactose 
and galacturonic acid while the structure of the protein was not significantly affected [25]. The 
lack of formation of colored products from Cor a 11 glycated at 37°C suggests an early stage 
of Maillard reaction which did not alter the susceptibility of Cor a 11 to pepsin hydrolysis nor 
the binding properties of rabbit IgG and human IgE to the treated protein. Similar results have 
been obtained for pea albumins glycated at 37°C during 7 days [38]. These data suggest that 
the structural changes caused by sugar moieties attached to the protein structure at 37°C or 
by the increase in temperature did not alter the immunological potential of the protein signifi-
cantly.
From the SDS-PAGE protein pattern of Cor a 11 heated at 60°C, a protective effect of glu-
cose on heat degradation was observed. A similar effect was observed by Maleki et al. who 
showed that the presence of sugar during heating of Ara h 1 and Ara h 2 purified from peanut 
at 55°C made the proteins more resistant to degradation [22]. Heating at 55-70°C induces a 
loss of tertiary and secondary structure of proteins, which makes the Maillard reaction occur 
more efficiently [23]. The degradation of Amadori compounds mainly through 2,3-enolisation 
and fission leads to the formation of brown nitrogenous polymers and co-polymers, known 
as melanoidins [23]. The effect of an advanced Maillard reaction was apparent from the SDS-
PAGE pattern of Cor a 11 heated at 145°C in the presence of glucose, as a smear was observed 
caused by cross-linking and non-cross-linking heterogeneous advanced gycation products 
[22,39,40]. The brown color of Cor a 11 glycated at 145°C, as well as the characteristic smell, 
are additional indicators of advanced Maillard reaction which were also observed by other 
researchers studying the properties of roasted peanuts [40-42].
The structural changes in soluble Cor a 11 upon subsequent steps of Maillard reaction oc-
curring at 60°C and 145°C resulted in decreased hydrolysis by pepsin. The Maillard reaction 
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was previously shown to decrease the susceptibility of different proteins to pepsin hydroly-
sis [43,44]. The 30% increase of susceptibility of Cor a 11 to pepsin hydrolysis observed by 
the effect of heating at 60°C in the absence of glucose may be explained by temperature-
induced reduction of disulfide bonds, which is an important parameter in protein digestibility 
[45] in combination with a destabilization of the globular fold, as observed by Koppelman et 
al. [40]. Moreover, the thermal denaturation of proteins treated at 145°C without glucose also 
decreased the digestibility of Cor a 11, probably due to protein aggregation [46]. It has to be 
remembered, that the analysis concerned only 9% of the total Cor a 11 fraction which was 
soluble after glycation at 145°C. The reduced solubility of roasted proteins was observed also 
by Kopper et al. who observed a loss of soluble protein from peanut flour after 10 minutes of 
roasting at 178°C [47] and similar results were observed for purified Ara h 1 treated at 145°C 
(Vissers et al., submitted). Covalent cross-linking of the protein as a consequence of Maillard 
reactions and formation of aggregates after heating explains the low protein extraction yield of 
Cor a 11 heated in the presence of glucose.
The physicochemical changes of Cor a 11 heated at 60°C in the presence of glucose caused 
significantly reduced IgG and IgE binding (2-fold and 3-fold respectively) whereas no reactivity 
was observed in the case of Cor a 11 heated at 145°C in the presence of glucose. Interestingly, 
a differential effect was observed for Cor a 11 heated at 60°C in the absence of glucose show-
ing an increase in IgG binding, while the IgE binding did not change or even decreased. The 
main effect of Maillard reaction on the conformational structure of proteins involves changes 
in hydrophobic interactions [48]. The observed decrease in IgG/IgE binding may result from 
changes in hydrophilic/hydrophobic areas and net charge at the protein surface caused by at-
tached sugar moieties. It was shown that masking of hydrophobic amino acid residues located 
in the center of the epitope was shown to be the most critical for IgE binding to Ara h 1 [49]. 
The strong reaction of specific IgE from human serum with crude hazelnut extract indicates 
that the patients were allergic to different hazelnut proteins and some patients were most 
probably not allergic to Cor a 11.
The decrease of IgE binding after treatment of Cor a 11 at 145°C led us to perform the ba-
sophil degranulation tests. An increased mediator-releasing capacity was observed for Cor a 11 
roasted both in the absence and presence of glucose, when using sera from the patients with 
a high titer for Cor a 11 specific IgE antibodies. This corroborates our previous study in which 
we showed an increase in degranulating capacity of the 7S globulin from peanut after roasting 
by the use of sera from peanut allergic patients (Vissers et al., submitted). However, roasting 
had no influence on the cross-linking capacity using sera from peanut allergic patients with low 
Cor a 11 specific IgE. Lauer et al. showed that glycosylated native Cor a 11 induced a similar 
histamine release from basophils compared to recombinant Cor a 11 [5]; however, the sera 
used were not tested for the amount of Cor a 11 specific IgE present, and high concentrations 
of the protein were needed to obtain a histamine release. These results would correspond to 
our results obtained using our sera low in HN 7S specific IgE. De Leon et al. speculated that the 
affinity of cross-reactive IgE antibodies for cross-reactive allergens might be low and therefore 
high allergen concentrations may be required to trigger basophils [50]. The relation between 
IgE-binding potential and clinical symptoms is influenced by physical properties (e.g. stability 
and size) and immunologic properties (affinity and epitope valence) [51]. Therefore, IgE used in 
the assays should preferably be obtained from individuals highly allergic to the protein tested, 
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and it is important to have well-characterized patients. This is even more important as differ-
ent results were obtained using sera containing most probably only cross-reactive IgE to Cor 
a 11, and sera showing high IgE titers to Cor a 11. In addition, IgG/IgE binding capacity did not 
correlate to IgE cross-linking capacity and conclusions drawn from individual assays have to be 
taken with care. 
In conclusion, we showed that the impact of Maillard reaction on the biological and al-
lergenic properties of Cor a 11 strongly depends on the conditions of treatment and are cor-
related with time and temperature of the reaction. Therefore, the Maillard reaction occurring 
during processing of hazelnuts may either not influence the physicochemical and biological 
properties of Cor a 11 significantly (treatment at 37°C), or may completely change its aller-
genic potential (treatment at 145°C). Moreover in our study we demonstrated that the use of 
a combination of tests is of importance to estimate the clinical relevance of modification of the 
allergenicity of Cor a 11.
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Summary statement: Soy IgE or soy CRD are both not sufficient to determine soy allergy.
Component-resolved diagnostics (CRD), evaluating the IgE profile of individual allergens, pro-
vides deepened insight into diagnosis of food allergy, as recently described for peanut allergy 
in children [1]. In soy-allergic patients, the soy seed storage allergens Gly m 5 and Gly m 6 have 
been associated with severe allergic reactions [2], while the clinical importance of the major 
soy allergen Gly m 4 is debated [3,4]. Although individual soy and peanut allergens share se-
quence homology and serological cross-reactivity, few studies exist on soy 2S albumins even 
though related 2S albumins from peanut (Ara h 2/6/7) are implicated as clinically important 
allergens. 
The goal of this study was to determine if CRD could better predict the clinical relevance of 
specific allergens inducing IgE sensitization to soy, in peanut and/or soy allergic patients. 
The medical records of patients seen at an allergy clinic (APA, Arnhem, the Netherlands) 
over the past 4 years were digitally screened for a clear medical history of anaphylactic reac-
tions to peanut and/or soy. Of these, all adult patients with a positive skin prick test to com-
mercial peanut and/or soy extract (ALK-Abellό, Nieuwegein, the Netherlands) and a positive 
specific IgE test to peanut and/or soy (Phadia ImmunoCAP, Uppsala, Sweden) and/or a positive 
allergen provocation test were selected for inclusion (n = 60). After informed consent, 20 pa-
tients volunteered to participate in this study. IgE levels to peanut, soy and pea extract, rAra 
h 1, 2, 3 and 8 from peanut, rGly m 4, nGly m 5, nGly m 6 and 2S from soy (kind gifts of Sigrid 
Sjölander, Phadia, Uppsala, Sweden), rBet v 1 from birch and cross-reactive carbohydrate de-
terminants (CCD) were determined by ImmunoCAP (Table 1).
Most (6/8) soy allergic patients had no specific IgE to soy extract or nGly m 5 and 6, but all 
patients showed IgE to rGly m 4 and four to soy 2S. Most (7/11) peanut, but clinically non-soy 
allergic patients, tested serologically positive for soy extract and for nGly m 5 and 6. IgE levels 
to peanut and soy extract were strongly correlated (Pearson r = 0.924, P < 0.001); and similar 
results were obtained for pea (r = 0.821, P < 0.001, data not shown). rGly m 4 was positive in 
four of the peanut allergic patients and its levels correlated in both soy and peanut allergic 
patients with IgE levels to rAra h 8 (r = 0.917, P < 0.001) and rBet v 1 (r = 0.940, P < 0.001). 
Cross-reactive carbohydrate determinants sensitization was negative for all patients except 
one (data not shown), which excludes the presence of cross-reactive IgE to legumes and grass 
pollen CCD.
Only rGly m 4 IgE levels were positive in all included soy allergic patients, which suggests 
rGly m 4 sensitization to be a valid indicator of severe soy allergy probably mediated by IgE 
cross-reactivity with Bet v 1 [5]. Thus Gly m 4 seems to be more relevant in detecting clinical 
soy allergy than nGly m 5, m 6, soy 2S or total soy extract. However, we cannot exclude a dif-
ferent soy sensitization profile in other countries. In our peanut allergic patients IgE sensitiza-
tion to soy and pea extract was found to have low diagnostic specificity probably because of 
clinically non-relevant cross-reactivity between peanut specific IgE and homologous soy or pea 
components. Even a positive rGly m 4 test in peanut allergic patients could be clinically non-
relevant as seen in 4 of 12 peanut allergic patients. 
In conclusion, soy CRD seems to discriminate between solely soy allergic patients and soy 
and/or peanut allergic patients. However, especially in peanut allergic patients with IgE to Gly 
m 4, a soy challenge test is still indicated to confirm a clinically relevant soy allergy.
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Abstract
Lactic acid bacterial strains have received interest for their immunomodulating activities and 
potential use in probiotic products. A wide variety of strain-dependent properties have been 
reported, but comparative studies on the species level are scarce. The objective of this study 
was to assess the immunomodulatory effect of Lactobacillus species on the cytokine profiles 
and proliferative response of human peripheral blood mononuclear cells (hPBMC), and in par-
ticular, on the comparison between the species Lactobacillus acidophilus and Lactobacillus 
plantarum. hPBMC from healthy donors were stimulated in the presence or absence of the lac-
tic acid bacteria and cytokine production, surface marker staining, proliferation and cell death 
were determined after 1 and 4 days of culture. All Lactobacillus strains tested were capable of 
inducing the production of interleukin (IL)-1β, IL-10, interferon-γ (IFN-γ), and tumor necrosis 
factor-α (TNF-α). The bacterial strains did not differentially influence the amount of proliferat-
ing, viable, apoptotic and necrotic cells. Generally, L. plantarum showed a significantly higher 
induction capacity of IFN-γ, IL-12 and TNF-α compared with L. acidophilus. We conclude that 
the variation in immunomodulatory effects between species is even larger than the variation 
between the strains of the same species. In addition we demonstrate that L. plantarum strains 
are most potent in skewing the T-cell differentiation toward a putative Th1 response.
Introduction
Strains of the genus Lactobacillus are increasingly being used as immunomodulating agents in 
probiotic products. Several clinical trials have demonstrated the health benefits of probiotic 
intake, and in many of these studies, immunomodulatory properties are key elements for the 
observed effects. These immunomodulatory studies using probiotics have mainly focused on 
inflammatory diseases of the gut and on allergic diseases, reviewed in Borchers et al. [1] and 
Ng et al. [2]. These studies generally confirm a large species and interstrain variation on the 
probiotic functionalities tested.
Frequently, the effects on the immune system are investigated in vitro by exposing human 
peripheral blood mononuclear cells (hPBMC) to bacteria or bacterial preparations. The capac-
ity of lactobacilli to induce cell proliferation and stimulate proinflammatory or anti-inflamma-
tory cytokines in coculture with hPBMC without affecting hPBMC cell viability, indicates that 
different strains of Lactobacillus may differentially stimulate immune cells. This signifies the 
ability of these bacteria to induce systemic effects that could modulate the immune response. 
Proposed immunomodulatory mechanisms include downregulation of local inflammatory re-
sponses through the modulation and subsequent expansion or induction of various subsets 
of T cells producing a collection of proinflammatory and anti-inflammatory cytokines. Alter-
natively, regulatory T cells could be induced by the activity of these bacteria and could be re-
sponsible for the systemically detectable immunomodulatory properties [3,4]. Understanding 
the bacteria-elicited cytokine patterns, and their systemic consequences, is of importance to 
develop better targeted applications for probiotic products.
It is recognized that the immunomodulating properties of lactic acid bacteria are strain 
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specific and that the effects of a specific strain must not be extrapolated to other strains [4,5]. 
Several studies have compared strains of different species within the genus Lactobacillus (e.g. 
[6-8]), but those studies have not compared species by including multiple representatives of 
the species. On the other hand, only a few studies have compared closely related strains and 
observed strain-dependent differences within a single species [5,9]. Studies on the compara-
tive in vitro immunomodulatory capacities of different Lactobacillus species using multiple 
representatives within these species are, to the best of our knowledge, not available. Lacto-
bacillus plantarum, Lactobacillus acidophilus and Lactobacillus paracasei are among the most 
predominant Lactobacillus species in the gut [10,11] and several strains within these species 
are marketed as probiotics.
Here, we have compared the in vitro immunomodulatory properties of L. plantarum, L. 
acidophilus and L. paracasei, both at the species level and at the strain level. Because Lactoba-
cillus casei and L. paracasei are closely related taxa that are frequently confused and for which 
the type strains have been redesignated recently [12], we have included strains from either of 
these species and analyzed them as one group.
Materials and methods
Bacterial strains
A set of 51 Lactobacillus strains of the species L. acidophilus, L. plantarum or the L. casei/
paracasei cluster were selected from our culture collections on the basis of high survival rates 
under conditions of low pH or the presence of bile, isolation from the gastrointestinal tract, or 
were strains from species that form the predominant Lactobacillus population in the gut. For 
subsequent experiments, five L. acidophilus and three L. plantarum strains were selected that 
were representative for the species with respect to cytokine induction (Table 1).
Table 1. Specification of the selected Lactobacillus strains
Species Strain Origin and/or source
acidophilus CBI 66 Unknown
acidophilus CBI 118 Unknown
acidophilus CBI 237 Unknown
acidophilus B1532 Rat feces
acidophilus B228 Human feces
plantarum B1836 Single colony isolate of NCIMB 8826 from human saliva
plantarum B2261 Silage
plantarum B2808 Human feces
Strains were cultured for 24 h at 37 °C in Man Rogosa Sharpe (MRS) broth (Merck, Darm-
stadt, Germany), after which fresh broth was inoculated with 1% (v/v) overnight culture. After 
an additional 24 h of incubation at 37 °C, bacterial cells were harvested by centrifugation at 
1000 g, washed twice with phosphate-buffered saline (PBS), and resuspended in PBS. The bac-
terial cell numbers were determined by plate counting on MRS agar, and OD
600 nm
 was meas-
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ured. The suspension was sterilized for 15 min at 115 °C and stored at -40 °C.
Isolation and culture of hPBMC
hPBMC were isolated by density gradient centrifugation on Ficoll-Paque PLUS (Amersham 
Biosciences, Uppsala, Sweden) from freshly collected buffy coats of healthy donors (Sanquin 
Blood bank of Nijmegen, the Netherlands). An informed consent was obtained before the sam-
ple collection, and the experiments performed were approved by the local ethical committee. 
The various experiments were performed with hPBMC from different blood donors (n = 1−3).
For the screening experiment of the 51 Lactobacillus strains one buffy coat was used and 
cells from the interphase were harvested, washed and cultured in 24-well plates at 1 x 106 
cells per well in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum, 2 mM 
glutamine, and 1% penicillin-streptomycin (all from Gibco-BRL, Paisley, Scotland). For all other 
experiments cells from the interphase were harvested, washed and cultured in 48-well plates 
at 1 x 106 cells per well in Yssel’s medium that consisted of IMDM containing GlutaMAX (IMDM) 
supplemented with 1% penicillin-streptomycin and 1% human AB serum (all from Gibco-BRL) 
with additions according to the previously described procedures [13].
Stimulation experiments
On the day of the experiment, the heat-killed bacteria were thawed, suspended in the ap-
propriate culture medium and added directly to the hPBMC culture. Except for a pilot experi-
ment to identify the most suitable ratio of bacteria to the hPBMC cells, a 1 : 1 ratio was used 
throughout this study. Medium with hPBMC, but without bacteria, was used as a negative 
(medium) control. The cultures were incubated at 37 °C in a humidified atmosphere with 5% 
CO
2
. Cultured cells and culture supernatants were harvested after 1 and 4 days of culture and 
these supernatants were stored at −20 °C and overnight transferred to −80 °C before analysis.
Cell viability
Trypan blue exclusion test
hPBMC viability after isolation was determined using the standard trypan blue exclusion test 
(Sigma-Aldrich, St. Louis, MO). The total number of viable and nonviable cells was counted us-
ing a Bürker counting chamber, and the percentage of viable cells was calculated accordingly.
Annexin V/propidium iodide (PI) staining
Measurement of early apoptosis and late apoptosis/necrosis was performed by double stain-
ing with APC Annexin V and PI. Half a million hPBMC were washed and incubated with 2 µl 
Annexin V (BD Biosciences, San Diego, CA) in 200 µl binding buffer [10 mM Hepes (pH 7.4), 140 
mM NaCl and 2.5 mM CaCl
2
]. After an incubation period of 15 min, cells were centrifuged and 
the supernatant was disregarded. After addition of 200 µl binding buffer and 2 µl PI (1 mg mL-1; 
Sigma-Aldrich), cells were analyzed on a flowcytometer (FACSCanto II, BD Biosciences). Cells 
that were negative for both Annexin V and PI were considered as viable cells. Annexin-positive 
but PI-negative cells were regarded as apoptotic cells and double-positive cells were regarded 
as necrotic. 
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Surface markers
Immunological phenotyping was performed on the cells at 1 and 4 days of bacterial stimulation 
or unstimulated medium control. Surface antigens were identified by the monoclonal antibod-
ies: anti-human CD3, CD4, CD8, CD14, CD19, CD25, CD16, CD56, CD45RA, CD45RO and anti-hu-
man CD69 (BD Pharmingen, San Diego). Appropriate isotype-matched controls were included.
Three monoclonal antibody mixtures were used: (1) α-hCD3 (PE-Cy7), α-hCD4 (PE), α-hCD8 
(APC), α-hCD25 (APC-Cy7); (2) α-hCD14 (APC), α-hCD16 (PE), α-hCD19 (APC-Cy7) and α-hCD56 
(PE); and (3) α-hCD45RA (PE), α-hCD45RO (APC) and α-hCD69 (APC-Cy7). The procedure was 
performed according to the instructions of the manufacturer. Four-color flowcytometric acqui-
sition was performed on a FACSCanto II (BD Biosciences), using the BD FACSDiva software. A 
gate was set to exclude debris, and the percentages of cells expressing CD3, CD4, CD8, CD25, 
CD16/CD56, CD14, CD19, CD45RA, CD45RO and CD69 were then calculated. The percentage 
positive cells was corrected for values of the isotype control.
Proliferation
Proliferation was studied by intracellular expression of the nuclear Ki-67 antigen (BD Pharmin-
gen) by flowcytometric analysis. Cultured cells were collected 4 days after bacterial stimulation 
or unstimulated medium control. In each assay, 5 x 105 hPBMC were incubated with 100 µl 
cytofix/cytoperm (BD Pharmingen) for 15−20 minutes on ice to fix and permeabilize the cells. 
Cells were washed twice with perm/wash buffer (BD Pharmingen) and incubated with an anti-
Ki-67 PE antibody (or the matched isotype control) diluted in perm/wash buffer for 30 min 
on ice in the dark. Then, the cells were washed once again with the perm/wash buffer, resus-
pended in PBS and measured on the flowcytometer. Values are expressed as the percentage of 
stimulated cells positive for the Ki-67 mAb corrected for the percentage of stimulated cells that 
were positively stained by the isotype control.
Cytokine analysis
For the screening experiment of the 51 Lactobacillus strains in the supernatants collected af-
ter 1 day of culture the production of the innate cytokines tumour necrosis factor-α (TNF-α), 
interleukin (IL)-12p70, IL-6 and IL-10 was detected with enzyme-linked immunosorbent assay 
(ELISA), using commercially available ELISA kits from Bioscource (Cytosets, Biosource Europe 
SA, Nivelles, Belgium). Values are expressed as pg mL-1 (average of strains within the same 
species ± SEM) deduced from the OD of the standard curve. The sensitivity limits for all tested 
cytokines were below 3 pg mL-1.
For the follow-up experiments, cytokine production by hPBMC was analyzed in the super-
natants of cells cultured for 1 and 4 days. The production of the innate and adaptive cytokines 
IL-1ß, IL-4, IL-5, IL-10, IL-12p70, interferon-γ (IFN-γ) and TNF-α was detected using Cytometric 
Bead Array (CBA, BD Biosciences). All buffers used in this protocol were obtained from the BD 
CBA Soluble Protein Master Buffer Kit (BD Pharmingen), and the procedure was performed 
according to the manufacturer’s protocol. The detection limits according to the manufacturer 
were as follows: 1.1 pg mL-1 IL-1β, 1.4 pg mL-1 IL-4, 1.1 pg mL-1 IL-5, 2.3 pg mL-1 IL-10, 2.2 pg mL-1 
IL-12, 0.3 pg mL-1 IFN-γ and 0.7 pg mL-1 TNF-α. The samples were measured on the FACSCanto 
II, using FCAP software (BD Biosciences).
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Statistics
For all tests, homogeneity of variance was assessed using Levene’s test. Strains (n = 3-19) from 
the same species were treated as one group. A one-way ANOVA followed by a Bonferroni test 
was used in case of equal variances between groups and a Games-Howell test in case of un-
equal variances between groups to analyze data comparing more than two groups. To compare 
two groups, an independent-sample t-test was used. When P < 0.05, the difference was inter-
preted as significant. The statistical analysis was performed by using SPSS software (version 
15.0, SPSS Inc., Chicago).
Results
Comparison of Lactobacillus species with respect to cytokine induction in hPBMC
Using hPBMC of two donors, 106 and 107 bacteria, both in combination with 106 hPBMC mL-1 
(bacteria : hPBMC ratio 1 : 1 or 10 : 1), were tested, and cytokine production was used as a 
read-out parameter. A medium control, two L. acidophilus (L. acidophilus B223 and L. acidophi-
lus CBI 118) and two L. plantarum strains (L. plantarum B1836 and L. plantarum B2261) were 
included in this experiment.
In L. plantarum-stimulated hPBMC the IL-12 and TNF-α production in both donors and 
on both day 1 (Fig. 1a) and day 4 (Fig. 1b) were consistently up to fourfold higher using the 
higher dose of L. plantarum bacteria as compared with the lower dose. On the contrary, in L. 
acidophilus-stimulated hPBMC the IL-12 production was up to 10-fold lower or remained un-
changed (with both bacterial concentrations tested below the detection limit) when stimulated 
for 1 and for 4 days with the higher concentration of L. acidophilus bacteria. Furthermore, the 
amounts of IL-12 in the supernatants detected on day 1 were strikingly similar to the amounts 
detected on day 4 and the variability between the two donors regarding IL-12 induction by the 
different strains is very low, underscoring the stability of this effect (Fig. 1). In both donors and 
with all tested Lactobacillus strains, IL-1β and IL-10 production levels were consistently up to 
threefold higher when hPBMC were stimulated for 4 days with the lower dose of bacteria com-
pared with the higher dose, while on day 1, this trend was not observed. Differences compar-
ing the L. acidophilus strains with the L. plantarum strains were not observed regarding IL-1β 
and IL-10 production. IL-4 and IL-5 levels were all below the detection limit (data not shown).
Based on the observed differences between the L. acidophilus and the L. plantarum strains 
particularly with respect to IL-12 induction capacity, a comparative study including 16 L. aci-
dophilus strains, 19 L. plantarum strains and 16 L. casei and L. paracasei ssp. paracasei strains 
was performed. Selected strains were screened for their capacity to modulate the production 
of the cytokines IL-6, IL-10, IL-12 and TNF-α after an overnight stimulation of hPBMC. As shown 
in Fig. 2, IL-12 production was strongly increased in cultures stimulated with strains from the L. 
plantarum species (127 ± 12 pg mL-1) compared with cultures stimulated with strains from the 
L. acidophilus species (8 ± 3 pg mL-1; P < 0.001) or the L. casei/paracasei (38 ± 14 pg mL-1; P < 
0.001) species. IL-10 production in response to the species L. casei/paracasei (372 ± 90 pg mL-1) 
was significantly lower compared with the L. plantarum species (723 ± 59 pg mL-1; P = 0.008) 
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and also lower, although not significantly, compared with the L. acidophilus (699 ± 113 pg mL-1; 
P = 0.077) species. The IL-10/IL-12 ratios were significantly enhanced for the L. acidophilus spe-
cies (ratio 414 ± 224) compared with the L. casei/paracasei (ratio 22 ± 5) and the L. plantarum 
(7 ± 1) species. This observed difference in IL-10/IL-12 ratio is mainly linked to the enhanced 
IL-12 production of the L. plantarum strains. TNF-α production was significantly higher when 
hPBMC were stimulated with L. plantarum strains (37252 ± 545 pg mL-1) (27761 ± 1864 pg mL-
1; P < 0.001 for L. acidophilus and 31152 ± 1130 pg mL-1; P < 0.001 for L. casei/paracasei). No 
significant differences were observed in IL-6 induction capacity between the three different 
species, with an average IL-6 production of the three species between 22000 and 25000 pg 
mL-1 (Fig. 2). The cytokine production values of the medium control were below the detection 
limit for IL-10, TNF-α and IL-6 and 3 pg mL-1 for IL-12. 
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Fig. 1. Cytokine production of 
IL-12 and TNF-α after 1 day 
(a) and 4 days (b) of stimula-
tion with two Lactobacillus 
acidophilus strains (circles), 
two Lactobacillus plantarum 
strains (squares) or the me-
dium unstimulated control (tri-
angles). Bacteria and hPBMC 
in concentrations of 106 bacte-
ria and 106 hPBMC mL-1 (ratio 
1 : 1) and 107 bacteria and 106 
hPBMC mL-1 (ratio 10 : 1) were 
used. Results of two donors 
are shown: donor A (left panel) 
and donor B (right panel). The 
dashed lines connect the cor-
responding strains.
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Fig. 2. IL-10, IL-12, TNF-α and IL-6 production by hPBMC isolated from one buffy coat and stimulated for 1 day with 
lactic acid bacteria from different Lactobacillus species. Concentrations of 106 bacteria mL-1 and 106 hPBMC mL-1 
were used. The bars represent the mean cytokine production of all strains within one tested species. Ac, Lacto-
bacillus acidophilus (tested 16 strains); Pl, Lactobacillus plantarum (tested 19 strains); Cas, Lactobacillus casei and 
Lactobacillus paracasei ssp. paracasei (tested 16 strains). Error bars represent SEM. Means without a common 
letter differ (P < 0.05).
Effects of L. acidophilus and L. plantarum on hPBMC regarding viability and proliferation
Five L. acidophilus and three L. plantarum strains were selected for further studies, using three 
different blood donors, and the results obtained were consistent in all three donors tested. 
The selected strains represented the variation in IL-12 that was observed before in the larger 
screening experiment. The in vitro immunomodulatory effect of these eight selected bacterial 
strains on the response of hPBMC was investigated in more detail by assessing immune param-
eters other than cytokine induction. The viability of hPBMC directly after isolation was above 
95%, and stimulation with Lactobacillus strains had no significant effect on the frequency of 
cells undergoing apoptosis or necrosis, either after 1 or 4 days of stimulation. After 1 day of 
culture, the average amounts of viable, apoptotic and necrotic cells were 90.0 ± 1.9%, 7.0 ± 
1.4% and 2.4 ± 0.7%, respectively. At 4 days of stimulation, the average amounts of viable, 
apoptotic and necrotic cells were 73.3 ± 1.3%, 16.1 ± 1.3% and 10.1 ± 1.0%, respectively. The 
percentage Ki-67-positive cells at day 4 was below 5%, and independent of the presence of 
bacteria. In parallel experiments, cells were harvested after 8 days of culture and no difference 
was observed in the percentage of proliferation comparing unstimulated cells (8.9 ± 2.8%) with 
cells cultured in the presence of bacteria (7.7 ± 5.8%). Furthermore, no strain-related differ-
ences were observed (data not shown).
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Effects of L. acidophilus compared with L. plantarum on hPBMC regarding the subset 
differentiation
To assess the differentiation of the hPBMC into subsets and their activation status after stimu-
lation with the different bacteria, a subset staining [CD3+ cells (T cells), CD4+ cells (T-helper 
cells), CD8+ cells (cytotoxic T cells) and CD25+ cells (activated cells)] was performed. In the 
medium control, only very low amounts of cells were activated (CD25+), and the addition of 
the different bacteria did not significantly change the T cell subset pattern nor the activation 
status of the T-cell subsets (Fig. 3a and b).
Figure 3c and d show the percentages of CD16+ CD56+ cells (NK cells), CD14+ cells (mono-
cytes) and CD19+ cells (B cells) on day 1 and day 4, respectively. There were no significant dif-
ferences in the percentages of NK, B or monocyte subsets between the L. acidophilus and the 
L. plantarum strains tested.
On day 4 of culture, the stimulation with L. plantarum strains induced significantly more 
CD45RA-positive cells (naïve cells) and fewer CD45RO-positive cells (antigen experienced or 
memory cells) compared with stimulation with L. acidophilus strains (P = 0.009 and 0.030, 
respectively). On day 4 of culture, L. plantarum stimulation also showed more CD69-positive 
cells (early activated cells) compared with the L. acidophilus strains (P = 0.001). Furthermore, 
on day 4, the amount of CD69-positive cells was consistently higher in the cultures to which a 
lactic acid bacterial strain was added compared with the medium control (Fig. 3f).
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Fig. 3. hPBMC were stimulated for 1 day 
(left panel) and for 4 days (right panel) 
with strains from the Lactobacillus aci-
dophilus and Lactobacillus plantarum 
species. Culture medium was used as 
an unstimulated medium control. Con-
centrations of 106 bacteria mL-1 and 106 
hPBMC mL-1 were used. hPBMC surface 
markers were stained with a mixture of 
α-hCD3, α-hCD4, α-hCD8 and α-hCD25 
(a and b), α-hCD16/α-hCD56, α-hCD14 
and α-hCD19 (c and d) and α-hCD45RA, 
α-hCD45RO and α-hCD69 (e and f).
Statistical tests were performed compar-
ing the L. acidophilus- and the L. plantar-
um-stimulated hPBMC cultures. Data are 
depicted as the average ± SD. *Significant 
differences between the L. acidophilus 
and the L. plantarum strains (P < 0.05). 
Results are shown for one representative 
donor (n = 3).
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Fig. 4. Balance between IL-12 and IL-10 (a) 
and the balance between IFN-γ and TNF-α 
(b) production by hPBMC stimulated with 
bacteria of different Lactobacillus strains. 
Concentrations of 106 bacteria mL-1 and 
106 hPBMC mL-1 were used. The circles rep-
resent the five Lactobacillus acidophilus 
strains, the squares show the three Lacto-
bacillus plantarum strains and the triangles 
indicate the medium control. hPBMC were 
stimulated for 1 day (closed symbols) and 
for 4 days (open symbols). The lines con-
nect the corresponding strains on the differ-
ent days. The dashed circles indicate strains 
from the same species on a specific day 
and are placed to more clearly differentiate 
strains from different species and on differ-
ent days of culture. Results are shown for 
one representative donor (n = 3).
Cytokine induction capacity profiles of the species L. acidophilus and L. plantarum after 1 and 
4 days of stimulation
The production by hPBMC of IFN-γ, TNF-α (Fig. 4b) and IL-10 (Fig. 4a) after 1 (closed symbols) 
and 4 (open symbols) days of culture and of IL-1β (Table 2) after 1 day of culture was induced 
upon interaction with all tested Lactobacillus strains (squares and circles) compared with the 
medium control (triangles). Comparing the IL-10 induction by the different species, no differ-
ence was observed in IL-10 induction capacity between the individual L. acidophilus and the L. 
plantarum strains. IL-10 production was significantly higher at 4 days compared with 1 day of 
stimulation (P < 0.001) (Fig. 4a).
A clear species-specific IL-12 induction was observed (Fig. 4a) both after 1 and 4 days of 
culture. Lactobacillus plantarum (squares) induced on average fivefold (2−11-fold) more IL-12 
both after 1 and 4 days than L. acidophilus (circles) (P = 0.015 and 0.001, respectively), and like 
in the previous experiment, whose results are shown in Fig. 1, the amounts of IL-12 detected 
after 1 day were similar to the amounts detected on day 4. The induction of the cytokine IFN-γ 
(Fig. 4b) by L. plantarum was on average fourfold (1.3−10-fold) enhanced compared with L. 
acidophilus after 1 day (P = 0.005) and after 4 days (P = 0.001) of stimulation. Furthermore, the 
production of the cytokine IFN-γ was on average two times higher at day 4 compared with day 
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1 (P = 0.002) in the cultures exposed to the L. plantarum strains. There was no significant in-
crease in IFN-γ induction observed at day 4 compared with day 1 for the L. acidophilus strains. 
As also observed in the initial screening experiment, the IL-10/IL-12 ratios were calculated 
for all strains and showed a significantly lower ratio for the L. plantarum strains (ratio 8 ± 1 on 
day 1 and 13 ± 4 on day 4) compared with the L. acidophilus strains (ratio 39 ± 13 on day 1 and 
87 ± 52 on day 4) both after 1 (P = 0.006) and 4 (P = 0.033) days of stimulation (Fig. 4a). Again, 
this lower ratio is more linked to increased IL-12 production of the L. plantarum strains. Upon 
interaction with either Lactobacillus species, low or undetectable levels of the cytokines IL-4 
and IL-5 (all below 5 pg mL-1) were produced by the hPBMC (data not shown). Furthermore, 
no significant differences were observed in IL-1β induction capacity after 1 or 4 days of culture 
between the two different species, although all strains increased the IL-1β production by the 
hPBMC as compared with the unstimulated hPBMC after 1 day of culture, with at least 7400 
pg mL-1 (Table 2). After 1 and 4 days of culture L. plantarum showed an increased induction 
capacity for TNF-α as compared with L. acidophilus; this finding was significant (P = 0.012) on 
day 1 but not significant (P = 0.141) on day 4 (Table 2). Furthermore, both IL-1β and TNF-α pro-
duction was significantly higher at 1 day compared with 4 days of stimulation (both P < 0.001).
Table 2. IL-1β, IL-10, IL-12, IFN-γ and TNF-α production (pg mL-1) by hPBMC stimulated with bacteria of five Lacto-
bacillus acidophilus and three Lactobacillus plantarum strains.
IL-1β IL-10 IL-12 IFN-γ TNF-α
Day 1
acidophilus
CBI 66 8763 267 4 79 287
CBI 118 14270 214 1 163 227
CBI 237 7433 293 3 125 125
B1532 8763 252 12 362 1518
B228 11054 184 9 447 616
Average 10057 242 6* 235* 554*
SD 2691 43 5 160 569
plantarum
B1836 14270 242 60 922 2376
B2261 11475 206 41 606 1615
B2808 13769 238 65 1157 1715
Average 13171 228 55 895 1902
SD 1491 20 13 276 413
Day 4
acidophilus
CBI 66 166 427 3 87 386
CBI 118 74 285 ND 149 386
CBI 237 101 536 4 137 304
B1532 -177 419 25 747 1376
B228 -54 213 11 747 718
Average 22 376 8* 373* 634
SD 137 127 10 342 444
plantarum
B1836 -69 492 59 2069 1171
B2261 -48 419 43 1560 1061
B2808 -123 242 68 2328 1026
Average -80 384 57 1986 1086
SD 39 129 13 391 76
hPBMC were stimulated for 1 day 
(upper table) or for 4 days (lower 
table). Concentrations of 106 bac-
teria mL-1 and 106 hPBMC mL-1 
were used. Cytokine production 
values of the medium control are 
subtracted from each value. Me-
dium values were as follows: IL-
1β, 7175 and 337 pg mL-1; IL-10, 
249 and 368 pg mL-1; IL-12, 8 and 
ND pg mL-1; IFN-γ, 169 and 156 pg 
mL-1; TNF-α, 2272 and 508 pg mL-1 
for day 1 and day 4, respectively. 
Results are shown for one repre-
sentative donor (n = 3).
*Significantly (P < 0.05) different 
compared with the average of the 
three L. plantarum strains on the 
same day. 
ND, nondetectable (below 2.2 pg 
mL-1).
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Cytokine induction capacity profiles between strains
Next to differences at the species level, strains within a species differed in their potential to 
induce cytokine production as compared with each other. To illustrate this: after 1 and 4 days 
of culture, the strains L. acidophilus CBI 66, CBI 118 and CBI 237 showed the lowest IL-12, IFN-γ, 
and TNF-α induction of the five L. acidophilus strains tested. On the contrary, at day 4, these 
three strains showed the highest IL-1β induction compared with the other two L. acidophilus 
strains, B1532 and B228. Addition of the latter two strains in the culture even caused a reduc-
tion in IL-1β production compared with the medium control (Table 2). Furthermore, L. acido-
philus B1532 is the most potent IL-12 and TNF-α inducer of the L. acidophilus strains. Regarding 
the L. plantarum strains, a similar production of IL-10 is seen for all L. plantarum strains on day 
1, while on day 4 L. plantarum B1836 and L. plantarum B2261 induced a twofold higher IL-10 
secretion compared with the L. plantarum B2808 strain (Table 2). Although strain-specific dif-
ferences in immunomodulatory capacity clearly exist, differences between species are more 
profound. The cytokine induction capacity of the strains on day 1 differed within a species 
maximal 2.5-fold, while between the two species L. acidophilus and L. plantarum, the cytokine 
induction capacity differed up to eightfold.
Discussion
The study described here confirms and extends the strain-specific characteristics of different 
species of lactic acid bacteria in their immunomodulatory potential of hPBMC. This illustrates 
the strain specificity of candidate probiotic characteristics, and indicates that probiotic bacte-
ria have to be selected with care, because immunomodulating capacity even differs between 
closely related strains. By comparing strains of lactic acid bacteria belonging to either L. acido-
philus, L. casei/paracasei or L. plantarum, we demonstrate the species-dependent characteris-
tics of Lactobacillus strains. Based on this improved insight into the characteristics of their im-
munomodulating activity, screening efforts to select new potential probiotic strains can benefit 
from a first focus on selected species rather than random screening of individual strains.
All Lactobacillus strains tested in our study stimulated IL-10, IFN-γ and TNF-α production 
both after 1 and 4 days of culture as well as IL-1β after 1 day of culture. In support of our 
results, Lactobacillus strains are generally strong inducers of the proinflammatory cytokines 
TNF-α [14-16] and IL-12 [15,17-19], although several studies observed that specific lactic acid 
bacteria yield a low or nonsignificant increase in IL-12 production by hPBMC [7,20]. In our 
study, all L. plantarum strains tested stimulated IL-12 production, while most L. acidophilus 
strains failed to do so, which confirms that the difference in IL-12 induction observed in the re-
ported studies is caused by the use of different species and strains. The data presented here in-
dicate that strains belonging to L. plantarum have a higher capacity to induce innate cytokines, 
like IL-12 and TNF-α in cultured hPBMC than strains of L. casei/paracasei or L. acidophilus. Also, 
increasing the bacteria : hPBMC ratio increased the levels of IL-12 for L. plantarum, while L. 
acidophilus failed to do so. Lactobacillus plantarum induced on average more IFN-γ, IL-12 and 
TNF-α and therefore has more capacity to induce a putative Th1 subset response as compared 
with L. acidophilus.
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Recent studies showed differences between Lactobacillus strains in their cytokine-in-
ducing properties such as for IL-10 and IL-12, by comparing only a few Lactobacillus strains 
[6,7,16,17,21]. Furthermore, Miettinen et al. [15] observed a strain-specific effect on the Th1 
cytokine induction capacity of three Lactobacillus strain on analyzing the cytokines IL-12 and 
IFN-γ. In the present study, initially, 51 strains were compared for their cytokine-inducing prop-
erties. The differential cytokine-inducing capacity within the Lactobacillus genus was used to 
select eight representative strains out of the L. acidophilus and L. plantarum species for further 
immunological characterization. To our knowledge, other studies have not determined inter-
species differences in immune responsiveness assessing various immune parameters, despite 
the fact that several studies have reported strain-specific differences. In the present study, we 
also studied cell viability, proliferation, cell differentiation and activation of hPBMC by the vari-
ous lactobacilli tested. No changes in cell viability or proliferation were observed after addition 
of the strains, which suggests that the stimulus provided is rather subtle, and that the bacteria 
by themselves do not promote lymphocyte survival nor induced immune proliferation in vitro. 
The observed increase in early activated cells (CD69) of the hPBMC stimulated with L. plantar-
um strains is significantly higher compared with the increase observed with the L. acidophilus 
strains. The performed double stainings showed that the CD69-positive cells are mostly naïve 
T cells (CD45RA), and together this finding is most consistent with an increased population of 
activated naïve T cells, despite the fact that B cells and NK cells also express this CD69 marker. 
This suggests that the L. plantarum strains have a more profound effect on both the monocyte 
and the T-cell fraction of the hPBMC, which could also explain the higher production of most 
cytokines analyzed here. IFN-γ production is also increased by addition of bacteria to the cul-
tures [18,19], although such an induction has not always been observed [15,22]. IL-12 plays an 
important role in driving the immune response toward a Th1 direction, which, by the release 
of IFN-γ, counteracts Th2 activity in vivo [23]. The increase in IFN-γ could therefore be partly 
explained by the induction of IL-12 production by the lactic acid bacteria. Our results show a 
clear positive correlation between IL-12 and IFN-γ production.
The anti-inflammatory cytokine IL-10 is increasingly regarded as a regulatory cytokine; it is 
a potent inhibitor of IL-12 and may suppress the emergence of an unbalanced Th1 response. 
Although the IL-10 production in our study increased significantly over time, IL-12 and IFN-γ 
production remained the same or even also increased. Furthermore, a significant decrease in 
the IL-10/IL-12 ratio was observed in the L. plantarum strains compared with the L. acidophilus 
strains or the medium control after 1 day of stimulation. The decreased IL-10/IL-12 ratio in the 
presence of L. plantarum strains is mainly due to enhanced IL-12 production, which is consist-
ent with the increased capacity to induce a T-helper 1 profile. The capacity of lactobacilli to 
stimulate proinflammatory or anti-inflammatory cytokines in coculture with hPBMC indicates 
that different Lactobacillus strains may differentially stimulate immune cells and could there-
fore even exert opposite immunomodulatory effects.
In addition to strain-specific analysis of the cytokine induction capacity, time-dependent 
and dose-dependent effects of cytokine release were observed in our hPBMC stimulation assay. 
Many studies conducted on the immunomodulatory capacity of lactic acid bacteria measured 
the cytokine production only after one particular time point of stimulation despite the notion 
that kinetics of production are cytokine-specific [22]. For example, Lammers et al. [24] found 
a time-dependent effect for L. casei and Bifidobacterium breve by exposing hPBMC for 24, 48 
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and 72 h to 20 μg mL-1 probiotic DNA. IL-1β, IL-6 and IL-10 secretion reached the maximal con-
centration after 24 h and remained at this level. Chen et al. (1999) showed a time-dependent 
effect for IL-10 that reached the highest level in the supernatants at 24-h incubation, after 
which the production clearly decreased. Cytokine induction in hPBMC by viable probiotics also 
showed a concentration-dependent and time-dependent response. TNF-α production reached 
the highest induction after 24 h with 106 CFU mL-1 [25]. The kinetic analysis of the production 
level of multiple cytokines in our study provides a better overview of relevant innate and adap-
tive immune responses and will improve the understanding of the effects of lactic acid bacteria 
on cell differentiation, proliferation and cytokine production by the hPBMC.
The mechanism by which Lactobacillus species differentially stimulate hPBMC is largely 
unknown. Bacterial cell wall components are in direct contact with several immune cell types 
by binding various pattern recognition receptors, including the well-characterized family of 
Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain proteins. TLR usage 
by lactobacilli is species-specific, which is probably partly attributable to the considerable vari-
ation in the cell wall composition between the lactobacilli. For example, alterations of the cell 
wall polysaccharide-peptidoglycan complex composition of an L. casei strain have been report-
ed to influence the cytokine responses of murine spleen cells and macrophages [26]. The TLRs 
identified as mediating certain activities of lactic acid bacterial strains include, among others, 
TLR2 and TLR9, reviewed in Borchers et al. [1]. Teichoic acids are considered to be one of the 
main immunostimulatory components of Gram-positive bacteria through their activation of 
TLR2 [27]. Teichoic acids are repeating units that are covalently anchored to either peptidogly-
cans (wall teichoic acids) or attached to the cytoplasmic membrane (lipoteichoic acids). There 
exist considerable differences between the wall teichoic acid and lipoteichoic acid molecules 
of different Lactobacillus strains, both in composition (e.g. the degree of substitution with D-
Ala and/or glucose) and in quantity, which may influence the immune stimulating properties of 
the different strains [28]. Although all lactobacilli have teichoic acids in their cell walls, L. casei 
strains appear to contain only lipoteichoic acids whereas most L. plantarum strains contain the 
two types of teichoic acids, reviewed in Lebeer et al. [4]. Although the composition of cell wall 
structures forms a logical candidate for differential immunomodulating properties, the pres-
ence of other surface-associated proteins cannot be excluded. A recent study showed that the 
major S layer protein of the L. acidophilus NCFM strain is functionally involved in the modula-
tion of dendritic cells and T-cells functions [29]. Furthermore, structural cell components such 
as pure genomic DNA and also to a minor extent secreted compounds of probiotics could also 
mediate part of the immune effects [1,5]. However, because the cells in the current study were 
washed and subsequently inactivated, it is not likely that secreted factors play a role, as dem-
onstrated for other bacteria [30].
Investigations into the in vitro immunomodulatory capacity of probiotics usually precede 
the in vivo trials in animals or humans necessitating the existence of a good correlation be-
tween in vitro and in vivo findings. Nevertheless, systematic studies linking in vitro data to 
in vivo effects have rarely been performed [31]. This may be explained by the variety of pa-
rameters that interfere with such a comparison of strains including the bacterial preparations 
used (viability, growth phase, dose and timing of administration) [32], the method of hPBMC 
preparation, and the variable responsiveness of the donors. Nevertheless, the in vitro immune 
profiling in hPBMC with respect to the IL-10/IL-12 ratio induced by 13 bacterial strains is in-
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deed predictive of their in vivo protective effect in a murine trinitrobenzene sulfonate model of 
acute colitis [31]. Whether this is true for inflammatory bowel disease in humans, or for other 
types of immune-related disorders, remains to be determined. Large numbers of candidate 
strains are often tested as probiotics for immunomodulating properties in a variety of in vitro 
models to select those strains with the best characteristics. A further selection takes place in 
vivo in animal models or human volunteers. Based on the study presented here, bacterial spe-
cies can be classified for their probiotic characteristics on the basis of their immune profiles. 
Generally, L. plantarum strains were high IL-12 inducers, whereas strains from L. acidophilus 
were recognized as low IL-12 inducers. Depending on the aimed health benefit, this informa-
tion would help to reduce the number of candidate strains to be tested.
In conclusion, in the present study, we have shown that several strains and species of lactic 
acid bacteria stimulate the T-cell response toward a putative Th1 response, which could be 
beneficial by downregulating a Th2-skewed disease such as IgE-mediated allergy. Especially, 
the L. plantarum strains, which, in our study, showed the highest IL-12 induction in vitro are 
promising candidates, as IL-12 plays a pivotal role in allergy by reducing the response of the 
Th2 pathway. To what extend probiotic Lactobacillus strains have differential in vivo immu-
nomodulatory effects, especially in the field of allergy reduction that can be linked to the spe-
cies level may be subject of further investigations. The immunomodulatory effects are shown 
to be species dependent, although the variation between strains is still of importance. This 
observed larger variation in the effects between species compared with within specific could 
be of practical value for the screening of new probiotic strains for their health-promoting prop-
erties.
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Abstract
The objective of this study was to assess the potential immunomodulatory effect of six Lacto-
bacillus strains on human peripheral blood mononuclear cells (hPBMC) isolated from allergic 
patients. hPBMC from patients allergic to birch pollen or grass pollen were cultured in vitro 
in the presence or absence of selective bacterial strains. Cultures were left unstimulated or 
stimulated with αCD3/αCD28 or Bet v 1. After 1, 4 and 8 days, cells and culture supernatants 
were harvested and the effect on cellular proliferation and the supernatant levels of several 
cytokines was assessed. All strains had the ability to repress IL-13 production but did show a 
differential effect on IFN-γ induction. Both strains B223 and B1697 showed a lower IFN-γ, IL-
12 and TNF-α induction as compared with the other tested strains. Strain B633 showed the 
best proliferation-suppressive properties in αCD3/αCD28-stimulated cells. Suppression of the 
T-helper type 2 (Th2) cytokine induction and induction of the Th1 cytokine production by spe-
cific strains might be beneficial for allergic patients having a disturbed Th1/Th2 immune bal-
ance. Furthermore, hPBMC of patients with seasonal allergy outside the pollen season can be 
used to determine immunomodulatory activities of probiotic bacteria.
Introduction
Atopic diseases such as allergic asthma, allergic rhinitis or allergic conjunctivitis, and atopic 
eczema have become an increasing health problem, and the use of probiotics appears to offer 
novel perspectives for treatment [1-5]. Lactic acid bacteria are well known for their practical 
application, while some lactic acid bacterial strains exert a beneficial effect on the host health 
and are therefore called probiotics. A variety of probiotic strains have been studied for their 
immunomodulating activities, including a selection of the 152 different species of the Lacto-
bacillus genus that have been identified to date (NCBI taxonomy database), which encompass 
an unusually high phylogenetic and functional diversity [6]. It is recognized that each strain can 
have unique and markedly different immunomodulating properties. Consequently, the pro-
biotic effects of a specific strain cannot be directly extrapolated to other strains of the same 
species, let alone across the species boundary [7-10].
An allergic reaction is characterized by a disrupted T-helper type 1 (Th1)/Th2 balance to-
ward a preferential allergen specifically induced Th2 cytokine profile, causing allergic inflam-
mation by releasing IL-4, IL-5, IL-9 and IL-13, inducing IgE antibody formation, promoting eo-
sinophil development and recruitment, and increasing production of mucus in the gut and 
airways [11,12]. Suppression of Th2 and induction of Th1 cytokine production and induction 
of T-regulatory (Treg) cells could thus be beneficial in treating allergic diseases by antagonizing 
the Th2 cell development, resulting in suppressed IgE formation [13,14]. 
A proposed effect of probiotics is down-regulation of the Th2 cytokine production either 
by stimulation of Th1 cytokines or by stimulation of the regulatory cytokine IL-10, produced 
by antigen presenting cells such as monocytes [15-17]. Furthermore, the activities of Th1 and 
Th2 are suppressed via IL-10 and TGF-β production by Treg cells, to help in balancing the in-
testine [11,18-20]. Deficiency in functional Treg cells is currently widely accepted as a possible 
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mechanism underlying the Th2-skewed response in allergy [21,22]. Lactobacilli can upregulate 
the induction of Treg cells, triggering the release of regulatory cytokines and controlling the 
delicate balance between Th1 and Th2 immunity as well as tolerance [5,13,23,24]. The dif-
ferential effects of probiotic strains are frequently investigated in vitro using human peripheral 
blood mononuclear cell (hPBMC) but generally derived from healthy donors [25-28], and only 
few studies have investigated the in vitro response of probiotics to hPBMC of allergic patients 
[15,17,29,30]. Healthy subjects, in contrast to allergic individuals, are assumed to regulate the 
Th1/Th2 balance by inducing sufficient Treg cell activity to maintain or restore immune toler-
ance to allergens [13,21].
The aim of the present study was to investigate the immunomodulatory capacity of six 
selected Lactobacillus strains and one mixture of two strains on hPBMC of pollen-allergic pa-
tients. Birch- and grass pollen-allergic patients were chosen as these are common seasonal 
allergies with a prevalence estimated up to 40% [31], and a possible benefit of probiotics could 
thus be of interest for a large part of the population. Human trials on probiotics have shown 
promising results for prevention of atopic eczema; however, the results on possible benefits for 
management of inhalant allergies, such as hay fever are not as conclusive [32,33]. Therefore, 
further research is needed to investigate whether probiotics can restore the disrupted immune 
balance in pollen-allergic patients, leading to a reduction of allergic symptoms.
The immunomodulatory properties of the selected Lactobacillus bacteria were assessed 
by measuring the induction of innate and adaptive cytokine production, proliferation and cell 
death of unstimulated, polyclonal stimulated and allergen-specific stimulated hPBMC. The Lac-
tobacillus strains studied showed an overall stimulating effect on IL-10, decreased prototypical 
Th2 cytokines and differentially stimulated signature Th1 cytokine induction.
Materials and methods 
Patients
Blood was collected from five birch pollen-allergic patients, two grass pollen-allergic patients 
and one adult healthy control. All birch- and grass-allergic patients reported having rhinocon-
junctivitis during the birch or grass pollen season, respectively, and had serum-specific IgE to 
birch or grass pollen of at least class 4 (except for one person who had class 3), measured 
by ImmunoCAP (Phadia AB, Uppsala, Sweden). The healthy donor displayed no birch or grass 
pollen-specific IgE in his sera ( < 0.35 kU L-1 / class 0). Blood was obtained outside the pollen 
season in September, and none of the patients showed allergic symptoms at the time of inves-
tigation. Furthermore, none of the patients had received allergen-specific immunotherapy or 
used antihistamines or corticosteroids in the month before the blood drawing. All participants 
gave their informed consent and the performed experiments were approved by the local ethi-
cal committee (Commissie Mensgebonden Onderzoek, regio Wageningen).
Preparation of bacteria
Six Lactobacillus strains (Table 1) of the species Lactobacillus acidophilus, Lactobacillus plantar-
um and Lactobacillus fermentum were selected from our culture collection on the basis of high 
survival rates under conditions of low pH and/or the presence of bile, isolation from gastroin-
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testinal tract, or were strains from species that are among the predominant Lactobacillus pop-
ulations in the human gut. Further selection, including 70 strains, was based on IL-10-inducing 
capacities in 24-h hPBMC cultures of a healthy donor according to standardized procedures in 
our laboratories. Furthermore, a mixture of strains B2261 and B633 was included, further re-
ferred to as a mixture of B2261 and B633. The choice for this mixture was based on combining 
the highest IL-10-inducing strain (B633) and the highest IL-12-inducing strain (B2261), of the 70 
strains included in this initial screening. Strains were cultured for 24 h at 37 °C in Man Rogosa 
Sharpe (MRS) broth (Merck, Darmstadt, Germany), after which fresh broth was inoculated with 
1% (v/v) overnight culture. After an additional 24 h of incubation at 37 °C, bacterial cells were 
harvested by centrifugation at 1000 g, washed twice with phosphate-buffered saline (PBS), 
and resuspended in PBS. The bacterial cell numbers were determined by plate counting on 
MRS agar, and OD was measured at a wavelength of 600 nm. The bacteria used in the immune-
stimulation assays were heat-killed (15 min at 115 °C) and stored at − 40 °C until use.
Table 1. Specification of the selected Lactobacillus strains
Species Strain Origin and/or source
L. plantarum B1836 Single colony isolate of NCIMB 8826 from human saliva
L. plantarum B1697 Isolate from soak water soya beans
L. plantarum B2261 Silage
L. fermentum B633 Unknown
L. acidophilus B223 Isolated from Acidophilus powder Laccillia
L. acidophilus CBI 118 Unknown
Isolation, culture and stimulation of hPBMC
hPBMC were isolated by density gradient centrifugation on Ficoll-Paque PLUS (Amersham Bio-
sciences, Uppsala, Sweden) from freshly collected EDTA blood. Cells from the interphase were 
harvested, washed and cultured in 48-well plates at 1 x 106 cells per well in Yssel’s medium, 
which consisted of IMDM-containing GlutaMAX (IMDM) (Gibco-BRL, Paisley, Scotland) supple-
mented with 1% penicillin-streptomycin and 1% human AB serum (all from Gibco-BRL) with 
additions according to previously described procedures [34].
On the day of the experiment, the heat-killed bacteria were thawed, suspended in the ap-
propriate culture medium and added directly to the hPBMC culture in a 1:1 ratio with the cells. 
This ratio was identified as the most suitable ratio for this study as determined from a previous 
experiment [10]. To the culture exposed to the mixture of strains B2261 and B633, 0.5 x 106 
bacteria of each strain were added to the 1 x 106 hPBMC per well. hPBMC were stimulated 
with αCD3/αCD28 (150 ng mL-1 αCD3, 100 ng mL-1 αCD28), rBet v 1.0101 (Bet v 1; 10 μg mL-1; 
Biomay) or left unstimulated. The cultures were incubated at 37 °C in a humidified atmosphere 
with 5% CO
2
. Cultured cells and culture supernatants were harvested after 1 day of culture 
without stimuli, after 4 days of culture without stimuli and with αCD3/αCD28 stimulation. Cul-
tured cells and culture supernatants were harvested after 8 days of culture of unstimulated 
and Bet v 1-stimulated cells, both with and without the addition of αCD3/αCD28 as a restimu-
lus on day 7. All supernatants were stored at − 20 °C and overnight transferred to − 80 °C before 
analysis. An overview of the in vitro experiments performed is presented in Fig. 1.
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Fig. 1. Timeline of the in vitro study design. hPBMC were isolated from eight donors and cultured in 48-well plates 
in the presence or absence of the heat-killed bacteria and/or a stimulus. On the day of isolation, cell viability and 
the surface marker (SM) profile of the hPBMC of all eight donors tested were assessed. After 1 day of culture, 
supernatants were collected for cytokine analysis of unstimulated cells. On day 4, supernatants were collected for 
cytokine analysis of both unstimulated and αCD3/αCD28-stimulated cells and cells were harvested to assess cell 
viability and proliferation. On day 7, αCD3/αCD28 was added in the restimulated condition, and the next day super-
natants were taken for cytokine analyses and cells were harvested to assess proliferation of unstimulated (Med) or 
Bet v 1-stimulated cells, both without (-) and with (+) restimulation with αCD3/αCD28 on day 7.
Annexin V/propidium iodide (PI) staining
Measurement of early apoptosis and late apoptosis/necrosis was performed by double stain-
ing with APC Annexin V and PI. Half a million hPBMC were washed and incubated with 2 µl An-
nexin V (BD Biosciences, San Diego, CA) in a 200 µL binding buffer [10 mM Hepes (pH 7.4), 140 
mM NaCl and 2.5 mM CaCl
2
]. After an incubation period of 15 min, cells were centrifuged and 
the supernatant disregarded. After the addition of 200 µL binding buffer and 2 µL PI (1 mg mL-
1; Sigma-Aldrich) to the cell suspension, cells were analyzed on a flow cytometer (FACSCanto 
II; BD Biosciences). Cells that were negative for both Annexin V and PI were considered as vi-
able cells. Annexin-positive but PI-negative cells were regarded as apoptotic cells and double-
positive cells were regarded as necrotic. The Annexin V/PI staining was performed on cells 
immediately after isolation and on αCD3/αCD28-stimulated cells after 4 days of culture in the 
presence or absence of the bacterial strains.
Surface markers
Immunological phenotyping was performed on cells immediately after isolation of the hPBMC. 
Two monoclonal antibody mixtures were used: (1) α-hCD3 (PE-Cy7), α-hCD4 (PE), α-hCD8 (APC) 
and α-hCD25 (APC-Cy7); (2) α-hCD14 (APC), α-hCD16 (PE), α-hCD19 (APC-Cy7) and α-hCD56 
(PE). The procedure was performed according to the instructions of the manufacturer and the 
acquisition and analysis was performed as described previously [10].
Proliferation
Proliferation was studied by intracellular expression of the nuclear Ki-67 antigen (BD Pharmin-
gen, San Diego, CA) by flow cytometric analysis. Cultured cells were collected on both 4 and 8 
days of culture. In each assay, 5 x 105 hPBMC were incubated with 100 µL cytofix/cytoperm (BD, 
day 0             1                                  4                                   7            8
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Pharmingen) for 15-20 min on ice to fix and permeabilize the cells. Cells were washed twice 
with perm/wash buffer (BD Pharmingen) and incubated with an anti-Ki-67 PE antibody (or the 
matched isotype control) diluted in perm/wash buffer for 30 min on ice in the dark. Hereafter, 
the cells were washed once again with the perm/wash buffer, resuspended in PBS and meas-
ured on the flow cytometer. Values are expressed as the percentage of stimulated cells positive 
for the Ki-67 mAb corrected for the percentage of stimulated cells that were positively stained 
by the isotype control.
Cytokine analysis
Cytokine production by hPBMC was analyzed in supernatants of cells cultured for 1, 4 and 8 
days. The production of the innate and adaptive cytokines IL-1ß, IL-10, IL-12p70, IL-13, IFN-γ 
and TNF-α was detected using cytometric bead array (CBA; BD Biosciences). All buffers used in 
this protocol were obtained from the BD CBA Soluble Protein Master Buffer Kit (BD Pharmin-
gen) and the procedure was performed according to the manufacturer’s protocol. The detec-
tion limits according to the manufacturer were as follows: 1.1 pg mL-1 IL-1β, 2.3 pg mL-1 IL-10, 
2.2 pg mL-1 IL-12p70, 1.6 pg mL-1 IL-13, 0.3 pg mL-1 IFN-γ and 0.7 pg mL-1 TNF-α. The samples 
were measured on the FACSCanto II, using FCAP software (BD Biosciences).
Statistics
Because of a nonnormal distribution of most of the data the nonparametric Wilcoxon signed-
rank test was used. This test allowed to compare data from cultures in the absence of a bac-
terial strain with cultures in the presence of the different strains and to compare data from 
cultures of different strains. The Wilcoxon signed-rank test was also used to compare cytokine 
data on different days and to compare cytokine data on day 8 of not-restimulated and res-
timulated cells. When P < 0.05, the difference was considered to be statistically significant. 
The statistical analysis was performed using SPSS Software (version 15.0; SPSS Inc., Chicago). 
Experimental data are presented as mean ± SEM.
Results
Composition of hPBMC subsets as measured directly after isolation
Although differences in hPBMC subset composition were observed between the different do-
nors, all values were within the normal range of leukocytes present in the peripheral blood as 
assessed by Erkeller-Yuksel et al. [35] and Jentsch-Ullrich et al. [36] (data not shown).
Viability of hPBMC after isolation and after culture in the presence of Lactobacillus strains
Viability of hPBMC directly after isolation was above 80% for all donors and the percentage late 
apoptotic/necrotic cells was below 5% (data not shown). Furthermore, an AnnexinV/PI staining 
was performed after 4 days of αCD3/αCD28-stimulated cultures. A slight but significant reduc-
tion of cell viability was observed in some but not all αCD3/αCD28-stimulated cultures exposed 
to the bacterial strains compared with the control in which cells were stimulated with αCD3/
αCD28 in the absence of bacterial strains (Fig. 2).
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Fig. 2. Effect of lactobacilli on the percentage of viable cells in 4-day αCD3/αCD28-stimulated cultures. Fresh 
 hPBMC were stimulated for 4 days with αCD3/αCD28 in the presence or absence (only stimulus) of a bacterial 
strain. hPBMC were stained with Annexin V and just before measurement, PI was added. All Annexin V-/PI-negative 
cells were regarded as viable cells. Data are mean ± SEM values for seven allergic patients.
*Significant difference with the control group (only stimulus) in which no lactobacilli strain was added to the cul-
ture (P < 0.05).
Effects of lactobacilli strains on proliferation of hPBMC
To assess whether the different bacterial strains would have the ability to promote or repress 
the proliferation of hPBMC, the percentages of proliferating cells were measured for both 
αCD3/αCD28-stimulated cultures and the long-term unstimulated or restimulated cultures ex-
posed or not exposed to the different lactobacilli. The percentage Ki-67-positive cells after 4 
days of culture that were not stimulated and without the addition of lactobacilli was below 5% 
(data not shown). As no effect was observed on the proliferation of hPBMC by the lactobacilli 
after 4 days of culture without an external stimulus [10], at day 4 in the current experiment, 
the Ki-67 staining was performed only for the αCD3/αCD28-stimulated cultures. All lactobacilli 
significantly inhibited the proliferation induced by the polyclonal αCD3/αCD28 stimulus (Ta-
ble 2). Furthermore, strain B633 showed a significantly stronger inhibition of the proliferation 
compared with all other strains tested.
After 8 days of culture without an extra stimulus given on day 7, no difference was observed 
in percentage of proliferating cells on comparing hPBMC cultured in the absence of bacterial 
strains (8.9 ± 1.0%) with hPBMC cultured in the presence of the various bacteria (average of all 
bacterial strains 7.3 ± 2.2%). Cells that were restimulated on day 7 with αCD3/αCD28 showed a 
consistent inhibition of proliferation on day 8 in cultures to which lactobacilli were added com-
pared with the control. An exception was strain B1697 which showed no or only a minor effect 
on the proliferation of hPBMC compared with control cultures, which were not exposed to a 
Lactobacillus strain. The observed inhibition of proliferation was significant for strains B2261, 
B633 and CBI 118 (Table 2).
  Chapter 8  
 152 
Table 2. Proliferation of hPBMC in the presence or absence of lactic acid strains.
 Control B1836 B1697 B2261 B2261 + B633 B633 B223 CBI 118
αCD3/αCD28 day 4 40.2 ± 3.5  32 ± 3.4* 29.2 ± 2.4* 30.7 ± 2.5* 25.6 ± 3.1* 9.4 ± 1.8* 24.5 ± 4.3* 26.9 ± 4.0*
Medium -   8.9 ± 1.0 6.9 ± 2.1   7.2 ± 2.5   7.4 ± 2.0   6.4 ± 1.9 6.9 ± 2.1 7.9 ± 2.0 8.4 ± 2.9
Medium + 18.9 ± 3.3 7.5 ± 3.2 17.6 ± 6.4   8.3 ± 2.6*   8.8 ± 3.5 6.5 ± 3.4* 9.9 ± 4.5 8.5 ± 2.8*
Fresh hPBMC were stimulated with αCD3/αCD28 for 4 days (αCD3/αCD28 day 4), or cultured for 8 days and not 
restimulated (medium -) or restimulated (medium +) with αCD3/αCD28 on day 7.
Data are mean percentage of Ki-67 positive cells ± SEM values for seven allergic patients. Asterisks indicate statisti-
cally significant differences between control and bacterial species (P < 0.05).
Induction of cytokine production by the lactobacilli strains
The effect of the different lactobacilli strains on innate and adaptive cytokine induction of un-
stimulated hPBMC was investigated in cultures exposed to the lactobacilli but without addition 
of an external stimulus. IL-1β production on day 1 (Fig. 3a) and TNF-α production on days 1 
and day 4 (Fig. 3c) were induced upon interaction with all Lactobacillus strains tested. On day 
4, both IL-1β and TNF-α production were in all cultures significantly lower compared with that 
on day 1 (18- and 3-fold, respectively). Strains B1836, B1697 and B223 showed a higher IL-1β 
induction compared with the control on day 4. IL-10 production was significantly induced for 
all strains and on both days compared with the control (Fig. 3b). Strains B1836, B2261, the mix-
ture of B2261 and B633, and B633 alone induced a higher IL-10 production on day 4 compared 
with day 1.
Production of IFN-γ by hPBMC after 4 days of culture (Fig. 3d) was induced upon interaction 
with all Lactobacillus strains compared with the control. After 1 day of culture, IFN-γ produc-
tion was consistently induced by all strains, except for strains B1697 and B223, and the IFN-γ 
induction was significantly higher on day 4 compared with that on day 1 (on average 16-fold). 
A clear difference in IFN-γ induction was observed for the different strains tested, with strains 
B1697 and B223 eliciting consistently low IFN-γ induction whereas the other strains were 
strong inducers. The strong IFN-γ-inducing strains also showed an increased IL-12 production, 
though IL-12 levels were, in all samples, below 25 pg mL-1 (data not shown). IL-13 could not be 
detected on day 1 and was < 25 pg mL-1 on day 4.
  Effects of LAB on hPBMC of pollen-allergic patients   
 153 
7
8
6
5
4
3
2IL-
1
(p
g
/m
l)

T
N
F
-
(p
g
/m
l)

0
200
400
600
800
1000
1200
1400
1600
1800
Cont B1836 B1697 B2261 B2261
+ B633
B633 B223 CBI 118
#
#
#
#
#
#
#
#
0
100
200
300
400
500
Cont B1836 B1697 B2261 B2261
+ B633
B633 B223 CBI 118
# #
#
#
0
200
400
600
800
1000
Cont B1836 B1697 B2261 B2261
+ B633
B633 B223 CBI 118
#
#
# #
#
#
0
500
1000
1500
2000
2500
3000
3500
4000
Cont B1836 B1697 B2261 B2261
+ B633
B633 B223 CBI 118
#
#
#
#
#
#
#
#
IF
N
-
(p
g
/m
l)

IL
-1
0
(p
g
/m
l)
ba
c d
Fig. 3. IL-1β, IL-10, TNF-α and IFN-γ production by hPBMC cultured for 1 day (white bars) and 4 days (gray bars) 
with lactic acid bacterial strains. The bars represent the mean cytokine production of all allergic donors tested (n 
= 6) and error bars represent SEM. *, #Significant difference with the control (Cont) group and day 4, respectively 
(P < 0.05).
To determine the effects of lactobacilli interacting with stimulated hPBMC, αCD3/αCD28 
was added to the culture and cells were cultured for 4 days. All strains inhibited IL-13 produc-
tion by αCD3/αCD28-stimulated hPBMC (Fig. 4f). Strain B2261, the mixture of strains B2261 
and B633, and strain B633 alone were significantly stronger IL-13 inhibitors (on average a factor 
7 inhibition) compared with the other strains tested (on average a factor 3 inhibition). There 
was a clear tendency of lactobacilli to inhibit IL-1β production, except for strains B1697 and 
B223 (Fig. 4a), while TNF-α (Fig. 4c) and IL-10 (Fig. 4b) production was increased compared 
with the control for most strains, except for strains B223 and CBI 118. Addition of the various 
Lactobacillus strains to the hPBMC had no effect on IFN-γ production, which was high in all cul-
tures after stimulation with αCD3/αCD28 (Fig. 4d). IL-12 (Fig. 4e) was induced by strains B1836, 
B2261, the mixture of B2261 and B633, B633 alone and CBI 118, which was the same group of 
strains that also induced IL-12 and IFN-γ production in the unstimulated cultures.
The polyclonal stimulus αCD3/αCD28 clearly induced IL-1β, IL-10, TNF-α, IFN-γ and IL-13 
production compared with the unstimulated cultures. The induction of IL-10 by the strains was 
significantly lower in the αCD3/αCD28-stimulated cultures compared with the unstimulated 
cultures for the mixture of strains B2261 and B633, and strain B633.
 
  Chapter 8  
 154 
0
200
400
600
800
1000
1200
Cont B1836 B1697 B2261 B2261
+ B633
B633 B223 CBI 118
*
*
*
0
50
100
150
200
250
300
350
400
450
Cont B1836 B1697 B2261 B2261
+ B633
B633 B223 CBI 118
*
*
* * *
0
2000
4000
6000
8000
10000
Cont B1836 B1697 B2261 B2261
+ B633
B633 B223 CBI 118
0
500
1000
1500
2000
2500
3000
3500
Cont B1836 B1697 B2261 B2261
+ B633
B633 B223 CBI 118
*
* *
*
*
0
100
200
300
400
500
600
700
800
900
Cont B1836 B1697 B2261 B2261
+ B633
B633 B223 CBI 118
* * *
*
*
*
0
10
20
30
40
50
60
70
Cont B1836 B1697 B2261 B2261
+ B633
B633 B223 CBI 118
*
*
*
*
T
N
F
-
(p
g
/m
l)

IL
-1
(p
g
/m
l)

IL
-1
2
(p
g
/m
l)
IL
-1
3
(p
g
/m
l)
IF
N
-
(p
g
/m
l)

IL
-1
0
(p
g
/m
l)
a b
c
d
fe
Fig. 4. IL-1β, IL-10, IL-12, IL-13, TNF-α and IFN-γ production by hPBMC stimulated for 4 days with αCD3/αCD28 in 
the presence or absence of lactic acid bacterial strains. Data are mean ± SEM values for seven allergic patients.
*Significant difference with the control (Cont) group to which no lactobacilli strain was added to the culture (P < 
0.05).
Antigen-specific stimulation with the major birch pollen allergen Bet v 1
To determine the effect of the different lactobacilli on antigen-specific stimulated cultures, 
hPBMC of the five birch pollen-allergic patients were cultured in the presence of the major 
birch pollen allergen Bet v 1 and in the presence or absence of the different lactobacilli. After 8 
days of culture, four stimulation conditions were compared. The restimulation condition with 
αCD3/αCD28 on day 7 was used to increase the amount of antigen-specific T cells in the cul-
tures which are still expected to be active in the culture and proliferate upon interaction with 
the specific antigen, Bet v 1. The addition of Bet v 1 did not result in significant differences in 
cytokine production profiles compared with the medium control. Only the IFN-γ production 
was higher in the Bet v 1-stimulated cultures compared with the respective medium control. 
The cytokine induction profile of medium compared with Bet v 1-stimulated cultures was simi-
lar and no Bet v 1-specific cytokine production could be detected (Table 3).
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Table 3. Interleukin (IL) 1β, IL-10, IL-12, IL-13, IFN-γ and TNF-α production by unstimulated or Bet v 1-stimulated 
hPBMC. 
IL-1β IL-10 IL-12 IL-13 IFN-γ TNF-α
Med-   40.8 ± 21.7     5.6 ± 0.5*      0 ± 0   131.4 ± 42.8     32.7 ± 20.2       5.2 ± 2.1
Bet v 1-   52.3 ± 18.1   10.3 ± 3.5      0 ± 0     94.8 ± 26.8     13.4 ± 1.6       2.9 ± 0.5
Med+ 109.4 ± 38.6 389.0 ± 47.6 29.1 ± 16.4 2106.7 ± 565.8 1498.4 ± 352.4* 2258.1 ± 640.9
Bet v 1+ 133.7 ± 26.3 372.7 ± 48.0 15.5 ± 10.0 1371.9 ± 192.5 2797.0 ± 623.8 3822.8 ± 1504.7
hPBMC were stimulated for 8 days with medium (Med) or Bet v 1 (Bet v 1), both without (-) and with (+) restimula-
tion with αCD3/αCD28 on day 7. Concentrations of 106 bacteria mL-1 and 106 hPBMC mL-1 were used. 
Data are mean ± SEM values for five birch pollen-allergic patients. Asterisks indicate statistically significant differ-
ences between Med- and Bet v 1- or between Med+ and Bet v 1+ (P < 0.05).
Cytokine induction capacity profiles of the bacterial strains in long-term cultures
Cytokine production profiles were determined in the 8-day cultures without Bet v 1 both res-
timulated with or without αCD3/αCD28 on day 7. This culture allows the detection of bacteria-
induced modulation of accumulated cytokine levels in the supernatant. A significant inhibition 
of IL-1β production was observed by strains B1836, the mixture of B2261 and B633, B633 and 
CBI 118 for both not-restimulated and restimulated cultures and also for strain B2261 in res-
timulated cultures compared with the respective controls (Fig. 5a and b). IL-12 production was 
low in both conditions, though similar effects of the various strains on IL-12 induction were ob-
served as detected on day 4 with a low or even inhibited IL-12 production of strains B1697 and 
B223 (Fig. 5c and d). TNF-α induction capacity was increased in all not-restimulated cultures 
exposed to the various strains compared with the control, while in the restimulated cultures, 
most strains inhibited the TNF-α induction significantly (Fig. 5e and f). Furthermore, TNF-α was 
highly induced by the addition of αCD3/αCD28 the day before harvesting the supernatants.
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Fig. 5. Interleukin (IL) 1β, IL-12 and TNF-α production by hPBMC cultured for 8 days in absence (Cont) or presence 
of lactic acid bacterial strains both without (left panel) or with (right panel) restimulation with αCD3/αCD28 on day 
7. Data are mean ± SEM values for seven allergic patients. 
*,#Significant difference with control (Cont) group and day 8 with restimulation, respectively (P < 0.05).
In 8-day cultures of not-restimulated cells, IL-10 was significantly induced by all lactoba-
cilli except for strain CBI 118 (Fig. 6a). In the restimulated condition, all strains significantly 
inhibited IL-10 induction capacity (Fig. 6b), and strains B1697 and B223 were significantly less 
strong IL-10 inhibitors compared with the other tested strains. Compared with IL-10 induc-
tion in 4-day αCD3/αCD28-stimulated cells, the 1-day restimulation at day 7 induced a higher 
IL-10 induction. IFN-γ production was also induced by the restimulation on day 7 compared 
with not-restimulated cultures and effects of the strains were less prominent in the restimu-
lated condition compared with the not-restimulated day 8 culture (Fig. 6c and d). IFN-γ pro-
duction was induced by strains B1836, B2261, the mixture of B2261 and B633, B633 and CBI 
118. Furthermore, IFN-γ production of unstimulated cultures was significantly higher on day 8 
compared with day 4. After 8 days of culture of not-restimulated cells, IL-13 was consistently 
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decreased in the presence of the strains compared with the control, though this effect was 
not shown to be significant for strains B1697 and B223. This same inhibition was observed in 
the restimulated cells, and was significant for all tested strains. Strains B1697 and B223 were 
significantly less strong IL-13 inhibitors compared with the other tested strains. A clear induc-
tion of IL-13 production was detected by the restimulation with αCD3/αCD28 on day 7 in the 
allergic patients (113 ± 40 pg mL-1 for not-restimulated cultures vs. 1572 ± 488 pg mL-1 for the 
restimulated cultures). This induction was much more clear in the allergic patients compared 
with the healthy control (56 for not-restimulated cultures vs. 204 pg mL-1 for the restimulated 
cultures). However, the healthy control analyses also displayed a lower IL-13 induction in the 
cultures where a bacterial strain was present (on average 21 ± 2.8 pg mL-1 in presence of a 
strain compared with 56 pg mL-1 for the control).
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Fig. 6. Interleukin (IL) 10, IFN-g and IL-13 production by human peripheral blood mononuclear cells (hPBMC) cul-
tured for 8 days in absence (Cont) or presence of lactic acid bacterial strains both without (left panel) or with (right 
panel) restimulation with αCD3/αCD28 on day 7. Data are mean ± SEM values for 7 allergic patients. 
*,#Significant difference with the control (Cont) group and day 8 with restimulation, respectively (P < 0.05).
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The healthy control showed similar effects upon exposure of hPBMC to the different strains 
with respect to the cytokine induction profile. A difference compared with the allergic subjects 
was observed in the day 8 cultures that were not restimulated, as addition of the strains yield-
ed higher IFN-γ values compared with the hPBMC cultures of the allergic patients. However, 
comparing the IFN-g stimulation factor of the strains compared with the control, this factor was 
similar for the healthy control compared with the allergic patients (both around 35-fold). IL-1β, 
TNF-α and IL-13 levels were lower in the healthy control compared with the allergic patients 
(results not shown).
Discussion
In this study, we aimed to determine whether different candidate probiotic strains of lactoba-
cilli could in vitro modulate immune markers of patients with proven pollen allergy. Only few 
studies address the altered balance in the immune system of allergic individuals, and mostly 
include healthy subjects who are assumed to regulate their Th1/Th2 balance. We analyzed the 
capacity of lactobacilli to modulate this intrinsic capacity in allergic donors even out of the pol-
len season and to restore the T-cell balance in their immune system. The lactobacilli used here 
could be grouped into two categories based on their cytokine induction profile: a poor IFN-
γ-inducing group, and a high IFN-γ-inducing group. This latter group, which also inducted the 
regulatory cytokine IL-10, and strongly inhibited the release of the Th2 cytokine IL-13, might 
beneficially modulate the disturbed Th1/Th2 balance observed in allergic patients.
Culturing hPBMC for 1 day showed a clear induction of IL-1β, TNF-α and IL-10 production by 
all strains tested, confirming the widely observed proinflammatory cytokine response induced 
by lactic acid bacteria. This response is presumably induced by monocytes as these respond 
rapidly after encountering bacteria or bacterial compounds by pattern recognition-mediated 
interaction [25,37,38]. While induction of IL-1β and TNF-α are the highest on day 1, the induc-
tion of IL-10 is generally higher on day 4, which might indicate the contribution of T-cell subsets 
producing IL-10. IL-13 levels are low on day 1 and 4, but by day 8, all strains clearly inhibited 
the IL-13 induction compared with the control. The strong IL-13-inhibiting strains were found 
also to be strong TNF-α inducers. In a recent study, lactic acid bacteria were shown to have the 
ability to induce a proinflammatory cytokine response in vitro that was most likely insufficient 
to result in an inflammatory outcome upon ingestion of these bacteria by the allergic patients, 
but induced a higher state of the host innate defence system alertness [39].
With respect to the IFN-γ induction profile, a profound differentiation could be made be-
tween strong IFN-γ inducers (strains B1836, B2261, the mixture of B2261 and B633, B633 alone 
and CBI 118) and poor IFN-γ inducers (B1697 and B223). This differentiation has been observed 
for other strains [10,40,41], and was already detectable on day 1, being the most prominent 
on day 8. Activation of Th1 cells (rather than CD8+ T-cells and natural killer cells) is possibly 
responsible for this observation. Even though IL-12 production was low, IFN-γ induction and 
IL-12 production correlated on all tested days, as IL-12 and IFN-γ act synergistically. The dif-
ferential cytokine activity profiles were also observed when comparing the IFN-γ/IL-13 ratio in 
the unstimulated day 8 cultures with strains B1697 and B223 having a 5 ± 3 and 30 ± 0 ratio, 
respectively, strain CBI 118 having a 188 ± 58 ratio and for all other strains, this ratio was be-
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tween 250 and 355. This lower IFN-γ/IL-13 ratio for strains B1697 and B223 is mainly due to the 
lower IFN-γ induction and subsequent lower IL-13-inhibiting capacity.
The percentage nonviable cells of αCD3/αCD28-stimulated cultures was in general higher 
than 50%, which is probably mainly caused by activation-induced cell death (AICD). AICD in T 
lymphocytes is the process by which cells undergo apoptosis in a controlled manner after ac-
tivation through the T-cell receptor by, for example, CD3 monoclonal antibodies [42]. Further-
more, often the trypan blue exclusion technique is used to analyze cell death, in which early 
apoptotic cells will not be visualized and cell death numbers are, therefore, lower compared 
with the use of an AnnexinV/PI staining and flow cytometric analysis. The polyclonal αCD3/
αCD28 stimulus is widely used to provide all T cells with the required activation signals, with 
an optimum in proliferation and cytokine induction at days 3−5 [34]. This could explain why no 
difference was observed in IFN-γ induction between the control and the tested strains, as the 
effect of the strains is generally much weaker than the stimulus applied. However, the bacteria 
do have an effect on modulating this polyclonal stimulation with respect to some of the tested 
cytokines and proliferation, which strengthens the evidence that the bacteria can induce strong 
immunomodulating activities in vitro. The inhibition of IL-13 induction provoked by all tested 
strains was also observed for other strains in hPBMC cultures stimulated polyclonally using 
the lectin phytohemagglutinin [16] or the superantigen Staphylococcus enterotoxin A [15,17]. 
The lower IL-10- and IL-12-inducing capacity, together with the lower IL-13-inhibiting ca-
pacity of strain CBI 118 compared with the other high IFN-γ-inducing strains, could make this 
strain less favourable for use in allergic patients. A mixture of two strains from two different 
lactobacilli species (a combination of a high IL-10- and a high IL-12-inducing strain) was in-
cluded in this study, but no clear synergistic effects were observed when compared with the in-
dividual strains. Although synergism is not always observed, some multispecies probiotic mix-
tures could expand the capacity for immunological modulation beyond that of the individual 
strains and might be effective in their immunomodulatory activity in selected patients [43-46].
Summarizing the differential cytokine production profiles of the tested strains, it was 
observed that specific strains selected on their IL-10-inducing properties, could be further 
grouped by their cytokine activity profile based on IFN-γ-inducing properties. The first group 
(represented by strains B1836, B2261, the mixture of B2261 and B633, B633 alone and CBI 
118) induced a stronger proinflammatory TNF-α response, had a better inducing capacity of 
the Th1 compartment and showed a better inhibition of the Th2 cell compartment compared 
with the other group (represented by strains B1836 and B223), and might therefore be more 
appropriate candidate probiotics for allergic patients.
A remarkable finding was the consistent inhibition of proliferation of hPBMC stimulated 
for 4 days with αCD3/αCD28 in the presence of all the applied bacterial strains with the most 
profound and significant inhibition by strain B633 in all seven allergic donors tested. However, 
addition of strain B633 did not impair cytokine induction, which strengthens the notion that 
various aspects of immunomodulation can be unique for a strain and that large species and 
strain differences exist in effects on inhibiting allergic inflammation, repression of hypersensi-
tivity reactions and clinical symptoms of allergy [8,10,47]. These data support the notion that 
the probiotic potential of lactic acid bacteria as antiallergic compounds is strain-specific and 
largely variable already in vitro as is also reported upon in vivo use in randomized double-blind, 
placebo-controlled clinical studies [32,47].
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Donors with a documented pollen allergy were recruited outside the pollen season, result-
ing in a low frequency of allergen-specific T cells that can be as low as 1 per 20 000 cells [48], 
consequently resulting in a low response to the Bet v 1 allergen. Enrichment of the allergen-
specific T cells or the use of allergen-specific T-cell clones would be necessary to study poten-
tial modulatory effects of bacterial strains under allergen-specific culture conditions [49,50]. 
A significantly higher induction of IL-13 was detected in cultures restimulated on day 7 with 
αCD3/αCD28 of the pollen-allergic subjects compared with the healthy control, which could 
indicate a higher number of Th2 cells in the culture in the pollen-allergic patients. Despite this, 
the lactobacilli inhibited IL-13 induction, regardless of donor, either allergic or not. In the long-
term cultures and the αCD3/αCD28-stimulated cultures, the increased IFN-γ and IL-12 secre-
tion in hPBMC cultures exposed to the lactobacilli could mediate the Th2-suppressive effect, 
as observed previously [17,51]. However, the Th2 cytokine inhibition could be dependent on 
several parameters depending on the strains used [7,17,24].
The exact mechanism by which probiotic lactic acid bacteria modulate the host immune 
response is largely unknown. Bacterial cell surface macromolecules (such as long surface ap-
pendages, extracellular polysaccharides and teichoic acids) are in direct contact with several 
immune cell types by binding various pattern recognition receptors of the host. The structure 
of the main cell wall macromolecules is strongly conserved, but various modifications, such as 
glycosylation and also quantitative differences, can contribute to the strain-specific properties 
of probiotics. As little information is available regarding the specific bacterial components that 
for example induce the expression and production of cytokines, advances can be made in this 
area through the sequencing of genomes and transcriptomes that can be correlated to meas-
ured effects and enable testing which bacterial genes and derived components are essential to 
specific immunomodulatory properties [6,13,52-54].
Large numbers of candidate strains are often tested as probiotics for immunomodulating 
properties in a variety of in vitro models to select those strains with the best characteristics. 
In these in vitro studies, effects of heat-killed bacteria may not be directly extrapolated to ef-
fects of viable bacteria. Nevertheless, recent literature shows similar effects comparing live 
bacteria with heat-killed bacteria or even with components from the respective bacteria [15, 
55, 56]. Very limited information is available with respect to the in vivo molecular responses 
to probiotic bacteria in human mucosal tissues; however, a recent study of van Baarlen et al. 
[57] showed a considerable overlap between in vivo human responses to live and heat-killed 
L. plantarum, provided that these bacteria were harvested from the same phase of growth. 
Systematic studies to link in vitro data to in vivo effects have rarely been performed so far and 
results are also not found to be consistent [58]. Based on the limitations of the in vitro model, 
extrapolations to in vivo effects must therefore be considered with caution.
Taken together, in this paper, the effect on probiotics on adaptive immune responses is 
included, by performing long-term cultures of hPBMC of allergic patients and analyzing typical 
T-cell-related cytokines and other read-out parameters. The present data clearly demonstrate 
that lactobacilli can modulate the cytokine induction profiles in hPBMC of allergic subjects 
in vitro. This modulation was most obvious in an increase in innate cytokine induction and 
a decreased synthesis of the Th2 cytokine IL-13 observed for all tested strains. Based on the 
present study, strains B1836, B2261, the mixture of B2261 and B633, and B633 alone could be 
chosen as most promising probiotic strains because of their stronger inhibition potential of IL-
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13 induction and higher induction of IFN-γ and IL-12 compared with the other tested strains. 
Furthermore, the analysis presented here provides a suitable model to compare candidate pro-
biotic strains for their immunomodulating properties in vitro in a Th2-skewed population and 
can even be used outside the pollen season, which makes this methodology a useful screening 
model.
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Summary
Background: Allergic diseases are increasing world-wide, and according to the hygiene hy-
pothesis may be related to a decreased exposure to environmental bacteria. Probiotic bacteria 
are recognized for their immunomodulating properties, and may benefit allergy patients. In 
vitro studies reveal immunomodulatory effects that are strain dependent. Differential immu-
nomodulatory in vitro capacities cannot be extrapolated directly to in vivo efficacy. Thus, in 
vitro screening should preferably be followed by a comparative analysis of the selected immu-
nomodulatory strains in an in vivo setting. 
Objective: We selected five Lactobacillus strains on their IL-10-inducing capacity, and evalu-
ated the immunomodulatory properties in birch-pollen-allergic subjects outside the hayfever 
season, with a reduction of IL-13 as the primary outcome.
Methods: A double-blind, placebo-controlled parallel study was performed in which 62 sub-
jects with a proven birch-pollen allergy consumed one of five different probiotic yoghurts con-
taining four Lactobacillus plantarum strains and one Lactobacillus casei strain or a placebo 
yoghurt. Blood samples were collected at the start and after 4 weeks. Several immune pa-
rameters were determined in serum and peripheral blood mononuclear cell cultures (PBMC) 
derived from these subjects.
Results: A decrease in birch-pollen-specific IgE was found for four probiotic strains. L. casei 
Shirota reduced the number of CD16+/CD56+ cells in peripheral blood mononuclear cells. For 
strain L. plantarum CBS125632, the decrease in IgE coincided with significant decreases in IL-5 
and IL-13 production by αCD3/αCD28-stimulated PBMC cultures.
Conclusion and Clinical Relevance: Subjects with seasonal allergy can be used to determine 
immunomodulatory responses outside the pollen season within a 4-week study period. L. 
plantarum CBS125632 decreased several immune markers related to allergy, and may have the 
potential to alleviate the severity of seasonal allergy symptoms.
Introduction
The prevalence of allergic diseases in the general population has increased alarmingly over 
the past 25 years, particularly in western industrialized countries [1]. According to the hygiene 
hypothesis, this increase in atopic diseases is due to a decreased exposure to microbial patho-
gens and changes in the intestinal microbiota [2-4]. Indeed, the microbiota of allergic children 
was found to harbour fewer lactobacilli as compared with non-allergic children [5]. However, 
the relation between microbiota and allergy development is likely more complex because a 
reduced diversity in the early fecal microbiota of infants with atopic eczema has also been 
reported [6]. This illustrates that the interplay between members of the microbiota and the 
host drives the development of a healthy immune system through mechanisms that are poorly 
understood.
Bacterial strains of the genus Lactobacillus are of interest as food-grade immunomodulat-
ing agents in so-called probiotic products. Probiotics are defined as live microorganisms, which 
when administered in adequate amounts confer a health benefit on the host [7]. Several clini-
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cal trials have demonstrated immunomodulatory properties of probiotics for the prevention or 
treatment of, e.g. inflammatory or allergic diseases [8]. Studies related to allergy have mainly 
focused on the use of Lactobacillus preparations for the prevention of early manifestations of 
allergic responses in newborns. Preparations given either to bottle-fed newborns or to breast-
feeding mothers significantly reduced the risk of infants to develop atopic diseases [9,10], and 
in one study, this protective effect could still be observed in later life, even at the age of 7 years 
[11]. However, studies focused on allergy prevention in newborns do not necessarily relate to 
a reduction of symptoms in patients with an existing allergy. Indeed, in contrast to the promis-
ing effects on allergy prevention in newborns given Lactobacillus rhamnosus GG, no effect on 
birch-pollen allergy was observed when the same strain was given to adults [12].
Several, mainly, Japanese studies claimed that orally administered Lactobacillus strains had 
small beneficial effects on perennial allergic rhinitis [13] and on symptoms of Japanese cedar 
pollen allergy [14-17]. However, effects on immune markers like specific IgE levels or T-helper 
type 1/2 (Th1/Th2) ratio were not always reported, indicating that underlying mechanisms 
remain unclear and may include other than immunomodulatory explanations. In a recent pilot 
study, Lactobacillus casei Shirota showed a significant reduction in levels of relevant cytokines 
in grass-pollen-allergic subjects that coincided with an increase in specific IgG and a decrease 
in specific IgE [18]. Although the study period included the grass pollen season, no effects on 
the severity of symptoms were observed.
It is recognized that the immunomodulating properties of lactic acid bacteria are largely 
strain-specific. IgE-mediated allergy is the result of a Th2-mediated immune response and is 
characterized by the production of high levels of interleukins IL-4, IL-5 and IL-13 that promote 
the formation of IgE-producing cells [19]. A frequently proposed strategy to counterbalance a 
high Th2 response is the promotion of cells that secrete IL-10 [20-22]. A widely accepted ap-
proach to investigate effects of bacterial strains on the immune system is the in vitro exposure 
of human cells to bacteria or sub-cellular bacterial preparations, followed by cytokine meas-
urements in the culture supernatant. This has led to the recognition that candidate probiotics 
have in vitro effects that are highly strain specific, although differential effects also occur at 
the bacterial species level [23]. Such studies demonstrate the potential of the bacteria used to 
modulate the immune response, but a straightforward extrapolation to the in vivo effects af-
ter oral administration of these bacteria is impossible [24]. Therefore, elucidation of probiotic 
functionality should preferably be based on in vivo validation of multiple strains, to validate the 
proposed immunomodulatory capacities observed in vitro. 
Function screening of candidate probiotic strains is an important but time consuming and 
costly aspect of the selection process. Selection of probiotic strains is usually based on in vitro 
screening only, in several cases supported by validation in animal models. There are numerous 
reasons why the outcome of these studies may not be similar to human trials, e.g. limitations 
due to the simplicity of an in vitro model, poor survival of the probiotic strain in the human gut 
or heterogeneity in the human population [25]. Because of high costs, clinical trials are mostly 
performed with just one probiotic product, which has the risk that not the most appropriate 
strain is studied. Currently, there is no good in vivo selection model that evaluates the best 
candidates from in vitro screening before clinical testing occurs. In such an approach, it is of 
importance to use relatively small groups of subjects in order to screen a maximum number 
of strains, although conclusions should still be based on statistically sound evidence. Here, 
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we present a human screening system in which a limited number of pre-selected candidate 
probiotics can be evaluated. The effect of probiotics on birch-pollen-allergic subjects with a 
Th2-skewed immune system was followed outside the hayfever season during which exposure 
to birch pollen is highly unlikely. Especially IgE is sensitive to changes due to the relatively short 
half life of 2-3 days for this immunoglobulin class [26]. Without exposure to birch pollen, one 
would expect that antigen-specific immunity is relatively stable. In addition, pollen-specific 
memory Th cells decrease after the pollen season, but 60% survive up to 8 months [27]. There-
fore, we hypothesized that birch-pollen-allergic subjects outside the hay fever season form a 
good read-out system for short-term immunomodulating interventions. Here we present a par-
allel study in which five probiotics selected for their high IL-10-inducing capacity and a placebo 
group were compared for their immunomodulating properties in birch-pollen-allergic subjects. 
Parameters of the study included changes in immunoglobulins, and cytokine secretion by pe-
ripheral blood mononuclear cells (PBMC).
Materials and Methods
In vitro selection of strains
Candidate probiotic strains were selected from our culture collections, and used to determine 
the in vitro IL-10-inducing properties as described previously [23]. Human PBMCs were isolated 
by density gradient centrifugation on Ficoll-Paque PLUS (Amersham Biosciences, Uppsala, Swe-
den) from freshly collected buffy coats of healthy donors (Sanquin Blood Bank of Nijmegen, 
Nijmegen, the Netherlands). Cells were washed and cultured in 24-well plates at 1 x 106 cells 
per well in RPMI 1640 medium (Gibco-BRL, Paisley, Scotland) containing 10% heat-inactivated 
fetal calf serum (FCS), 2 mM glutamine and 1% penicillin-streptomycin (all from Gibco-BRL). 
Heat-killed bacteria were dissolved in the appropriate culture medium, and added directly to 
the PBMC culture in a 1:1 ratio. The production of IL-10 was detected in supernatants collected 
after 1 day of culture using a commercially available ELISA kit (Cytosets, Biosource Europe SA, 
Nivelles, Belgium). A total of seven assays were performed in which a variety of strains were 
included with PBMC from different donors. Some strains were repeatedly tested in all assays, 
whereas others were included only in one or a few assays.
Patients and study design
Ethical approval for this double-blind, placebo-controlled parallel study was given by the lo-
cal ethics committee (Commissie Mensgebonden Onderzoek regio Arnhem-Nijmegen, Ni-
jmegen, the Netherlands). The trial was registered at ClinicalTrials.gov (registration identifier 
NCT01137357). The study occurred during the period November-December 2008 at the Rijn-
state Hospital in Arnhem, the Netherlands. Candidate subjects with birch-pollen allergy were 
selected from the outpatient allergy clinic. The main inclusion criteria were age 18-50 years; 
a clinical history of significant, troublesome, symptoms of seasonal allergic rhinoconjunctivitis 
with/without asthma of a duration of at least 2 years during the birch-pollen season; positive 
(wheal diameter ≥ 3 mm) skin prick test to birch pollen (Soluprick® SQ; ALK-Abello A/S, Hør-
sholm, Denmark) and with specific IgE (≥ CAP allergy, class 2) to birch pollen. A total of 658 
candidate subjects were sent a written invitation letter to participate in the study. Exclusion 
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criteria were use of probiotics during the last month before the trial, use of medication to in-
fluence the immune system, use of antibiotics in the last 2 months before the start of the trial, 
pregnancy, lactose intolerance, and blood values suggesting an ongoing infection at the start 
of the study. The first 62 positively responding subjects who met the selection criteria were in-
cluded in the study, and stratified over 6 groups of 10 or 11 subjects (five experimental groups 
and one placebo). In order to balance groups as much as possible, the allocation was based on 
gender as the primary criterion, and the most recent data on severity of birch-pollen sensitivity 
in their medical record as the second criterion. The number of patients per group was based 
on an average of 30% reduction of IL-13 as the primary outcome. The person that formed the 
groups was not involved in the further study. The subjects were kept blind to probiotic assign-
ment. All subjects were given a subject number for the study and received separately packaged 
fresh yoghurt drinks containing the same number. They were instructed to take one portion 
of the product each day for a period of 4 weeks. Consumption of any other yoghurt products 
during this period was not allowed. After the intervention period, the subjects’ remarks on 
the consumed product, medicine usage and other allergy-related information (if any) were 
collected in a short questionnaire. At both the start and end of the intervention period, blood 
samples were collected and used to determine relevant markers (Fig. 1). The investigators were 
kept blind to probiotic assignment of the participants until all measurements were completed.
658 invited
62 included
Randomized on gender,
age and last documented
severity of birch pollen
allergy
n=10
Placebo
n=(11-1=)10
L. casei
Shirota
n=(10-1=)9
L. plantarum
WCFS1
n=10
L. plantarum
NIZO3400
n=11
L.plantarum
NIZO2877
n=10
L. plantarum
CBS 125632
4 week probiotic intervention
Blood parameters before and after intervention:
• Immunoglobulins (birch pollen-specific IgE, IgG and IgG4)
• PBMC surface markers (CD3+, CD4+, CD8+, CD14+, CD16+ , CD19+, CD25+, CD56+)
• Cytokines after polyclonal stimulation of PBMC (IL5, IL10, IL12, IL13, IL17, IFNγ)
• Cytokines after stimulation with Betv1 (IL-1ß, IL-5, IL-10, IL-12, IL-13, IL-17, IFN-γ and TNF-α)
• Infection-related parameters (CRP, leukocyte count, erythrocyte sedimentation)
• Liver function (ALT, AST, GGT, creatinine, bilirubine)
Fig. 1. Overview of the experimental design and tested parameters.
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Probiotic or placebo drinks
Yoghurt drinks were prepared by inoculating pasteurized skimmed milk with a commercial 
yogurt starter (placebo) and in addition one of the following strains: L. casei Shirota, Lacto-
bacillus plantarum WCFS1, L. plantarum NIZO3400, L. plantarum NIZO2877 or L. plantarum 
CBS125632. Milk fermentation by the product-specific lactic acid bacterium consortium was 
carried out for 10-14 h to reach a final pH of 4.2-4.3, followed by the addition and mixing of 
5-15% lemon-lime flavoured syrup. The mixture was subsequently pumped, sheared, cooled 
and packaged in portions of 100 mL, each containing ca. 1010 CFU of the probiotic strain per 
portion. The probiotic and placebo drinks were identical in packaging, appearance and com-
position, except for the presence or absence of a probiotic strain. Subjects were instructed to 
store the product in their refrigerator and consume one bottle each day. To further assure the 
viability of the probiotic strains, the products were distributed on two occasions and consumed 
within 3 weeks after production. Stability of non-distributed test products was followed, and 
log
10
 reduction in time was < 0.30 for all yoghurts.
Isolation and culture of human peripheral blood mononuclear cells
A total of 50 mL blood per time-point was collected in K-EDTA-coated tubes (for PBMC), lith-
ium-heparin tubes (for automated blood cell differentiation) and uncoated tubes (for serum 
collection). PBMCs were isolated by density gradient centrifugation on Ficoll-Paque PLUS (Am-
ersham Biosciences) from freshly collected EDTA blood of the volunteers. We used a consistent 
way of isolation and cryopreservation of PBMCs in our experiments according to a protocol 
developed in our own laboratory as described previously [28]. Cells from the interphase were 
harvested, washed and frozen, and thereafter stored in liquid nitrogen until analysis. For cell-
stimulation experiments, the cryopreserved samples were thawed by rapidly immersing them 
in a 37 °C water bath until they could be decanted. The cell suspension was transferred to a 50 
mL polypropylene tube containing a 10 times larger volume of IMDM (Gibco-BRL) + 20% FCS. 
The cells were washed twice with IMDM + 20% FCS and then resuspended in Yssel’s medium 
that consisted of IMDM-containing GlutaMAX (IMDM) supplemented with 1% penicillin-strep-
tomycin and 2% human AB serum (all from Gibco-BRL) with additions according to previously 
described procedures [28]. Cells were cultured in 48-well plates at 1 x 106 cells/well and incu-
bated at 37 °C in a humidified atmosphere with 5% CO
2
. The supernatants were stored at −20 
°C and overnight transferred to −80 °C before analysis.
Direct blood and serum analysis
The erythrocyte sedimentation analysis was carried out using the StaRRsed Compact Blood 
Sedimentation Instrument (Sysmex, Kobe, Japan) according to routine procedures. C-reactive 
protein, bilirubin, creatinine, ALT, AST and GGT were analysed using automated clinical chem-
istry analyzers (Roche, Basel, Switzerland). 
Peripheral blood was centrifuged at 800 g for 10 min at room temperature, and the serum 
was removed for storage at −80 °C until analysis. Birch-pollen-specific IgE, IgG and IgG4 anti-
bodies were determined using ImmunoCAP (Phadia AB, Nieuwegein, the Netherlands) accord-
ing to the instructions of the manufacturer.
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Surface markers
Immunological phenotyping was performed on the cells after thawing. Surface antigens were 
identified by the following monoclonal antibodies: anti-human CD3, CD4, CD8, CD14, CD19, 
CD25, CD16, and anti-human CD56 (BD Pharmingen, San Diego, CA, USA). Appropriate isotype-
matched controls were included.
Two monoclonal antibody mixtures were used: (1) α-hCD3 (PE-Cy7), α-hCD4 (PE), α-hCD8 
(APC) and α-hCD25 (APC-Cy7); and (2) α-hCD14 (APC), α-hCD16 (PE), α-hCD19 (APC-Cy7) and 
α-hCD56 (PE). The procedure was performed according to the instructions of the manufac-
turer. Four-color flowcytometric acquisition was performed on a FACSCanto II (BD Biosciences, 
San Diego, CA), using the BD FACSDiva software. A gate was set to exclude debris, and the 
percentages of cells expressing CD3, CD4, CD8, CD25, CD16/CD56, CD14, and CD19 were then 
calculated. The percentage of positive cells was corrected for values of the isotype control.
PBMC stimulation and cytokine analysis
After overnight adaptation to the culture conditions, the cells were stimulated either poly-
clonally using αCD3/αCD28 antibodies (BD Biosciences; 150 and 100 ng/mL, respectively) or 
antigen specifically with rBet v 1.0101 (Bet v 1; Biomay, Vienna, Austria, 10 μg/mL). Culture 
supernatants were harvested after 4 days of culture for αCD3/αCD28-stimulated cells and af-
ter 1 and 7 days for Bet v 1-stimulated cells. PMA (Sigma-Aldrich, St Louis, MO, USA, 2 μg/mL) 
plus Ca-I (Sigma-Aldrich, 1 μg/mL) was added to the Bet v 1-stimulated cultures at day 6. The 
production of the innate and adaptive cytokines IL-1ß, IL-4, IL-5, IL-10, IL-12p70, IL-13, IL-17A, 
IFN-γ and TNF-α was detected using a Cytometric Bead Array (CBA, BD Biosciences). All buff-
ers used in this protocol were obtained from the BD CBA Soluble Protein Master Buffer Kit (BD 
Pharmingen) and the procedure was performed according to the manufacturer’s protocol. The 
detection limits according to the manufacturer were as follows: 1.1 pg/mL IL-1β, 1.1 pg/mL 
IL-5, 2.3 pg/mL IL-10, 2.2 pg/mL IL-12, 0.6 pg/mL IL-13, 0.3 pg/mL IL-17, 0.3 pg/mL IFN-γ and 
0.7 pg/mL TNF-α. The samples were measured on the FACSCanto II, using FCAP software (BD 
Biosciences).
Statistics
Because of the small group size and large number of parameters, minor differences between 
groups at the start of the intervention were inevitable for at least some of the parameters that 
were not used for randomization. Therefore, the main focus was given to intra-group variation. 
Data collected before treatment and after treatment were compared using the paired t-test. 
Although immune parameters may not be normally distributed, paired data were considered 
to be normally distributed as these are repeated measurements. Kruskal Wallis ANOVA and the 
Mann-Whitney U-test were used for comparisons between treatment groups because these 
data were not normally distributed. Data were considered statistically significant at the P < 
0.05 level.
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Results
In vitro screening for IL-10 production
A total of seven assays were performed with blood from PBMC from different donors. Stim-
ulation of PBMC with candidate probiotic strains revealed a wide diversity in their capacity 
to induce IL-10. Whereas some strains consistently showed a strong effect (e.g. L. plantarum 
WCFS1) others repeatedly fell into the group of poor inducers of IL-10. L. plantarum strains 
were in general potent inducers of IL-10, as we have reported before [23], and therefore new 
strains of this species were included in the later assays. In order to combine results from these 
7 independent assays, results of each assay were expressed as the relative IL-10 induction com-
pared with the highest inducing strain found in that assay. Thereafter, for each strain, the re-
sults were averaged, and results are presented in Fig. 2. As the best IL-10-inducing strain varied 
between the different in vitro studies, and as we have averaged the results from 7 assays, we 
do not find a single strain that consistently had a relative IL-10 induction of one. L. plantarum 
strains looked most promising for the stimulation of IL-10. Based on these results, L. plantarum 
WCFS1, L. plantarum NIZO3400, L. plantarum NIZO2877 and L. plantarum CBS125632 were 
selected for a subsequent in vivo screening, although it cannot be excluded that further screen-
ing with new strains would reveal equally well or even better candidates. L. casei Shirota, also 
found to be a high IL-10 inducer, was selected as a strain for which immunomodulatory ef-
fects in allergic patients have been described previously [18]. These strains were subsequently 
tested in an in vivo study (Fig. 1). 
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
L. plantarum NIZO3400
L. plantarum WCFS1
L. plantarum NIZO2877
L. casei Shirota
L. plantarum CBS125632
L. plantarum NIZO2893
L. plantarum NIZO1697
L. acidophilus NIZO228
L. plantarum NIZO2261
L. paracasei NIZO1355
L. rhamnosus GG
L. plantarum 299v
L. fermentum NIZO3895
L. acidophilus NIZO223
Relative IL-10 secretion
Fig. 2. Relative induction of IL-10 in a peripheral blood mononuclear cell culture assay after 24 h of stimulation with 
a selection of candidate probiotic bacteria. Relative values were defined as IL-10 induction by a strain compared 
with the highest inducing strain in the same assay. Relative data on IL-10 induction from seven assays were aver-
aged. Bars represent average ± standard error (n = 1−7).
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Study population and groups
An in vivo screening was performed with the selected strains because the various in vitro stud-
ies gave variable results, and direct exposure of PBMC to candidate probiotics may not be fully 
predictive for immunomodulation after oral intake of the same strains. A total of 62 subjects 
with proven birch-pollen allergy were included in the study. Two subjects withdrew from the 
study for personal reasons that were not related to the study. Data from these subjects were 
not included in the further analysis. No subjects were excluded on basis of their blood profile; 
ongoing infections were not found, as was judged from the absence of high leukocyte counts, 
high C-reactive protein values, and/or high erythrocyte sedimentation values. In total, 60 sub-
jects (14 men and 46 women) completed the study. As anticipated, all groups were comparable 
in terms of number of subjects, age, and male : female distribution (Table 1). At the start of the 
intervention period, serum IgE, IgG and IgG4 levels were not significantly different between 
placebo and any of the probiotic groups. 
Table 1. Characteristics of placebo and intervention groups.
Treatment
Number 
of subjects
Sex 
(M:F)
Mean age 
(years) 
Mean birch 
pollen-specific 
IgE (kU/L) 
Mean birch 
pollen-specific 
IgG (mg/L)
Mean birch 
pollen-specific 
IgG4 (mg/L) 
Placebo 10 2 : 8 36 (21-49) 27 ± 36 7.6 ± 11.2 0.7 ± 0.7
L. casei Shirota 10 2 : 8 35 (19-50) 17 ± 21 3.3 ± 1.7 0.4 ± 0.5
L. plantarum WCFS1 9 2 : 7 37 (25-48) 26 ± 30 4.8 ± 2.9 1.1 ± 1.0
L. plantarum NIZO3400 10 3 : 7 37 (21-46) 22 ± 28 3.5 ± 1.7 0.6 ± 0.4
L. plantarum NIZO2877 11 2 : 9 34 (21-47) 38 ± 50 3.7 ± 1.6 0.4 ± 0.4
L. plantarum CBS125632 10 3 : 7 35 (22-50) 26 ± 37 3.5 ± 1.9 0.5 ± 0.6
For age, the mean and range are presented. For antibodies, mean values ± SD are presented as determined before 
the intervention.
The safety of the probiotics was confirmed by clinical testing of serum parameters and by 
the absence of reported adverse effects during the last study visit. As anticipated, probiotic 
treatment did not result in increases of erythrocyte sedimentation, leukocyte counts and se-
rum C-reactive protein concentration. The safety markers serum creatinine, bilirubin, ALT, AST 
and GGT were not affected in any of the treatment groups. Taken together, none of these pa-
rameters pointed to any adverse effect, which was in agreement with the absence of adverse 
effects of the probiotic products indicated by the subjects. 
Probiotics reduce birch-pollen-specific IgE, but not IgG and IgG4
The birch-pollen-specific immunoglobulin measurements for IgE, IgG and IgG4 did not reveal 
statistical differences between the groups, although due to the small size of the groups, the 
mean values were not fully comparable (Table 1). Immunoglobulins IgE, IgG and IgG4 in the pla-
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cebo group were unaffected during the 4-week study period. In contrast, birch-pollen-specific 
IgE levels were significantly decreased in groups receiving L. casei Shirota, or L. plantarum 
strains WCFS1, NIZO3400 and CBS125632. Birch-pollen-specific IgG and IgG4 levels were not 
affected by probiotic treatment (Fig. 3).
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Fig. 3. Changes in immunoglobulins during the intervention period. Mean values ± standard error are presented. 
P-values are presented when titers before intervention were different from titers after intervention.
L. casei Shirota affects PBMC cell composition by lowering CD16+/CD56+ cells
Human PBMCs were characterized for surface markers, to evaluate whether the tested probiot-
ics had a direct effect on the composition of blood cell populations. Large individual differences 
in PBMC cell composition were observed at the start of the study but all values were within the 
normal ranges as reported by others [29]. Before intervention, due to the relatively small group 
size, differences between probiotic and placebo group were observed for percentage of CD3+ 
cells (higher for the group receiving NIZO2877), percentage of CD16+/CD56+ cells (lower for 
NIZO2877), CD8+ fraction of the CD3+ cells (lower for WCFS1 and NIZO3400), and CD4+ fraction 
of the CD3+ cells (higher for WCFS1). L. casei Shirota induced a decrease in CD16/CD56-positive 
cells. No effect of probiotic intervention was seen in any of the other groups (Table 2). 
L. plantarum CBS125632 affects cytokine production of αCD3/αCD28-stimulated PBMC
Human PBMCs were subjected to polyclonal or antigen-specific stimulation in order to induce 
cytokine production, and in this way evaluate the responsiveness of the immune system. Al-
though cytokine production varied between individuals, stimulation with αCD3/αCD28 anti-
bodies for 4 days resulted in a clear cytokine production in all PBMC preparations, and detect-
able levels of IL-5, IL-10, IL-13, IL-17 and IFN-γ. The cytokine IL-12 was not detectable in five 
samples before intervention and in three samples after intervention. Probiotic treatment with 
L. plantarum CBS125632 led to a significant change in IL-5, IL-13, and IL-10 induction (Fig. 4). 
IL-5 was reduced by 29 ± 11% and IL-13 by 21 ± 11%. IL-10 was increased by 24 ± 13%. Such 
an effect was not seen with cells from the placebo group, or any of the other probiotic strains. 
The ratios between IL-10 and IL-5, indicative of the ratio between regulatory T cell activity and 
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Th2 activity, were significantly increased with 38% for L. plantarum NIZO2877, and 68% for 
CBS125632.
Table 2. Composition of PBMC as revealed by flowcytometry.
Placebo Shirota WCFS1 NIZO3400 NIZO2877 NIZO2877
CD3+
Before intervention 51.9 ± 2.0 57.5 ± 2.2 53.3 ± 3.0 53.7 ± 4.1 59.0 ± 2.4 56.8 ± 3.0
CD4-/CD8+ 36.7 ± 2.6 34.0 ± 3.2 29.7 ± 2.1 29.0 ± 2.3 32.5 ± 1.8 31.0 ± 1.4
CD4+/CD8- 56.9 ± 2.8 60.1 ± 3.6 64.2 ± 2.3 64.8 ± 3.2 60.8 ± 2.3 62.7 ± 2.1
CD4-/CD8- 4.8 ± 0.8 4.3 ± 1.1 4.6 ± 0.8 4.6 ± 1.2 5.5 ± 1.1 5.2 ± 0.9
CD4+/CD8+ 1.7 ± 0.4 1.6 ± 0.3 1.4 ± 0.2 1.7 ± 0.4 1.3 ± 0.1 1.1 ± 0.2
After intervention 51.7 ± 2.3 57.4 ± 2.2 52.5 ± 3.1 56.4 ± 2.3 63.1 ± 2.3 60.9 ± 2.3
CD4-/CD8+ 37.7 ± 2.7 33.1 ± 3.2 28.9 ± 1.4 29.8 ± 2.5 32.5 ± 1.8 31.3 ± 1.7
CD4+/CD8- 55.5 ± 3.1 60.0 ± 3.7 64.9 ± 1.6 64.1 ± 3.6 61.4 ± 2.2 61.9 ± 2.3
CD4-/CD8- 5.1 ± 0.8 4.4 ± 0.8 4.4 ± 0.9 4.6 ± 1.3 5.0 ± 1.0 5.5 ± 1.2
CD4+/CD8+ 1.8 ± 0.4 2.4 ± 0.7 1.8 ± 0.2 1.6 ± 0.2 1.1 ± 0.1 1.3 ± 0.2
CD25+
Before intervention 1.3 ± 0.2 1.5 ± 0.3 1.4 ± 0.3 1.4 ± 0.2 1.3 ± 0.1 1.0 ± 0.2
After intervention 1.5 ± 0.2 2.3 ± 0.8 1.6 ± 0.3 1.3 ± 0.2 1.2 ± 0.2 1.0 ± 0.1
CD19+
Before intervention 9.1 ± 1.0 9.5 ± 1.0 11.0 ± 0.9 10.2 ± 0.9 8.0 ± 0.7 9.0 ± 0.9
After intervention 9.7 ± 1.0 10.6 ± 1.0 10.0 ± 1.2 9.6 ± 1.0 8.0 ± 0.7 8.4 ± 1.0
CD16+/CD56+
Before intervention 10.2 ± 1.4 11.3 ± 1.3 13.2 ± 2.1 9.1 ± 1.1 7.0 ± 0.9 11.2 ± 1.9
After intervention 10.0 ± 1.6 8.9 ± 1.2 13.6 ± 2.1 8.8 ± 1.1 6.8 ± 1.3 10.4 ± 1.7
CD14+
Before intervention 25.6 ± 2.4 19.7 ± 1.2 19.5 ± 1.9 25.0 ± 4.2 22.7 ± 2.1 20.3 ± 2.2
After intervention 25.7 ± 2.7 20.4 ± 1.4 21.0 ± 2.3 23.5 ± 2.1 19.0 ± 1.6 18.3 ± 1.5
Mean percentages ± SEM are presented for the surface markers before and after the intervention period. Only 
strain Lactobacillus casei Shirota induced a shift in PBMC composition, by lowering the percentage of CD16+/CD56+ 
cells (in grey; P = 0.03).
To determine modulatory effects of the candidate probiotics on the proinflammatory re-
sponses, PBMCs were antigen-specifically stimulated with Bet v 1. These cells produced low 
but detectable levels of IL-1β, TNF-α and IL-10 within 24 h. Cytokines IL-12, IL-17 and IFN-g 
were only detectable in 16, 8 and 33% of the samples, respectively. Because of the relatively 
high variation between samples and subjects, no effect of probiotic intervention was seen in 
any of the groups (data not shown).
Because of the expected low frequency of Bet v 1-specific cells in PBMC, we extended the 
Bet v 1-stimulated cultures to 7 days and during the last day, all viable cells were stimulated 
with PMA+Ca-I. The cytokines IL-5, IL-10, IL13, IL-17 and IFN-g were detected in all superna-
tants. Despite the extended culture conditions, the cytokine concentrations were in general 
twofold to tenfold lower than from αCD3/αCD28-stimulated cells that were analysed at day 4. 
IL-12 was detectable in 43% of the supernatants. Because of high variation in the results from 
this antigen-specific assay, no statistically significant effects of probiotic intervention were seen 
in any of the groups (data not shown).
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Fig. 4. Cytokines in culture medium of peripheral blood mononuclear cells stimulated with αCD3/αCD28 antibodies 
after 4 days of growth. Mean values ± standard error before intervention (grey bars), and after intervention (black 
bars) are represented. P-values indicate when measurements before and after intervention were different. 
Discussion
The aim of this study was to determine whether candidate probiotic strains, selected for their 
in vitro IL-10-inducing capacity, would have a potentially beneficial immunomodulatory effect 
in subjects with proven birch-pollen allergy outside the hay fever season. This approach, with 
relatively small groups for multiple probiotics, may serve as an in vivo confirmation of the 
functionality of candidate probiotic strains that were selected on basis of in vitro data. The use 
of paired data for statistical analysis of the immune parameters highly reduces the number of 
subjects. However, the study does not contain clinical end-points of allergy, and therefore the 
true impact of the probiotics should be addressed in additional studies where end of treatment 
data should be compared between groups. 
We observed an effect on plasma IgE levels after consumption of four candidate probi-
otic strains that was not seen after placebo treatment, and supporting changes in cytokine 
responses of stimulated PBMC after intervention with L. plantarum CBS125632. The candidate 
probiotic L. casei Shirota was the only strain that showed a decrease in CD16+/CD56+ cells, 
as well as a decline in IgE. Because safety concerns have been raised for immunomodulating 
probiotics [30], we included appropriate safety parameters in this study, such as infecti on pa-
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rameters (CRP, erythrocyte sedimentation and leukocyte counts) and liver function parameters 
(ALT, AST, GGT and bilirubin). As anticipated, there were no probiotic-induced changes in any 
of these parameters in any of the included patients. 
The decrease in birch-pollen-specific serum IgE that was found in four probiotic treatment 
groups, but not in the placebo group, was not influenced by recurrent exposure to the relevant 
allergens, because the study was performed during a period of the year in which antigenic 
stimulation with birch pollen is highly unlikely. In contrast to other antibody classes, IgE is an 
antibody isotype with a relatively short half life of only a few days [26]. This might explain 
why after this relatively short intervention period of 4 weeks we observed effects on antigen-
specific IgE but not on IgG and IgG4 levels. Because the half life of IgE bound to mast cells is 
substantially longer than that of free serum IgE [31], the observed changes in serum do not 
necessarily predict changes in allergy symptoms within the time span of the study.
Allergy has long been regarded as an imbalance in Th2 and Th1 responses. Therefore, it 
was thought that stimulation of a Th1 response should result in a lowering of a Th2 response. 
However, it is suggested that Th2 responses are physiologically normal responses that can ex-
ist in the absence of allergy, and that IFN-γ secreted by Th1 cells can contribute to allergy by 
increasing inflammatory reactions [21], and promoting survival and functionality of eosinophils 
[32] and mast cells [33]. Consumption of L. casei Shirota led to a reduction of CD16+/CD56+ cells 
that was not seen for the placebo group or any of the other strains. This is a separate finding 
that is not backed up by other findings on this strain, and therefore we cannot fully exclude 
the chance finding for our observation. In contrast to our result, other studies demonstrate an 
increase of NK activity by this probiotic strain, either in vitro [34] or in vivo [35]. CD16+/CD56+ 
cells form a population of NK cells that is known for its ability to produce IFN-γ, which con-
tributes to an increased Th1 profile. Although in our study this decrease in CD16+/CD56+ cells 
was not found to correlate with a decrease in IFN-γ, IL-5 or IL-13, a similar study reported a 
reduction of IFN-γ as well as IL-5 by L. casei Shirota [18]. The discrepancy between the cytokine 
responses in that study and our results presented here is not clear, although there are some 
differences between the design of the studies. One of the most striking differences is that in 
our study, the probiotic strains were included in a normal fermented yoghurt, which may have 
intrinsic immunomodulatory effects [36] or may influence the behaviour of the probiotic strain 
as is seen for other micro-organisms [37]. Therefore, the role of L. casei Shirota and the product 
matrix in relation to the reduction of allergy needs further investigation.
The intervention with L. plantarum CBS125632 led to a reduction in the production of IL-5 
and IL-13 by αCD3/αCD28-stimulated PBMC that coincided with an increase in IL-10 produc-
tion. This pattern was not seen for the placebo group, and points to the direction of a promo-
tion of T regulatory (Treg) cells that subsequently down-regulates Th2 cytokines. A role for Treg 
cells in the induction of tolerance has been postulated to control the development of allergy 
[21]. It has been reported that the number of Treg cells inversely correlates with height of the 
symptom scores [38]. Whether intake of L. plantarum CBS125632 indeed leads to reduction 
of allergy symptoms during the hayfever season has not been investigated and remains the 
subject of further studies. Although strains L. plantarum WCFS1 and L. plantarum NIZO3400 
showed reduced IgE titres, the underlying mechanism to this reduction remains unclear. In ad-
dition, it would be of interest to determine whether dead probiotic cells would have a similar 
effect.
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In this study, we have used cryopreserved cells for the cultivation of PBMC. Cryopreserva-
tion has been described to influence cell surface markers [39] and cytokine production [40]. We 
used in our experiments an optimized protocol for the isolation and cryopreservation of PBMC 
which was developed in our own laboratory as described previously [28]. We showed that no 
significant differences existed in the cytokine production (both in the monocyte-derived cy-
tokines and the T cell-derived cytokines) after αCD3/αCD28 stimulation. Therefore, we do not 
believe that our outcome is influenced by the use of cryopreserved cells instead of fresh cells.
We were not able to detect probiotic effects after stimulation of PBMC with the birch-
pollen antigen Bet v 1 because of high variation in cytokine secretion elicited within this ex vivo 
stimulation assay. This might be explained by the longer incubation period due to the relatively 
low number of reactive T cells in PBMC of birch-pollen-allergic patients outside the pollen 
season, which are usually as low as 1 per 20 000 cells [41]. In order to monitor an effect of 
probiotics on this specific cell population, a pre-enrichment may be required. Nevertheless, for 
L. plantarum CBS125632, the combination of probiotic-induced changes in IgE together with 
supporting changes in cytokine production in αCD3/αCD28-stimulated PBMC strongly suggests 
that the activity of the Bet v 1-specific sub-population of T cells is also modulated by this pro-
biotic.
It remains speculative how oral intake of probiotic bacteria achieves the observed modula-
tion of the immune responsiveness to allergens. It is probable that interactions between pro-
biotic bacteria and gut mucosal tissues play a role and most likely occur in the small intestine. 
The gastro-intestinal tract contains the largest outer surface area of the human body, and has 
a high concentration of non-self molecules, such as food molecules and commensal bacteria, 
which are in close contact with the gut epithelium. Intake of lactic acid bacteria has an im-
mediate effect on gene expression of the small intestinal mucosa, as has been evidenced for 
L. plantarum WCFS1 [42] and several other lactobacilli [43], but it is unclear whether this leads 
to systemic effects on the immune system. An alternative explanation could be that probiotic 
bacteria alter the microbiota composition because bacterial cell numbers and diversity of the 
microbiota were significantly different between allergic subjects and healthy controls, even 
outside the pollen season [5,6,44].
In conclusion, we present a methodology to compare candidate probiotic bacteria for their 
immunomodulating properties in a Th2-skewed population, as an intermediate step between 
in vitro screening and testing for clinical efficacy. Using this approach, candidate strains with 
a proven effect on the immune system can be selected in vivo. The true impact of the immu-
nomodulation by the most effective strain, in this study L. plantarum CBS125632, on symptoms 
of birch-pollen allergy needs to be addressed in a follow-up clinical trial that targets clinical 
endpoints, i.e. allergic symptoms.
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Currently there is no curative therapy available for peanut allergy, while the need for such ther-
apy is growing both because of the severity of these allergic reactions as well as the increasing 
number of sufferers worldwide. Several approaches aiming at decreasing both the number of 
allergies as well as the severity of the food allergic reactions are now under investigation. Com-
monly studied therapies showing promising results are allergen-specific immunotherapy (ASIT) 
and anti-IgE immunotherapy (ESIT). However, for food allergy, these therapies are not yet well 
established and more research must provide more knowledge on the effectiveness and use-
fulness of these therapies. Two different approaches studied in this dissertation, are the food 
technological approach studied for peanuts and the immunomodulatory approach studied in 
birch pollen allergic patients. Our finding on these aspects will be discussed below.
Influence of processing on allergenicity of proteins
The way in which processing modifies an allergen and thereby, possibly, its allergenicity is com-
plex and may be different from food to food or protein to protein [1]. Practical issues make it 
even more difficult to assess effects of processing on food allergens and, consequently, also on 
the whole food product. The extent of the alterations induced by processing depends on sev-
eral factors, including the allergen studied (its biochemical and immunological properties), the 
food matrix, processing conditions applied, thermo-dynamics of allergen–IgE interaction, and 
patient sensitivity (threshold, tolerance, and permanency of allergenic reaction to a specific 
allergen) [2,3].
Mainly in vitro tests are used to study effects of processing as it is ethically difficult to 
perform in vivo tests in humans; however, the available in vitro tests all have their own draw-
backs. Contradicting results between studies could be explained firstly by the use of different 
processing methods, performing the processing method on the whole peanut and afterwards 
extract the protein, or first isolating the protein and subjecting it to model thermal treatments 
designed to mimic the processing of the food or food ingredient itself. The impact of thermal 
treatment on the aggregation of proteins and hence on their (frequently resulting) insolubility, 
even to denaturing solvents and detergents, adds further variation to the nature of the solubi-
lised protein, as discussed below. Secondly, differences in systems used to determine allergenic 
activity, such as ELISAs, Western blot or cellular assays and the clinical profile of the patients 
used as a source for IgE, might influence the final results.
Why processing effects are important
Humans are widely exposed to insoluble aggregated particulate forms of many allergens that 
might have very different properties compared to the non-aggregated soluble proteins [4]. 
However, with the exception of a DBPCFC, all available methods for detection and assessment 
of food allergens in research, clinic, and industry rely on soluble allergens, and although a SPT 
can be performed with the actual food, clinicians generally utilize solubilized, commercially 
prepared extracts for this procedure.
Even though humans mainly consume processed foods containing aggregated, insoluble 
fractions, studies investigating allergenic properties generally focus on soluble proteins. To 
study the insoluble fraction, it should first be made soluble, which will involve solubilisation 
  General discussion   
 185 
10
6
5
4
3
2
methods that could affect the structure and available epitopes of the protein. Also standardi-
zation and development of ELISA-based immunoassays is mainly based on extracts from un-
processed or raw food products [5], even though allergic individuals showed similar or higher 
IgE antibodies against processed food antigens as compared to raw food antigens [6]. In the 
recently published work of Schmitt et al., the solubility of proteins in the peanut extract and 
protein profiles, as well as IgE-binding properties of peanut proteins in both the soluble and 
the insoluble fractions were assessed following different thermal processes. Overall protein 
solubility is reduced as a consequence of processing and IgE binding is increased in the insolu-
ble fractions due to increased amounts of insoluble proteins, with increased time of heating in 
all processes tested [5]. As a consequence, the eff ect of the processing methods on the struc-
ture of the protein itself and thereby its change in IgE-binding capacity could not be assessed. 
In our studies described in chapters 2-6, we were mainly interested in the effect of processing 
on the allergenicity of the allergen itself, while correcting for the soluble protein concentration 
after processing. Chapter 4 showed a profound decrease in solubility of Ara h 1 after heating, 
which was much more pronounced for Ara h 1 than for Ara h 2/6. This difference in solubility 
after heating was also shown recently [5] and is most probably due to difference in aggregation 
behaviour. In our studies we solubilized the protein by addition of Milli-Q water and leaving the 
samples on a rotator for about 1 hour. We chose not to use detergents for further solubilisation 
as this could change the structure of the protein. Moreover, we carefully reported the protein 
yield after solubilisation of the treated proteins. Future experiments on the effect of processing 
of allergens using denaturing solvents and detergents should also take into consideration the 
possibility that part of the protein will eventually still stay insoluble. 
To conclude, more knowledge on the influence of processing is relevant to improve the 
power of in vitro methods for diagnosing allergy, including CRD methods and cell-based assays, 
since most foods we eat are thermally processed and hence the original sensitising agent may 
be a modified, non-native, allergen or fractions thereof.
Effects of processing of Ara h 1, Ara h 2/6 and Cor a 11 on protein structure and IgE-binding 
and cross-linking capacity
Table 1 shows the results from our studies on effects of processing as described in chapters 2-6. 
The structural analysis, IgE-binding and IgE-cross-linking results are briefly discussed below.
Both the purified and the thermally treated Ara h 1 and Ara h 2/6 as well as the soluble Ara 
h 1 and Ara h 2/6 fractions of roasted peanuts were biochemically characterized. The analysis 
included SDS-PAGE, Far-UV CD, SEC, FT-IR, light scattering and AFM and these were all per-
formed to assess both secondary and tertiary structure while FT-IR, OPA assay, anthron-sulfuric 
acid colorimetric microassay and NBT were performed in some of our studies to assess the 
extent of the Maillard reaction. Methods to assess the allergenicity of the treated allergens 
included IgE-binding tests, such as immunoblot, direct and indirect reversed EAST and CAP 
IgE measurements. However, IgE binding (immunoreactivity) does not necessarily reflect the 
potential of an allergen to also cause mediator release from basophils by cross-linking IgE on 
its surface (allergenicity). Therefore, the clinical relevance of mediator release assays using 
basophils is principally higher than for IgE-binding assays. IgE cross-linking was measured in our 
experiments by the RBL assay and the BHR test. 
In chapters 2-6 and other literature [5], it was shown that proteins become less soluble with 
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increased time and temperature of heating, consistent with aggregation of proteins via cova-
lent modifications other than disulfide linkages, observed as high-molecular-weight smears 
of the proteins in a SDS-PAGE gel. Also a low water content present during the processing, 
potentially enhances the Maillard reaction [5] and the propensity to aggregate and therefore 
also to decrease solubility. This was clearly observed from the low solubility of Ara h 1 and Cor 
a 11 after dry-heating in the presence of glucose described in chapters 4 and 5, respectively. 
Accordingly, boiling (wet-heating) compared to roasting (dry-heating) clearly decreased the 
rate of aggregate formation, presumably also due to the presence of water, which inhibits or 
decreases the extent of the Maillard reaction.
Allergen aggregation due to wet versus dry heating
After performing our wet-heating procedure of Ara h 1 described in chapter 3, the protein 
showed a rod-like branched aggregate structure, having a mean diameter of about 70 nm, vari-
able heights between 10-15 nm and a Mr of > 640 kDa. Dry heating clearly resulted in hydroly-
sis as observed from the SDS-PAGE analysis; however, especially when heated in the presence 
of glucose, these degradation products assembled into very large aggregates with a diameter 
of 200-1000 nm. Relating these results to the effect on IgE binding and IgE cross-linking, we 
observed interesting differences between the wet- and the dry-heating. All treatments resulted 
in a decrease in IgE-binding capacity, which corresponded to a small, but significant, decrease 
in cross-linking capacity for the wet-heating procedures likely due to the smaller aggregates 
formed. Surprisingly, dry-heating resulted in a clear increase in IgE-cross-linking capacity which 
might be due to the very large aggregates formed of this treated protein. As the aggregates 
formed after wet-heating did not increase IgE cross-linking, probably the more strongly ag-
gregated Ara h 1 fractions after dry-heating were responsible for this increase in IgE-cross-
linking capacity. Interestingly, a similar result was obtained for dry-heated Cor a 11 (chapter 
5), which was also shown to be strongly aggregated. We propose that large aggregates, having 
a high epitope density, are more efficient in cross-linking receptor bound IgE on the mast cell 
or the basophil surface which decreases threshold of the protein concentration to effectuate 
a detectable mediator release. In theory it might be possible that already one or a few large 
aggregates containing multiple epitopes are able to cross-link more than 100 IgE antibodies 
which can already induce basophil activation and subsequent degranulation [7]. In addition, 
epitopes present on one large aggregated protein might also cause degranulation of more than 
one basophil. A schematic representation of this effect is shown below.
Smaller aggregates exhibit both a reduced IgE binding capacity in fluid phase and a reduced 
IgE cross-linking capacity
Dimerization of allergens can be important for in vitro [8] and in vivo IgE-cross-linking potential 
as seen for the Bet v 1 allergen in mice [9]. The Bet v 1 molecule is rather small (17 kDa) also in 
comparison with IgE antibodies (188 kDa) and moreover, IgE is rather rigid through the absence 
of a hinge region, and its flexibility is limited when bound to FcεRI, where IgE is fixed in a bent 
shape [10,11]. This could make cross-linking by this small allergen diffi  cult from a stereochemi-
cal point of view. The distance between adjacent FcεR1-bound IgE molecules is between 8-24 
nm to make a stable contact with the protein, therefore small molecules might have difficulty 
to cross-link two IgE molecules [7]. However, in our experiments, we showed that the native 
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monomeric Ara h 2/6, having a comparable Mr (15-19 kDa) was able to cross-link IgE, possi-
bly due to different amounts and different spatial arrangements of IgE-epitopes on Ara h 2/6 
versus Bet v 1, as well as a possible difference in percentage of allergen-specific IgE to total 
IgE in the sera used in these studies. As a consequence, cross-linking may already have been 
effective for monomeric Ara h 2/6, but not for monomeric Bet v 1. In addition, dimerization 
or oligomerization of Ara h 2/6 occurring after processing further decreased IgE-cross-linking 
capacity, possibly because epitopes were less well accessible to the cell-bound IgE antibodies. 
This would corroborate a recently proposed model explaining the hypoallergenic activity of a 
Bet v 1 trimer (Fig. 1). 
a b Fig. 1. Model for hypoallergenic be-
haviour of rBet v 1 trimer. Mono-
meric Bet v 1 or the trimeric Bet v 1 
can bind a comparable number of 
IgE antibodies in solution. Mono-
meric molecules (a) may be more 
efficient in cross-linking of effector 
cell-bound IgE than the trimer (b) as 
only a portion of the IgE epitopes 
on the aggregated timers comes 
into an optimal position for cross-
linking of effector cell-bound IgE 
(Adapted from [12]).
A recombinant Bet v 1 trimer was shown to exhibit a strongly reduced ability to induce ba-
sophil activation, showed a stronger IgE reactivity in a solid phase immunoassay, but a reduced 
allergenic activity in fluid phase IgE experiments. The Bet v 1 trimer occurred in fluid phase in 
the form of high molecular weight aggregates (>600 kDa) of which only a certain percentage 
of the IgE epitopes available on the surface of this molecule formed a spatial arrangement 
that allows cross-linking of cell-bound IgE. A considerable number of the IgE epitopes is less 
well accessible to cell-bound IgE antibodies, which could explain the decrease in cross-linking 
capacity of this trimer (Fig. 1 [12]). The spatial arrangement of IgE epitopes on a given protein 
may thus have an important influence on the allergenic activity of this protein in cross-linking 
effector cell-bound IgE.
Differential IgE cross-linking capacity for processed Ara h 1
This model (Fig. 1) might also explain the decrease in cross-linking capacity of the ‘small’ ag-
gregated structures observed for Ara h 1 after wet-heating applied in our study. An extension 
of this model is proposed in Fig. 2. Native Ara h 1 (Fig. 2A), present as a trimer, is able to 
cross-link IgE more effectively (cross-linking more FcεR1 per surface area) compared to the ag-
gregated structure obtained after wet-heating in the presence or absence of glucose (Fig. 2B). 
In addition, our processing procedures might also have caused destruction of IgE epitopes and 
epitope masking because of the oligomerisation which could all contribute to the decrease in 
IgE binding and IgE cross-linking. Dry-heating in the absence of glucose resulted in hydrolysis 
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products or possibly monomers of Ara h 1. The resulting increase in the number of fragments 
of different sizes leads to an enhanced ability to cross-link more receptor bound IgE molecules. 
Part of the degradation products were assembled into much larger aggregate structures, hav-
ing a high epitope density and therefore one aggregate might cross-link more receptor-bound 
IgE molecules at once (Fig. 2C). The very large Ara h 1 aggregates formed upon dry-roasting 
in the presence of glucose contain a high epitope density and one aggregate can therefore 
cross-link several IgE molecules at once which could cause a rapid degranulation of the cell 
(Fig. 2D). In addition, when a few epitopes are bound to the antibody, other receptors, having 
the flexibility to migrate in the membrane, also bind to the epitopes present on the aggregate 
(binding cooperatively) resulting in dense spots of bound IgE molecules on the membrane of 
the basophil all cross-linking a large number of FcεR1.
A
B
C
D
Ara h 1 trimer
Ara h 1 fragment / monomer
IgE‘small’ aggregated structure
‘large’ aggregated structure
Fig. 2. Model for differential behaviour of Ara h 1 before and after processing for IgE cross-linking in the mediator 
release assay. (A) Native Ara h 1 (B) wet-heated Ara h 1 heated in the presence or absence of glucose for 15 min at 
100°C (C-D) dry-heated Ara h 1 heated in the absence (C) or presence (D) of glucose for 20 min at 145°C.
Differential IgE binding capacity for processed Ara h 1
For IgE binding in the EAST inhibition assays, all treated Ara h 1 allergens showed a decrease 
in IgE binding capacity. Also here, interesting differences were observed between the different 
treatments which might be explained by the model shown in Fig. 3. Overall, larger structures 
will be sterically hindered and therefore less able to reach the IgE which is bound to the anti-IgE 
fixed on the plate. The tracer molecules (N-Ara h 1) are much smaller and are more easily able 
to reach and bind to the IgE molecules. The decrease in IgE-binding capacity is therefore most 
pronounced for Ara h 1 dry-heated in the presence of glucose (Fig. 3D). Ara h 1 dry-heated in 
the absence of glucose showed only a minor decrease in IgE-binding capacity, as more small 
Ara h 1 hydrolysate products and possible Ara h 1 monomers are present which still contain 
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intact epitopes and can easily bind to the IgE. The few large aggregates present will be less able 
to bind to the IgE (Fig. 3C).
A
B
C
D
Ara h 1 trimer
Ara h 1 monomer
‘small’ aggregate
‘large’ aggregate
N-Ara h 1 tracer
IgE
anti-IgE
Fig. 3. Model for differential behaviour of Ara h 1 before and after processing for IgE binding in the EAST inhibition 
assay. (A) Native Ara h 1 (B) wet-heated Ara h 1 heated in the presence or absence of glucose for 15 min at 100°C 
(C-D) dry-heated Ara h 1 heated in the absence (C) or presence (D) of glucose for 20 min at 145°C.
Maillard reaction
A more extensive Maillard reaction occurring during dry-heating of both Ara h 1 and Ara h 2/6 
in the presence of glucose, seems to partly counteract the increase and respectively decrease 
in IgE cross-linking capacity (Table 1). A protective effect of glucose was also observed for dry-
heated Ara h 2/6 but not for dry-heated Ara h 1, with respect to IgE binding. In addition, for 
wet-heated Ara h 2/6, both MRAs indicated a protective effect of the presence of glucose dur-
ing heating. However, for IgE cross-linking of Ara h 1 and for both IgE binding of Ara h 1 and 
Ara h 2/6 the presence of glucose during wet-heating even slightly further decreased the IgE-
cross-linking and IgE-binding capacity. Therefore, the effect of Maillard reaction does not seem 
to be consistent, which was also shown in the literature mentioned in the introduction section. 
However, a protective effect of glycation has also been observed after applying a severe heat-
treatment of the LTP from apple (Mal d 3) which resulted in a significant decrease in allergenic-
ity and a protective effect of glycation [3].
Ara h 1 isolated from roasted peanuts lost much of its native structure, was highly dena-
tured and showed no evidence of glycation but showed a similar IgE-binding capacity as native 
Ara h 1. It was previously demonstrated that new IgE binding sites might be created by Mail-
lard reactions on peanut allergens [13,14]; however, as Ara h 1 isolated from roasted peanuts 
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was not as extensively glycated as the model processed G-Ara h 1 which showed a reduction in 
IgE binding and cross-linking capacity, this suggests that other modifications than the Maillard 
reaction contributed to its allergenicity. The question remains if the fraction isolated from the 
roasted peanuts resembles the protein when it is still in the peanut itself. 
Ara h 2/6 (chapter 2) clearly shows different properties than Ara h 1 (chapter 3) with respect 
to the wet-heating procedure. The wet-heating procedure also resulted in a clear decrease in 
IgE-binding capacity, as measured with the reverse EAST inhibition, which corresponded with a 
decrease in cross-linking capacity, measured using both the RBL-assay as well as the BHR-test 
(Table 1). In contrast to Ara h 1, the decrease in reacti vity aft er heati ng seemed more pro-
nounced in the MRAs than in the IgE-binding assay. 
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Clinical relevance of IgE cross-linking and IgE binding affinity
Differences in the amount of the allergen required to degranulate FcεR1 cells could give an 
indication of the clinical relevance of the allergen (e.g. 1-10 ug/ml, most probably non-clinically 
cross-reactive protein, 0.001-10 ng/ml for major purified class 1 allergens) [15-21]. This was 
also observed from the RBL assay performed in chapter 5, in which we showed that a 50% 
release was obtained around 2 µg/ml using peanut sera containing cross-reactive IgE to the 
hazelnut protein tested, Cor a 11. Sera high in Cor a 11 specific IgE showed a 50% release at 
lower concentrations of ~0.2 µg/ml, which were even lower after dry-heating (~1 ng/ml). The 
rather low sequence similarity (33-34%) of Cor a 11 and Ara h 1 compared to other 7S globulins 
[22], could yield fewer, low-affinity allergen-IgE antibody reactions [23]. The allergen-specific 
IgE antibodies concentration, affinity, clonality (epitope-specificity) and the ratio of allergen-
specific IgE to total IgE are all shown to impact on the extent of effector cell activation, and e.g. 
a higher-affinity IgE binding to Der p 2 was associated with higher levels of basophil activation 
[15,24]. Moreover, individual IgE antibodies are able to bind single allergenic epitopes present 
in the different isoallergens with a broad range of affinities. This further contributes to the 
complexity of IgE-allergen interactions at the effector cell surface [16].
Recently it was also found that IgE against unheated and heated products could be func-
tionally different (specificity, clonality, affinity) and therefore could differentiate allergic from 
sensitized patients. By using a competitive peptide microarray assay, it was observed that IgE 
binding from unheated-milk and baked-milk tolerant individuals was primarily of low affinity, 
while milk allergic individuals had IgE that bound certain epitopes of milk proteins with high 
affinity. Therefore, besides a greater IgE epitope diversity, a higher affinity could also be associ-
ated with clinical phenotypes and severity of milk allergy [25,26]. This difference in IgE affinity, 
will most probably also be important in cross-reactive IgE, as discussed above. Table 2 gives an 
overview of the different IgE binding and degranulation tests and the linear and or conforma-
tional epitopes that the test recognizes, including remarks on affinity of the antibody binding.
Table 2. Overview of IgE binding and degranulation tests.
Method
Epitopes recognized 
(L or both L & C)
Measuring IgE binding/
cross-linking
Remarks on affinitya
Specific IgE (RAST/CAP/
direct ELISA)
Linear IgE binding Detects also low-affinity IgE Ab
SPT Both
IgE cross-linking (by mast 
cell activation in skin
Immunoblotting Linear IgE binding Detects also low-affinity IgE Ab
Reverse EAST inhibition Both IgE binding Affinity is important
Mediator release assays Both IgE cross-linking
Quantity of allergen needed 
for release might indicate al-
lergenicity
L: linear; C: conformational; a Range of affinity of IgE Kd is 10
-10 – 10-12 M. Sensitivity of Der p 2-induced histamine 
release from human basophils was closely related to the IgE-antibody affinity of Der p 2. IgE-antibody affinity for 
Der p 2 ranged from 0.056 to 1.77 x 10-10 M [24].
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Linear and conformational epitopes 
A recent meta-analysis was performed on allergy-related data from the immune epitope da-
tabase and revealed over 4,500 allergy-related epitopes derived from 270 different allergens 
covering about 17% of known allergens. The majority of epitopes were defined for B cells/
antibodies and IgE-mediated reactivity, and relatively fewer T-cell epitopes, mostly related to 
CD4+/MHC class II. Interestingly, the majority of food allergen epitopes were B-cell epitopes 
[27]. The epitopes reported represent unique molecular structures experimentally shown to 
react with a B-cell or T-cell receptor. The structures are generally categorized as minimal/op-
timal epitopes (11–15 amino acid residues), larger less well-defined regions (20–50 residues), 
and key residues identified as being involved in binding (1-2 residues for T cells and 4-5 amino 
acid residues for IgE binding). The majority of known epitopes on allergens comprise linear 
epitopes. To identify linear epitopes on allergens, epitope mapping with synthetic peptides 
has been demonstrated to be a suitable tool. IgE-binding abilities are subsequently evaluated 
by a method based on ELISA using patient sera [28,29]. However, conformational IgE epitopes 
generally represent the main IgE-binding structural motif on allergens. It has been postulated 
that reactivity and thus specific IgE antibodies to conformational epitopes of foods, mainly egg 
or milk, are more associated with development of tolerance, while reactivity to linear epitopes 
are more associated with food allergy persistence. Children who outgrew their milk allergy 
showed milk-specific IgE antibodies primarily directed against conformational epitopes while 
those with persistent milk allergy also showed IgE antibodies directed against specific sequen-
tial epitopes [30,31].
Short peptides representing the main IgE-binding regions of Ara h 2 were used in compe-
tition experiments (both ELISA and RBL cell assay) and showed little contribution to the IgE 
binding nor to the cross-linking of the allergen. Therefore, sequential epitopes, even though 
they can readily be identified by direct IgE binding to short peptides, contribute little to the IgE 
binding of Ara h 2, particularly in fluid phase antibody/target interaction. Assuming that fluid 
phase binding of IgE antibodies is more relevant in relation to in vivo allergenicity, it is pos-
sible that solid phase approaches for epitope identification may generate partially misleading 
results. Similar results were obtained with unfolded rAra h 2, which indicates a predominance 
of IgE recognition of conformational epitopes on Ara h 2 and minor involvement of sequential 
epitopes [32]. However, conformati onal epitopes are in general more suscepti ble to destruc-
tion by physical and chemical treatments as observed for the conformational epitope in Ana o 
2, the 11S globulin from cashew [33,34]. Currently, there is still a debate about the relevance 
of conformational epitopes in peanut allergens and food allergens in general.
So far, not many potentially relevant IgE-binding regions of food allergens, particularly con-
formational epitopes formed by sequentially discontinuous amino acid residues, have been de-
scribed. The dominance of protruding areas and the presence of a region with alternating sign 
in the electrostatic potential are compatible with favourable antigen–antibody interactions. It 
has been proposed that strong electrostatic interactions should be expected in high-affinity 
antibody–antigen complexes, whereas weaker electrostatic activity inherent to less specific 
contacts should be indicative of cross-reactivity. Most of antibody epitopes are described to 
be conformational and hence, sequential approaches may render limited information, besides 
might exhibit reduced antibody-affinity [35,36]. Many of the structural requirements for bind-
ing of epitopes to antibodies were resolved for IgG antibodies which have a preference for pro-
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truding loops and secondary structures in antigens. IgE antibodies, however, recognise differ-
ent binding sites than IgG antibodies as was described for α-lactalbumin [37] and with crystal 
structures of β-lactoglobulin, Phl p 2, Api m 2, Bet v 1 and Bla g 2 [38,39]. So far, however, only 
a few sequences of allergen-specific IgE antibodies have been characterized that are comple-
mentary to the known allergenic epitopes. Thus, further studies on the exact nature of B-cell 
activating and IgE-binding epitopes on allergens is necessary to elucidate further functional 
studies on allergenicity of (food derived) allergens.
Conclusions and future research
Depending on the test system, heating of allergens may have no effect or it may decrease or 
increase their immunoreactivity (IgE binding capacity) and/or allergenicity (basophil degranu-
lation capacity). The existence of sequential and conformational epitopes, the demasking of 
new epitopes or the modification of existing epitopes can explain effects conferred by different 
processing methods. In addition, protein oligomerization and aggregation, as a result of pro-
cessing, was found in our studies to be an important factor in how processing alters allergenic-
ity of proteins. Moreover, physiologically relevant in vitro models of digestion testing the ability 
of these large aggregated fragments to survive digestion, could indicate possible differences in 
digestibility between the native and the aggregated allergens, which might contribute to the 
overall allergenicity of the protein. Aggregated structures might be more resistant to digestion 
and could reach the intestinal lumen in an undigested form and thereby protect the epitopes 
from digestive enzymes. In addition, it is essential to relate changes in IgE binding and in IgE-
cross-linking capacity to changes in the minimum eliciting dose in a DBPCFC and therefore of 
relevance in establishing a proper diagnosis of the individual allergic patient. As an example it 
has been observed that a 100-fold reduction in IgE binding increased the minimum eliciting 
dose by only 2-fold [40]. Therefore, to establish thresholds for processed foods, would still 
require the use of the DBPCFC.
Even though the boiling method tested for Ara h 1 and Ara h 2/6 might only partially de-
crease the allergenicity of these peanut proteins and thereby possibly the allergenicity of the 
whole peanut, other methods are also under investigation. Recently physical processing by ir-
radiation has been described to promote polypeptide fragmentation and hydrophobic surface 
modification, leading to protein misfolding, and subsequently, to aggregation. Effects on stabil-
ity of food allergens after gamma irradiation might contribute to the development of methods 
to reduce allergenicity [41], however the allergenicity of these aggregates formed should be 
tested in IgE binding and IgE cross-linking assays. Complete elimination of the allergenic po-
tential of foods by using processing methods will be unlikely given the current knowledge on 
processing and allergenicity. The allergenic potential of a food protein can be divided into its 
capacity to sensitize susceptible individuals resulting in the production of specific IgE antibod-
ies and its ability to elicit an allergic reaction in already sensitized patients. In the current thesis 
the allergenic potential of a food protein to elicit an allergic reaction was studied. Ara h 1 and 
Ara h 2/6 are relevant major allergens, however studying these allergens is not sufficient to 
predict the effect on whole peanuts.
Studying the IgE-binding reactivity and the cross-linking capacity of the insoluble and thus 
more heavily aggregated proteins will provide insight into the role that these physico-chemical 
modifications play in the overall allergenic reaction cascade. It will be a challenge to purify and 
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test these strongly aggregated structures. In addition to test our hypothesis, dry-heating can be 
applied to more allergens to assess tertiary structure and thereby the extent of aggregate for-
mation from fragmented polypeptides. Afterwards these processed allergens could be tested 
for their allergenic potential in both IgE-binding and IgE-cross-linking assays. Better charac-
terization of interactions with other proteins, fat, and carbohydrates in the food matrix will be 
important for future studies on the effect of processing on a whole food product.
Immunomodulation by lactic acid bacteria
In the introduction section several approaches for allergy management are described that are 
currently under investigation. One of these approaches is the use of lactic acid bacteria as 
potential probiotics. Clinical studies support that lactic acid bacteria such as lactobacilli may 
represent a promising preventive and therapeutic strategy for allergic diseases. However, the 
scientific proof of the effect of lactic acid bacteria in allergic patients has been controversial as 
some studies do not seem to prove a beneficial effect. Modulation of the immune system by 
lactic acid bacteria is presumed to be an important mode of action and was the main focus of 
the studies on lactic acid bacteria performed in this thesis.
Comparison of results of both in vitro and in vivo studies of different research groups is 
complicated because each study used different study conditions. The choice of the probiotic 
species/strains used, growth phase of the bacteria, dosing and time of exposure, use of live 
or dead bacteria, the patient populations studied and the read-out system and markers used 
could all influence the outcome and conclusions of the study. In addition, for in vivo studies 
host factors such as current immune status and age, and also standardization of components 
in the diet that may bias the effect of the lactic acid bacteria and food matrix composition and 
processing effects should be taken into account when designing the protocol [42]. The design 
of the study is therefore of utmost importance as this will enhance the likelihood of finding 
significant effects and/or finding clinical benefit of the tested lactic acid bacteria.
In vitro studies
Even though the final proof of principle is to perform a well-designed double-blind placebo 
controlled in vivo trial, in vitro studies are indispensible to properly design such a study. The 
number of claims and effects attributed to lactic acid bacteria are increasing tremendously. 
New scientific requirements for proving solid evidence of health claims of probiotics related 
to gut and immune function are urgently needed as more and more health claims of probiot-
ics are currently being rejected by the European Food Safety Authority (EFSA). However, sub-
stantial research on probiotics shows clear strain-specific immunomodulatory effects [43-48], 
which is also confirmed by our studies described in chapter 7-9. Thus it is essential to reliably 
select the most promising candidates for desired health applications.
Large numbers of candidate strains are often tested for immunomodulating properties in a 
variety of in vitro models to select those strains with the best characteristics according to single 
immune parameters, like IL-10, IFN-γ or IL-12 inductive capacity [49-53]. Based on the study 
presented in chapter 7, in which initially 51 Lactobacillus strains were tested, bacterial species 
could be classified for their probiotic characteristics on the basis of their immune profiles. 
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Generally, L. plantarum strains were high IL-12 inducers whereas strains from L. acidophilus 
were recognized as low IL-12 inducers. As we were specifically interested in a possible benefit 
of these strains in allergic patients, we hypothesized that L. plantarum strains were better can-
didates as they might be better in skewing T-cells differentiation toward a Th1-like response. 
To test this hypothesis, immune cells were cultured of patients with a proven pollen allergy, 
who are known to have Th2-skewed allergic immune responses with high specific IgE levels in 
the serum, and selected strains were tested for their immunomodulatory properties in chapter 
8. Differences were observed between the strains in their capacity to induce IFN-γ, IL-12 and 
TNF-α production and interestingly, all strains were able to suppress IL-13 induction, one of 
the hallmark cytokines in allergy. PBMC derived from healthy patients are most often used to 
investigate possible probiotic effects. However as immunomodulatory effects could exert a 
differential effect in patients having different diseases reflected by a different immune status, 
we chose patients with seasonal allergy as the target group for in vitro testing (chapter 8). Our 
results show that PBMC of patients with seasonal allergy were appropriate to determine im-
munomodulatory activities of probiotic bacteria in vitro.
In vivo studies
A further selection of lactic acid bacteria was applied in vivo in birch-pollen-allergic subjects. 
Often the selection of probiotic strains is based on in vitro screening only, in several cases sup-
ported by validation in animal models. However, only few studies compare in vitro to in vivo 
data and a good correlation was found in some studies [54-56], but not in all [57]. Clinical trials 
are often performed with only a single probiotic strain, which bears the risk that not the most 
appropriate strain is used if the selection was based on in vitro studies only. Therefore, eluci-
dation of probiotic functionality should preferably be based on in vivo validation of multiple 
strains, to validate the proposed immunomodulatory capacities observed in vitro. Based on 
results from chapter 7 and 8 and on an additional screening on IL-10 inducing properties, five 
Lactobacillus strains were selected for an in vivo study, including 62 birch-pollen allergic sub-
jects who consumed yoghurts for 4 weeks. The human in vivo screening system used in chapter 
9, was found appropriate to evaluate selected immunomodulatory strains prior to testing for 
clinical efficacy. 
From our in vitro studies, Lactobacillus plantarum appeared the most promising strains for 
potential use in allergic patients and in our in vivo study L. plantarum CBS125632 showed both 
a decrease in birch-pollen-specific IgE as well as a decrease in Th2 cytokines by anti-CD3/anti-
CD28-stimulated PBMC and an increase in IL-10 production. This strain might confer its effect 
by stimulating Treg cells and would thus be a good candidate for a follow-up clinical trial that 
targets clinical endpoints of allergy.
Lactic acid bacteria and allergy
There is insufficient but very promising evidence to recommend the addition of probiotics to 
foods for prevention and treatment of allergic diseases. Several recent reviews discuss the 
current evidence for beneficial effects of probiotics in allergy and overall, most success has 
been obtained for prevention of atopic dermatitis [42,58-65]. Clinical improvement especially 
in allergic rhinitis and IgE-sensitized (atopic) eczema has been reported too, but these studies 
are less conclusive. Data for food allergy/hypersensitivity and allergic airway diseases are less 
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adequate at this moment. Heterogeneity between studies preclude evaluation of efficacy of 
probiotics and might explain the differential effects with respect to the outcome measures 
observed between studies.
Several randomized controlled trials (RCTs) have been performed to study the role of probi-
otics as a treatment modality in allergic rhinitis. Probiotic intake generally improved quality of 
life score in patients with allergic rhinitis and decreased the number of episodes of rhinitis per 
year. Adverse events were not recorded and probiotic therapy might thus be useful in rhinitis, 
but the present data do not yet allow any treatment recommendations [62].
Moreover, probiotic bacteria engineered to deliver IL-10 or IL-12 might be able to decrease 
food-induced anaphylaxis and provide a proof of principle and a putative treatment option to 
prevent IgE-type sensitization to food allergens [66,67].
Mechanism of action of lactic acid bacteria
Lactic acid bacteria are known to influence both mucosal and systemic innate and adaptive 
immune function. Of particular importance is their potential to elicit antigen-specific secre-
tory IgA responses at mucosal surfaces and their intrinsic adjuvant properties to induce strain-
dependent pro-inflammatory and regulatory cytokines in vitro and in vivo. Different probiotic 
strains result in differential cytokine production in human PBMC and it has been shown that 
there were strain-specific differences in the production of IL-12 and IFN-g, but that all bacteria 
tested did induce TNF-α [50-53]. Probioti cs can exert a plethora of immune-mediated func-
tions as described by Turpin et al., including their responsive factors. These immunostimula-
tory factors include bacterial DNA, lipoteichoic acid, MAMPs, secreted factors such as H
2
O
2
, 
passive and active binding and indirect increase in butyrate levels [52].
Bacterial cell wall components are in direct contact with several immune cell types by bind-
ing various PRRs of the host. The variation in composition and quantity of cell-wall structures 
such as the polysaccharide-peptidoglycan complex, teichoic acid composition and extent of 
glycosylation between lactobacilli might partly explain differential immunomodulation proper-
ties of different strains. For example, recent studies on DNA from Lactobacilli showed anti-in-
flammatory effects of natural commensal-origin DNA on the gut which was mediated via TLR9 
signalling [68,69] and provided the basis for the rational design of a TLR-9 vaccine based on 
a Amb a 1 - CpG DNA construct for ragweed allergic individuals. Vaccination activates TLR-9 
in dendritic cells inducing activation of intracellular signalling pathways leading the immune 
response away from a pro-allergic response with Th2 cytokines (IL-4 and IL-5). In addition, the 
vaccine reduces the ability of the Amb a 1 allergen to bind and cross-link IgE bound to mast 
cells. As is clear from many in vitro studies, dendritic cells play a key role in regulating T-cell 
responses and lactic acid bacteria have been shown to differentially modulate dendritic cells 
maturation in a strain-dependent manner [51]. Activation of human dendritic cells by Lactoba-
cilli was shown to skew T-cell responses toward Th1 and Tc1 pathways [70]. Currently, there is 
a lot of interest into Treg inducing capacities of probiotics [50,71,72]. As we observed in both 
our in vitro and in vivo studies an increase in IL-10 production, that coincided with a reduction 
in the production of IL-5 and IL-13, these specific lactic acid strains tested in our studies might 
also have been responsible for promotion of Treg cells that subsequently downregulated Th2 
cytokines, although this has not been elucidated on the level of individual cytokine producing 
CD4+ T-cells.
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Apart from TLR, lactic acid bacterial antigens can be also recognized through molecules like 
nucleotide-binding oligomerization domain receptors (NODs) or lectins, including the C-type 
lectin dendritic cells specific intra-cellular adhesion molecule 3-grabbing nonintegrin (dendritic 
cells-SIGN) and even the mannose receptor CD206 on the gut immune cells in mice [73-75]. 
However, additional work is needed to delineate how different lactic acid strains could exert 
their effect. This could give more inside on the use of specific strains for targeted application 
in specific diseases. As also faecal transplantation becomes part of mainstream medicine [76], 
studies on interactions of humans with their microbiota will allow better insight into their syn-
ergistic functionality.
Essential characteristics of lactic acid bacteria
The debate is still on-going whether probiotics should be alive to exert their effect, as beneficial 
responses can both be generated by both live and dead cells in probiotic products. Live probi-
otic cells can influence both the gastrointestinal microbiota and the immune response whilst 
the (cell-wall) components of dead cells exert a, possibly TLR-mediated, immunomodulating 
response in the gastrointestinal tract and beyond. There is no evidence that probiotic supple-
ments are able to replace the existing microbiota when these have been killed off and bacterial 
levels in faeces disappear within days when supplementation ceases. Modification of the mi-
crobiota in the gut could be useful in the treatment of clinical conditions affecting the gastro-
intestinal tract while potential benefits extend beyond the gut by modulation of the immune 
system possibly beneficial for inflammatory diseases, allergy, respiratory diseases and others 
[77]. Comparable studies between live and dead cells showed confl icti ng results [78-80]. How-
ever, dependent on the mechanism of action of the probiotic strain in the target group tested, 
live bacteria could exert a more pronounced effect. Especially if colonization of probiotics to 
the wall of the gut is thought to exert the beneficial effect, e.g. resulting in reduction of the 
virulence of the pathogens by competition for binding sites or direct killing of the pathogenic 
bacteria, live bacteria will be a better choice. Several studies show immunomodulating effects 
by inactivated bacteria [81-85] which was also shown from our study described in chapters 7 
and 8. In addition, both live cells surviving the GI-tract, dead cells, and their metabolites can 
contribute to the effects in the GI-tract as these are all present in probiotic preparations. With 
respect to the commercial use of probiotics, dead cells would be desirable as they are easier to 
use in a great variety of products. They are considerably safer for the host, the shelf life is no 
longer a restriction and standardization in their formulation is easier than for live preparations 
[77,86,87]. Especially the standardization of probiotic formulations can be a very important 
factor because the culture method of the bacteria and potentially even the growth stage of 
bacteria in a preparation can induce differential responses in humans [88]. In our in vitro stud-
ies we used heat-killed bacteria, to compare different strains and to enable the analysis of 
possible immunomodulating effects of lactic acid bacteria on the T-cell level, which requires 
extended culture periods. 
To conclude, even though the definition of probiotics specifically states that the bacteria 
should be alive, immunomodulating effects are also observed by inactivated bacteria like in our 
studies described in chapters 7 and 8. Several important advantages of the use of dead cells, 
could make them a better choice to use in a probiotic product. 
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Lactic acid bacteria in the diet: the future
The potential to influence the immunological response via immunomodulatory food ingredi-
ents such as probiotics, has shown to have potential not only from the perspective of allergy 
prevention, but also from a more general health related perspective. It has been clearly dem-
onstrated that diet, including therapy by probiotics has a considerable effect on the composi-
tion of the gut microbiota and immune responses [89-91]. Studies on the therapeutic use of 
probiotic formulations in irritable bowel syndrome, Crohn’s disease, Helicobacter pylori ther-
apy, cancer induction, allergy, skin and urogenital diseases as well as administration to ease 
post-operative complications are on-going. Recently, it has even been shown that adult germ-
free mice displayed a different behaviour from mice with normal microbiota, suggesting that 
during a critical period early in life microorganisms affect the brain and change the behaviour 
later in life [92]. Although the conclusions from the different studies are still controversial with 
respect to the beneficial effects of probiotic supplementation on allergy development, these 
studies provide a valuable lesson for the therapeutic use of lactic acid bacteria. Careful strain 
selection and characterization of the immunomodulatory properties will be essential prior to 
application in prophylactic and therapeutic settings.
Rather than developing new anti-inflammatory drugs, carefully designed trials to establish 
whether diet directly affects inflammatory disease as well as through what cellular and mo-
lecular mechanisms, could be more cost-effective [90]. Sequencing of genomes and transcrip-
tomes that can be correlated to measured effects and thereby enable testing which bacterial 
genes and derived components are essential to specific immunomodulatory properties could 
reveal more about the mechanisms [50,51,93-95]. Development of probiotics from microbiota 
derived from human communities in which allergies and asthma are almost completely non-
existent could also be an approach which is worthwhile to investigate further. In addition, as 
the underlying immunological mechanisms of allergies might be similar for patients having 
seasonal allergies and patients having food allergy, it will be interesting to test strains which 
have been shown to have a beneficial effect in patients having seasonal allergies (e.g. possibly 
strain L. plantarum CBS125632 tested in our studies) also for their immunomodulating effects 
in food allergic patients.
Conclusions and future research
That specific lactic acid bacteria confer a beneficial effect in specific patients with diverse dis-
eases and that an array of mechanisms could be responsible for the different observed effects 
has become clear over the last years. This opens opportunities for specific and differential 
use of lactic acid bacteria in allergic individuals. However, future well-designed clinical trials, 
testing a diverse array of strains and involving large numbers of a diverse array of diseased 
patients, will be mandatory to achieve definite evidence of the preventive and curative role 
of lactic acid bacteria in medical practice and to finally develop proper advice and guidelines 
[61]. Therefore, also with respect to allergy, the use of probiotics should be further investigated 
before this could be recommended as a common treatment of allergic patients.
In addition, there is a need to invest greater efforts to properly select candidate probiotic 
strains to be included in clinical trials and translation of in vitro models to in vivo models for 
different diseases will be crucial for this. Small-scale human trials, like the methodology pre-
sented in chapter 9 used to compare candidate probiotic bacteria for their immunomodulating 
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properties in a Th2-skewed population, could be an appropriate choice to select candidate 
strains for testing in clinical trials.
Concluding remarks
The described studies which are part from the EuroPrevall project, showed that the model boil-
ing procedure applied on the purified allergens, resulted for both Ara h 1 and Ara h 2/6 in a de-
crease in IgE-binding capacity as well as in IgE-cross-linking capacity. This is likely caused by the 
smaller aggregates formed after boiling. In contrast, dry-heating of Ara h 1 but not Ara h 2/6 
resulted in formation of very large aggregates composed of fragmented polypeptides contain-
ing a high epitope density which are likely responsible for the decrease in IgE-binding capacity 
and the increase in IgE-cross-linking capacity observed. Moreover, our data demonstrated that 
using only IgE-binding assays is insufficient to fully assess allergenicity of a modified allergen 
and that effects on the biological activity, such as mediator release, must also be considered.
As we showed that processing procedures have a profound effect on the allergenicity of the 
allergen, we consider our results of importance in studies of the allergenic potential of food 
proteins and for the proper diagnostic allergy testing of the individual patient using both CRD 
and DBPCFC. For diagnostic purposes purity of a protein is often checked by SDS PAGE how-
ever, aggregation could also play an important role. Moreover, standardization of the allergenic 
products used in DBPCFC, will be important to facilitate comparison of test results between al-
lergology centres and can also be important to improve the test procedure. In addition, includ-
ing these considerations could be effective to improve the current risk assessment of allergenic 
proteins, however no general rules can be formulated at this moment.
In the second part of this thesis, strain-specific immunomodulatory effects were observed 
of the lactic acid bacteria tested. This stresses the importance of a proper pre-selection of 
candidate strains which would enable to choose the most promising strains for clinical test-
ing. Overall, the lactic acid bacteria tested in our studies were capable to modulate PBMC of 
healthy and allergic patients to induce innate cytokines, decrease synthesis of the Th2 cytokine 
IL-13, increase synthesis of the regulatory cytokine IL-10 and differentially induce IFN-γ and IL-
12 production. Lactobacilli might confer a beneficial effect in allergic patients based on these 
immunomodulatory effects. Five strains were selected for a small-scale human trial and four 
strains showed a decrease in birch-pollen specific IgE. Additionally, one strain also decreased 
Th2 cytokine induction and a follow-up clinical trial should prove the clinical efficacy of this 
strain for probiotic use in patients having a seasonal allergy.
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Summary
Allergic diseases such as allergic rhinitis, allergic asthma, atopic eczema and food allergy have 
become an increasing health problem world-wide, affecting between 20-30% of the total pop-
ulation. Peanut allergy (prevalence ~1%) is a common and persistent food allergy account-
ing for severe allergic reactions. Peanuts are often consumed after thermal processing (e.g. 
boiling, roasting) which can alter the protein structure and change its immunoreactivity and 
allergenicity. In vitro diagnostic testing, however, is generally performed using the native, un-
processed protein and more knowledge on the effect of processing on allergens is necessary 
to improve these diagnostic procedures. In addition, rationally designed processing could also 
lead to reduction of the allergen content in certain products and therefore be an effective food 
technological approach in allergy management. Another approach in allergy management is 
the use of immunomodulating foods, such as probiotics. There are indications that probiotics, 
e.g. specific lactic acid bacteria, could be beneficial for many conditions, including different 
clinical expressions of allergy.
Chapter 1 gives an overview of several aspects of allergy with a focus on food allergy. Firstly 
the basic mechanism and the involved immune cells are discussed, after which the prevalence 
of food allergy in the context of the EuroPrevall project is described. Different food allergens 
are discussed with an emphasis on the allergens from peanut and different methods are de-
scribed to assess the potential allergenicity of proteins under widely used processing condi-
tions, including heating and the Maillard reaction. Lastly, different methods to prevent or treat 
allergies are discussed with a special emphasis on immunomodulation by lactic acid bacteria. 
This introduction chapter is concluded with the research aim and thesis outline.
Section 1: Influence of processing on allergenicity of proteins
In our first study, described in Chapter 2, Ara h 2/6 was purified from raw peanut and heated 
in solution (boiling) in the presence or absence of glucose. Ara h 2 and 6 were also purified 
from roasted peanuts for comparison. Structural changes, the capacity to induce cell prolifera-
tion and cytokine production, and IgE-binding and IgE cross-linking capacity were evaluated. 
Although no effect of processing on T-cell reactivity was observed, heat-induced denaturation 
reduced the IgE-binding and cross-linking capacity. Interestingly, the soluble fraction of the Ara 
h 2/6 isolated from roasted peanuts retained the conformation and allergenic activity of the 
native protein. 
In Chapter 3 similar methods were used to assess the effect of heating and glycation on 
Ara h 1. Heating in solution, irrespective of their level of glycation, resulted in formation of 
aggregates having reduced IgE-binding and cross-linking capacity, while T-cell reactivity was 
retained. The soluble fraction of Ara h 1 isolated from roasted peanuts appeared to be highly 
denatured, formed more globular and smaller aggregates, and showed no evidence of glyca-
tion. However, these smaller aggregates retained IgE-binding capacity, unlike the aggregates 
formed after heating and glycating purified Ara h 1. These results could account for observed 
differences between boiled and roasted peanuts and suggest that other modifications than the 
Maillard reaction affect the allergenicity of Ara h 1. 
As peanuts are often consumed after roasting, the wet-thermal processing procedures, em-
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ployed in the two previous described studies, were related to the effect of thermal treatment 
and Maillard reaction under low moisture conditions, which is described in Chapter 4. The ex-
tensive heating at low moisture resulted in hydrolysis of both Ara h 1 and Ara h 2/6. However, 
in contrast to Ara h 2/6, soluble Ara h 1 formed large aggregates. Thermally treated Ara h 2/6 
had both a lower IgE-binding and degranulation capacity compared to the native form, and 
the presence of glucose during heating partly counteracted both the decrease in IgE-binding 
and degranulation capacity. The IgE-binding capacity of Ara h 1 was also decreased; however, 
the basophil degranulation capacity increased significantly. This demonstrates the importance 
of including degranulation assays in addition to IgE-binding assays, when assessing allergenic 
potency of allergens. In addition, we here propose a role for large aggregates in the increased 
IgE-cross-linking capacity of individual allergens.
Chapter 5 describes the effect of glycation on the immunoreactivity and basophil degranu-
lation capacity of Cor a 11, the 7S globulin from hazelnut (and thus a homologue of Ara h 1). 
Three processing methods (heating at low moisture content at 37, 60 and 145°C) resulted in 
proteins with increasing degrees of glycation. Glycation at 37°C did not influence the specific 
IgG or IgE binding, while both were decreased after heating at 60°C and 145°C. However, heat-
ing at 145°C in the absence or presence of glucose resulting in the formation of aggregated 
structures, increased the basophil degranulation capacity of Cor a 11 using sera high in Cor a 11 
specific IgE, but not when using sera from peanut allergic patients low in Cor a 11 specific IgE. 
Therefore, this study besides showing the importance of the use of a combination of tests also 
indicated the importance of using well-characterized sera as a source of IgE.
In Chapter 6 we focused on the clinical features of all our clinically well-defined peanut al-
lergic patients of which immune cells and sera were used for the previously described studies. 
In addition, soy allergic patients were included and an extensive IgE profile was determined for 
all patients. Gly m 4 (Bet v 1 homologue from soy) sensitization was suggested to be an impor-
tant indicator of severe soy allergy in the soy allergic patients, while in peanut allergic patients 
sensitization to allergens from soy and pea extract nor Gly m 5 and 6 was found to have a good 
diagnostic specificity. This is likely due to the presence of clinically non-relevant cross-reactivity 
between peanut-specific IgE and homologues soy and pea components.
Section 2: Immunomodulation by Lactobacillus strains
In the first in vitro study, described in Chapter 7, initially 51 Lactobacillus strains were screened 
of which 8 were selected and tested for their immunomodulating effects on peripheral blood 
mononuclear cells (PBMC) of healthy donors. All tested Lactobacillus strains were capable of 
inducing the production of IL-1β, IL-10, IFN-γ and TNF-α. Clear strain-specific effects were ob-
served with L. plantarum strains showing significantly higher induction capacity of IFN-γ, IL-12 
and TNF-α compared with L. acidophilus strains. We therefore concluded that especially L. 
plantarum strains are promising candidates in IgE-mediated allergy by their stimulation poten-
tial of the T-cell response toward a putative Th1 response.
As healthy subjects, in contrast to allergic individuals, are assumed to finely regulate the 
Th1/Th2 balance by inducing sufficient Treg cell activity, immunomodulatory effects of six se-
lected Lactobacillus strains were investigated on PBMC of pollen-allergic patients in Chapter 
8. All strains could modulate PBMC to induce innate cytokine production and in addition, all 
strains had the ability to repress IL-13 production. Again a differential effect on IFN-γ and IL-12 
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induction was observed. In addition, one strain could extensively suppress proliferation in-
duced by anti-CD3/anti-CD28 stimulation. Specific strains that were able to suppress the Th2 
cytokine induction and induce Th1 cytokines might be beneficial for allergic patients.
Effects found in vitro cannot directly be extrapolated to in vivo and therefore, in Chapter 9, 
we performed an in vivo screening including five Lactobacillus strains. Blood samples were col-
lected before and after a 4-week intervention with probiotics from all 62 birch-pollen-allergic 
patients included. Four strains caused a decrease in birch-pollen-specific IgE and for one spe-
cific strain this coincided with significant decreases in IL-5 and IL-13 and an increase in IL-10 
production by anti-CD3/anti-CD28 stimulated PBMC cultures and might therefore have the po-
tential to alleviate seasonal allergy symptoms.
The last chapter, Chapter 10, gives an overview of the most important results of this thesis 
and discusses the research limitations and future research perspectives. We hypothesize the 
role of protein aggregation in allergenicity and we elaborate on the importance of a proper 
stepwise approach to realize selection of a proper lactic acid strain for in vivo human testing.
In conclusion, this thesis showed that processing effects can have profound and specific 
effects on the structure and the allergenicity of relevant allergens. However, to test putative 
effects on allergenicity, IgE-binding tests only are not sufficient and mediator release assays are 
important to include, particularly when testing aggregated proteins. These results might have 
consequences for the proper diagnosis of food allergy in daily practice. Finally, as effects of 
lactic acid bacteria are strain specific, a proper pre-selection of candidate strains is important 
to choose the most promising strains for clinical testing. In our in vivo screening, one strain, L. 
plantarum CBS125632, was found to be promising because of its desired immunomodulatory 
activity to test in a follow-up trial to reduce symptoms of birch-pollen allergy.
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Allergische aandoeningen zoals allergische rhinitis, allergische astma, atopisch eczeem en 
voedselallergie zijn wereldwijd een steeds belangrijker gezondheidsprobleem geworden, 
waaraan 20-30% van de totale bevolking lijdt. Pinda-allergie is een veel voorkomende (~1% 
van de bevolking) en persistente voedselallergie, verantwoordelijk voor ernstige allergische 
reacties. Pinda’s worden vaak gegeten na een bepaalde thermische behandeling (bijv. koken 
of roosteren) en deze behandeling kan de eiwitstructuur en daarbij de immuunreactiviteit en 
allergeniciteit veranderen. Diagnostische in vitro testen worden echter meestal uitgevoerd 
met natieve, onbehandelde eiwitten en meer kennis over het effect van de behandeling van 
allergenen is nodig om deze diagnostische testen te verbeteren. Daarnaast kunnen specifieke 
behandelmethoden ook leiden tot een afname van de hoeveelheid allergeen in een product. 
Deze methoden kunnen daardoor een effectieve voedingstechnologische aanpak zijn voor 
het onder controle houden van allergie. Een andere aanpak van allergiemanagement is het 
gebruik van immuunmodulerende voedingsproducten zoals probiotica. Er zijn indicaties dat 
probiotica, bijvoorbeeld melkzuurbacteriën, heilzaam zijn voor diverse lichamelijke condities, 
o.a. bij diverse allergische symptomen.
Hoofdstuk 1 geeft een overzicht van diverse allergische aspecten, met een focus op 
voedselallergie. Eerst worden het basale mechanisme en de diverse betrokken immuuncellen 
bediscussieerd, waarna de prevalentie van voedselallergieën in de context van het EuroPrevall 
project wordt beschreven. Verschillende voedselallergenen, met de nadruk op allergenen uit 
de pinda, en verschillende methoden om de allergeniciteit van eiwitten te bepalen worden 
besproken. Tot slot worden diverse methoden aangehaald om allergieën te voorkomen en te 
behandelen, met de nadruk op immuunmodulatie door melkzuurbacteriën. Deze introductie 
wordt afgesloten met het onderzoeksdoel en een inhoudelijk overzicht van het proefschrift.
Sectie 1: Invloed van behandeling op de allergeniciteit van eiwitten
In de eerste studie, beschreven in hoofdstuk 2, werd Ara h 2/6 gezuiverd uit pinda’s die 
verhit werden in een waterige omgeving (koken), in de aan- of afwezigheid van glucose. Ara 
h 2 en 6 werden ter vergelijking ook gezuiverd uit geroosterde pinda’s. Veranderingen in de 
eiwitstructuur, de capaciteit om celdeling te bewerkstelligen, cytokine productie te induceren, 
IgE-antistoffen te binden en IgE-antistoffen te crosslinken werden geëvalueerd. Hoewel het 
koken geen effect had op de T-cel reactiviteit, was de IgE-binding en IgE-crosslinking capaciteit 
van het door hitte gedenatureerde eiwit verminderd. Tevens was het opmerkelijk dat de 
oplosbare fractie van Ara h 2/6 dat uit geroosterde pinda gezuiverd werd, de conformatie en 
de allergeniciteit van het native eiwit wel behield.
In hoofdstuk 3 werden vergelijkbare methoden gebruikt om het effect van verhitten 
en niet-enzymatische glycosylering op een ander pinda-allergeen, Ara h 1, te bepalen. 
Onafhankelijk van de mate van glycosylering, resulteerde verhitting van Ara h 1 in een waterige 
oplossing in de vorming van aggregaten met een verminderde IgE-binding en IgE-crosslinking 
capaciteit, terwijl de T-cel reactiviteit werd behouden. De oplosbare fractie van Ara h 1 uit 
geroosterde pinda’s bleek in grote mate te zijn gedenatureerd, vormde rondere en kleinere 
aggregaten, en was niet geglycosyleerd. Deze kleinere aggregaten behielden echter wel de IgE-
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bindende capaciteit, in tegenstelling tot de aggregaten die gevormd werden na verhitting en 
glycosylering van geïsoleerd Ara h 1. Deze resultaten zouden een verklaring kunnen zijn voor de 
waargenomen verschillen tussen gekookte en geroosterde pinda’s en suggereren dat andere 
veranderingen dan de Maillardreactie de allergeniciteit van Ara h 1 beïnvloeden. 
Aangezien pinda’s vaak geroosterd worden geconsumeerd, zijn de behandelmethoden van 
de allergenen in oplossing beschreven in de vorige twee studies opgevolgd door een studie 
naar het effect van een hitte-behandeling en de Maillardreactie onder lage vochtigheid, 
zoals beschreven in hoofdstuk 4. De intensieve verhitting bij lage vochtigheid resulteerde 
in hydrolyse van zowel Ara h 1 als Ara h 2/6. In tegenstelling tot Ara h 2/6 vormde Ara h 1 
echter grote aggregaten. Hitte-behandeld Ara h 2/6 vertoonde een verlaagde IgE-binding en 
degranulatiecapaciteit vergeleken met de natieve vorm. De aanwezigheid van glucose tijdens 
de verhitting werkte zowel de afname in IgE-binding als de afname in degranulatiecapaciteit 
tegen. De IgE-bindingscapaciteit van Ara h 1 werd ook verminderd na verhitten, maar de 
capaciteit om basofielen te degranuleren werd significant verhoogd. Dit laat zien dat het zeer 
belangrijk is om een degranulatietest naast de IgE-bindingstest mee te nemen bij het bepalen 
van de allergische potentie van allergenen. Bovendien stellen we voor dat de grote aggregaten 
een rol spelen bij de toename van de IgE-crosslinking capaciteit van individuele allergenen.
Hoofdstuk 5 beschrijft het effect van glycosylering op de immuunreactiviteit, gemeten als 
basofieldegranulatiecapaciteit, van Cor a 11, de 7S-globuline uit hazelnoot (een homoloog 
van Ara h 1). Drie behandelmethoden (verhitten bij lage vochtigheid en 37, 60 of 145 °C), 
resulteerden in eiwitten met een verhoogd glycosylatieniveau bij de oplopende temperaturen. 
Glycosylering bij 37 °C had geen invloed op de specifieke IgG- of IgE-binding, terwijl beide waren 
afgenomen bij 60 en 145 °C. Verhitting bij 145 °C in aan- of afwezigheid van glucose resulteerde 
echter in de vorming van aggregaten en vergrootte de basofieldegranulatiecapaciteit van 
Cor a 11 getest met sera met een hoog gehalte van Cor a 11-specifiek IgE. Bij gebruik van 
pinda-allergische patiëntensera met een laag gehalte van Cor a 11-specifiek IgE werd echter 
geen verschil in degranulatiecapaciteit waargenomen. Deze studie laat, naast het naar voren 
brengen van het belang van het gebruik van een combinatie van testen, ook het belang van het 
gebruik van goed gekarakteriseerde sera als bron van IgE zien.
In hoofdstuk 6 richtten we onze aandacht op de klinische kenmerken van al onze klinisch 
goed gedefinieerde pinda-allergische patiënten van wie de immuuncellen en sera werden 
gebruikt in de hiervoor beschreven studies. Daarnaast zijn er soja-allergische patiënten aan 
de studie toegevoegd en werd van alle patiënten een uitgebreid IgE-profiel bepaald. In dit 
hoofdstuk wordt voorgesteld dat Gly m 4 (een Bet v 1 homoloog eiwit uit soja)-sensibilisatie 
een belangrijke indicator is voor ernstige soja-allergie in soja-allergische patiënten, terwijl in 
pinda-allergische patiënten sensibilisatie voor allergenen uit een soja- of erwtextract, net als 
Gly m 5 en 6, een slechte diagnostische voorspellende waarde bleken te hebben. Dit kwam 
waarschijnlijk door de aanwezigheid van klinisch niet-relevante kruisreactiviteit tussen pinda-
specifiek IgE en homologe soja en erwt componenten.
Sectie 2: Immuunmodulatie door Lactobacillus stammen
In de eerste in vitro studie, beschreven in hoofdstuk 7, werden 51 Lactobacillus stammen 
gescreend, waarvan er 8 werden geselecteerd en getest op hun immuunmodulerende 
effecten op perifere mononucleaire cellen uit bloed (PBMC) van gezonde donoren. Alle 
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geteste Lactobacillus stammen induceerden de productie van IL-1β, IL-10, IFN-γ en TNF-α. 
Duidelijke stam-specifieke effecten zoals een significant hogere productie van IFN-γ, IL-12 
en TNF-α werden geobserveerd wanneer de L. plantarum stammen werden vergeleken met 
L. acidophilus stammen. Hieruit concludeerden we dat voornamelijk L. plantarum stammen 
veelbelovende kandidaat-stammen zijn in IgE-gemedieerde allergieën door hun mogelijkheid 
om de T-cel reactie in de richting van een potentiële Th1 reactie te stimuleren.
In hoofdstuk 8 werden de immuunmodulerende effecten van zes geselecteerde Lactobacillus 
stammen onderzocht op PBMCs van pollen-allergische patiënten. Alle stammen waren in staat 
om de ‘innate’ cytokineproductie door PBMCs te stimuleren en daarnaast waren alle stammen 
ook in staat om de IL-13-productie te onderdrukken. Ook hier was een stam-specifiek effect 
waarneembaar qua IFN-γ- en IL-12-inductie. Eén stam was in staat om anti-CD3/anti-CD28 
geïnduceerde celdeling te onderdrukken. De specifieke stammen die de Th2-cytokineproductie 
verminderden, en daarnaast Th1-cytokines versterkten, zouden mogelijk heilzaam kunnen zijn 
voor allergische patiënten.
Effecten die verkregen zijn met in vitro testen kunnen niet direct worden vertaald naar 
de in vivo situatie, en daarom hebben we in hoofdstuk 9 een in vivo screening uitgevoerd 
met vijf Lactobacillus-stammen. Bloedmonsters van 62 berkenpollen-allergische patiënten 
werden zowel voor als na een 4-weken durende probiotica-interventie verzameld. Interventie 
met 4 van de 5 stammen zorgde voor een afname in berkenpollen-specifiek IgE en voor één 
specifieke stam ging dit samen met een significante afname in IL-5 en IL-13 en een toename in 
IL-10 productie in anti-CD3/anti-CD28 gestimuleerde PBMC-kweken. Deze stam zou hierdoor 
mogelijk geschikt kunnen zijn om seizoensgebonden allergische symptomen te verlichten.
In het laatste hoofdstuk, hoofdstuk 10, wordt een overzicht gegeven van de belangrijkste 
resultaten uit dit proefschrift en worden de beperkingen van de uitgevoerde studies en 
toekomstige onderzoeksmogelijkheden besproken. We bespreken de mogelijke rol van 
eiwitaggregatie in relatie tot de allergeniciteit en we wijden uit over het belang van een goede 
stapsgewijze aanpak om tot een selectie van melkzuurbacteriën te komen voor in vivo-testen.
Uit dit proefschrift kan worden geconcludeerd dat behandeling van eiwitten belangrijke en 
eiwit-specifieke effecten kan hebben op zowel de structuur als de allergeniciteit van relevante 
allergenen. Om de allergeniciteit van eiwitten te kunnen testen is het echter niet voldoende 
om alleen IgE-bindingstesten te gebruiken maar ook basofielhistaminedegranulatietesten 
zijn hierbij van groot belang, in het bijzonder als men geaggregeerde eiwitten wil testen. 
Deze resultaten kunnen consequenties hebben voor het stellen van een goede diagnose van 
voedselallergie in de dagelijkse praktijk. 
Gezien de aangetoonde stam-specifieke effecten van melkzuurbacteriën, is een goede 
voorselectie van potentiële stammen van groot belang alvorens de meest belovende stammen 
te kiezen voor een klinische studie. In onze in vivo screening werd L. plantarum CBS125632 
gezien als de meest belovende stam vanwege de gewenste immuunmodulerende effecten 
van deze stam. Deze stam zou daarom getest kunnen worden in een follow-up trial voor 
symptoomvermindering bij patiënten die lijden aan berkenpollenallergie.
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Shen, Min Zheng, Lynn J. Frewer and Luud J.W.J.Gilissen, Co-publishing by Zhejiang 
University Publishing and Springer, 2011 (in press)
Article in Dutch allergy journal
Vissers Y, Wichers HJ, Savelkoul HFJ; Voedseleiwitten en allergische reacties. Ned Tijdschr 
Allergie 2007(7), pp. 160-165
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Overview of completed training activities
Name of the course    Graduate school/institute      Year 
Discipline specific activities
Courses
Industrial proteins    VLAG              2006
Ecophysiology of the gastrointestinal tract  VLAG              2007
Medical immunology    Avans Hogeschool           2007
Conferences and meetings
Allergy Consortium Wageningen PhD day ‡  ACW              2006
NVvI course     NVvI             2007
Allergy School Bischoffsheim   EAACI             2007
Gut Day      WUR/TNO/VLAG           2007
WIAS Science day     WIAS             2007
Minisymposium on food allergy                      Wenckebach Inst (UMCG)           2008
Allergy and research ACW       Studium Generale WUR                2008
Meeting Dutch Research School Allergology †  DRSA                      2008
Minisymposium food allergy; defence M.A. Bollen  WUR             2009
Allergy School Norwich †                           EAACI / GA2LEN            2009
Genetics and immunology of IBH in horses   WIAS             2009
NVvA meeting     NVvA             2010
Fish immunology workshop   WIAS             2010
Utrecht allergy symposium    UAC             2010
EAACI Congress, Londen †    EAACI             2010
EMF symposium     WIAS             2010
Symposium advances in biology of APCs and T cells VUMC             2010
Symposium immunology; defence C.M.S. Ribeiro WIAS             2010
Congress FAAM, Venice ‡    EAACI             2011
Conferences ‡                             EuroPrevall                         06/10
(Doorwerth, Madrid, Warsaw, Berlin, Vienna, Florence)
General courses/activities
Organising and supervising thesis work  DO             2006
VLAG PhD week     VLAG             2007
PhD competence test    WGS             2007
Project and time management   WGS                       2007
Scientific writing     Language Centre WUR                    2008
BD FACS Diva workshop    BD                            2008
Mini symposium Bibliometrics   WUR library                     2009
BD Multicolor workshop    BD                        2009
NWO Talent Days     NWO                      09/10
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Optional courses and activities
Preparation of PhD research proposal                2006
PhD study trip United Kingdom, France                2006
Organization of PhD study trip China                           2008
PhD study trip China ‡                  2008
Meetings in the group                06/11
Visit Institute of Food Research (IFR), Norwich, UK  IFR             2009
Visit Paul-Ehrlich-Institute (PEI), Langen, Germany  PEI             2009
Visit INRA, Jouy-en-Josas, France    INRA             2009
† Poster presentation
‡ Oral presentation
Abbreviations
ACW Allergy Consortium Wageningen
APCs Antigen presenting cells
BD Becton, Dickinson and Company
DO Educational Staff Development Group
DRSA Dutch Research School Allergology
EAACI European Academy of Allergy and Clinical Immunology
EMF Electromagnetic field
FAAM Food Allergy and Anaphylaxis Meeting
GA2LEN Global Allergy and Asthma European Network
IBH Insect bite hypersensitivity
IFR Institute of Food Research
INRA Institut National de la Recherche Agronomique
NVvA Dutch Society for allergology
NVvI Dutch Society for immunology
NWO Dutch Organisation for Scientific Research
PEI Paul-Ehrlich-Institute
UAC Utrecht Allergy Consortium
UMCG University Medical Center Groningen
VUMC VU university medical center
VLAG Graduate School for Nutrition, Food Technology, Agrobiotechnology, and Health Sciences
WGS Wageningen Graduate Schools
WIAS Wageningen Institute of Animal Sciences
WUR Wageningen University and Research Centre
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Curriculum vitae   
Yvonne Maria Vissers was born in Veghel on 8th of July 
1982. In 2000, after graduating from the Kruisheren College 
in Uden (vwo), she started her study in Human Nutrition and 
Health at the Wageningen University. She chose for a free 
master program in which she completed several projects. A 
minor thesis at the department of Toxicology discussed the 
problem of combination toxicology. It investigated the influ-
ence of different flavonoids on the transport of an important 
heterocyclic amine in the human diet using Caco-2 cells as a 
model. During her major thesis performed at the Cell Biology and Immunology department she 
optimized the cryopreservation method of peripheral blood mononuclear cells and performed 
allergen specific stimulation cultures. Yvonne spent the last 6 months of her study in Vancou-
ver, Canada, where she took part in the Nutrition Research Program at the University of British 
Columbia. There she studied the uptake, incorporation and function of n-3 and n-6 fatty acids 
in primary neurons of rats.
After graduating in November 2005 she shortly worked at the company BioMerieux on a 
literature research on decontamination methods applicable in the NASBA manufacturing build-
ing. She also spent 4 months at the Cell Biology and Immunology department at the Wagenin-
gen University working on a project on summer eczema occurring in horses.
In September 2006 she started her PhD, the results and outcomes of which are described 
in this thesis. The research was carried out at the Cell Biology and Immunology Group and the 
Food Chemistry Group of the Wageningen University, under the supervision of prof. dr. Harry 
Wichers, prof. dr. ir. Huub Savelkoul and prof. dr. Clare Mills. The PhD project was partly funded 
by the EuroPrevall project, an EU-funded multidisciplinary project which aimed to improve 
quality of life for food allergic people. The objective was to analyse the impact of processing on 
the immuno-(allergo-) reactivity of allergenic proteins. As a second research topic, funded by 
FrieslandCampina and in cooperation with NIZO, several probiotic bacteria were screened and 
their potential immunomodulating capacity was investigated. Immunomodulation by probiotic 
bacteria could be beneficial in allergic diseases. 
During her PhD project she was involved in teaching activities of three courses. Under her 
supervision seven students performed their theses in the subject of her PhD. Yvonne present-
ed her work at several international conferences and organized a two-week ‘PhD-study trip’ to 
China. Furthermore she attended several international courses, thereby extending her knowl-
edge and scientific network.
In September 2010 she was appointed to start up a project financed by Mead Johnson for 
the period of 6 months. This project investigates immunomodulatory dietary factors in dairy 
milk products for the treatment of cow’s milk allergy. Currently, she has a temporary position 
as immunologist at the Life Science department of FrieslandCampina Research in Deventer.
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